2016 Annual Report OMEGA HEALTHCARE INVESTORS, INC. a are We real self-administered estate investment trust (“REIT”), providing financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities located in the United States and the United Kingdom. Operating in accordance with federal tax laws and regulations governing REITs, income is distributed to stockholders without federal tax liability to our company. consisted investments At December 31, 2016, our domestic and 996 international healthcare facilities containing approximately 99,209 operating beds in 41 states, operated by 79 third-party healthcare operating companies. The table below sets forth the portion of our total investments represented by facilities operated by each operator. of INVESTMENT BY OPERATOR Public Companies Private Companies – continued Genesis HealthCare 3.99% . . . . . . . . . . . . . . . . . . . . . . Alabama, California, Colorado, Idaho, Massachusetts, New Hampshire, North Carolina, Ohio, Rhode Island, Tennessee, Vermont, Washington, West Virginia Diversicare Healthcare Services 3.14% . . . . . . . . . . . . . . . . . . . . . . Alabama, Florida, Indiana, Kentucky, Missouri, Ohio, Tennessee, Texas Other Investment Less than 1% 0.22% . . . . . . . . . . . . . . . . . . . . . . California, Georgia Public Companies Total 7.35% . . . . . . . . . Private Companies Ciena Healthcare 10.28% . . . . . . . . . . . . . . . . . . . . . . Indiana, Michigan, North Carolina, Ohio, Virginia New Ark Investments, Inc. 6.99% . . . . . . . . . . . . . . . . . . . . . . Georgia, Idaho, Indiana, Mississippi, North Carolina, Oregon, South Carolina, Tennessee, Texas, Utah, Virginia, Washington Signature Holdings II, LLC 6.30% . . . . . . . . . . . . . . . . . . . . . . Florida, Georgia, Kentucky, Maryland, Tennessee Maplewood Real Estate Holdings, LLC 6.01% . . . . . . . . . . . . . . . . . . . . . . Connecticut, Massachusetts, New Jersey, New York, Ohio Saber Health Group 5.52% . . . . . . . . . . . . . . . . . . . . . . Florida, North Carolina, Ohio, Pennsylvania, Virginia CommuniCare Health Services, Inc. 4.42% . . . . . . . . . . . . . . . . . . . . . . Maryland, Ohio, Pennsylvania, West Virginia Daybreak Venture, LLC 3.83% . . . . . . . . . . . . . . . . . . . . . . Texas $353,797,464 277,979,412 19,656,209 $651,433,085 $910,430,967 619,281,496 557,985,685 532,599,812 489,392,682 391,948,108 339,617,057 Health and Hospital Corporation 3.44% . . . . . . . . . . . . . . . . . . . . . . Indiana EmpRes Healthcare Group, Inc. 3.02% . . . . . . . . . . . . . . . . . . . . . . California, Idaho, Montana, Nevada, Oregon Washington Healthcare Homes 2.86% . . . . . . . . . . . . . . . . . . . . . . United Kingdom Other Investment Greater than 1% 23.81% . . . . . . . . . . . . . . . . . . . . . . Arizona, Arkansas, California, Colorado, Florida, Iowa, Kansas, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Mexico, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Texas, West Virginia, Wisconsin Other Investment Less than 1% 16.13% . . . . . . . . . . . . . . . . . . . . . . Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Mississippi, Missouri, Nevada, New Mexico, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin Private Companies Total 92.61% . . . . . . . . 304,711,459 267,739,063 253,137,981 2,109,331,209 1,429,449,786 $8,205,625,305 Closed Facilities Closed Facilities 0.04% . . . . . . . . . . . . . . . . . . . . . . Connecticut, Minnesota, Missouri . . . . . . . Closed Facilities Total 0.04% . . . . . . . . . . Grand Total 100.00% . . . . . . . . . . . . . . $ 3,448,937 $ 3,448,937 $8,860,507,327 Dear Stockholders, TO OUR STOCKHOLDERS 2016 was another successful year for Omega Healthcare Investors, Inc. as we continued to achieve substantial and consistent long-term returns to our stockholders. We grew our portfolio and strengthened our balance sheet allowing us to continue our quarterly increase in dividends paid to our stockholders. Our May 2017 dividend payment will be our 19th consecutive quarterly dividend increase. Omega ranked 2nd among healthcare REITs with a 247.1% ten year total shareholder return and was 9th in total shareholder return among all REITs. Omega’s ten year total shareholder return also outperformed the RMS (62.3%), S&P 500 (95.7%) and the DJIA (106.4%). It marked the seventh consecutive year in which Omega was in the top ten of all REITs in ten year total shareholder return. Important highlights included, but were not limited to: New Investment Activity We closed over $1.3 billion in new investments consisting of: • • • • • In Q4 we invested $50 million in a joint venture. In Q3 we invested $428 million in new investments. In Q2 we invested $220 million in new investments. In Q1 we invested $494 million in new investments. Throughout 2016, we continued to renovate our skilled nursing portfolio by investing approximately $137 million in over 100 facilities. We ended 2016 with over $300 million committed to our operators for capital improvement projects (including new builds) that will be completed over the next 36 months. Dividends • We increased our quarterly common dividend 9% with dividend payments of $0.57, $0.58, $0.60 and $0.61, for stockholders of record on February 2, 2016, May 2, 2016, August 1, 2016 and October 31, 2016, respectively. • • 19 consecutive quarterly dividend increases through May 2017. 14% of the common dividends paid in 2016 were treated for tax purposes as a return of capital to our stockholders. Financing Activity • • • • In Q3 we issued and sold $700 million aggregate principal amount of 4.375% Senior Notes due 2023. In Q3 we repurchased an outstanding $180 million secured term loan due 2019. In Q1 we entered into a $350 million senior unsecured 5-year term loan. During 2016, we issued a combined 7.9 million shares of common stock under our Equity Shelf Programs and under our Dividend Reinvestment and Direct Stock Purchase Program generating combined proceeds of $260 million. We believe by continuing to actively managing our tenant relationships, maintaining our strong balance sheet, and seeking attractive investment opportunities we will continue to deliver strong stockholder returns. Very truly, C. Taylor Pickett Chief Executive Officer April 21, 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF FORM 10-K THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016. For the transition period from to Commission file number 1-11316 OMEGA HEALTHCARE INVESTORS, INC. (Exact Name of Registrant as Specified in its Charter) Maryland (State or Other Jurisdiction of Incorporation or Organization) 200 International Circle, Suite 3500 Hunt Valley, MD (Address of Principal Executive Offices) 38-3041398 (I.R.S. Employer Identification No.) 21030 (Zip Code) Registrant’s telephone number, including area code: 410-427-1700 Securities Registered Pursuant to Section 12(b) of the Act: Title of Each Class Common Stock, $.10 Par Value Name of Exchange on Which Registered New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐ Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒ The aggregate market value of the common stock of the registrant held by non-affiliates was $6,465,433,450.70 as of June 30, 2016, the last business day of the registrant’s most recently completed second fiscal quarter. The aggregate market value was computed using the $33.95 closing price per share for such stock on the New York Stock Exchange on such date. As of February 17, 2017, there were 196,743,251 shares of common stock outstanding. DOCUMENTS INCORPORATED BY REFERENCE Proxy Statement for the registrant’s 2016 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission not later than 120 days after December 31, 2016, is incorporated by reference in Part III herein. OMEGA HEALTHCARE INVESTORS, INC. 2016 FORM 10-K ANNUAL REPORT TABLE OF CONTENTS PART I Item 1. Business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Overview; Recent Events . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Summary of Financial Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Description of the Business Taxation of Omega . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Government Regulation and Reimbursement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Executive Officers of Our Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Item 1A. Risk Factors Item 1B. Unresolved Staff Comments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Item 2. Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Item 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mine Safety Disclosures Item 4. Item 5. Item 6. Item 7. PART II Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Selected Financial Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Management’s Discussion and Analysis of Financial Condition and Results of Operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Forward-Looking Statements, Reimbursement Issues and Other Factors Affecting Future Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Overview and Outlook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2016 and Recent Highlights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Portfolio and Other Developments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Asset Sales, Impairments and Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Results of Operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Liquidity and Capital Resources . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Critical Accounting Policies and Estimates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Item 7A. Quantitative and Qualitative Disclosures About Market Risk . . . . . . . . . . . . . . . . . . . . Financial Statements and Supplementary Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Item 8. Changes in and Disagreements with Accountants on Accounting and Financial Item 9. Disclosure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Item 9A. Controls and Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Item 9B. Other Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . PART III Item 10. Directors, Executive Officers of the Registrant and Corporate Governance . . . . . . . . . . Executive Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Item 11. Security Ownership of Certain Beneficial Owners and Management . . . . . . . . . . . . . . . Item 12. Certain Relationships and Related Transactions, and Director Independence . . . . . . . . . Item 13. Principal Accountant Fees and Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Item 14. Item 15. Item 16. Exhibits and Financial Statement Schedules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . PART IV Page 1 1 2 3 5 15 19 20 37 38 41 41 42 44 44 44 45 46 48 51 52 56 59 62 63 63 63 64 65 65 65 65 65 66 66 Item 1 — Business Overview; Recent Events Omega Healthcare Investors, Inc. (“Omega,” “we,” “our” or the “Company”) was incorporated in the State of Maryland on March 31, 1992. We are a self-administered real estate investment trust (“REIT”), investing in income producing healthcare facilities, principally long-term care facilities located in the United States (“U.S.”) and the United Kingdom (“U.K.”). We provide lease or mortgage financing to qualified operators of skilled nursing facilities (“SNFs”) and, to a lesser extent, assisted living facilities (“ALFs”), independent living facilities and rehabilitation and acute care facilities. We have historically financed investments through borrowings under our revolving credit facilities, private placements or public offerings of our debt and equity securities, the assumption of secured indebtedness, retention of cash flow, or a combination of these methods. In April 2015, Aviv REIT, Inc., a Maryland corporation (“Aviv”), merged (the “Aviv Merger”) with and into a wholly-owned subsidiary of Omega, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of October 30, 2014 (the “Merger Agreement”), by and among the Company, Aviv, OHI Healthcare Properties Holdco, Inc., a Delaware corporation and a direct wholly-owned subsidiary of Omega (“Merger Sub”), OHI Healthcare Properties Limited Partnership, a Delaware limited partnership (“Omega OP”), and Aviv Healthcare Properties Limited Partnership, a Delaware limited partnership (the “Aviv OP”). Prior to April 1, 2015 and in accordance with the Merger Agreement, Omega restructured the manner in which it holds its assets by converting to an umbrella partnership real estate investment trust structure (the “UPREIT Conversion”). As a result of the UPREIT Conversion and following the consummation of the Aviv Merger, substantially all of the Company’s assets are held by Omega OP. Omega OP is governed by the Second Amended and Restated Agreement of Limited Partnership of OHI Healthcare Properties Limited Partnership, dated as of April 1, 2015 (the “Partnership Agreement”). Pursuant to the Partnership Agreement, the Company and Merger Sub are the general partners of Omega OP, and have exclusive control over Omega OP’s day-to-day management. As of December 31, 2016, the Company owned approximately 96% of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and other investors owned approximately 4% of the Omega OP Units. In 2016, we completed the following transactions totaling approximately $1.3 billion in new investments: • • • • $248 million of new investments with an existing operator. The investments included 21 SNFs from an unrelated third party for $212.5 million and leased them to an existing operator. The SNFs are located in Virginia (7) and North Carolina (14). Omega also acquired title to certain ancillary facilities which include an office building, a pharmacy building, and other miscellaneous real estate. The SNFs and other real estate were combined into a single 12-year master lease with an existing operator. The Company also provided a $20 million term loan and $15 million secured working capital loan to the operator. The master lease and term loan have an initial annual cash yield of 8.5% with 2.5% annual escalators. The secured working capital loan has an initial annual cash yield of 8.5%. $337 million of new investments with an existing operator. The investment included 31 SNFs and a $37 million term loan acquired for approximately $337 million from an unrelated third party. The SNFs, located in Florida (6), Kentucky (5) and Tennessee (20), were being operated by an existing operator of the Company. The 31 SNFs were added to the operator’s existing master lease with an initial annual cash yield of 9.0% with 2.5% annual escalators. In addition to aforementioned investments, we also acquired 18 SNFs and 20 ALFs for approximately $480.7 million throughout the U.S. and U.K. $50 million mezzanine loan with a new operator. The mezzanine loan bears interest at LIBOR plus 9.75% per annum (with a 10.50% floor) that matures in February 2019. 1 • We invested $50 million for an approximate 15% ownership interest in an unconsolidated joint venture. • $136.8 million of investments in our capital expenditure programs. As of December 31, 2016, our portfolio of investments included 996 healthcare facilities located in 42 states and the U.K. and operated by 79 third-party operators. We use the term “operator” to refer to our tenants and mortgagors and their affiliates who manage and/or operate our properties. This portfolio was made up of: • • • 809 SNFs, 101 ALFs, 16 specialty facilities and one medical office building; fixed rate mortgages on 44 SNFs and two ALFs; and 23 facilities closed or held-for-sale. As of December 31, 2016, our gross investments in these facilities, net of impairments and reserves for uncollectible loans, totaled approximately $8.9 billion. In addition, we held other investments of approximately $256.8 million at December 31, 2016, consisting primarily of secured loans to third-party operators of our facilities. Our filings with the Securities and Exchange Commission (“SEC”), including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports are accessible free of charge on our website at www.omegahealthcare.com. The contents of our website are not incorporated by reference herein or in any of our filings with the SEC. Summary of Financial Information The following table summarizes our revenues by asset category for 2016, 2015 and 2014. (See “Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Note 3 – Properties”, “Note 4 – Direct Financing Leases”, “Note 5 – Mortgage Notes Receivable” and “Note 6 – Other Investments”). Revenues by Asset Category (in thousands) Year Ended December 31, 2016 2015 2014 Core assets: Rental income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Income from direct financing leases . . . . . . . . . . . . . . . . . . . . . . . . Mortgage interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $743,885 62,298 69,811 $605,991 59,936 68,910 $388,443 56,719 53,007 Total core assets revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 875,994 734,837 498,169 Other investment income – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Miscellaneous income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21,852 2,981 7,534 1,246 6,369 249 Total operating revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $900,827 $743,617 $504,787 2 The following table summarizes our real estate assets by asset category as of December 31, 2016 and 2015: Core assets: Assets by Category (in thousands) As of December 31, 2016 2015 Total real estate investments Buildings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Land . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Furniture, fixtures and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Site improvements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Construction in progress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investments in direct financing leases – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mortgage notes receivable – net Total core assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investment in unconsolidated joint venture . . . . . . . . . . . . . . . . . . . . . . . . . . Total real estate assets before held for sale assets . . . . . . . . . . . . . . . . . . . . Held for sale assets – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $5,954,771 759,295 454,760 206,206 191,326 7,566,358 601,938 639,343 8,807,639 256,846 48,776 9,113,261 52,868 $9,166,129 $5,320,482 670,916 426,040 132,182 194,338 6,743,958 587,701 679,795 8,011,454 89,299 — 8,100,753 6,599 $8,107,352 Description of the Business Investment Strategy. We maintain a portfolio of long-term healthcare facilities and mortgages on healthcare facilities located in the U.S. and the U.K. Our investments are generally geographically diverse and operated by a diverse group of established, middle-market healthcare operators that meet our standards for quality and experience of management and creditworthiness. Our criteria for evaluating potential investments includes but is not limited to: • • • • • • • the quality and experience of management and the creditworthiness of the operator of the facility; the facility’s historical and forecasted cash flow and its ability to meet operational needs, capital expenditure requirements and lease or debt service obligations; the construction quality, condition and design of the facility; the location of the facility; the tax, growth, regulatory and reimbursement environment of the applicable jurisdiction; the occupancy rate for the facility and demand for similar healthcare facilities in the same or nearby communities; and the payor mix of private, Medicare and Medicaid patients at the facility. We seek to obtain (i) contractual rent escalations under long-term, non-cancelable, “triple-net” leases and (ii) fixed-rate mortgage loans. We typically obtain substantial liquidity deposits, covenants regarding minimum working capital and net worth, liens on accounts receivable and other operating assets, and various provisions for cross-default, cross-collateralization and corporate and or personal guarantees, when appropriate. We prefer to invest in equity ownership of properties. Due to regulatory, tax or other considerations, we may pursue alternative investment structures. The following summarizes our primary investment structures. The average annualized yields described below reflect existing contractual arrangements. 3 However, due to the nature of the long-term care industry, we cannot assure that the operators of our facilities will meet their payment obligations in full or when due. Therefore, the annualized yields as of December 31, 2016, set forth below, are not necessarily indicative of future yields, which may be lower. Triple-Net Operating Leases. Triple-net operating leases typically range from 5 to 15 years, plus renewal options. Our leases generally provide for minimum annual rentals that are subject to annual formula increases based on factors such as increases in the Consumer Price Index. At December 31, 2016, our average annualized yield from operating leases was approximately 9.5%. Direct Financing Leases. In addition to our typical lease agreements, seven of our leases are being accounted for as direct financing leases which include annual escalators. At December 31, 2016, our average annualized yield from the direct financing leases was 10.5%. Fixed-Rate Mortgages. Our mortgages typically have a fixed interest rate for the mortgage term and are secured by first mortgage liens on the underlying real estate and personal property of the mortgagor. At December 31, 2016, our average annualized yield on these investments was approximately 9.6%. The table set forth in “Item 2 – Properties” contains information regarding our properties and investments as of December 31, 2016. Borrowing Policies. We generally attempt to match the maturity of our indebtedness with the maturity of our investment assets and employ long-term, fixed-rate debt to the extent practicable in view of market conditions in existence from time to time. We may use the proceeds of new indebtedness to finance our investments in additional healthcare facilities. In addition, we may invest in properties subject to existing loans, secured by mortgages, deeds of trust or similar liens on properties. Policies With Respect To Certain Activities. With respect to our capital requirements, we typically rely on equity offerings, debt financing and retention of cash flow (subject to provisions in the Internal Revenue Code (the “Code”) concerning taxability of undistributed REIT taxable income), or a combination of these methods. Our financing alternatives include bank borrowings, publicly or privately placed debt instruments, purchase money obligations to the sellers of assets or securitizations, any of which may be issued as secured or unsecured indebtedness. We have the authority to issue our common stock or other equity or debt securities in exchange for property and to repurchase or otherwise reacquire our securities. Subject to the percentage of ownership limitations and gross income and asset tests necessary for REIT qualification, we may invest in securities of other REITs, other entities engaged in real estate activities or securities of other issuers, including for the purpose of exercising control over such entities. We may engage in the purchase and sale of investments. We do not underwrite the securities of other issuers. Our officers and directors may change any of these policies without a vote of our stockholders. In the opinion of our management, our properties are adequately covered by insurance. Competition. The healthcare industry is highly competitive and will likely become more competitive in the future. We face competition from other REITs, investment companies, private equity and hedge fund investors, healthcare operators, lenders, developers and other institutional investors, some of whom have greater resources and lower costs of capital than us. Our operators compete on a local and regional basis with operators of facilities that provide comparable services. The basis of competition for our operators includes the quality of care provided, reputation, the physical appearance of a facility, price, the range of services offered, family preference, alternatives for healthcare delivery, the supply of competing properties, physicians, staff, referral sources, the population and surrounding areas. location and the size and demographics of Increased competition makes it more challenging for us to identify and successfully capitalize on opportunities that meet our objectives. Our ability to compete is also impacted by national and local economic trends, availability of investment alternatives, availability and cost of capital, construction and renovation costs, existing laws and regulations, new legislation and population trends. For additional information on the risks associated with our business, please see “Item 1A – Risk Factors” below. 4 Taxation of Omega The following is a general summary of the material United States federal income tax considerations applicable to (i) us, (ii) the holders of our securities and (iii) our election to be taxed as a REIT. It is not tax advice. This summary is not intended to represent a detailed description of the United States federal income tax consequences applicable to a particular holder of our securities in view of any person’s particular circumstances, nor is it intended to represent a detailed description of the United States federal income tax consequences applicable to holders of our securities subject to special treatment under the federal income tax laws such as insurance companies, institutions, securities broker-dealers, non-U.S. persons, persons holding our securities as part of a hedge, straddle, or other risk reduction, constructive sales or conversion transaction, investors in pass-through entities, expatriates and taxpayers subject to alternative minimum taxation. tax-exempt organizations, financial The following discussion, to the extent it constitutes matters of law or legal conclusions (assuming the facts, representations and assumptions upon which the discussion is based are accurate), represents some of the material United States federal income tax considerations relevant to ownership of our securities. The sections of the Code relating to the qualification and operation as a REIT are highly technical and complex. The following discussion sets forth certain material aspects of those sections. The information in this section is based on, and is qualified in its entirety by the Code; current, temporary and proposed Treasury Regulations (“Treasury Regulations”) promulgated under the Code; the legislative history of the Code; current administrative interpretations and practices of the Internal Revenue Service (“IRS”); and court decisions, in each case, as of the date of this report. In addition, the administrative interpretations and practices of the IRS include its practices and policies as expressed in private letter rulings, which are not binding on the IRS, except with respect to the particular taxpayers who requested and received those rulings. General. We have elected to be taxed as a REIT, under Sections 856 through 860 of the Code, beginning with our taxable year ended December 31, 1992. We believe that we were organized and have operated in such a manner as to qualify for taxation as a REIT. We intend to continue to operate in a manner that will allow us to maintain our qualification as a REIT, but no assurance can be given that we have operated or will be able to continue to operate in a manner so as to qualify or remain qualified as a REIT. If we qualify for taxation as a REIT, we generally will not be subject to federal corporate income taxes on our net income that is currently distributed to stockholders. However, we will be subject to certain federal income taxes as follows. First, we will be taxed at regular corporate rates on any undistributed REIT taxable income, including undistributed net capital gains; provided, however, that if we have a net capital gain, we will be taxed at regular corporate rates on our undistributed REIT taxable income, computed without regard to net capital gain and the deduction for capital gains dividends, plus a 35% tax on undistributed net capital gain, if our tax as thus computed is less than the tax computed in the regular manner. Second, under certain circumstances, we may be subject to the “alternative minimum tax” on our items of tax preference that we do not distribute or allocate to our stockholders. Third, if we have (i) net income from the sale or other disposition of “foreclosure property,” which is held primarily for sale to customers in the ordinary course of business, or (ii) other nonqualifying income from foreclosure property, we will be subject to tax at the highest regular corporate rate on such income. Fourth, if we have net income from prohibited transactions (which are, in general, certain sales or other dispositions of property (other than foreclosure property) held primarily for sale to customers in the ordinary course of business by us, (i.e., when we are acting as a dealer), such income will be subject to a 100% tax. Fifth, if we should fail to satisfy the 75% gross income test or the 95% gross income test (as discussed below), but nonetheless have maintained our qualification as a REIT because certain other remedial requirements have been met, we will be subject to a 100% tax on an amount equal to (a) the gross income attributable to the greater of the amount by which we fail the 75% or 95% test, multiplied by (b) a fraction intended to reflect our profitability. Sixth, if we should fail to distribute by the end of each year at least the sum of (i) 85% of our REIT ordinary income for such year, (ii) 95% of our REIT capital gain net income for such year, and (iii) any undistributed taxable income from prior periods, we will be subject to a 4% excise tax on the excess of such required distribution over the amounts actually distributed. Seventh, we will be subject to a 100% excise tax on transactions with a taxable REIT subsidiary (“TRS”) that are not conducted on an 5 arm’s-length basis. Eighth, if we acquire any asset that is defined as a “built-in gain asset” from a C corporation that is not a REIT (i.e., generally a corporation subject to full corporate-level tax) in a transaction in which the basis of the built-in gain asset in our hands is determined by reference to the basis of the asset (or any other property) in the hands of the C corporation, and we recognize gain on the disposition of such asset (for dispositions made in taxable years beginning after December 31, 2016) during the 5-year period beginning on the date on which such asset was acquired by us (such period, the “recognition period”), then, to the extent of the built-in gain (i.e., the excess of (a) the fair market value of such asset on the date such asset was acquired by us over (b) our adjusted basis in such asset on such date), our recognized gain will be subject to tax at the highest regular corporate rate. The results described above with respect to the recognition of built-in gain assume that we will not make an election pursuant to Treasury Regulations Section 1.337(d)-7(c)(5). Requirements for Qualification. The Code defines a REIT as a corporation, trust or association: (1) which is managed by one or more trustees or directors; (2) the beneficial ownership of which is evidenced by transferable shares, or by transferable certificates of beneficial interest; (3) which would be taxable as a domestic corporation, but for Sections 856 through 859 of the Code; (4) which is neither a financial institution nor an insurance company as defined in provisions of the Code; (5) the beneficial ownership of which is held by 100 or more persons; (6) during the last half year of each taxable year not more than 50% in value of the outstanding stock of which is owned, actually or constructively, by five or fewer individuals (as defined in the Code to include certain entities); and (7) which meets certain other tests, described below, regarding the nature of its income and assets and the amount of its annual distributions to stockholders. The Code provides that conditions (1) to (4) inclusive, must be met during the entire taxable year and that condition (5) must be met during at least 335 days of a taxable year of twelve months, or during a proportionate part of a taxable year of less than twelve months. For purposes of conditions (5) and (6), pension funds and certain other tax-exempt entities are treated as individuals, subject to a “look-through” exception in the case of condition (6). We may avoid disqualification as a REIT for a failure to satisfy any of these tests if such failure is due to reasonable cause and not willful neglect, and we pay a penalty of $50,000 for each such failure. Income Tests. To maintain our qualification as a REIT, we annually must satisfy two gross income requirements. First, at least 75% of our gross income (excluding gross income from prohibited transactions) for each taxable year must be derived directly or indirectly from investments relating to real property or mortgages on real property (including generally “rents from real property,” interest on mortgages on real property, and gains on sale of real property and real property mortgages, other than property described in Section 1221(a)(1) of the Code) and income derived from certain types of temporary investments. Second, at least 95% of our gross income (excluding gross income from prohibited transactions) for each taxable year must be derived from such real property investments, dividends, interest and gain from the sale or disposition of stock or securities other than property held for sale to customers in the ordinary course of business. Rents received by us will qualify as “rents from real property” in satisfying the gross income requirements for a REIT described above only if several conditions are met. First, the amount of the rent must not be based in whole or in part on the income or profits of any person. However, any amount received or accrued generally will not be excluded from the term “rents from real property” solely by reason of being based on a fixed percentage or percentages of receipts or sales. Second, the Code provides that rents received from a tenant (other than rent from a tenant that is a TRS that meets the requirements described below) will not qualify as “rents from real property” in satisfying the gross income tests if we, or an owner (actually or constructively) of 10% or more of the value of our stock, actually or constructively owns 10% or more of such tenant, which is defined as a related party tenant taking into account certain complex attribution rules. Third, if rent attributable to personal property, leased in connection with a lease of real property, is greater than 15% of the total rent received under the lease, then the portion of rent attributable to such personal property will not qualify as “rents from real property.” Finally, for rents received to qualify as “rents from real property,” we generally must not operate or manage the property or furnish or render services to the tenants of such property, other than through an independent contractor from which we derive no revenue. We may, however, directly perform certain services that are “usually or customarily rendered” in connection with the rental of space for occupancy only and are not otherwise considered “rendered to the occupant” of the property. In addition, we may directly provide a minimal 6 amount of “non-customary” services to the tenants of a property as long as our income from the services does not exceed 1% of our income from the related property. Furthermore, we may own up to 100% of the stock of a TRS, which may provide customary and non-customary services to our tenants without tainting our rental income from the related properties. The term “interest” generally does not include any amount received or accrued (directly or indirectly) if the determination of such amount depends in whole or in part on the income or profits of any person. However, an amount received or accrued generally will not be excluded from the term “interest” solely by reason of being based on a fixed percentage or percentages of gross receipts or sales. In addition, an amount that is based on the income or profits of a debtor will be qualifying interest income as long as the debtor derives substantially all of its income from the real property securing the debt from leasing substantially all of its interest in the property, but only to the extent that the amounts received by the debtor would be qualifying “rents from real property” if received directly by a REIT. If a loan contains a provision that entitles us to a percentage of the borrower’s gain upon the sale of the real property securing the loan or a percentage of the appreciation in the property’s value as of a specific date, income attributable to that loan provision will be treated as gain from the sale of the property securing the loan, which generally is qualifying income for purposes of both gross income tests. Interest on debt secured by mortgages on real property or on interests in real property generally is qualifying income for purposes of the 75% gross income test. However, if the highest principal amount of a loan outstanding during a taxable year exceeds the fair market value of the real property securing the loan as of the date we agreed to originate or acquire the loan, a portion of the interest income from such loan will not be qualifying income for purposes of the 75% gross income test, but will be qualifying income for purposes of the 95% gross income test. The portion of the interest income that will not be qualifying income for purposes of the 75% gross income test will be equal to the portion of the principal amount of the loan that is not secured by real property. Prior to January 1, 2016, in the case of a mortgage loan that is secured by both real and personal property, an allocation of the interest received between qualified mortgage interest and interest that was not qualified mortgage interest on the loan was required to be made if the fair market value of the real property at the time the loan was made was less than the principal amount of the loan. For taxable years beginning after December 31, 2015, in the case of a mortgage loan that is secured by both real and personal property, such allocation is required only if the fair market value of the personal property exceeds 15% of the value of the property. We do not expect the change in the rules for allocation of mortgage interest to have an impact on our ability to satisfy either of the gross income tests going forward. A modification of a mortgage loan, if it is deemed significant for income tax purposes, could be considered to be the deemed issuance of a new mortgage loan that is subject to re-testing under these rules, with the possible re-characterization of the mortgage interest on such loan as non-qualifying income for purposes of the 75% gross income test (but not the 95% gross income test, which is discussed below), as well as non-qualifying assets under the asset test (discussed below) and the deemed exchange of the modified loan for the new loan could result in imposition of the 100% prohibited transaction tax (also discussed below). The IRS recently issued guidance providing relief in the case of certain existing mortgage loans held by a REIT that are modified in response to these market conditions such that (i) the modified mortgage loan need not be re-tested for purposes of determining whether the income from the mortgage loan continues to be qualified income for purposes of the 75% gross income test or whether the mortgage loan retains its character as a qualified REIT asset for purposes of the asset test (discussed below), and (ii) the modification of the loan will not be treated as a prohibited transaction. At present, we do not hold any mortgage loans that have been modified, which would require us to take advantage of these rules for special relief. We monitor our mortgage loans and direct financing leases for compliance with the above rules. Prohibited Transactions. We will incur a 100% tax on the net income derived from any sale or other disposition of property, other than foreclosure property, that we hold primarily for sale to customers in the ordinary course of a trade or business. We believe that none of our assets is primarily held for sale to customers and that a sale of any of our assets would not be in the ordinary course of our business. Whether a REIT holds an asset primarily for sale to customers in the ordinary course of a trade or business depends, however, on the facts and circumstances in effect from time to time, including those related to a particular 7 asset. Nevertheless, we will attempt to comply with the terms of safe-harbor provisions in the federal income tax laws prescribing when an asset sale will not be characterized as a prohibited transaction. The Code also provides a number of alternative exceptions from the 100% tax on “prohibited transactions” if certain requirements have been satisfied with respect to property disposed of by a REIT. These requirements relate primarily to the number and/or amount of properties disposed of by a REIT, the period of time the property has been held by the REIT, and/or aggregate expenditures made by the REIT with respect to the property being disposed of. The conditions needed to meet these requirements have been lowered for taxable years beginning in 2009 and thereafter. However, we cannot assure that we will be able to comply with the safe-harbor provisions or that we would be able to avoid the 100% tax on prohibited transactions if we were to dispose of an owned property that otherwise may be characterized as property that we hold primarily for sale to customers in the ordinary course of a trade or business. Foreclosure Property. We will be subject to tax at the maximum corporate rate on any income from foreclosure property, other than income that otherwise would be qualifying income for purposes of the 75% gross income test, less expenses directly connected with the production of that income. However, gross income from foreclosure property is treated as qualifying for purposes of the 75% and 95% gross income tests. Foreclosure property is any real property, including interests in real property, and any personal property incident to such real property: • • • that is acquired by a REIT as the result of (i) the REIT having bid on such property at foreclosure, or having otherwise reduced such property to ownership or possession by agreement or process of law, after there was a default, or (ii) default was imminent on a lease of such property or on indebtedness that such property secured; for which the related loan or lease was acquired by the REIT at a time when the default was not imminent or anticipated; and for which the REIT makes a proper election to treat the property as foreclosure property. Such property generally ceases to be foreclosure property at the end of the third taxable year following the taxable year in which the REIT acquired the property, or longer (for a total of up to six years) if an extension is granted by the Secretary of the Treasury. In the case of a “qualified health care property” acquired solely as a result of termination of a lease, but not in connection with default or an imminent default on the lease, the initial grace period terminates on the second (rather than third) taxable year following the year in which the REIT acquired the property (unless the REIT establishes the need for and the Secretary of the Treasury grants one or more extensions, not exceeding six years in total, including the original two-year period, to provide for the orderly leasing or liquidation of the REIT’s interest in the qualified health care property). This grace period terminates and foreclosure property ceases to be foreclosure property on the first day: • • • on which a lease is entered into for the property that, by its terms, will give rise to income that does not qualify for purposes of the 75% gross income test, or any amount is received or accrued, directly or indirectly, pursuant to a lease entered into on or after such day that will give rise to income that does not qualify for purposes of the 75% gross income test; on which any construction takes place on the property, other than completion of a building or any other improvement, where more than 10% of the construction was completed before default became imminent; or which is more than 90 days after the day on which the REIT acquired the property and the property is used in a trade or business that is conducted by the REIT, other than through an independent contractor from whom the REIT itself does not derive or receive any income or, with respect to taxable years beginning after December 31, 2015, through a TRS. The definition of foreclosure property includes any “qualified health care property,” as defined in Code Section 856(e)(6) acquired by us as the result of the termination or expiration of a lease of such property. We have from time to time operated qualified healthcare facilities acquired in this manner for up to two years (or longer if an extension was granted). However, we do not currently own any property with respect to which we have made foreclosure property elections. Properties that we had taken back in a foreclosure or 8 bankruptcy and operated for our own account were treated as foreclosure properties for income tax purposes, pursuant to Code Section 856(e). Gross income from foreclosure properties was classified as “good income” for purposes of the annual REIT income tests upon making the election on the tax return. Once made, the income was classified as “good” for a period of three years, or until the properties were no longer operated for our own account. In all cases of foreclosure property, we utilized an independent contractor to conduct day-to-day operations to comply with certain REIT requirements. In certain cases, we operated these facilities through a taxable REIT subsidiary. For those properties operated through the taxable REIT subsidiary, we utilized an eligible independent contractor to conduct day-to-day operations to comply with certain REIT requirements. As a result of the foregoing, we do not believe that our participation in the operation of nursing homes increased the risk that we would fail to qualify as a REIT. Through our 2015 taxable year, we had not paid any tax on our foreclosure property because those properties had been producing losses. We cannot predict whether, in the future, our income from foreclosure property will be significant and whether we could be required to pay a significant amount of tax on that income. Hedging Transactions. Our hedging activities may include entering into interest rate swaps, caps and floors, options to purchase these items and futures and forward contracts. To the extent that we enter into an interest rate swap or cap contract, option, futures contract, forward rate agreement, or any similar financial instrument for the purpose of hedging our indebtedness incurred to acquire or carry “real estate assets,” any periodic income or gain from the disposition of that contract should be qualifying income and excluded from the computations determining compliance with the 95% and 75% gross income tests. As described in “Item 7A – Quantitative and Qualitative Disclosures About Market Risk”, we have entered into certain interest rate swap agreements to hedge our risk against fluctuations in interest rates and the swaps have been structured to satisfy the requirements of the tax treatment outlined above. Accordingly, our income and gain from our interest rate swap agreements generally is qualifying income and may be excluded from our computations in determining compliance with the 95% and 75% gross income tests. To the extent that we hedge with other types of financial instruments, or in other situations, it is not entirely clear how the income from those transactions will be treated for purposes of the gross income tests. We believe that we have structured and intend to continue to structure any hedging transactions in a manner that does not jeopardize our status as a REIT. TRS Income. A TRS may earn income that would not be qualifying income if earned directly by the parent REIT. Both the subsidiary and the REIT must jointly elect to treat the subsidiary as a TRS. A corporation of which a TRS directly or indirectly owns more than 35% of the voting power or value of the stock will automatically be treated as a TRS. Overall, no more than 25% of the value of a REIT’s assets may consist of securities of one or more TRSs and, with respect to taxable years beginning after December 31, 2017, no more than 20% of the value of a REIT’s assets may consist of securities of one or more TRSs. Prior to 2009, a TRS was not permitted to directly or indirectly (i) operate or manage a health care (or lodging) facility, or (ii) provide to any other person (under a franchise, license, or otherwise) rights to any brand name under which a health care (or lodging) facility is operated. Beginning in 2009, TRSs became permitted to own or lease a health care facility provided that the facility is operated and managed by an “eligible independent contractor.” A TRS will pay income tax at regular corporate rates on any income that it earns. In addition, the new rules limit the deductibility of interest paid or accrued by a TRS to its parent REIT to assure that the TRS is subject to an appropriate level of corporate taxation. The rules also impose a 100% excise tax on transactions between a TRS and its parent REIT or the REIT’s operators that are not conducted on an arm’s-length basis. As stated above, we do not lease any of our facilities to any of our TRSs. Failure to Satisfy Income Tests. If we fail to satisfy one or both of the 75% or 95% gross income tests for any taxable year, we may nevertheless qualify as a REIT for such year if we are entitled to relief under certain relief provisions of the Code. These relief provisions will be generally available if our failure to meet such tests was due to reasonable cause and not due to willful neglect, we attach a schedule of the sources of our income to our tax return, and any incorrect information on the schedule was not due to fraud with intent to evade tax. It is not possible, however, to state whether in all circumstances we would be entitled to the benefit of these relief provisions. Even if these relief provisions apply, we would incur a 100% tax on the 9 gross income attributable to the greater of the amounts by which we fail the 75% and 95% gross income tests, multiplied by a fraction intended to reflect our profitability and we would file a schedule with descriptions of each item of gross income that caused the failure. Asset Tests. At the close of each quarter of our taxable year, we must also satisfy the following tests relating to the nature of our assets. First, at least 75% of the value of our total assets must be represented by real estate assets (including (i) our allocable share of real estate assets held by partnerships in which we own an interest and (ii) stock or debt instruments held for less than one year purchased with the proceeds of a stock offering or long-term (at least five years) debt offering of our company), cash, cash items and government securities. Second, of our investments not included in the 75% asset class, the value of our interest in any one issuer’s securities may not exceed 5% of the value of our total assets. Third, we may not own more than 10% of the voting power or value of any one issuer’s outstanding securities. Fourth, with respect to taxable years beginning after December 31, 2015, no more than 25% of the value of our total assets may be represented by nonqualified publicly offered REIT debt instruments. Fifth, no more than 25% of the value of our total assets may consist of the securities of one or more TRSs and, with respect to taxable years beginning after December 31, 2017, no more than 20% of the value of our total assets may consist of the securities of one or more TRSs. Sixth, no more than 25% of the value of our total assets may consist of the securities of TRSs and other non-TRS taxable subsidiaries and other assets that are not qualifying assets for purposes of the 75% asset test. For purposes of the second and third asset tests described above the term “securities” does not include our equity or debt securities of a qualified REIT subsidiary, a TRS, or an equity interest in any partnership, since we are deemed to own our proportionate share of each asset of any partnership of which we are a partner. Furthermore, for purposes of determining whether we own more than 10% of the value of only one issuer’s outstanding securities, the term “securities” does not include: (i) any loan to an individual or an estate; (ii) any Code Section 467 rental agreement; (iii) any obligation to pay rents from real property; (iv) certain government issued securities; (v) any security issued by another REIT; and (vi) our debt securities in any partnership, not otherwise excepted under (i) through (v) above, (A) to the extent of our interest as a partner in the partnership or (B) if 75% of the partnership’s gross income is derived from sources described in the 75% income test set forth above. We may own up to 100% of the stock of one or more TRSs. However, overall, no more than 25% (or 20% with respect to taxable years beginning after December 31, 2017) of the value of our assets may consist of securities of one or more TRSs, and no more than 25% of the value of our assets may consist of the securities of TRSs and other non-TRS taxable subsidiaries (including stock in non-REIT C corporations) and other assets that are not qualifying assets for purposes of the 75% asset test. We do not anticipate that the reduction in value of TRSs that may be owned by a REIT will have an impact on us as we believe that the value of our TRSs is substantially less than 20% of the value of our assets and we do not expect the value of our TRSs to increase materially in the future. If the outstanding principal balance of a mortgage loan exceeds the fair market value of the real property securing the loan, a portion of such loan likely will not be a qualifying real estate asset for purposes of the 75% test. The nonqualifying portion of that mortgage loan will be equal to the portion of the loan amount that exceeds the value of the associated real property. Prior to January 1, 2016, in the case of a mortgage loan that is secured by both real and personal property, a portion of the mortgage loan was required to be treated as a nonqualifying assets for purposes of the 75% tests if the fair market value of the real property at the time the loan was made was less than the principal amount of the loan. For taxable years beginning after December 31, 2015, in the case of a mortgage loan that is secured by both real and personal property, such allocation is required only if the fair market value of the personal property exceeds 15% of the value of the property. We do not expect the change in the rules for allocation of mortgage interest to have an impact on our ability to satisfy either of the asset test going forward. As discussed under the 75% gross income test (see above), the IRS recently provided relief from re-testing certain mortgage loans held by a REIT that have been modified as a result of the current distressed market conditions with respect to real property. At present, we do not hold any mortgage loans that have been modified, which would require us to take advantage of these rules for special relief. 10 After initially meeting the asset tests at the close of any quarter, we will not lose our status as a REIT for failure to satisfy any of the asset tests at the end of a later quarter solely by reason of changes in asset values. If the failure to satisfy the asset tests results from an acquisition of securities or other property during a quarter, the failure can be cured by disposition of sufficient nonqualifying assets within 30 days after the close of that quarter. Subject to certain de minimis exceptions, we may avoid REIT disqualification in the event of certain failures under the asset tests, provided that (i) we file a schedule with a description of each asset that caused the failure, (ii) the failure was due to reasonable cause and not willful neglect, (iii) we dispose of the assets within 6 months after the last day of the quarter in which the identification of the failure occurred (or the requirements of the rules are otherwise met within such period) and (iv) we pay a tax on the failure equal to the greater of (A) $50,000 per failure and (B) the product of the net income generated by the assets that caused the failure for the period beginning on the date of the failure and ending on the date we dispose of the asset (or otherwise satisfy the requirements) multiplied by the highest applicable corporate tax rate. Annual Distribution Requirements. To qualify as a REIT, we are required to distribute dividends (other than capital gain dividends) to our stockholders in an amount at least equal to (A) the sum of (i) 90% of our “REIT taxable income” (computed without regard to the dividends paid deduction and our net capital gain) and (ii) 90% of the net income (after tax), if any, from foreclosure property, minus (B) the sum of certain items of noncash income. Such distributions must be paid in the taxable year to which they relate, or in the following taxable year if declared before we timely file our tax return for such year and paid on or before the first regular dividend payment after such declaration. In addition, such distributions are required to be made pro rata, with no preference to any share of stock as compared with other shares of the same class, and with no preference to one class of stock as compared with another class except to the extent that such class is entitled to such a preference. To the extent that we do not distribute all of our net capital gain, or distribute at least 90%, but less than 100% of our “REIT taxable income,” as adjusted, we will be subject to tax thereon at regular ordinary and capital gain corporate tax rates. Furthermore, if we fail to distribute during a calendar year, or by the end of January following the calendar year in the case of distributions with declaration and record dates falling in the last three months of the calendar year, at least the sum of: • • • 85% of our REIT ordinary income for such year; 95% of our REIT capital gain income for such year; and any undistributed taxable income from prior periods, we will incur a 4% nondeductible excise tax on the excess of such required distribution over the amounts we actually distribute. We may elect to retain and pay income tax on the net long-term capital gain we receive in a taxable year. If we so elect, we will be treated as having distributed any such retained amount for purposes of the 4% excise tax described above. We have made, and we intend to continue to make, timely distributions sufficient to satisfy the annual distribution requirements. We may also be entitled to pay and deduct deficiency dividends in later years as a relief measure to correct errors in determining our taxable income. Although we may be able to avoid income tax on amounts distributed as deficiency dividends, we will be required to pay interest to the IRS based upon the amount of any deduction we take for deficiency dividends. The availability to us of, among other things, depreciation deductions with respect to our owned facilities (which reduce our taxable income and the amount of our required dividend distributions) depends upon the determination that, for federal income tax purposes, we are the true owner of such facilities for federal income tax purposes, which is dependent on the classification of the leases to operators or our facilities as “true leases” rather than financing arrangements for federal income tax purposes. The determinations of whether (1) we are the owner of such facilities, and (2) the leases are true leases, for federal tax purposes are essentially factual matters. We believe that we will be treated as the owner of each of the facilities that we lease, and such leases will be treated as true leases for federal income tax purposes. However, no assurances can be given that the IRS will not successfully challenge our status as the owner of our facilities subject to leases, and the status of such leases as true leases, asserting that the purchase of the facilities by us and the leasing of such facilities merely constitute steps in secured financing transactions in 11 which the lessees are owners of the facilities and we are merely a secured creditor. In such event, we would not be entitled to claim depreciation deductions with respect to any of the affected facilities. As a result, we might fail to meet the 90% distribution requirement or, if such requirement is met, we might be subject to corporate income tax or the 4% excise tax. Reasonable Cause Savings Clause. We may avoid disqualification in the event of a failure to meet certain requirements for REIT qualification if the failures are due to reasonable cause and not willful neglect, and if the REIT pays a penalty of $50,000 for each such failure. This reasonable cause safe harbor is not available for failures to meet the 95% and 75% gross income tests or the assets tests. Failure to Qualify. If we fail to qualify as a REIT in any taxable year, and the reasonable cause relief provisions do not apply, we will be subject to tax (including any applicable alternative minimum tax) on our taxable income at regular corporate rates. Distributions to stockholders in any year in which we fail to qualify will not be deductible, and our failure to qualify as a REIT would reduce the cash available for distribution by us to our stockholders. In addition, if we fail to qualify as a REIT, all distributions to stockholders will be taxable as dividend income, to the extent of our current and accumulated earnings and profits. However, in such a case, subject to certain limitations of the Code, corporate distributees may be eligible for the dividends received deduction with respect to dividends that we make, and in the case of an individual, trust, or an estate, dividends are treated the same as capital gain income, which currently is subject to a maximum income tax rate that is lower than regular income tax rates. In addition, in the case of an individual, trust or an estate, to the extent such taxpayer’s unearned income (including dividends) exceeds certain threshold amounts, the Medicare Tax on unearned income also will apply to dividend income. Unless entitled to relief under specific statutory provisions, we would also be disqualified from taxation as a REIT for the four taxable years following the year during which qualification was lost. It is not possible to state whether in all circumstances we would be entitled to such statutory relief. Failure to qualify could result in our incurring indebtedness or liquidating investments to pay the resulting taxes. Our Subsidiaries. We own and operate a number of properties through subsidiaries and the classification of such subsidiaries varies for federal income tax purposes as described in this section. Some of the subsidiaries elected to be taxed as REITs beginning with the calendar year ending December 31, 2015. The stock of the REIT subsidiaries, and dividends received from the REIT subsidiaries, will qualify under the asset tests and income tests, respectively, as described above, provided that such subsidiaries maintain their REIT qualification. Some of the subsidiaries are classified as qualified REIT subsidiaries, which we refer to as QRSs. Code Section 856 (i) provides that a corporation that is a QRS shall not be treated as a separate corporation, and all assets, liabilities, and items of income, deduction, and credit of a qualified REIT subsidiary shall be treated as assets, liabilities and such items (as the case may be) of the REIT. Thus, in applying the tests for REIT qualification described above, the QRSs will be ignored, and all assets, liabilities and items of income, deduction, and credit of such QRSs will be treated as our assets, liabilities and items of income, deduction, and credit. Some of the subsidiaries are classified as TRSs. As described above, a TRS may earn income that would not be qualifying income if earned directly by the parent REIT; however, no more than 25% of the value of a REIT’s assets may consist of securities of one or more TRSs and, with respect to taxable years beginning after December 31, 2017, no more than 20% of the value of a REIT’s assets may consist of securities of one or more TRSs. One or more of our TRSs hold a number of assets that cannot be owned directly by a REIT. The value of the securities of our TRSs is far less than the permitted percentage thresholds described in this section. Some of the subsidiaries are classified as partnerships. In the case of a REIT that is a partner in a partnership, such REIT is treated as owning its proportionate share of the assets of the partnership and as earning its allocable share of the gross income of the partnership for purposes of the applicable REIT qualification tests. Thus, our proportionate share of the assets, liabilities, and items of income of any partnership, joint venture, or limited liability company that is treated as a partnership for federal income tax purposes in which we own an interest, directly or indirectly, will be treated as our assets and gross income for purposes of applying the various REIT qualification requirements. See “Tax Aspects of Our Investments in our Operating Partnership and Subsidiary Partnerships” below. 12 Tax Aspects of Investments in our Operating Partnership and Subsidiary Partnerships The following discussion summarizes certain federal income tax considerations applicable to our direct or indirect investments in our operating partnership and any subsidiary partnerships or limited liability companies that we form or acquire including such subsidiary partnerships or limited liability companies that are treated as disregarded for income tax purposes (collectively, “Omega OP”). This discussion does not cover state or local tax laws or any federal tax laws other than income tax laws. Classification as Partnerships. We will be entitled to include in our income our distributive share of each item of Omega OP’s income and to deduct our distributive share of each item of Omega OP’s losses only if Omega OP is classified for federal income tax purposes as a partnership (or an entity that is disregarded for federal income tax purposes if the entity is treated as having only one owner for federal income tax purposes) rather than as a corporation or an association taxable as a corporation. An unincorporated entity with at least two owners or members will be classified as a partnership, rather than as a corporation, for federal income tax purposes if it: • • is treated as a partnership under the Treasury Regulations relating to entity classification (the “check-the-box regulations”); and is not a “publicly-traded partnership.” Under the check-the-box regulations, an unincorporated entity with at least two owners or members may elect to be classified either as an association taxable as a corporation or as a partnership. If such an entity fails to make an election, it generally will be treated as a partnership (or an entity that is disregarded for federal income tax purposes if the entity is treated as having only one owner for federal income tax purposes) for federal income tax purposes. Omega OP intends to be classified as a partnership for federal income tax purposes and will not elect to be treated as an association taxable as a corporation under the check-the-box regulations. A publicly traded partnership is a partnership whose interests are traded on an established securities market or are readily tradable on a secondary market or the substantial equivalent thereof. A partnership whose interests are traded on an established securities market or are readily tradable on a secondary market or the substantial equivalent thereof, and thus will be characterized as a publicly traded partnership that is characterized as a corporation for U.S. federal income tax purposes, may avoid characterization as a corporation for any taxable year if, for each taxable year beginning after December 31, 1987, in which it was classified as a publicly traded partnership, 90% or more of the partnership’s gross income for such year consists of certain passive-type income, including real property rents, gains from the sale or other disposition of real property, interest, and dividends (the “Qualifying Income Exception”). The Treasury Regulations provide limited safe harbors under which certain transfers of interests in the partnership may be ignored or not taken into account in the determination of whether a partnership’s interests are considered to be readily tradable on a secondary market or the substantial equivalent thereof (the “PTP Transfer Exceptions”). Omega OP’s partnership agreement contains provisions enabling its general partner to take such steps as are necessary or appropriate to prevent the issuance and transfers of interests in Omega OP that do not satisfy one of the PTP Transfer Exceptions, and thus, cause Omega OP to be treated as a publicly traded partnership. To date, we believe that all transfers of Omega OP Units have satisfied one of the PTP Transfer Exceptions. However, even if the transfers of Omega OP Units failed to qualify for any of the PTP Transfer Exceptions, and Omega OP was considered to be a publicly traded partnership, we believe that Omega OP would have sufficient qualifying income to satisfy the Qualifying Income Exception, and therefore, would not be treated as a corporation for U.S. federal income tax purposes. We have not requested, and do not intend to request, a ruling from the IRS that Omega OP will be classified as a partnership and not as a corporation for federal income tax purposes. If for any reason the Omega OP were taxable as a corporation, rather than as a partnership, for U.S. federal income tax purposes, we likely would not be able to qualify as a REIT unless we qualified for certain relief provisions. See the discussions entitled “Failure to Satisfy Income Tests,” “Asset Tests” and “Failure to Qualify” set forth above. In addition, any change in a partnership’s status for tax purposes might be treated as a taxable event, in which case we might incur tax liability without any related cash distribution. See “Annual Distribution Requirements” above. Further, items of income and deduction of such partnership would not 13 pass through to its partners, and its partners would be treated as stockholders for tax purposes. Consequently, such partnership would be required to pay income tax at corporate rates on its net income, and distributions to its partners would constitute dividends that would not be deductible in computing such partnership’s taxable income. Partners, Not the Partnerships, Subject to Tax. A partnership is not a taxable entity for federal income tax purposes. Rather, we are required to take into account our allocable share of each item of Omega OP’s income, gains, losses, deductions, and credits for any taxable year of Omega OP ending within or with our taxable year, without regard to whether we have received or will receive any distribution from Omega OP. Partnership Allocations. Although a partnership agreement generally will determine the allocation of income and losses among partners, such allocations will be disregarded for tax purposes if they do not comply with the provisions of the Code and Treasury Regulations governing partnership allocations. If an allocation is not recognized for federal income tax purposes, the item subject to the allocation will be reallocated in accordance with the partners’ interests in the partnership, which will be determined by taking into account all of the facts and circumstances relating to the economic arrangement of the partners with respect to such item. Tax Allocations With Respect to Partnership Properties. Income, gain, loss, and deduction attributable to property that has appreciated or depreciated that is contributed to a partnership in exchange for an interest in the partnership must be allocated in a manner such that the contributing partner is charged with, or benefits from, respectively, the unrealized gain or unrealized loss associated with the property at the time of the contribution (the ”704(c) Allocations”). The amount of such unrealized gain or unrealized loss, referred to as “built-in gain” or “built-in loss”, generally is equal to the difference between the fair market value of the contributed property at the time of contribution and the adjusted tax basis of such property at the time of contribution (a “book-tax difference”). Allocations with respect to book-tax differences are solely for federal income tax purposes and do not affect the book capital accounts or other economic or legal arrangements among the partners. A book-tax difference attributable to depreciable property generally is decreased on an annual basis as a result of the allocation of depreciation deductions to the contributing partner for book purposes but not for tax purposes. The Treasury Regulations require entities taxed as partnerships to use a “reasonable method” for allocating items with respect to which there is a book-tax difference and outline several reasonable allocation methods. Any gain or loss recognized by Omega OP on the disposition of contributed properties will be allocated first to the partners of Omega OP who contributed such properties to the extent of their built-in gain or loss on those properties for federal income tax purposes. The partners’ built-in gain or loss on such contributed properties will equal the difference between the partners’ proportionate share of the book value of those properties and the partners’ tax basis allocable to those properties at the time of the contribution as reduced for any decrease in the book-tax difference. Any remaining gain or loss recognized by Omega OP on the disposition of the contributed properties, and any gain or loss recognized by Omega OP on the disposition of the other properties, generally will be allocated among the partners in accordance with the partnership agreement, unless such allocations and agreement do not satisfy the requirements of applicable Treasury Regulations, in which case the allocation will be made in accordance with the partners’ interests in the partnership. On April 1, 2015, we acquired substantially all of the assets of Aviv, through a merger of Aviv, with and into our wholly-owned subsidiary, which merger included a combination which resulted in the acquisition by Omega OP of substantially all of our assets and all of the assets of Aviv Healthcare Properties Limited Partnership. We treated such transfer of the properties to Omega OP as a contribution to which Omega OP received a “carryover” tax basis in the contributed properties. As a result, such properties had significant built-in gain or loss subject to Section 704(c) of the Code. As the general partner of Omega OP, we may account for the book-tax difference with respect to the properties contributed to Omega OP under any method approved by Section 704(c) of the Code and the Treasury Regulations, except with respect to those properties acquired by Omega OP that were contributed by Aviv REIT, Inc., with respect to which Omega OP elected to use the “remedial method” of allocation pursuant to Treasury Regulations Section 1.704-3(d). 14 Sale of a Partnership’s Property. Generally, any gain realized by a partnership on the sale of property held by the partnership for more than one year will be long-term capital gain, except for any portion of such gain that is treated as depreciation or cost recovery recapture. Our share of any gain realized by Omega OP on the sale of any property held by Omega OP as inventory or other property held primarily for sale to customers in the ordinary course of Omega OP’s trade or business will be treated as income from a prohibited transaction that is subject to a 100% penalty tax. Such prohibited transaction income also may have an adverse effect upon our ability to satisfy the income tests for REIT status. See “Income Tests” above. We do not presently intend to acquire or hold or to allow Omega OP to acquire or hold any property that represents inventory or other property held primarily for sale to customers in the ordinary course of Omega OP’s trade or business. Government Regulation and Reimbursement The healthcare industry is heavily regulated. Our operators are subject to extensive and complex federal, state and local healthcare laws and regulations. These laws and regulations are subject to frequent and substantial changes resulting from the adoption of new legislation, rules and regulations, and administrative and judicial interpretations of existing law. The ultimate timing or effect of these changes, which may be applied retroactively, cannot be predicted. Changes in laws and regulations impacting our operators, in addition to regulatory non-compliance by our operators, can have a significant effect on the operations and financial condition of our operators, which in turn may adversely impact us. The following is a discussion of certain laws and regulations generally applicable to our operators, and in certain cases, to us. Healthcare Reform. A substantial amount of rules and regulations have been issued under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education and Reconciliation Act of 2010 (collectively referred to as the “Healthcare Reform Law”). We expect additional rules, regulations and interpretations under the Healthcare Reform Law to be issued that may materially affect our operators’ financial condition and operations. For example, the new administration and certain members of Congress have affirmatively indicated that they will pursue full repeal of, or significant amendment to, the Healthcare Reform Law. Even if the Healthcare Reform Law is not amended or repealed, the new administration could propose changes impacting implementation of the Healthcare Reform Law. The ultimate composition and timing of any legislation enacted under the new administration that would impact the current implementation of the Healthcare Reform Law remains uncertain. Given the complexity of the Healthcare Reform Law and the substantial requirements for regulation thereunder, the impact of the Healthcare Reform Law on our operators or their ability to meet their obligations to us cannot be predicted, whether in its current form or as amended or repealed. Reform Requirements for Long-Term Care Facilities. On October 4, 2016, the Centers for Medicare and Medicaid Services (“CMS”) issued a final rule modifying the conditions of participation in Medicare and Medicaid for SNFs. CMS stated that the regulations, last updated in 1991, were “necessary to reflect the substantial advances that had been made over the past several years in the theory and practice of service delivery and safety” within long-term care. The extensive modifications require SNFs to implement new processes; make changes to current practices; and create new policies and procedures within a short timeframe to remain in compliance with their conditions for participation. Changes include provisions related to staff training, discharge planning, infection prevention and control programs, and pharmacy services, among others. While many of the regulations become effective on November 28, 2016, some of the regulations become effective in Phase 2, beginning on November 28, 2017, with others becoming effective in Phase 3, beginning on November 28, 2019. According to CMS, it is estimated that the average cost for a SNF to implement the new regulations is estimated to be $62,900 the first year and $55,000 each year thereafter. Reimbursement Generally. A significant portion of our operators’ revenue is derived from government-funded reimbursement programs, consisting primarily of Medicare and Medicaid. As federal and state governments focus on healthcare reform initiatives, and as the federal government and many states face significant current and future budget deficits, efforts to reduce costs by government payors will likely continue, which may result in reductions in reimbursement at both the federal and state levels. Additionally, new and evolving payor and provider programs, including but not limited to Medicare Advantage, dual eligible, accountable care organizations, and bundled payments could adversely impact our tenants’ and operators’ liquidity, financial condition or results of operations. 15 We currently believe that our operator coverage ratios are adequate and that our operators can absorb moderate reimbursement rate reductions and still meet their obligations to us. However, significant limits on the scope of services reimbursed and/or reductions of reimbursement rates could have a material adverse effect on our operators’ results of operations and financial condition, which could adversely affect our operators’ ability to meet their obligations to us. Medicaid. State budgetary concerns, coupled with the implementation of rules under the Healthcare Reform Law, or prospective changes to the Healthcare Reform Law under the new administration, may result in significant changes in healthcare spending at the state level. Many states are currently focusing on the reduction of expenditures under their state Medicaid programs, which may result in a reduction in reimbursement rates for our operators. The need to control Medicaid expenditures by the states may be exacerbated by the potential for increased enrollment in Medicaid due to unemployment and declines in family incomes. Since our operators’ profit margins on Medicaid patients are generally relatively low, more than modest reductions in Medicaid reimbursement or an increase in the number of Medicaid patients could adversely affect our operators’ results of operations and financial condition, which in turn could negatively impact us. The Healthcare Reform Law provided for Medicaid coverage to be expanded to all individuals under age 65 with incomes up to 133% of the federal poverty level, beginning January 1, 2014. While the federal government committed to paying the entire cost for Medicaid coverage for newly eligible beneficiaries from 2014 through 2016, the federal share declines to 95% in 2017, 94% in 2018, 93% in 2019, and 90% in 2020 and subsequent years. Although the Supreme Court ruled on June 28, 2012 that states could not be required to expand Medicaid or risk losing federal funding of their existing Medicaid programs, as of December 31, 2016, thirty-one (31) states and the District of Columbia have expanded Medicaid eligibility with additional states continuing to consider expansion. Medicare. On July 29, 2016, CMS issued a final rule regarding the fiscal year (“FY”) 2017 Medicare payment rates and quality programs for SNFs, which continues the trend of shifting Medicare payments from volume to value. Aggregate payments to SNFs effective October 1, 2016 for FY 2017 were expected to increase by $920 million, or 2.4%, over FY 2016 payments. This reimbursement increase is attributable to a 2.7% market basket increase, reduced by 0.3% in accordance with the multifactor productivity adjustment required by law. In addition to FY 2017 Medicare payment rates, SNFs continue to be impacted by the “Bipartisan Budget Act of 2015” (“BBA”) signed on November 2, 2015 which provided $80 billion in discretionary spending sequestration relief over two years, and extended Medicare sequestration, which generally cuts Medicare provider and plan payments by 2% across the board, for an additional year, through 2025. The FY 2025 sequestration will be “front loaded,” such that a 4% reduction will apply during the first six months of the fiscal year and no reduction will be imposed during the second half of the fiscal year. Furthermore, the “Medicare Access and CHIP Reauthorization Act of 2015” continues to have the potential to negatively impact Medicare revenues through the extension of the Medicare therapy cap exceptions process through December 31, 2017; modification of the requirement for manual medical review for services over the $3,700 therapy thresholds; and extension of the application of therapy caps, and related provisions, to outpatient hospitals until January 1, 2018. The statutory Medicare Part B outpatient cap for occupational therapy is $1,980 for 2017, with the combined cap for physical therapy and speech therapy also set at $1,980 for 2017. While the caps do not apply to therapy services covered under Medicare Part A for SNFs and the exception process permits medically necessary therapy services beyond the cap limits, the caps apply in most other circumstances involving patients in SNFs or long-term care facilities who receive therapy services covered under Medicare Part B. Expiration of the therapy cap exceptions process in the future could have a material adverse effect on our operators’ financial condition and operations, which could adversely impact their ability to meet their obligations to us. As indicated above, reimbursement methodology reforms, such as value-based purchasing, continue to be increasingly prevalent and attempt to hold providers accountable for the cost and quality of care provided by redistributing a portion of a provider or facility’s reimbursement based on the relative performance on designated economic, satisfaction metrics. These reimbursement methodologies and similar programs are expected to expand, both in public and commercial health plans. clinical quality, and patient 16 For example, the “Protecting Access to Medicare Act of 2014” called for the U.S. Department of Health and Human Services (“HHS”) to develop a value based purchasing program for SNFs aimed at tying a reimbursement adjustment to lower readmission rates effective October 1, 2018, and on April 26, 2015, CMS announced its goal to have 30% of Medicare payments for quality and value through alternative payment models such as accountable care organizations or bundled payments by the end of 2016 and up to 50% by the end of 2018. In March 2016, CMS announced that its 30% target for 2016 had already been reached. Additionally, CMS’s bundled payment program for Lower Extremity Joint Replacement (“CJR”) procedures went into effect on April 1, 2016, and is mandatory for all hospitals paid under the Medicare Inpatient Prospective Payment System that are located in the 67 selected metropolitan statistical areas. Through this bundled payment model, hospitals in the 67 selected metropolitan areas receive additional payments if quality and costs exceed defined parameters or, if not, must repay Medicare for a portion of the spending. On July 25, 2016, CMS proposed rulemaking to extend the CJR bundled payment models effective July 1, 2017 for both hip/femur fracture surgeries in the same 67 metropolitan as well as additional bundled payment models for heart attacks and bypass surgeries in 98 randomly selected metropolitan statistical areas. SNFs receiving Medicare revenues related to hospital discharges subject to CJR bundled payment programs in the identified geographic areas could be either positively or negatively affected by the CJR bundled payment program. Quality of Care Initiatives. In addition to quality or value based reimbursement reforms, CMS has implemented a number of initiatives focused on the quality of care provided by long term care facilities that could affect our operators. On December 2008, CMS released quality ratings for all of the nursing homes that participate in Medicare or Medicaid under its “Five Star Quality Rating System.” Facility rankings, ranging from five stars (“much above average”) to one star (“much below average”) are updated on a monthly basis. SNFs are required to provide information for the CMS Nursing Home Compare website regarding staffing and quality measures. Based on this data and the results of state health inspections, SNFs are then rated based on the five-star rating system. In August 2016, CMS announced a modification to the Five Star Quality Rating System through the introduction of new quality measures based primarily on Medicare claims data submitted by hospitals, including: (1) percentage of short-stay residents who were successfully discharged to the community; short-stay residents who have had an outpatient emergency department visit; (2) percentage of (3) percentage of short-stay residents who were re-hospitalized after a nursing home admission; (4) percentage of short-stay residents who made improvements in function; and (5) percentage of long-stay residents whose ability to move independently worsened. These ratings were incorporated into the nursing home rating system in July 2016 and were phased in through January 2017. Effective September 1, 2016, SNFs that received a Five Star Quality Indicators Survey deficiency cited at a Scope and Severity level J or higher are automatically and immediately assessed civil monetary penalties by CMS, with no opportunity to correct the deficiencies to avoid the heightened and costly monetary penalties. It is possible that this or any other ranking system could lead to future reimbursement policies that reward or penalize facilities on the basis of the reported quality of care parameters. Office of the Inspector General Activities. The Office of Inspector General’s (the “OIG”) Work Plan for government fiscal year 2017, which describes projects that the OIG plans to address during the fiscal year, includes seven projects related specifically to nursing homes: (1) determining to what extent State agencies investigate serious nursing home complaints within the required timeframes; (2) unreported incidents of potential abuse and neglect in SNFs; (3) review of SNF Medicare reimbursement documentation (determine if it meets requirements for each particular resource utilization group); (4) the SNF Adverse Event Screening Tool, which will disseminate practical information about the SNF Adverse Event Trigger Tool; (5) review of the National Background Check Program for long-term care employees; (6) compliance with the SNF prospective payment system requirement related to a three-day qualifying inpatient hospital stay; and (7) review of potentially avoidable hospitalizations of Medicare and Medicaid-Eligible nursing facility residents and prevention and detection services provided by nursing homes. Department of Justice. SNFs are under intense scrutiny for the quality of care being rendered to residents and appropriate billing practices. The Department of Justice launched ten regional Elder Justice Task Forces in 2016 which are coordinating and enhancing efforts to pursue SNFs that provide grossly 17 substandard care to their residents. They are also focusing on therapy billing issues. These Task Forces are composed of representatives from the U.S. Attorneys’ Offices, State Medicaid Fraud Control Units, state and local prosecutors’ offices, HHS, State Adult Protective Services agencies, Long Term Care Ombudsmen programs, and law enforcement. Fraud and Abuse. There are various federal and state civil and criminal laws and regulations governing a wide array of healthcare provider referrals, relationships and arrangements, including laws and regulations prohibiting fraud by healthcare providers. Many of these complex laws raise issues that have not been clearly interpreted by the relevant governmental authorities and courts. These laws include: (i) federal and state false claims acts, which, among other things, prohibit providers from filing false claims or making false statements to receive payment from Medicare, Medicaid or other federal or state healthcare programs; (ii) federal and state anti-kickback and fee-splitting statutes, including the Medicare and Medicaid Anti-kickback statute, which prohibit the payment or receipt of remuneration to induce referrals or recommendations of healthcare items or services, such as services provided in a SNF; (iii) federal and state physician self-referral laws (commonly referred to as the Stark Law), which generally prohibit referrals by physicians to entities for designated health services (some of which are provided in SNFs) with which the physician or an immediate family member has a financial relationship; (iv) the federal Civil Monetary Penalties Law, which prohibits, among other things, the knowing presentation of a false or fraudulent claim for certain healthcare services and (v) federal and state privacy laws, including the privacy and security rules contained in the Health Insurance Portability and Accountability Act of 1996, which provide for the privacy and security of personal health information. Violations of healthcare fraud and abuse laws carry civil, criminal and administrative sanctions, imprisonment, denial of Medicare and Medicaid including punitive sanctions, monetary penalties, reimbursement and potential exclusion from Medicare, Medicaid or other federal or state healthcare programs. Additionally, there are criminal provisions that prohibit filing false claims or making false statements to receive payment or certification under Medicare and Medicaid, as well as failing to refund overpayments or improper payments. Violation of the Anti-kickback statute or Stark Law may form the basis for a federal False Claims Act violation. These laws are enforced by a variety of federal, state and local agencies and can also be enforced by private litigants through, among other things, federal and state false claims acts, which allow private litigants to bring qui tam or whistleblower actions, which have become more frequent in recent years. Privacy. Our operators are subject to various federal, state and local laws and regulations designed to protect the confidentiality and security of patient health information, including the federal Health Insurance Portability and Accountability Act of 1996, as amended, the Health Information Technology for (“HITECH”), and the corresponding regulations promulgated Economic and Clinical Health Act thereunder (collectively referred to herein as “HIPAA”). The HITECH Act expanded the scope of these provisions by mandating individual notification in instances of breaches of protected health information, providing enhanced penalties for HIPAA violations, and granting enforcement authority to states’ Attorneys General in addition to the HHS Office for Civil Rights. HHS continued its auditing program in 2016 to assess compliance efforts by covered entities and business associates. Through a second phase of audits, which commenced for covered entities in July 2016, HHS focused on a review of policies and procedures adopted and employed by covered entities and their business associates to meet selected standards and implementation specifications of the HIPAA Privacy, Security, and Breach Notification Rules. Various states have similar laws and regulations that govern the maintenance and safeguarding of patient records, charts and other information generated in connection with the provision of professional medical services. These laws and regulations require our operators to expend the requisite resources to secure protected health information, including the funding of costs associated with technology upgrades. Operators found in violation of HIPAA or any other privacy law or regulation may face large penalties. In addition, compliance with an operator’s notification requirements in the event of a breach of unsecured protected health information could cause reputational harm to an operator’s business. Licensing and Certification. Our operators and facilities are subject to various federal, state and local licensing and certification laws and regulations, including laws and regulations under Medicare and Medicaid requiring operators of SNFs and ALFs to comply with extensive standards governing operations. 18 Governmental agencies administering these laws and regulations regularly inspect our operators’ facilities and investigate complaints. Our operators and their managers receive notices of observed violations and deficiencies from time to time, and sanctions have been imposed from time to time on facilities operated by them. In addition, many states require certain healthcare providers to obtain a certificate of need, which requires prior approval for the construction, expansion or closure of certain healthcare facilities, which has the potential to impact some of our operators’ abilities to expand or change their businesses. Americans with Disabilities Act (the “ADA”). Our properties must comply with the ADA and any similar state or local laws to the extent that such properties are public accommodations as defined in those statutes. The ADA may require removal of barriers to access by persons with disabilities in certain public areas of our properties where such removal is readily achievable. Should barriers to access by persons with disabilities be discovered at any of our properties, we may be directly or indirectly responsible for additional costs that may be required to make facilities ADA-compliant. Noncompliance with the ADA could result in the imposition of fines or an award of damages to private litigants. Our commitment to make readily achievable accommodations pursuant to the ADA is ongoing, and we continue to assess our properties and make modifications as appropriate in this respect. Other Laws and Regulations. Additional federal, state and local laws and regulations affect how our operators conduct their operations, including laws and regulations protecting consumers against deceptive practices and otherwise generally affecting our operators’ management of their property and equipment and the conduct of their operations (including laws and regulations involving fire, health and safety; quality of services, including care and food service; residents’ rights, including abuse and neglect laws; and the health standards set by the federal Occupational Safety and Health Administration). General and Professional Liability. Although arbitration agreements have been effective in limiting general and professional liabilities for SNF and long term care providers, there have been numerous lawsuits challenging the validity of arbitration agreements in long term care settings. As set forth in the recent conditions of participation final rule issued on October 4, 2016, pre-dispute arbitration agreements between SNFs and residents are prohibited by CMS effective November 28, 2016, thereby increasing potential liabilities for SNFs and long-term care providers. However, the authority of CMS to restrict the rights of these parties to arbitrate is uncertain as the prohibition on pre-dispute arbitration agreements is being challenged by litigation in various jurisdictions. Executive Officers of Our Company As of February 1, 2017, the executive officers of our company were as follows: C. Taylor Pickett (55) is our Chief Executive Officer and has served in this capacity since June 2001. Mr. Pickett has also served as Director of the Company since May 30, 2002. Mr. Pickett’s term as a Director expires in 2017. Mr. Pickett has also been a member of the board of trustees of Corporate Office Properties Trust, an office REIT focusing on U.S. government agencies and defense contractors, since November 2013. From January 1993 to June 2001, Mr. Pickett served as a member of the senior management team of Integrated Health Services, Inc., most recently as Executive Vice President and Chief Financial Officer. Prior to joining Integrated Health Services, Inc. Mr. Pickett held various positions at PHH Corporation and KPMG Peat Marwick. Daniel J. Booth (53) is our Chief Operating Officer and has served in this capacity since October 2001. From 1993 to October 2001, Mr. Booth served as a member of the management team of Integrated Health Services, Inc., most recently serving as Senior Vice President, Finance. Prior to joining Integrated Health Services, Inc., Mr. Booth served as a Vice President in the Healthcare Lending Division of Maryland National Bank (now Bank of America). Steven J. Insoft (52) is our Chief Corporate Development Officer and has served in this capacity since April 1, 2015. Mr. Insoft served as President and Chief Operating Officer of Aviv REIT, Inc. since 2012, while previously serving as Chief Financial Officer and Treasurer. Prior to joining Aviv REIT, Inc. in 2005, Mr. Insoft spent eight years as a Vice President and Senior Investment Officer of Nationwide Health Properties, Inc., a publicly-traded REIT. Before that, he was President and Chief Financial Officer of CMI 19 Senior Housing & Healthcare, Inc., a privately-held nursing home and assisted living facility operations and development company, for seven years. Mr. Insoft received an M.B.A. from Columbia University and a B.S.E. in Electrical Engineering from the University of Pennsylvania. Robert O. Stephenson (53) is our Chief Financial Officer and has served in this capacity since August 2001. From 1996 to July 2001, Mr. Stephenson served as the Senior Vice President and Treasurer of Integrated Health Services, Inc. Prior to joining Integrated Health Services, Inc., Mr. Stephenson held various positions at CSX Intermodal, Inc., Martin Marietta Corporation and Electronic Data Systems. Michael D. Ritz (48) is our Chief Accounting Officer and has served in this capacity since February 2007. From April 2005 to February 2007, Mr. Ritz served as the Vice President, Accounting & Assistant Corporate Controller of Newell Rubbermaid Inc., and from August 2002 to April 2005, Mr. Ritz served as the Director, Financial Reporting of Newell Rubbermaid Inc. From July 2001 through August 2002, Mr. Ritz served as the Director of Accounting and Controller of Novavax Inc. As of December 31, 2016, we had 60 full-time employees, including the five executive officers listed above. Item 1A — Risk Factors Following are some of the risks and uncertainties that could cause the Company’s financial condition, results of operations, business and prospects to differ materially from those contemplated by the forward-looking statements contained in this report or the Company’s other filings with the SEC. These risks should be read in conjunction with the other risks described in this report, including but not limited to those described in “Taxation” and “Government Regulation and Reimbursement” under “Item 1” above. The risks described in this report are not the only risks facing the Company and there may be additional risks of which the Company is not presently aware or that the Company currently considers unlikely to significantly impact the Company. Our business, financial condition, results of operations or liquidity could be materially adversely affected by any of these risks, and, as a result, the trading price of our common stock could decline. Risks Related to the Operators of Our Facilities Our financial position could be weakened and our ability to make distributions and fulfill our obligations with respect to our indebtedness could be limited if our operators, or a portion thereof, become unable to meet their obligations to us or fail to renew or extend their relationship with us as their lease terms expire or their mortgages mature, or if we become unable to lease or re-lease our facilities or make mortgage loans on economically favorable terms. We have no operational control over our operators. Adverse developments concerning our operators could arise due to a number of factors, including those listed below. The bankruptcy or insolvency of our operators could limit or delay our ability to recover on our investments. We are exposed to the risk that a distressed or insolvent operator may not be able to meet its lease, loan, mortgage or other obligations to us or other third parties. This risk is heightened during a period of economic or political instability. Although each of our lease and loan agreements typically provides us with the right to terminate, evict an operator, foreclose on our collateral, demand immediate payment and exercise other remedies upon the bankruptcy or insolvency of an operator, title 11 of the United States Code (the “Bankruptcy Code”) would limit or, at a minimum, delay our ability to collect unpaid pre-bankruptcy rents and mortgage payments and to pursue other remedies against a bankrupt operator. While we sometimes have third party guarantees of an operator’s lease or loan obligations, such guarantees can be expensive to enforce, and have their own risks of collection as against the guarantors. Leases. A bankruptcy filing by one of our lessee operators would typically prevent us from collecting unpaid pre-bankruptcy rents or evicting the operator, absent approval of the bankruptcy court. The Bankruptcy Code provides a lessee with the option to assume or reject an unexpired lease within certain specified periods of time. Generally, a lessee is required to pay all rent that becomes payable between the date of its bankruptcy filing and the date of the assumption or rejection of the lease (although such payments will likely be delayed as a result of the bankruptcy filing). If one of our lessee operators chooses 20 to assume its lease with us, the operator must promptly cure all monetary defaults existing under the lease (including payment of unpaid pre-bankruptcy rents) and provide adequate assurance of its ability to perform its future lease obligations. Even where a lessee operator assumes its lease with us, it will first often threaten to reject that lease to obtain better lease terms from us, and we sometimes have to consider making, or we do make, such economic concessions to avoid rejection of the lease and our taking a closed facility back. If one of our lessee operators opts to reject its lease with us, we would have a claim against such operator for unpaid and future rents payable under the lease, but such claim would be subject to a statutory “cap” under the Bankruptcy Code, and would likely result in a recovery substantially less than the face value of such claim. Although the operator’s rejection of the lease would permit us to recover possession of the leased facility, we would likely face losses, costs and delays associated with repairs and/or maintenance of the facility and then re-leasing the facility to a new operator, or costs associated with selling the facility. In any event, re-leasing a facility or selling it could take a material amount of time, and the pool of interested and qualified tenants or buyers will be limited due to the unique nature of our properties, which may depress values and our eventual recovery. Finally, whether a lease operator in bankruptcy ends up assuming or rejecting our lease, we will incur legal and collection costs, which can be difficult or impossible to recover. Several other factors could impact our rights under leases with bankrupt operators. First, the operator could seek to assign its lease with us to a third party. The Bankruptcy Code disregards anti-assignment provisions in leases to permit the assignment of unexpired leases to third parties (provided all monetary defaults under the lease are promptly cured and the assignee can demonstrate its ability to perform its obligations under the lease). Second, in instances in which we have entered into a master lease agreement with an operator that operates more than one facility, the bankruptcy court could determine that the master lease was comprised of separate, divisible leases (each of which could be separately assumed or rejected), rather than a single, integrated lease (which would have to be assumed or rejected in its entirety). Finally, the bankruptcy court could re-characterize our lease agreement as a disguised financing arrangement, which could require us to receive bankruptcy court approval to foreclose or pursue other remedies with respect to the facility. Mortgages. A bankruptcy filing by an operator to which we have made a loan secured by a mortgage would typically prevent us from collecting unpaid pre-bankruptcy mortgage payments and foreclosing on our collateral, absent approval of the bankruptcy court. As an initial matter, we could ask the bankruptcy court to order the operator to make periodic payments or provide other financial assurances to us during the bankruptcy case (known as “adequate protection”), but the ultimate decision regarding “adequate protection” (including the timing and amount of any “adequate protection” payments) rests with the bankruptcy court. In addition, we would need bankruptcy court approval before commencing or continuing any foreclosure action against the operator’s collateral (including a facility). The bankruptcy court could withhold such approval, especially if the operator can demonstrate that the facility or other collateral is necessary for an effective reorganization and that we have a sufficient “equity cushion” in the facility or that we are otherwise protected from any diminution in value of the collateral. If the bankruptcy court does not either grant us “adequate protection” or permit us to foreclose on our collateral, we may not receive any loan payments until after the bankruptcy court confirms a plan of reorganization for the operator. In addition, in any bankruptcy case of an operator to which we have made a loan, the operator may seek bankruptcy court approval to pay us (i) over a longer period of time than the terms of our loan, (ii) at a different interest rate, and/or (iii) for only the value of the collateral, instead of the full amount of the loan. Finally, even if the bankruptcy court permits us to foreclose on the facility, we would still be subject to the losses, costs and other risks associated with a foreclosure sale, including possible successor liability under government programs, indemnification obligations and suspension or delay of third-party payments. Should such events occur, our income and cash flow from operations would be adversely affected. Failure by our operators to comply with various local, state and federal government regulations may adversely impact their ability to make debt or lease payments to us. Our operators are subject to numerous federal, state and local laws and regulations, including those described below, that are subject to frequent and substantial changes (sometimes applied retroactively) resulting from new legislation, adoption of rules and regulations, and administrative and judicial interpretations of existing law. The ultimate timing or effect of these changes cannot be predicted. These 21 changes may have a dramatic effect on our operators’ costs of doing business and on the amount of reimbursement by both government and other third-party payors. The failure of any of our operators to comply with these laws, requirements and regulations could adversely affect their ability to meet their obligations to us. • • • • Reimbursement; Medicare and Medicaid. A significant portion of our operators’ revenue is derived from governmentally-funded reimbursement programs, primarily Medicare and Medicaid. See “Item 1. Business – Government Regulation and Reimbursement – Healthcare Reform,” “– Reimbursement,” “– Medicaid,” and ”– Medicare,” and the risk factor entitled “Our operators depend on reimbursement from governmental and other third-party payors, and reimbursement rates from such payors may be reduced” for a further discussion on governmental and third-party payor reimbursement and the associated risks presented to our operators. Failure to maintain certification in these programs would result in a loss of reimbursement from such programs and could result in a reduction in an operator’s revenues and operating margins, thereby negatively impacting an operator’s ability to meet its obligations to us. Quality of Care Initiatives. The CMS has implemented a number of initiatives focused on the quality of care provided by nursing homes that could affect our operators, including a quality rating system for nursing homes. See “Item 1. Business – Government Regulation and Reimbursement – Quality of Care Initiatives.” Any unsatisfactory rating of our operators under any rating system promulgated by the CMS could result in the loss of our operators’ residents or lower reimbursement rates, which could adversely impact their revenues and our business. governing operations. See “Item 1. Business – Government Regulation licensing and certification laws and regulations, Licensing and Certification. Our operators and facilities are subject to various federal, state and local including laws and regulations under Medicare and Medicaid requiring operators of SNFs and ALFs to comply with extensive and standards Reimbursement – Licensing and Certification.” Governmental agencies administering these laws and regulations regularly inspect our operators’ facilities and investigate complaints. Our operators and their managers receive notices of observed violations and deficiencies from time to time, and sanctions have been imposed from time to time on facilities operated by them. Failure to obtain any required licensure or certification, the loss or suspension of any required licensure or certification, or any violations or deficiencies with respect to relevant operating standards may require a facility to cease operations or result in ineligibility for reimbursement until the necessary licenses or certifications are obtained or reinstated, or any such violations or deficiencies are cured. In such event, our revenues from these facilities could be reduced or eliminated for an extended period of time or permanently. Additionally, many states require certain healthcare providers to obtain a certificate of need, which requires prior approval for the construction, expansion, closure or change of ownership of certain healthcare facilities, which has the potential to impact some of our operators’ abilities to expand or change their businesses. Further, Medicare and Medicaid provider approvals, as applicable, may be needed prior to an operator’s change of ownership. Fraud and Abuse Laws and Regulations. There are various federal and state civil and criminal laws and regulations governing a wide array of healthcare provider referrals, relationships and arrangements, including laws and regulations prohibiting fraud by healthcare providers. Many of these complex laws raise issues that have not been clearly interpreted by the relevant governmental authorities and courts and are subject to change. In addition, federal and state governments are devoting increasing attention and resources to anti-fraud investigations and initiatives against healthcare providers, and provide for, among other things, claims to be filed by qui tam relators. See “Item 1. Business – Government Regulation and Reimbursement – Fraud and Abuse.” The violation by an operator of any of these extensive laws or regulations, including the Anti-kickback statute, False Claims Act and the Stark Law, could result in the imposition of criminal fines and imprisonment, civil monetary penalties, and exclusion from Medicare, Medicaid and all other federal and state healthcare programs. Such fines or penalties, in addition to expending considerable resources responding to an investigation or enforcement action, could adversely affect an operator’s financial position and jeopardize an operator’s ability to make lease or 22 • • • mortgage payments to us or to continue operating its facility. Additionally, many states have adopted or are considering legislative proposals similar to the federal anti-fraud and abuse laws, some of which extend beyond the Medicare and Medicaid programs to third-party payors, to prohibit the payment or receipt of remuneration for the referral of patients and physician self-referrals, regardless of whether the service was reimbursed by Medicare or Medicaid. Privacy Laws. Our operators are subject to federal, state and local laws and regulations designed to protect the privacy and security of patient health information, including HIPAA, among others. See “Item 1. Business – Government Regulation and Reimbursement – Privacy.” These laws and regulations require our operators to expend the requisite resources to protect and secure patient health information, including the funding of costs associated with technology upgrades. Operators found in violation of HIPAA or any other privacy or security law may face significant monetary penalties. In addition, a breach of unsecured protected health information could cause reputational harm to an operator’s business in addition to a material adverse effect on the operator’s financial position and cash flows. Other Laws. Other federal, state and local laws and regulations affect how our operators conduct their operations. See “Item 1. Business – Government Regulation and Reimbursement – Other Laws and Regulations.” We cannot predict the effect that the costs of complying with these laws may have on the revenues of our operators, and thus their ability to meet their obligations to us. Legislative and Regulatory Developments. Each year, legislative and regulatory proposals are introduced at the federal, state and local levels that, if adopted, would result in major changes to the healthcare system. See “Item 1. Business – Government Regulation and Reimbursement” in addition to the other risk factors set forth below. We cannot accurately predict whether any proposals will be adopted, and if adopted, what effect (if any) these proposals would have on our operators or our business. If we fail to effectively implement or appropriately adjust our operational and strategic initiatives with respect to the implementation of new laws and regulations, or do not do so as effectively as our competitors, our results of operations may be materially adversely affected. Changes to, or repeal of, the Healthcare Reform Law, which the new administration and certain members of Congress have affirmatively indicated that they will pursue, could materially and adversely affect our business and financial position, results of operations or cash flows. Even if the Healthcare Reform Law is not amended or repealed, the new administration could propose changes impacting implementation of the Healthcare Reform Law, which could materially and adversely affect our financial position or operations. However, the ultimate content, timing or effect of any potential future legislation enacted under the new administration cannot be predicted. Alternative payment models require certain changes to reimbursement and studies of reimbursement policies that may adversely affect payments to SNFs. Alternative payment models, as well as other legislative initiatives included in the Protecting Access to Medicare Act of 2014, have the potential affect Medicare payments to SNFs, including, but not limited to, provisions changing the payment methodology, setting reimbursement caps, implementing value-based purchasing and payment bundling, and studying the appropriateness of restrictions on payments for health care acquired conditions. Several commercial payors have expressed an intent to pursue certain value-based purchasing models and initiatives. These provisions are in various stages of implementation. See “Item 1. Business – Government Regulation and Reimbursement – Healthcare Reform,” “– Reimbursement,” and “– Medicare.” Although we cannot accurately predict the extent to which or how such provisions may be implemented, or the effect any such implementation would have on our operators or our business, these provisions could result in decreases in payments to our operators, increase our operators’ costs or otherwise adversely affect the results of operations or financial condition of our operators, thereby negatively impacting their ability to meet their obligations to us. The Healthcare Reform Law imposes additional requirements on SNFs regarding compliance and disclosure. The Healthcare Reform Law required SNFs to implement, by March 2013, a compliance and ethics program that is effective in preventing and detecting criminal, civil and administrative violations and in promoting quality of care. HHS included in Final Rule published on October 4, 2016 the requirement for 23 operators to implement a compliance and ethics program as a condition of participation in Medicare and Medicaid. Long-term care facilities, including SNFs, have until November 28, 2019 to comply. See “Item 1. Business – Government Regulation and Reimbursement – Reform Requirements for Long-Term Care Facilities” for a further discussion of the reform requirements set forth in the Final Rule. If our operators fall short in their compliance and ethics programs and quality assurance and performance improvement programs, if and when required, their reputations and ability to attract residents could be adversely affected. Our operators depend on reimbursement from governmental and other third-party payors, and reimbursement rates from such payors may be reduced. Changes in the reimbursement rate or methods of payment from third-party payors, including the Medicare and Medicaid programs, or the implementation of other measures to reduce reimbursements for services provided by our operators has in the past, and could in the future, result in a substantial reduction in our operators’ revenues and operating margins. Additionally, reimbursement from governmental and other third party payors could be reduced as part of retroactive adjustments during claims settlement processes or as result of post-payment audits. See “Item 1. Business – Government Regulation and Reimbursement – Reimbursement,” “– Medicaid,” and “– Medicare.” We currently believe that our operator coverage ratios are adequate and that our operators can absorb moderate reimbursement rate reductions and still meet their obligations to us. However, significant limits on the scope of services reimbursed and on reimbursement rates, as well as changes in reimbursement policies or other measures altering payment methodologies for services provided by our operators, could have a material adverse effect on our operators’ results of operations and financial condition, which could cause the revenues of our operators to decline and negatively impact their ability to meet their obligations to us. Additionally, net revenue realizable under third-party payor agreements can change after examination and retroactive adjustment by payors during the claims settlement processes or as a result of post-payment audits. Payors may disallow requests for reimbursement based on determinations that certain costs are not reimbursable or reasonable, additional documentation is necessary or certain services were not covered or were not medically necessary. New legislative and regulatory proposals could impose further limitations on government and private payments to healthcare providers. In some cases, states have enacted or are considering enacting measures designed to reduce Medicaid expenditures and to make changes to private healthcare insurance. We cannot make any assurances that adequate third-party payor reimbursement levels will continue to be available for the services provided by our operators. Government spending cuts could lead to a reduction in Medicare and Medicaid reimbursement. Approved or proposed cost-containment measures, spending cuts and tax reform initiatives have resulted or could result in changes (including substantial reductions in funding) to Medicare, Medicaid or Medicare Advantage Plans. Any such federal legislation that reduces reimbursement payments to healthcare providers could have a material adverse effect on certain of our operators’ liquidity, financial condition or results of operations, which could adversely affect their ability to satisfy their obligations to us and could have a material adverse effect on us. Additionally, as a result of state budget crises and financial shortfalls, many states are focusing on the reduction of expenditures under their Medicaid programs, which may result in a freeze on Medicaid rates or a reduction in reimbursement for our operators. See “Item 1. Business – Government Regulation and Reimbursement – Reimbursement,” “– Medicaid,” and “– Medicare.” These potential reductions could be compounded by the potential for federal cost-cutting efforts that could lead to reductions in reimbursement to our operators under both the Medicare and Medicaid programs. Potential reductions in Medicare and Medicaid reimbursement to our operators could reduce the cash flow of our operators and their ability to make rent or mortgage payments to us. The need to control Medicaid expenditures may be exacerbated by the potential for increased enrollment in Medicaid due to unemployment and declines in family incomes. Medicaid enrollment may continue to increase in the future, as the Healthcare Reform Law allowed states to increase the number of people who are eligible for Medicaid in 2014. Since our operators’ profit margins on Medicaid patients are generally relatively low, more than modest reductions in Medicaid reimbursement and an increase in the number of Medicaid rates 24 patients could place some operators in financial distress, which in turn could adversely affect us. If funding for Medicare and/or Medicaid is reduced, it could have a material adverse effect on our operators’ results of operations and financial condition, which could adversely affect our operators’ ability to meet their obligations to us. We may be unable to find a replacement operator for one or more of our leased properties. From time to time, we may need to find a replacement operator for one or more of our leased properties for a variety of reasons, including upon the expiration of the lease term or the occurrence of an operator default. During any period in which we are attempting to locate one or more replacement operators, there could be a decrease or cessation of rental payments on the applicable property or properties. We cannot assure you that any of our current or future operators will elect to renew their respective leases with us upon expiration of the terms thereof. Similarly, we cannot assure you that we will be able to locate a suitable replacement operator or, if we are successful in locating a replacement operator, that the rental payments from the new operator would not be significantly less than the existing rental payments. Our ability to locate a suitable replacement operator may be significantly delayed or limited by various state licensing, receivership, certificate of need or other laws, as well as by Medicare and Medicaid change-of-ownership rules. We also may incur substantial additional expenses in connection with any such licensing, receivership or change-of-ownership proceedings. Any such delays, limitations and expenses could materially delay or impact our ability to collect rent, obtain possession of leased properties or otherwise exercise remedies for default. Our operators may be subject to significant legal actions that could result in their increased operating costs and substantial uninsured liabilities, which may affect their ability to meet their obligations to us. Our operators may be subject to claims for damages relating to the services that they provide. We can give no assurance that the insurance coverage maintained by our operators will cover all claims made against them or continue to be available at a reasonable cost, if at all. In some states, insurance coverage for the risk of punitive damages arising from professional and general liability claims and/or litigation may not, in certain cases, be available to operators due to state law prohibitions or limitations of availability. As a result, our operators operating in these states may be liable for punitive damage awards that are either not covered or are in excess of their insurance policy limits. We also believe that there has been, and will continue to be, an increase in governmental investigations of long-term care providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Insurance is not available to our operators to cover such losses. Any adverse determination in a legal proceeding or governmental investigation, whether currently asserted or arising in the future, could have a material adverse effect on an operator’s financial condition. If an operator is unable to obtain or maintain insurance coverage, if judgments are obtained in excess of the insurance coverage, if an operator is required to pay uninsured punitive damages, or if an operator is subject to an uninsurable government enforcement action, the operator could be exposed to substantial additional liabilities. Such liabilities could adversely affect the operator’s ability to meet its obligations to us. In addition, we may in some circumstances be named as a defendant in litigation involving the services provided by our operators. Although we generally have no involvement in the services provided by our operators, and our standard lease agreements and loan agreements generally require our operators to indemnify us and carry insurance to cover us in certain cases, a significant judgment against us in such litigation could exceed our and our operators’ insurance coverage, which would require us to make payments to cover the judgment. Increased competition as well as increased operating costs result in lower revenues for some of our operators and may affect the ability of our operators to meet their obligations to us. The long-term healthcare industry is highly competitive and we expect that it may become more competitive in the future. Our operators are competing with numerous other companies providing similar healthcare services or alternatives such as home health agencies, life care at home, community-based service programs, retirement communities and convalescent centers. Our operators compete on a number of 25 different levels including the quality of care provided, reputation, the physical appearance of a facility, price, the range of services offered, family preference, alternatives for healthcare delivery, the supply of competing properties, physicians, staff, referral sources, location and the size and demographics of the population in the surrounding areas. We cannot be certain that the operators of all of our facilities will be able to achieve occupancy and rate levels that will enable them to meet all of their obligations to us. Our operators may encounter increased competition in the future that could limit their ability to attract residents or expand their businesses and therefore affect their ability to pay their lease or mortgage payments. In addition, the market for qualified nurses, healthcare professionals and other key personnel is highly competitive and our operators may experience difficulties in attracting and retaining qualified personnel. Increases in labor costs due to higher wages and greater benefits required to attract and retain qualified healthcare personnel incurred by our operators could affect their ability to meet their obligations to us. This situation could be particularly acute in certain states that have enacted legislation establishing minimum staffing requirements. We may be unable to successfully foreclose on the collateral securing our mortgage loans, and even if we are successful in our foreclosure efforts, we may be unable to successfully find a replacement operator, or operate or occupy the underlying real estate, which may adversely affect our ability to recover our investments. If an operator defaults under one of our mortgage loans, we may foreclose on the loan or otherwise protect our interest by acquiring title to the property. In such a scenario, we may be required to make substantial improvements or repairs to maximize the facility’s investment potential. Operators may contest foreclosure or other remedies, seek bankruptcy protection against our exercise of enforcement of enforcement or other remedies and/or bring claims for lender liability in response to actions to enforce mortgage obligations. Even if we are able to successfully foreclose on the collateral securing our mortgage loans, we may be unable to expeditiously find a replacement operator, if at all, or otherwise successfully operate or occupy the property, which could adversely affect our ability to recover our investment. Uninsured losses or losses in excess of our operators’ insurance coverage could adversely affect our financial position and our cash flow. Under the terms of our leases, our operators are required to maintain comprehensive general liability, fire, flood, earthquake, boiler and machinery, nursing home or long-term care professional liability and extended coverage insurance with respect to our properties with policy specifications, limits and deductibles set forth in the leases or other written agreements between us and the operator. However, our properties may be adversely affected by casualty losses which exceed insurance coverages and reserves. In addition, we cannot provide any assurances that our tenants will maintain the required coverages, that we will continue to require the same levels of insurance under our leases, or that such insurance will be available at a reasonable cost in the future or that the policies maintained will fully cover all losses on our properties upon the occurrence of a catastrophic event. We also cannot make any guaranty as to the future financial viability of the insurers that underwrite the policies maintained by our tenants, or, alternatively if our tenants utilize captive or self-insurance programs, that such programs will be adequately funded. Should an uninsured loss or a loss in excess of insured limits occur, we could lose both our investment in, and anticipated profits and cash flows from, the property. Even if it were practicable to restore the property to its condition prior to the damage caused by a major casualty, the operations of the affected property would likely be suspended for a considerable period of time. In the event of any substantial loss affecting a property, disputes over insurance claims could arise. Risks Related to Us and Our Operations We rely on external sources of capital to fund future capital needs, and if we encounter difficulty in obtaining such capital, we may not be able to make future investments necessary to grow our business or meet maturing commitments. To qualify as a REIT under the Code, we are required to, among other things, distribute at least 90% of our REIT taxable income each year to our stockholders. Because of this distribution requirement, we may not be able to fund, from cash retained from operations, all future capital needs, including capital needed to 26 make investments and to satisfy or refinance maturing commitments. As a result, we rely on external sources of capital, including debt and equity financing. If we are unable to obtain needed capital at all or only on unfavorable terms from these sources, we might not be able to make the investments needed to grow our business, or to meet our obligations and commitments as they mature, which could negatively affect the ratings of our debt and even, in extreme circumstances, affect our ability to continue operations. Our access to capital depends upon a number of factors over which we have little or no control, including the performance of the national and global economies generally; competition in the healthcare industry; issues facing the healthcare industry, including regulations and government reimbursement policies; our operators’ operating costs; the ratings of our debt securities; the market’s perception of our growth potential; the market value of our properties; our current and potential future earnings and cash distributions; and the market price of the shares of our capital stock. While we currently have sufficient cash flow from operations to fund our obligations and commitments, we may not be in a position to take advantage of future investment opportunities in the event that we are unable to access the capital markets on a timely basis or we are only able to obtain financing on unfavorable terms. Our ability to raise capital through equity sales is dependent, in part, on the market price of our common stock, and our failure to meet market expectations with respect to our business could negatively impact the market price of our common stock and availability of equity capital. As with other publicly-traded companies, the availability of equity capital will depend, in part, on the market price of our common stock which, in turn, will depend upon various market conditions and other factors that may change from time to time including: • • • • • • • • • the extent of investor interest; the general reputation of REITs and the attractiveness of their equity securities in comparison to other equity securities, including securities issued by other real estate-based companies; the financial performance of us and our operators; concentrations in our investment portfolio by tenant and facility type; concerns about our tenants’ financial condition due to uncertainty regarding reimbursement from governmental and other third-party payor programs; analyst reports on us and the REIT industry in general; general stock and bond market conditions, including changes in interest rates on fixed income securities, which may lead prospective purchasers of our common stock to demand a higher annual yield from future distributions; our failure to maintain or increase our dividend, which is dependent, to a large part, on the increase in funds from operations, which in turn depends upon increased revenues from additional investments and rental increases; and other factors such as governmental regulatory action and changes in REIT tax laws. The market value of the equity securities of a REIT is generally based upon the market’s perception of the REIT’s growth potential and its current and potential future earnings and cash distributions. Our failure to meet the market’s expectation with regard to future earnings and cash distributions would likely adversely affect the market price of our common stock and, as a result, the availability of equity capital to us. We are subject to risks associated with debt financing, which could negatively impact our business and limit our ability to make distributions to our stockholders and to repay maturing debt. The financing required to make future investments and satisfy maturing commitments may be provided by borrowings under our credit facilities, private or public offerings of debt or equity, the assumption of secured indebtedness, mortgage financing on a portion of our owned portfolio or through joint ventures. To the extent we must obtain debt financing from external sources to fund our capital requirements, we cannot guarantee such financing will be available on favorable terms, if at all. In addition, if we are unable to 27 refinance or extend principal payments due at maturity or pay them with proceeds from other capital transactions, our cash flow may not be sufficient to make distributions to our stockholders and repay our maturing debt. Furthermore, if prevailing interest rates, changes in our debt ratings or other factors at the time of refinancing result in higher interest rates upon refinancing, the interest expense relating to that refinanced indebtedness would increase, which could reduce our profitability and the amount of dividends we are able to pay. Moreover, additional debt financing increases the amount of our leverage. The degree of leverage could have important consequences to stockholders, including affecting our investment grade ratings and our ability to obtain additional financing in the future, and making us more vulnerable to a downturn in our results of operations or the economy generally. We may be subject to additional risks in connection with our recent and future acquisitions of long-term care facilities. We may be subject to additional risks in connection with our recent and future acquisitions of long-term care facilities, including but not limited to the following: • • • • • our limited prior business experience with certain of the operators of the facilities we have recently acquired or may acquire in the future; including unfavorable terms and the facilities may underperform due to various factors, conditions of the lease agreements that we assume, disruptions caused by the management of the operators of the facilities or changes in economic conditions impacting the facilities and/or the operators; diversion of our management’s attention away from other business concerns; exposure to any undisclosed or unknown potential liabilities relating to the facilities; and potential underinsured losses on the facilities. We cannot assure you that we will be able to manage our recently acquired or future new facilities without encountering difficulties or that any such difficulties will not have a material adverse effect on us. Our assets may be subject to impairment charges. We periodically, but not less than annually, evaluate our real estate investments and other assets for impairment indicators. The judgment regarding the existence of impairment indicators is based on factors such as market conditions, operator performance and legal structure. If we determine that a significant impairment has occurred, we are required to make an adjustment to the net carrying value of the asset, which could have a material adverse effect on our results of operations. We may not be able to sell certain closed facilities for their book value. From time to time, we close facilities and actively market such facilities for sale. To the extent we are unable to sell these properties for our book value, we may be required to take a non-cash impairment charge or loss on the sale, either of which would reduce our net income. Our indebtedness could adversely affect our financial condition. We have a material amount of indebtedness and we may increase our indebtedness in the future. Our level and type of indebtedness could have important consequences for our stockholders. For example, it could: • • • increase our vulnerability to adverse changes in general economic, industry and competitive conditions; limit our ability to borrow additional funds, on satisfactory terms or at all, for working capital, capital expenditures, acquisitions, debt service requirements, execution of our business plan or other general corporate purposes; increase our cost of borrowing; 28 • • • • • • require us to dedicate a substantial portion of our cash flow from operations to make payments on our indebtedness, thereby reducing the availability of our cash flow to fund working capital, capital expenditures and other general corporate purposes; limit our ability to make material acquisitions or take advantage of business opportunities that may arise; limit our ability to make distributions to our stockholders, which may cause us to lose our qualification as a REIT under the Code or to become subject to federal corporate income tax on any REIT taxable income that we do not distribute; expose us to fluctuations in interest rates, to the extent our borrowings bear variable rates of interest; limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate; and place us at a competitive disadvantage compared to our competitors that have less debt. Further, we have the ability to incur substantial additional debt, including secured debt. If we incur additional debt, the related risks described above could intensify. In addition, if we are unable to refinance any of our floating rate debt, we would continue to be subject to interest rate risk. The short-term nature of some of our debt also subjects us to the risk that market conditions may be unfavorable or may prevent us from refinancing our debt at or prior to their existing maturities. In addition, our cash flow from operations may not be sufficient to repay all of our outstanding debt as it becomes due, and we may not be able to borrow money, sell assets or otherwise raise funds on acceptable terms, if at all, to refinance our debt. Covenants in our debt documents limit our operational flexibility, and a covenant breach could materially adversely affect our operations. The terms of our credit agreements and note indentures require us to comply with a number of customary financial and other covenants that may limit our management’s discretion by restricting our ability to, among other things, incur additional debt, redeem our capital stock, enter into certain transactions with affiliates, pay dividends and make other distributions, make investments and other restricted payments, engage in mergers and consolidations, create liens, sell assets or engage in new lines of business. In addition, our credit facilities require us to maintain compliance with specified financial covenants, including those relating to maximum total leverage, maximum secured leverage, maximum unsecured leverage, minimum fixed charge coverage, minimum consolidated tangible net worth, minimum unsecured debt yield, minimum unsecured interest coverage and maximum distributions. Any additional financing we may obtain could contain similar or more restrictive covenants. Our continued ability to incur indebtedness, conduct our operations, and take advantage of business opportunities as they arise is subject to compliance with these financial and other covenants. Breaches of these covenants could result in defaults in addition to any other indebtedness under the instruments governing the applicable indebtedness, cross-defaulted against such instruments. Any such breach could materially adversely affect our business, results of operations and financial condition. We are subject to particular risks associated with real estate ownership, which could result in unanticipated losses or expenses. Our business is subject to many risks that are associated with the ownership of real estate. For example, if our operators do not renew their leases, we may be unable to re-lease the facilities at favorable rental rates, if at all. Other risks that are associated with real estate acquisition and ownership include, without limitation, the following: • • • general liability, property and casualty losses, some of which may be uninsured; the inability to purchase or sell our assets rapidly to respond to changing economic conditions, due to the illiquid nature of real estate and the real estate market; leases that are not renewed or are renewed at lower rental amounts at expiration; 29 • • • • • contingent rent escalators tied to changes in the Consumer Price Index or other parameters; the exercise of purchase options by operators resulting in a reduction of our rental revenue; costs relating to maintenance and repair of our facilities and the need to make expenditures due to changes in governmental regulations, including the Americans with Disabilities Act; environmental hazards created by prior owners or occupants, existing tenants, mortgagors or other persons for which we may be liable; and acts of God or terrorism affecting our properties. Our real estate investments are relatively illiquid. Real estate investments are relatively illiquid and generally cannot be sold quickly. The real estate market is affected by many factors which are beyond our control, including general economic conditions, availability of financing, interest rates and supply and demand. Additional factors that are specific to our industry also tend to limit our ability to vary our portfolio promptly in response to changes in economic or other conditions. For example, all of our properties are ‘‘special purpose’’ properties that cannot be readily converted into general residential, retail or office use. In addition, transfers of operations of nursing homes and other healthcare-related facilities are subject to extensive regulatory approvals. We cannot predict whether we will be able to sell any property for the price or on the terms set by us or whether any price or other terms offered by a prospective purchaser would be acceptable to us. We also cannot predict the length of time needed to find a willing purchaser and to close the sale of a property, or that we will have funds available to make necessary repairs and improvements to a property held for sale. To the extent we are unable to sell any properties for our book value, we may be required to take a non-cash impairment charge or loss on the sale, either of which would reduce our net income. As an owner or lender with respect to real property, we may be exposed to possible environmental liabilities. Under various federal, state and local environmental laws, ordinances and regulations, a current or previous owner of real property or a secured lender may be liable in certain circumstances for the costs of investigation, removal or remediation of, or related releases of, certain hazardous or toxic substances at, under or disposed of in connection with such property, as well as certain other potential costs relating to hazardous or toxic substances, including government fines and damages for injuries to persons and adjacent property. Such laws often impose liability without regard to whether the owner knew of, or was responsible for, the presence or disposal of such substances. As a result, liability may be imposed on the owner in connection with the activities of an operator of the property. The cost of any required investigation, remediation, removal, fines or personal or property damages and the owner’s liability therefore could exceed the value of the property and/or the assets of the owner. In addition, the presence of such substances, or the failure to properly dispose of or remediate such substances, may adversely affect an operators’ ability to attract additional residents and our ability to sell or rent such property or to borrow using such property as collateral which, in turn, could negatively impact our revenues. Although our leases and mortgage loans generally require the lessee and the mortgagor to indemnify us for certain environmental liabilities, the scope of such obligations may be limited. For instance, most of our leases do not require the lessee to indemnify us for environmental liabilities arising before the lessee took possession of the premises. Further, we cannot assure you that any such mortgagor or lessee would be able to fulfill its indemnification obligations to us. The industry in which we operate is highly competitive. Increasing investor interest in our sector and consolidation at the operator level or REIT level could increase competition and reduce our profitability. Our business is highly competitive and we expect that it may become more competitive in the future. We compete for healthcare facility investments with other healthcare investors, including other REITs, some of which have greater resources and lower costs of capital than we do. Increased competition makes it more challenging for us to identify and successfully capitalize on opportunities that meet our business goals. If we cannot capitalize on our development pipeline, identify and purchase a sufficient quantity of healthcare facilities at favorable prices, or are unable to finance such acquisitions on commercially favorable terms, our 30 business, results of operations and financial condition may be materially adversely affected. In addition, if our cost of capital should increase relative to the cost of capital of our competitors, the spread that we realize on our investments may decline if competitive pressures limit or prevent us from charging higher lease or mortgage rates. We may be named as defendants in litigation arising out of professional liability and general liability claims relating to our previously owned and operated facilities that if decided against us, could adversely affect our financial condition. We and several of our wholly-owned subsidiaries were named as defendants in professional liability and general liability claims related to our owned and operated facilities prior to 2005. Other third-party managers responsible for the day-to-day operations of these facilities were also named as defendants in these claims. In these suits, patients of certain previously owned and operated facilities have alleged significant damages, including punitive damages, against the defendants. Although all of these prior suits have been settled, we or our affiliates could be named as defendants in similar suits in the future. There can be no assurance that we would be successful in our defense of such potential matters or in asserting our claims against various managers of the subject facilities or that the amount of any settlement or judgment would be substantially covered by insurance or that any punitive damages will be covered by insurance. Our charter and bylaws contain significant anti-takeover provisions which could delay, defer or prevent a change in control or other transactions that could provide our stockholders with the opportunity to realize a premium over the then-prevailing market price of our common stock. Our charter and bylaws contain various procedural and other requirements which could make it difficult for stockholders to effect certain corporate actions. Our Board of Directors has the authority to issue additional shares of preferred stock and to fix the preferences, rights and limitations of the preferred stock without stockholder approval. In addition, our charter contains limitations on the ownership of our capital stock intended to ensure we continue to meet the requirements for qualification as a REIT. These provisions could discourage unsolicited acquisition proposals or make it more difficult for a third party to gain control of us, which could adversely affect the market price of our securities and/or result in the delay, deferral or prevention of a change in control or other transactions that could provide our stockholders with the opportunity to realize a premium over the then-prevailing market price of our common stock. Our primary assets are the units of partnership interest in Omega OP and, as a result, we will depend on distributions from the Partnership to pay dividends and expenses. The Company is a holding company and has no material assets other than units of partnership interest in Omega OP. We intend to cause the Partnership to make distributions to its partners, including the Company, in an amount sufficient to allow us to qualify as a REIT for U.S. federal income tax purposes and to pay all of our expenses. To the extent we need funds and the Partnership is restricted from making distributions under applicable law or otherwise, or if the Partnership is otherwise unable to provide such funds, the failure to make such distributions could materially adversely affect our liquidity and financial condition. Members of our management and Board of Directors are holders of units of partnership interest in Omega OP, and their interests may differ from those of our public stockholders. Some members of our management and Board of Directors are holders of units of partnership interest in Omega OP. Those unitholders may have conflicting interests with holders of the Company’s common stock. For example, such unitholders of OP Units may have different tax positions from the Company or holders of the Company’s common stock, which could influence their decisions in their capacities as members of management regarding whether and when to dispose of assets, whether and when to incur new or refinance existing indebtedness and how to structure future transactions. 31 Ownership of property outside the U.S. may subject us to different or greater risks than those associated with our U.S. investments. We have investments in the U.K., and may from time to time may seek to acquire other properties in the U.K. or otherwise outside the U.S. Although we currently have investments in the U.K., we have limited experience investing in healthcare properties or other real estate-related assets located outside the U.S. International development, investment, ownership and operating activities involve risks that are different from those we face with respect to our U.S. properties and operations. These risks include, but are not limited to, any international currency gain recognized with respect to changes in exchange rates may not qualify under the 75.0% gross income test or the 95.0% gross income test that we must satisfy annually in order to qualify and maintain our status as a REIT; challenges with respect to the repatriation of foreign earnings and cash; changes in foreign political, regulatory, and economic conditions, including regionally, nationally, and locally; challenges in managing international operations; challenges of complying with a wide variety of foreign laws and regulations, including those relating to real estate, corporate governance, operations, taxes, employment and legal proceedings; foreign ownership restrictions with respect to operations in countries; diminished ability to legally enforce our contractual rights in foreign countries; differences in lending practices and the willingness of domestic or foreign lenders to provide financing; regional or country-specific business cycles and economic instability; and changes in applicable laws and regulations in the U.S. that affect foreign operations. In addition, we have limited investing experience in international markets. If we are unable to successfully manage the risks associated with international expansion and operations, our results of operations and financial condition may be adversely affected. We may be adversely affected by fluctuations in currency exchange rates. Our ownership of properties in the U.K. currently subjects us to fluctuations in the exchange rates between U.S. dollars and the British pound, which may, from time to time, impact our financial condition and results of operations. If we continue to expand our international presence through investments in, or acquisitions or development of healthcare assets outside the U.S. or the U.K., we may transact business in other foreign currencies. Although we may pursue hedging alternatives, including borrowing in local currencies, to protect against foreign currency fluctuations, we cannot assure you that such fluctuations will not have a material adverse effect on our results of operations or financial condition. The vote by the U.K. to leave the European Union could adversely affect us. The U.K. held a referendum on June 23, 2016 on its membership in the European Union (“E.U.”). A majority of U.K. voters voted to exit the E.U. (“Brexit”), and negotiations will commence to determine the future terms of the U.K.’s relationship with the E.U., including the terms of trade between the U.K. and the E.U. The effects of Brexit will depend on any agreements the U.K. makes to retain access to E.U. markets either during a transitional period or more permanently. Brexit could adversely affect European or worldwide economic or market conditions and could contribute to instability in global financial markets. In addition, Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the U.K. determines which E.U. laws to replace or replicate. Any of these effects of Brexit, and others we cannot anticipate, could adversely affect our business, business opportunities, results of operations, financial condition and cash flows. Our success depends in part on our ability to retain key personnel and our ability to attract or retain other qualified personnel. Our future performance depends to a significant degree upon the continued contributions of our executive management team and other key employees. The loss of the services of our current executive management team could have an adverse impact on our operations. Although we have entered into employment agreements with the members of our executive management team, these agreements may not assure their continued service. In addition, our future success depends, in part, on our ability to attract, hire, train and retain other qualified personnel. Competition for qualified employees is intense, and we compete for qualified employees with companies with greater financial resources. Our failure to successfully attract, hire, retain and train the people we need would significantly impede our ability to implement our business strategy. 32 Failure to properly manage and integrate our rapid growth could distract our management or increase our expenses. We have experienced rapid growth and development in a relatively short period of time and expect to continue this rapid growth in the future. This growth has resulted in increased levels of responsibility for our management. Future acquisitions or investments could place significant additional demands on, and require us to expand, our management, resources and personnel. In addition, we cannot assure you that we will be able to adapt our administrative, accounting and operational systems to integrate and manage the long-term care facilities we have acquired or may acquire in a timely manner. Our failure to manage any such rapid growth effectively could harm our business and, in particular, our financial condition, results of operations and cash flows, which could negatively affect our ability to make distributions to stockholders and the trading price of our common stock. Our growth could also increase our capital requirements, which may require us to issue potentially dilutive equity securities and incur additional debt. We rely on information technology in our operations, and any material failure, inadequacy, interruption or security failure of that technology could harm our business. We rely on information technology networks and systems, including the Internet, to process, transmit and store electronic information, and to manage or support a variety of business processes, including financial transactions and records, personal identifying information, tenant and lease data. We purchase some of our information technology from vendors, on whom our systems depend. We rely on commercially available systems, software, tools and monitoring to provide security for processing, transmission and storage of confidential tenant and other customer information, such as individually identifiable information, including information relating to financial accounts. Although we have taken steps to protect the security of our information systems and the data maintained in those systems, it is possible that our safety and security measures will not be able to prevent the systems’ improper functioning or damage, or the improper access or disclosure of personally identifiable information such as in the event of cyber attacks. Security breaches, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches, can create system disruptions, shutdowns or unauthorized disclosure of confidential information. Any failure to maintain proper function, security and availability of our information systems could interrupt our operations, damage our reputation, subject us to liability claims or regulatory penalties and could have a material adverse effect on our business, financial condition and results of operations. Failure to maintain effective internal control over financial reporting could have a material adverse effect on our business, results of operations, financial condition and stock price. We are required to provide a report by management on internal control over financial reporting, including management’s assessment of the effectiveness of such control. Changes to our business will necessitate ongoing changes to our internal control systems and processes. Internal control over financial reporting may not prevent or detect misstatements due to inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Therefore, even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. In addition, projections of any evaluation of effectiveness of internal control over financial reporting to future periods are subject to the risk that the control may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. If we fail to maintain the adequacy of our internal controls, including any failure to implement required new or improved controls, or if we experience difficulties in their implementation, our business, results of operations and financial condition could be materially adversely harmed, we could fail to meet our reporting obligations and there could be a material adverse effect on our stock price. If we fail to maintain our REIT status, we will be subject to federal income tax on our taxable income at regular corporate rates. We were organized to qualify for taxation as a REIT under Sections 856 through 860 of the Code. See “Item 1. Business – Taxation.” We believe that we have operated in such a manner as to qualify for taxation as a REIT under the Code and intend to continue to operate in a manner that will maintain our qualification as a REIT. Qualification as a REIT involves the satisfaction of numerous requirements, some on an annual and some on a quarterly basis, established under highly technical and complex provisions of 33 the Code for which there are only limited judicial and administrative interpretations and involve the determination of various factual matters and circumstances not entirely within our control. We cannot assure that we will at all times satisfy these rules and tests. If we were to fail to qualify as a REIT in any taxable year, as a result of a determination that we failed to meet the annual distribution requirement or otherwise, we would be subject to federal income tax, including any applicable alternative minimum tax, on our taxable income at regular corporate rates with respect to each such taxable year for which the statute of limitations remains open. Moreover, unless entitled to relief under certain statutory provisions, we also would be disqualified from treatment as a REIT for the four taxable years following the year during which qualification is lost. This treatment would significantly reduce our net earnings and cash flow because of our additional tax liability for the years involved, which could significantly impact our financial condition. We generally must distribute annually at least 90% of our taxable income to our stockholders to maintain our REIT status. To the extent that we do not distribute all of our net capital gain or do distribute at least 90%, but less than 100% of our “REIT taxable income,” as adjusted, we will be subject to tax thereon at regular ordinary and capital gain corporate tax rates. Even if we remain qualified as a REIT, we may face other tax liabilities that reduce our cash flow. Even if we remain qualified for taxation as a REIT, we may be subject to certain federal, state and local taxes on our income and assets, including taxes on any undistributed income, tax on income from some activities conducted as a result of a foreclosure, and state or local income, property and transfer taxes. Any of these taxes would decrease cash available for the payment of our debt obligations. In addition, to meet REIT qualification requirements, we may hold some of our non-healthcare assets through taxable REIT subsidiaries or other subsidiary corporations that will be subject to corporate level income tax at regular rates. Prior to the completion of the Aviv Merger, Aviv availed itself of the self-determination provisions and the deficiency dividend procedures under the REIT sections of the Code and supporting Treasury Regulations and IRS pronouncements to remedy certain potential technical violations of the REIT requirements. If there is an adjustment to Aviv’s REIT taxable income or dividends paid deductions as a result of Aviv taking such action, or other determinations by the IRS, the Company could be required to further implement the deficiency dividend procedures in order to maintain Aviv’s REIT status or take other steps to remedy any past non-compliance by Aviv. Any such further implementation of the deficiency dividend procedures could require the Company to make significant distributions to its stockholders and to pay significant penalties and interest to the IRS, which could impair the Company’s ability to expand its business and raise capital, reduce its cash available for distribution to its stockholders and materially adversely affect the value of the Company’s common stock. Qualifying as a REIT involves highly technical and complex provisions of the Code and complying with REIT requirements may affect our profitability. Qualification as a REIT involves the application of technical and intricate Code provisions. Even a technical or inadvertent violation could jeopardize our REIT qualification. To qualify as a REIT for federal income tax purposes, we must continually satisfy tests concerning, among other things, the nature and diversification of our assets, the sources of our income and the amounts we distribute to our stockholders. Thus, we may be required to liquidate otherwise attractive investments from our portfolio, or be unable to pursue investments that would be otherwise advantageous to us, to satisfy the asset and income tests or to qualify under certain statutory relief provisions. We may also be required to make distributions to stockholders at disadvantageous times or when we do not have funds readily available for distribution (e.g., if we have assets which generate mismatches between taxable income and available cash). Having to comply with the distribution requirement could cause us to: (i) sell assets in adverse market conditions; (ii) borrow on unfavorable terms; or (iii) distribute amounts that would otherwise be invested in future acquisitions, capital expenditures or repayment of debt. As a result, satisfying the REIT requirements could have an adverse effect on our business results and profitability. 34 Future changes in the tax laws could impact our ability to qualify as a REIT in the future. Future changes in the tax laws, such as the “Protecting Americans from Tax Hikes Act of 2015” (the “PATH Act”) that was enacted on December 18, 2015, which contains several provisions pertaining to REIT qualification and taxation, could impact our ability to qualify as a REIT in the future. We have included in the discussion regarding our taxation as a REIT, see “Item 1. Business – Taxation,” some of the provisions from the PATH Act that could have an impact on us. However, we do not believe that any of these provisions will materially impact our ability to maintain our qualification as a REIT going forward. While many of the recent changes to the tax laws impacting REITs have been “relief ” that generally ease the burden of complying with the REIT tax rules, there can be no assurance that future changes in tax laws will not adversely impact our ability qualify as a REIT in the future. Risks Related to Our Stock In addition to the risks related to our operators and our operations described above, the following are additional risks associated with our stock. The market value of our stock could be substantially affected by various factors. Market volatility may adversely affect the market price of our common stock. As with other publicly traded securities, the share price of our stock depends on many factors, which may change from time to time, including: • • • • • • • • • the market for similar securities issued by REITs; changes in financial estimates or recommendations by securities analysts with respect to us, our competitors or our industry; our ability to meet analysts’ estimates; prevailing interest rates; our credit rating; changes in legal and regulatory taxation obligations; litigation and regulatory proceedings; general economic and market conditions; and the financial condition, performance and prospects of us, our tenants and our competitors. Our issuance of additional capital stock, warrants or debt securities, whether or not convertible, may reduce the market price for our outstanding securities, including our common stock, and dilute the ownership interests of existing stockholders. We cannot predict the effect, if any, that future sales of our capital stock, warrants or debt securities, or the availability of our securities for future sale, will have on the market price of our securities, including our common stock. Sales of substantial amounts of our common stock or preferred shares, warrants or debt securities convertible into or exercisable or exchangeable for common stock in the public market, or the perception that such sales might occur, could negatively impact the market price of our stock and the terms upon which we may obtain additional equity financing in the future. Our Board of Directors has the authority to designate and issue preferred stock that may have dividend, liquidation and other rights that are senior to those of our common stock. In addition, we may issue additional capital stock in the future to raise capital or as a result of the following: • the issuance and exercise of options to purchase our common stock or other equity awards under remuneration plans (we may also issue equity to our employees in lieu of cash bonuses or to our directors in lieu of director’s fees); 35 • • • • • the issuance of shares pursuant to our dividend reinvestment and direct stock purchase plan or at-the-market offerings; the issuance of debt securities exchangeable for our common stock; the exercise of warrants we may issue in the future; the issuance of warrants or other rights to acquire shares to current or future lenders in connection with providing financing; and the sales of securities convertible into our common stock. Any debt securities, preferred shares, warrants or other rights to acquire shares or convertible or exchangeable securities that we issue in the future may have rights, preferences and privileges more favorable than those of our common stock and may result in dilution to owners of our common stock. Holders of our common stock are not entitled to preemptive rights or other protections against dilution. Our preferred shares, if issued, could have a preference on liquidating distributions or a preference on dividend payments that could limit our ability pay dividends or other distributions to the holders of our common stock. Because our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings. Thus, our stockholders bear the risk that our future offerings could reduce the per share trading price of our common stock and dilute their interest in us. Your ownership percentage in our company may be diluted in the future. In the future, your percentage ownership in us may be diluted because of equity issuances for acquisitions, capital market transactions or otherwise. We also anticipate that we will grant future compensatory equity-based incentive awards to directors, officers and employees who provide services to us. Such awards will have a dilutive effect on our earnings per share, which could adversely affect the market price of our common stock. In addition, our certificate of incorporation authorizes us to issue, without the approval of our stockholders, one or more classes or series of preferred stock having such designation, powers, preferences and relative, participating, optional and other special rights, including preferences over our common stock respecting dividends and distributions, as our board of directors generally may determine. The terms of one or more classes or series of preferred stock could dilute the voting power or reduce the value of our common stock. For example, we could grant the holders of preferred stock the right to elect some number of our directors in all events or on the occurrence of specified events, or the right to veto specified transactions. Similarly, the repurchase or redemption rights or liquidation preferences we could assign to shares of preferred stock could affect the residual value of the common stock. There are no assurances of our ability to pay dividends in the future. Our ability to pay dividends may be adversely affected upon the occurrence of any of the risks described herein. Our payment of dividends is subject to compliance with restrictions contained in our credit agreements, the indentures governing our senior notes and any preferred stock that our Board of Directors may from time to time designate and authorize for issuance. All dividends will be paid at the discretion of our Board of Directors and will depend upon our earnings, our financial condition, maintenance of our REIT status and such other factors as our Board of Directors may deem relevant from time to time. There are no assurances of our ability to pay dividends in the future. In addition, our dividends in the past have included, and may in the future include, a return of capital. Legislative or regulatory action could adversely affect purchasers of our stock. Significant legislative, judicial and administrative changes to the federal income tax laws could adversely impact the income tax consequences of owning our stock. The rules dealing with U.S. federal income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Department of the Treasury. Such changes have occurred in the past and are likely to continue to occur in the future, and we cannot assure you that any of these changes will not adversely affect an 36 investment in our stock or on our stock’s market value or resale potential. Stockholders are urged to consult with their own tax advisor with respect to the impact that past legislative, regulatory or administrative changes or potential legislation may have on their investment in our stock. A downgrade of our credit rating could impair our ability to obtain additional debt financing on favorable terms, if at all, and significantly reduce the trading price of our common stock. If any rating agency downgrades our credit rating, or places our rating under watch or review for possible downgrade, then it may be more difficult or expensive for us to obtain additional debt financing, and the trading price of our common stock may decline. Factors that may affect our credit rating include, among other things, our financial performance, our success in raising sufficient equity capital, adverse changes in our debt and fixed charge coverage ratios, our capital structure and level of indebtedness and pending or future changes in the regulatory framework applicable to our operators and our industry. We cannot assure that these credit agencies will not downgrade our credit rating in the future. Item 1B — Unresolved Staff Comments None. 37 Item 2 — Properties At December 31, 2016, our real estate investments included long-term care facilities and rehabilitation hospital investments, in the form of (i) owned facilities that are leased to operators or their affiliates, (ii) investments in direct financing leases to operators or their affiliates and (iii) mortgages on facilities that are operated by the mortgagors or their affiliates. The properties are located in 42 states and the U.K. and are operated by 79 operators. We use the term “operator” to refer to our tenants and mortgagors and their affiliates who manage and or operate our properties. In some cases, our tenants and mortgagors contract with a healthcare operator to operate the facilities. The following table summarizes our property investments as of December 31, 2016: Investment Structure/Operator Operating Lease Facilities(1) Signature Holdings II, LLC . . . . . . . . . . . . . . . . . . . . . . . . Maplewood Real Estate Holdings, LLC . . . . . . . . . . . . . . . . . . Saber Health Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ciena Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CommuniCare Health Services, Inc. . . . . . . . . . . . . . . . . . . . . Daybreak Venture, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . Genesis HealthCare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Health and Hospital Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Diversicare Healthcare Services EmpRes Healthcare Group, Inc. . . . . . . . . . . . . . . . . . . . . . . Healthcare Homes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Airamid Health Management . . . . . . . . . . . . . . . . . . . . . . . Fundamental Long Term Care Holding, LLC . . . . . . . . . . . . . . Affiliates of Capital Funding Group, Inc. . . . . . . . . . . . . . . . . . S&F Management Company, LLC . . . . . . . . . . . . . . . . . . . . . Gulf Coast Master Tenant I, LLC . . . . . . . . . . . . . . . . . . . . . Sun Mar Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mission Health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Guardian LTC Management Inc. . . . . . . . . . . . . . . . . . . . . . Preferred Care, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Consulate Health Care . . . . . . . . . . . . . . . . . . . . . . . . . . . Nexion Health Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Trillium Healthcare Group . . . . . . . . . . . . . . . . . . . . . . . . . Providence Group, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . Essex Healthcare Corporation . . . . . . . . . . . . . . . . . . . . . . . Bridgemark Healthcare LLC . . . . . . . . . . . . . . . . . . . . . . . . TenInOne Acquisition Group, LLC . . . . . . . . . . . . . . . . . . . . Peregrine Health Services, Inc. . . . . . . . . . . . . . . . . . . . . . . . Civitas Senior Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . Trinity HealthCare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pinon Management, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . Swain/Herzog . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ide Management Group, LLC . . . . . . . . . . . . . . . . . . . . . . . Prestige Care, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CareMeridian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sovran Management Company, LLC . . . . . . . . . . . . . . . . . . . Southern Administrative Services, LLC . . . . . . . . . . . . . . . . . . New ARK Investments, Inc. . . . . . . . . . . . . . . . . . . . . . . . . StoneGate Senior Care LP . . . . . . . . . . . . . . . . . . . . . . . . . Sava Senior Care, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . Lakeland Holding Company . . . . . . . . . . . . . . . . . . . . . . . . HI-Care Mgmt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cardinal Care Management, Inc. . . . . . . . . . . . . . . . . . . . . . Physician’s Hospital Group . . . . . . . . . . . . . . . . . . . . . . . . . Fellowship Senior Living . . . . . . . . . . . . . . . . . . . . . . . . . . Lion Health Centers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Reliance Health Care Management, Inc. . . . . . . . . . . . . . . . . . Safe Haven Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . Transitions Healthcare, LLC . . . . . . . . . . . . . . . . . . . . . . . . 38 Number of Operating Beds Number of Facilities Gross Real Estate Investment (in thousands) 7,057 1,132 4,579 3,517 3,934 4,317 5,730 4,606 4,279 2,287 1,848 4,347 2,818 1,990 1,920 2,514 1,268 1,345 1,655 1,607 2,143 2,067 1,299 864 1,183 1,100 1,271 624 367 954 869 1,008 1,285 542 183 475 1,084 489 713 469 274 278 185 67 214 162 138 135 135 63 13 44 36 32 49 51 44 35 27 35 37 26 21 15 20 11 20 23 16 18 19 17 10 13 11 9 4 3 12 9 9 14 8 16 2 11 4 7 3 1 3 2 3 3 1 1 2 1 $ 557,986 529,405 469,041 461,277 355,984 339,617 337,845 304,711 277,979 267,739 253,138 246,361 235,713 219,456 217,073 202,626 179,219 132,519 125,971 123,136 121,954 92,065 89,296 85,035 83,183 82,138 73,563 72,779 67,096 63,244 62,180 59,746 56,318 55,111 52,891 45,000 44,843 44,700 39,385 36,970 34,001 30,008 28,629 23,394 22,700 20,458 19,333 15,960 15,370 Investment Structure/Operator Operating Lease Facilities(1) . . . . . . . . . . . . . . . . . . . . . . . . . . Orion Operating Services . . . . . . . . . . . . . . . . . . . . . . . . . . Rest Haven Nursing Center Inc. . . . . . . . . . . . . . . . . . . . . . . Health Systems of Oklahoma LLC . . . . . . . . . . . . . . . . . . . . Washington N&R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Phoenix Senior Living . . . . . . . . . . . . . . . . . . . . . . . . . . . . Health Dimensions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Care Initiatives, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Adcare Health Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . Ensign Group, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . NuCare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Markleysburg Healthcare Investors, LP . . . . . . . . . . . . . . . . . . Covenant Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Community Eldercare Services, LLC . . . . . . . . . . . . . . . . . . . UltraCare Healthcare, LLC . . . . . . . . . . . . . . . . . . . . . . . . . Elite Senior Living, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . AMFM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sante Operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Brius Management Company . . . . . . . . . . . . . . . . . . . . . . . HMS Holdings at Texarkana, LLC . . . . . . . . . . . . . . . . . . . . Hoosier Enterprises Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . Castle Rock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Life Generations Healthcare, Inc. . . . . . . . . . . . . . . . . . . . . . Hickory Creek Healthcare Foundation . . . . . . . . . . . . . . . . . . Hidden Acres Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . Diamond Care Vida Encantada, LLC . . . . . . . . . . . . . . . . . . . Closed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Assets Held for Sale Genesis HealthCare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hope Healthcare Reliance Health Care Management, Inc. . . . . . . . . . . . . . . . . . Saber Health Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Southwest LTC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . International Equity Partners, Inc. . . . . . . . . . . . . . . . . . . . . . Better Senior Living Consulting LLC . . . . . . . . . . . . . . . . . . . Investment in Direct Financing Leases . . . . . . . . . . . . . . . . . . . . . . . . New ARK Investments, Inc. Reliance Health Care Management, Inc. . . . . . . . . . . . . . . . . . Sun Mar Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Markleysburg Healthcare Investors, LP . . . . . . . . . . . . . . . . . . Mortgages(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ciena Healthcare Guardian LTC Management Inc. . . . . . . . . . . . . . . . . . . . . . CommuniCare Health Services, Inc. . . . . . . . . . . . . . . . . . . . . Phoenix Senior Living . . . . . . . . . . . . . . . . . . . . . . . . . . . . Saber Health Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Maplewood Real Estate Holdings, LLC . . . . . . . . . . . . . . . . . . Closed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Benchmark Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Number of Operating Beds Number of Facilities Gross Real Estate Investment (in thousands) 93 176 407 239 125 90 188 301 271 94 207 102 100 141 105 150 52 99 114 47 60 59 63 102 102 — 86,814 464 371 194 140 150 96 310 1,725 5,440 120 83 52 5,695 3,534 808 455 — 99 — — 79 4,975 99,209 1 1 3 2 2 1 1 2 3 1 2 1 1 3 1 2 1 1 1 1 1 1 1 1 1 1 871 6 4 2 2 1 2 3 20 55 1 1 1 58 32 9 3 — 1 — 1 1 47 996 $ 15,251 14,400 12,470 12,152 10,800 10,430 10,347 10,000 9,656 9,570 8,926 8,610 7,572 7,000 5,893 5,786 5,750 4,546 4,281 3,622 3,620 3,007 2,834 2,712 2,028 949 7,566,358 15,952 9,361 9,128 8,097 5,100 3,250 1,980 52,868 574,581 15,498 11,443 416 601,938 449,154 112,500 35,964 23,775 12,255 3,195 2,000 500 639,343 $8,860,507 (1) Certain of our lease agreements contain purchase options that permit the lessees to purchase the underlying properties from us. (2) In general, many of our mortgages contain prepayment provisions that permit prepayment of the outstanding principal amounts thereunder. 39 The following table presents the concentration of our real estate investments by state and in the U.K. as of December 31, 2016: Location Ohio (1) . . . . . . . . . . . . . . . . . . . . . . . . . . Florida (1) . . . . . . . . . . . . . . . . . . . . . . . . . Texas (1) . . . . . . . . . . . . . . . . . . . . . . . . . . Michigan . . . . . . . . . . . . . . . . . . . . . . . . . California (1) . . . . . . . . . . . . . . . . . . . . . . . . Pennsylvania . . . . . . . . . . . . . . . . . . . . . . . Indiana . . . . . . . . . . . . . . . . . . . . . . . . . . Tennessee . . . . . . . . . . . . . . . . . . . . . . . . . Virginia . . . . . . . . . . . . . . . . . . . . . . . . . . South Carolina . . . . . . . . . . . . . . . . . . . . . . North Carolina . . . . . . . . . . . . . . . . . . . . . . United Kingdom . . . . . . . . . . . . . . . . . . . . . Kentucky . . . . . . . . . . . . . . . . . . . . . . . . . Connecticut . . . . . . . . . . . . . . . . . . . . . . . . Mississippi . . . . . . . . . . . . . . . . . . . . . . . . . Arkansas (1) . . . . . . . . . . . . . . . . . . . . . . . . Massachusetts (1) . . . . . . . . . . . . . . . . . . . . . Washington . . . . . . . . . . . . . . . . . . . . . . . . Maryland . . . . . . . . . . . . . . . . . . . . . . . . . New York . . . . . . . . . . . . . . . . . . . . . . . . . Missouri . . . . . . . . . . . . . . . . . . . . . . . . . . Illinois . . . . . . . . . . . . . . . . . . . . . . . . . . . Georgia . . . . . . . . . . . . . . . . . . . . . . . . . . Colorado . . . . . . . . . . . . . . . . . . . . . . . . . Arizona . . . . . . . . . . . . . . . . . . . . . . . . . . Idaho . . . . . . . . . . . . . . . . . . . . . . . . . . . New Mexico . . . . . . . . . . . . . . . . . . . . . . . . West Virginia . . . . . . . . . . . . . . . . . . . . . . . Iowa . . . . . . . . . . . . . . . . . . . . . . . . . . . . Louisiana . . . . . . . . . . . . . . . . . . . . . . . . . Wisconsin . . . . . . . . . . . . . . . . . . . . . . . . . Nevada . . . . . . . . . . . . . . . . . . . . . . . . . . Minnesota . . . . . . . . . . . . . . . . . . . . . . . . . Kansas . . . . . . . . . . . . . . . . . . . . . . . . . . . Oregon . . . . . . . . . . . . . . . . . . . . . . . . . . . Alabama . . . . . . . . . . . . . . . . . . . . . . . . . . Rhode Island . . . . . . . . . . . . . . . . . . . . . . . Oklahoma . . . . . . . . . . . . . . . . . . . . . . . . . Nebraska . . . . . . . . . . . . . . . . . . . . . . . . . New Hampshire . . . . . . . . . . . . . . . . . . . . . . Utah . . . . . . . . . . . . . . . . . . . . . . . . . . . . Montana . . . . . . . . . . . . . . . . . . . . . . . . . . Vermont . . . . . . . . . . . . . . . . . . . . . . . . . . New Jersey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total Number of Facilities 89 98 109 46 58 43 59 41 16 22 31 35 31 6 19 32 16 19 12 — 20 17 13 14 10 12 10 11 12 13 9 6 4 17 7 9 4 9 7 3 4 2 1 — 996 Number of Operating Beds 8,886 11,634 11,064 4,802 4,749 4,011 5,711 5,196 2,174 2,228 3,456 1,848 2,787 494 2,017 3,092 1,569 1,482 1,642 — 1,989 1,674 1,314 1,577 1,046 1,006 948 1,255 890 1,390 913 650 548 838 410 1,081 558 842 650 221 347 105 115 — 99,209 Gross Real Estate Investment (in thousands) $ 850,371 787,490 785,222 600,538 519,307 468,119 406,469 345,106 294,113 264,818 256,768 253,138 243,584 239,190 230,926 217,071 192,513 156,696 142,026 132,352 131,854 117,762 107,959 107,900 97,864 82,184 77,791 75,919 73,745 66,667 65,853 64,324 63,625 62,147 54,115 48,089 43,534 40,897 24,742 23,082 21,499 13,018 6,925 3,195 $8,860,507 % of Gross Real Estate Investment 9.6% 8.9% 8.9% 6.8% 5.9% 5.3% 4.6% 3.9% 3.3% 3.0% 2.9% 2.9% 2.7% 2.7% 2.6% 2.4% 2.2% 1.8% 1.6% 1.5% 1.5% 1.3% 1.2% 1.2% 1.1% 0.9% 0.9% 0.9% 0.8% 0.8% 0.7% 0.7% 0.7% 0.7% 0.6% 0.5% 0.5% 0.5% 0.3% 0.3% 0.2% 0.1% 0.1% 0.0% 100.0% (1) These states each include a facility/property that is classified as held-for-sale as of December 31, 2016. Geographically Diverse Property Portfolio. Our portfolio of properties is broadly diversified by geographic location. Our portfolio includes healthcare properties located in 42 states and the U.K. In addition, the majority of our rental, direct financing lease and mortgage income are generally derived from facilities in states that require state approval for development and expansion of healthcare facilities. We believe that such state approvals may limit competition for our operators and enhance the value of our properties. 40 Large Number of Tenants. Our facilities are operated by 79 different public and private healthcare providers and/or managers. Except for Ciena Healthcare (10%), New Ark Investments, Inc. (7%), Signature Holdings II, LLC (6%), Maplewood Real Estate Holdings, LLC (6%) and Saber Health Group (6%), which together hold approximately 35% of our portfolio (by investment), no other single tenant holds greater than 5% of our portfolio (by investment). Significant Number of Long-term Leases and Mortgage Loans. At December 31, 2016, approximately 91.2% of our operating leases, 93.4% of our mortgages and 99.9% of our direct financing leases have primary terms that expire after 2021. The majority of our leased real estate properties are leased under provisions of master lease agreements. We also lease facilities under single facility leases. The initial terms of our operating leases typically range from 5 to 15 years, plus renewal options. Our direct financing leases have initial terms in excess of 20 years. All of our leased properties are leased under long term, triple-net leases. The following table displays the expiration of the annualized straight-line rental revenues under our operating lease agreements as of December 31, 2016 by year without giving effect to any renewal options: Expiration Year Annualized Straight-line Rental Revenue Expiring ($ in thousands) Number of Leases Expiring 2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2024 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2025 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2026 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2027 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Thereafter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 7,772 39,238 1,791 6,821 11,476 67,107 56,782 65,067 25,715 26,906 145,580 304,038 $758,293 7 13 5 9 24 27 19 11 8 9 12 25 169 Item 3 — Legal Proceedings We are subject to various legal proceedings, claims and other actions arising out of the normal course of business. While any legal proceeding or claim has an element of uncertainty, management believes that the outcome of each lawsuit, claim or legal proceeding that is pending or threatened, or all of them combined, will not have a material adverse effect on our consolidated financial position or results of operations. Item 4 — Mine Safety Disclosures Not applicable. 41 PART II Item 5 — Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Our shares of common stock are traded on the New York Stock Exchange under the symbol “OHI.” The following table sets forth, for the periods shown, the high and low prices as reported on the New York Stock Exchange Composite for the periods indicated and cash dividends declared per common share: Quarter First Second Third Fourth 2016 High $35.97 35.94 38.09 35.40 Low $26.96 30.58 32.22 28.11 Dividends Declared Per Share $0.57 0.58 0.60 0.61 $2.36 Quarter First Second Third Fourth 2015 High $45.46 42.00 37.24 37.16 Low $37.76 34.18 32.01 31.56 Dividends Declared Per Share $0.89(1) 0.18(2) 0.55 0.56 $2.18 (1) In addition to the regular $0.53 per share quarterly dividend declared and paid in the first quarter of 2015, on March 5, 2015 the Board of Directors declared a prorated dividend of $0.36 per share of Omega’s common stock in view of the then pending Aviv Merger. This $0.36 per share dividend amount represented dividends for February and March 2015 at a quarterly dividend rate of $0.54 per share of common stock. The $0.36 per share dividend was paid in cash on April 7, 2015 to stockholders of record as of the close of business on March 31, 2015. (2) On April 15, 2015, the Board of Directors declared a prorated dividend of $0.18 per share of Omega’s common stock in view of the recently closed Aviv Merger. The $0.18 per share dividend amount represented dividends for April 2015 at a quarterly dividend rate of $0.54 per share of common stock. The $0.18 per share dividend was paid in cash on May 15, 2015 to stockholders of record as of the close of business on April 30, 2015. The closing price for our common stock on the New York Stock Exchange on February 17, 2017 was $31.71 per share. As of February 17, 2017 there were 196,743,251 shares of common stock outstanding with approximately 3,112 registered holders. The following table provides information about shares available for future issuance under our equity compensation plans as of December 31, 2016: Equity Compensation Plan Information (a) (b) (c) Number of securities to be issued upon exercise of outstanding options, warrants and rights(1) Weighted-average exercise price of outstanding options, warrants and rights(2) Number of securities remaining available for future issuance under equity compensation plans excluding securities reflected in column (a)(3) Plan category Equity compensation plans approved by security holders . . . . . . . . . . . . . . . . . . 1,930,143 Equity compensation plans not approved by security holders . . . . . . . . . . . . . . . . — Total . . . . . . . . . . . . . . . . . . . . . . . 1,930,143 $ — — $ — 2,001,672 — 2,001,672 (1) Reflects (i) 106,778 restricted stock units that were granted on January 1, 2014, (ii) 62,286 restricted stock units that were granted on December 31, 2013, (iii) 109,985 restricted stock units that were granted on March 31, 2015, (iv) 274,498 shares that could be issued if certain performance conditions are achieved related to the March 31, 2015 award of performance restricted stock units and long term incentive plan units (“LTIP Units”), (v) 61,983 restricted stock units that were granted on April 1, 2015, (vi) 108,302 shares that could be issued if certain performance conditions are achieved related to the April 1, 2015 award of performance restricted stock units and LTIP Units, (vii) 11,649 shares that could be issued if certain performance conditions are achieved related to the July 31, 2015 award of performance restricted stock units and LTIP Units, (viii) 131,006 restricted stock units that were granted on March 17, 2016, (ix) 679,549 shares that could be issued if certain performance conditions are 42 achieved related to the March 17, 2016 award of performance restricted stock units and, (x) 384,107 shares in respect of outstanding deferred stock units. Does not include 26,012 shares issuable upon the exercise of outstanding options that were assumed in the Aviv Merger, with a weighted-average exercise price of $18.97 as of December 31, 2016. (2) No exercise price is payable with respect to the restricted stock units and performance restricted stock units. (3) Reflects shares of common stock remaining available for future awards under our 2013 Stock Incentive Plans. During the fourth quarter of 2016, we purchased 778 outstanding shares of our common stock from employees to pay the withholding taxes related to the vesting of restricted stock. Issuer Purchases of Common Stock (a) (b) (c) Period October 1, 2016 to October 31, 2016 . . . . . . . November 1, 2016 to November 30, 2016 . . . . December 1, 2016 to December 31, 2016 . . . . Total . . . . . . . . . . . . . . . . . . . . . . . . . . Total Number of Shares Purchased(1) — 778 — 778 Average Price Paid per Share $ — 29.56 — $29.56 Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs — — — — (d) Maximum Number (or Approximate Dollar Value) of Shares that may be Purchased Under these Plans or Programs — — — — (1) Represents shares purchased from employees to pay the withholding taxes related to the vesting of restricted stock. The shares were not part of a publicly announced repurchase plan or program. Unregistered Sales of Equity Securities and Use of Proceeds In 2016, Omega issued an aggregate of 71,910 shares of Omega common stock, in exchange for an equivalent number of Omega OP Units tendered to Omega OP for redemption in accordance with the provisions of the Partnership Agreement. None of these transactions occurred in the quarterly reporting period ended December 31, 2016. The Company issued these shares of Omega common stock in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), based upon factual representations received from the limited partners who received the Omega common stock. From March 5, 2016 to December 31, 2016, we issued 6,559,960 shares of our common stock at a weighted average price per share of $33.61 in cash pursuant to our Dividend Reinvestment and Stock Purchase Plan (“DRSPP”). The automatic shelf registration statement on Form S-3 relating to the DRSPP expired March 4, 2016. As a result, these shares were inadvertently sold under an expired registration statement and do not appear to qualify for an exemption from registration under the Securities Act. On January 4, 2017, a new automatic shelf registration statement on Form S-3 relating to the DRSPP was filed with the SEC and became effective. 43 Item 6 — Selected Financial Data The following table sets forth our selected financial data and operating data for our Company on a historical basis. The following data should be read in conjunction with our audited consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere herein. Our historical operating results may not be comparable to our future operating results. The comparability of our selected financial data is significantly affected by our acquisitions and new investments from 2012 to 2016. See “Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations – Portfolio and Other Developments.” Operating Data Revenues . . . . . . . . . . . . . . . . . . . . . Net income . . . . . . . . . . . . . . . . . . . . Net income available to common 2016 Year Ended December 31, 2013 2014 2015 (in thousands, except per share amounts) 2012 $ 900,827 $ 383,367 $ 743,617 $ 233,315 $ 504,787 $ 221,349 $ 418,714 $ 172,521 $ 350,460 $ 120,698 stockholders . . . . . . . . . . . . . . . . . $ 366,415 $ 224,524 $ 221,349 $ 172,521 $ 120,698 Per share amounts: Net income available to common stockholders: Basic . . . . . . . . . . . . . . . . . . . . . Net income: Diluted . . . . . . . . . . . . . . . . . . . Dividends, Common Stock(1) . . . . Weighted-average common shares $ $ 1.91 $ 1.30 $ 1.75 $ 1.47 $ 1.12 1.90 2.36 $ 1.29 2.18 $ 1.74 2.02 $ 1.46 1.86 $ 1.12 1.69 outstanding, basic . . . . . . . . . . . . . 191,781 172,242 126,550 117,257 107,591 Weighted-average common shares outstanding, diluted . . . . . . . . . . . . 201,635 180,508 127,294 118,100 108,011 2016 2015 2014 2013 2012 As of December 31, ( in thousands) Balance Sheet Data Gross investments . . . . . . . . . . . . . . . Total assets (2) . . . . . . . . . . . . . . . . . . Revolving line of credit . . . . . . . . . . . Term loans, net (2) . . . . . . . . . . . . . . . Other long-term borrowings, net (2) . . . Total equity . . . . . . . . . . . . . . . . . . . $9,166,129 8,949,260 190,000 1,094,343 3,082,511 4,211,986 $8,107,352 7,989,936 230,000 745,693 2,564,320 4,100,865 $4,472,840 3,896,674 85,000 198,721 2,069,811 1,401,327 $3,924,917 3,439,907 326,000 196,901 1,479,208 1,300,103 $3,325,533 2,960,232 158,000 98,896 1,546,263 1,011,329 (1) Dividends per share are those declared and paid during such period. (2) As of December 31, 2016, we adopted new accounting guidance on the presentation of debt issuance costs. This guidance requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability. Adopting this guidance resulted in a reduction to total assets, term loans and other long-term borrowings, which are presented for all periods above in accordance with this new guidance. See “Note 2 – Summary of Significant Accounting Policies” to our consolidated financial statements for additional information. Item 7 — Management’s Discussion and Analysis of Financial Condition and Results of Operations Forward-Looking Statements, Reimbursement Issues and Other Factors Affecting Future Results The following discussion should be read in conjunction with the financial statements and notes thereto in the federal intentions, plans, objectives, goals, appearing elsewhere in this document, reimbursement. This document contains forward-looking statements within the meaning of securities laws. These statements relate to our expectations, beliefs, including statements regarding potential future changes 44 strategies, future events, performance and underlying assumptions and other statements other than statements of historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology including, but not limited to, terms such as “may,” “will,” “anticipates,” “expects,” “believes,” “intends,” “should” or comparable terms or the negative thereof. These statements are based on information available on the date of this filing and only speak as to the date hereof and no obligation to update such forward-looking statements should be assumed. Our actual results may differ materially from those reflected in the forward-looking statements contained herein as a result of a variety of factors, including, among other things: (i) (ii) (iii) those items discussed under “Risk Factors” in Part I, Item 1A of this report; uncertainties relating to the business operations of the operators of our assets, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels; the ability of any operators in bankruptcy to reject unexpired lease obligations, modify the terms of our mortgages and impede our ability to collect unpaid rent or interest during the process of a bankruptcy proceeding and retain security deposits for the debtors’ obligations; (iv) our ability to sell closed or foreclosed assets on a timely basis and on terms that allow us to realize the carrying value of these assets; (v) our ability to manage, re-lease or sell any owned and operated facilities; (vi) the availability and cost of capital to us; (vii) changes in our credit ratings and the ratings of our debt securities; (viii) competition in the financing of healthcare facilities; (ix) regulatory and other changes in the healthcare sector; (x) changes in the financial position of our operators; (xi) the effect of economic and market conditions generally and, particularly, in the healthcare industry; (xii) changes in interest rates; (xiii) the amount and yield of any additional investments; (xiv) changes in tax laws and regulations affecting REITs; (xv) the potential impact of changes in the SNF and ALF market or local real estate conditions on our ability to dispose of assets held for sale for the anticipated proceeds or on a timely basis, or to redeploy the proceeds therefrom on favorable terms; and (xvi) our ability to maintain our status as a real estate investment trust. Overview and Outlook We have one reportable segment consisting of investments in healthcare-related real estate properties. Our core business is to provide financing and capital to the long-term healthcare industry with a particular focus on SNFs located in the U.S. and the U.K. Our core portfolio consists of long-term leases and mortgage agreements. All of our leases are “triple-net” leases, which require the tenants to pay all property-related expenses. Our mortgage revenue derives from fixed rate mortgage loans, which are secured by first mortgage liens on the underlying real estate and personal property of the mortgagor. Our portfolio of investments at December 31, 2016, included 996 healthcare facilities, located in 42 states and the U.K. that are operated by 79 third-party operators. Our real estate investment in these facilities totaled approximately $8.9 billion at December 31, 2016, with 99% of our real estate investments related to long-term healthcare facilities. The portfolio is made up of (i) 809 SNFs, (ii) 101 ALFs, (iii) 16 45 specialty facilities, (iv) one medical office building, (v) fixed rate mortgages on 44 SNFs and two ALFs and (vi) 23 SNFs that are currently closed or held-for-sale. At December 31, 2016, we also held other investments of approximately $256.8 million, consisting primarily of secured loans to third-party operators of our facilities. Our consolidated financial statements include the accounts of (i) Omega, (ii) Omega OP and (iii) all direct and indirect wholly-owned subsidiaries of Omega. All inter-company accounts and transactions have been eliminated in consolidation, and our net earnings are reduced by the portion of net earnings attributable to noncontrolling interests. Current market and economic conditions, including deficits at both the federal and state levels could result in additional cost-cutting at both the federal and state levels resulting in additional reductions to reimbursement rates and levels to our operators under both the Medicare and Medicaid programs. State deficits could be exacerbated by the potential for increased enrollment in Medicaid due to prolonged high unemployment levels and declining family incomes, which could cause states to reduce state expenditures under their respective state Medicaid programs by lowering reimbursement rates. Our operator coverages modestly declined throughout 2016 due to a number of factors, including increased labor costs, a dip in the overall quality mix (Medicare, Medicaid, and private pay) as a percentage of operator revenue, which has been driven by continued pressure on the length of stay. We currently believe that our operators can absorb moderate reimbursement rate reductions under Medicaid and Medicare and still meet their obligations to us. However, significant limits on the scope of services reimbursed and on reimbursement rates and fees could have a material adverse effect on an operator’s results of operations and financial condition, which could adversely affect the operator’s ability to meet its obligations to us. We believe that our operating results display the strength of our conservative balance sheet and operating model against the backdrop of an increasingly difficult operating environment. Increasing labor and liability costs, evolving reimbursement models and an increasingly aggressive regulatory and enforcement environment may put near term financial strain on many operators within the skilled nursing industry. 2016 and Recent Highlights Acquisition and Other Investments In 2016, we completed the following transactions totaling approximately $1.3 billion in new investments. • • • • $248 million of new investments with an existing operator. The investments included 21 SNFs from an unrelated third party for $212.5 million and leased them to an existing operator. The SNFs are located in Virginia (7) and North Carolina (14). Omega also acquired title to certain ancillary facilities which includes an office building, a pharmacy building, and other miscellaneous real estate. The SNFs and other real estate were combined into a single 12-year master lease with an existing operator. The Company also provided a $20 million term loan and a $15 million secured working capital loan to the operator. The master lease and term loan have an initial annual cash yield of 8.5% with 2.5% annual escalators. The secured working capital loan has an initial annual cash yield of 8.5%. $337 million of new investments with an existing operator. The investment included 31 SNFs and a $37 million term loan acquired for approximately $337 million from an unrelated third party. The SNFs, located in Florida (6), Kentucky (5) and Tennessee (20), were being operated by an existing operator of the Company. The 31 SNFs were added to the operator’s existing master lease with an initial annual cash yield of 9.0% with 2.5% annual escalators. In addition to aforementioned investments, we also acquired 18 SNFs and 20 ALFs for approximately $480.7 million throughout the U.S. and U.K. $50 million mezzanine loan with a new operator. The mezzanine loan bears interest at LIBOR plus 9.75% per annum (with a 10.50% floor) that matures in February 2019. 46 • We invested $50 million for an approximate 15% ownership interest in an unconsolidated joint venture. • $136.8 million of investments in our capital expenditure programs. See “Portfolio and Other Developments” below for a description of 2016 acquisitions and other investments. Financing Activities Mortgage Term Loan As a result of the Aviv Merger in April 2015, we acquired two subsidiaries that were borrowers under a $180.0 million mortgage term loan secured by mortgages on 28 healthcare facilities owned by one of the borrowers. On July 25, 2016, we purchased the $180.0 million mortgage term loan, effectively eliminating the debt on our consolidated financial statements. The term loan was secured by real estate assets having a net carrying value of $290.5 million at June 30, 2016. We paid $180.0 million plus a 1% premium to purchase the debt. $700 Million 4.375% Senior Notes due 2023 On July 12, 2016, we issued $700 million aggregate principal amount of our 4.375% Senior Notes due 2023 (the “2023 Notes”). The 2023 Notes were sold at an issue price of 99.739% of their face value before the underwriters’ discount. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately $692.0 million. The net proceeds from the offering were used to repay outstanding borrowings under our revolving credit facility, to purchase the $180.0 million mortgage term loan and for general corporate purposes. The 2023 Notes mature on August 1, 2023 and pay interest semi-annually. Unsecured Credit Facility On January 29, 2016, we entered into the Third Amendment to Credit Agreement (the “Third Amendment to Omega Credit Agreement,”) which amended and restated the existing Credit Agreement, dated June 27, 2014 (as amended and restated pursuant to the First Amendment to Credit Agreement, dated April 1, 2015, the Second Amendment to Credit Agreement, dated August 7, 2015 and the Third Amendment to Omega Credit Agreement, collectively the “Omega Credit Agreement”). As a result of the amendments, the Omega Credit Facilities (as defined below) now includes a $1.25 billion senior unsecured revolving credit facility (the “Revolving Credit Facility”), a $200 million senior unsecured term loan facility (the “Tranche A-1 Term Loan Facility”), a $200 million senior unsecured incremental term loan facility (the “Tranche A-2 Term Loan Facility”) and a $350 million senior unsecured incremental term loan facility (the “Tranche A-3 Term Loan Facility” and, together with the Revolving Credit Facility, the Tranche A-1 Term Loan Facility and the Tranche A-2 Term Loan Facility, collectively, the “Omega Credit Facilities”). The Tranche A-1 Term Loan Facility, the Tranche A-2 Term Loan Facility and the Tranche A-3 Term Loan Facility may be referred to collectively herein as the “Omega Term Loan Facilities”. See “Financing Activities and Borrowing Arrangements” below for a description of the 2016 financing activities and borrowing arrangements. 47 Portfolio and Other Developments The following tables summarize the significant transactions that occurred between 2016 and 2014. The 2015 table excludes the acquisition of Care Homes in the U.K. and the Aviv Merger in the second quarter of 2015, which are discussed separately below. 2016 Acquisitions and Other Number of Facilities Period SNF ALF Country/ State Total Investment Land Building & Site Improvements Furniture & Fixtures Initial Annual Cash Yield (%) Q1 . . . — Q1 . . . — 1 1 UK UK 10 — OH, VA, MI Q1 . . . Q1 . . . — 2 Q1 . . . 3 — Q1 . . . 21 — Q2 . . . — 10 3 Q2 . . . — 3 — Q2 . . . 1 Q3 . . . — 1 Q3 . . . — 1 Q3 . . . — 1 — Q3 . . . Q3 . . . 1 — Q3 . . . GA MD VA, NC UK TX CO, MO FL GA FL SC OH 31 — FL, KY, TN $ 8.3 $ 1.4 $ 6.7 $ 0.2 (in millions) 6.1 169.0(3) 20.2 25.0 212.5 111.9(4) 66.0(5) 31.8 4.3 2.5 16.5 10.1 9.0(6) 329.6(1)(2) 0.6 10.5 0.8 2.5 19.3 24.8 5.8 3.1 2.3 0.2 1.8 2.7 — 24.6 5.3 152.5 18.3 19.9 181.1 83.9 58.6 26.2 1.8 2.1 14.3 6.5 8.6 290.8 0.2 6.0 1.1 2.6 12.1 3.2 1.6 2.5 0.2 0.2 0.4 0.9 0.4 14.2 7.00 7.00 8.50 7.50 8.50 8.50 7.00 6.80 9.00 8.00 8.00 8.00 9.00 9.00 9.00 Total . . 70 20 $1,022.8 $100.4 $876.6 $45.8 (1) (2) The Company estimated the fair value of the assets acquired on the acquisition date based on certain valuation analyses that have yet to be finalized, and accordingly, the assets acquired, as detailed, are subject to adjustment once the analysis is completed. The Company’s investment includes a purchase option buyout obligation with a fair value of approximately $29.6 million. The future buyout obligation is recorded in accrued expenses and other liabilities on our Consolidated Balance Sheet. The Company also acquired a term loan with a fair value of approximately $37.0 million which is recorded in other investments on our Consolidated Balance Sheet. Refer to Note – 6 Other Investments. (3) Acquired from a related party. Refer to Note – 2 Summary of Significant Accounting Policies – Related Party Transactions. (4) Omega also recorded a deferred tax asset of approximately $1.9 million in connection with the acquisition. (5) The Company paid $63.0 million in cash at closing to acquire the facilities. We have agreed to pay an additional $1.5 million in April 2017 and the remaining $1.5 million in April 2018. The additional consideration to be paid is contractually determined and not contingent on other factors. The $3.0 million liability is recorded in unsecured borrowings – net on our Consolidated Balance Sheet. The Company paid approximately $3.5 million in cash to acquire the facility. The remainder of (approximately $5.5 million) was funded with the redemption of an other investment note. the purchase price (6) During 2016, the Company also acquired five parcels of land which are not reflected in the table above for approximately $8.3 million with the intent of building new facilities for existing operators. For the year ended December 31, 2016, we recognized rental revenue of approximately $58.1 million and expensed approximately $9.6 million of acquisition related costs in connection with the aforementioned acquisitions. No goodwill was recorded in connection with these acquisitions. 48 2015 Acquisitions and Other Number of Facilities Period SNF ALF State Total Investment Land Building & Site Improvements Furniture & Fixtures Initial Annual Cash Yield (%) (in millions) Q1 . . . . . . . . . 1 — TX $ 6.8 $ Q3 . . . . . . . . . 6 — NE Q3 . . . . . . . . . 1 Q3 . . . . . . . . . — 2 WA 2 GA Q3 . . . . . . . . . Q3 . . . . . . . . . 1 — VA 2 — FL Q3 . . . . . . . . . — — NY 1 — AZ Q4 . . . . . . . . . 1 — TX Q4 . . . . . . . . . 15.0 18.0 10.8 28.5(1) 32.0 111.7(2)(3) 0.6(3) 5.3 0.1 1.4 2.2 1.2 1.9 1.4 111.7 0.3 1.8 $ 6.1 $0.6 12.1 14.9 9.0 24.2 29.0 — 0.3 3.0 1.5 0.9 0.6 2.4 1.6 — — 0.5 Total . . . . . . . . 13 4 $228.7 $122.0 $98.6 $8.1 9.50 9.00 8.00 7.00 9.25 9.00 — 9.00 9.50 In July 2015, we leased the facility to a new operator with an initial lease term of 10 years. (1) (2) On July 24, 2015, we purchased five buildings located in New York City, New York for approximately $111.7 million. We and our operator plan to construct a 201,000 square-foot assisted living and memory care facility. The properties were added to the operator’s existing master lease. The lease provides for a 5% annual cash yield on the land during the construction phase. Upon issuance of a certification of occupancy, the annual cash yield will increase to 7% in year one and 8% in year two with 2.5% annual escalators thereafter. (3) Accounted for as an asset acquisition. For the year ended December 31, 2015, we recognized rental revenue of approximately $4.9 million and expensed $2.2 million of acquisition related costs related to the aforementioned acquisitions. No goodwill was recorded in connection with these acquisitions. Acquisition of Care Homes in the U.K. On May 1, 2015, we closed on a purchase/leaseback Care Homes Transaction (the “Care Homes Transaction”) for 23 care homes located in the U.K. and operated by Healthcare Homes Holding Limited (“Healthcare Homes”). As part of the transaction, we acquired title to the 23 care homes with 1,018 registered beds and leased them to Healthcare Homes pursuant to a 12-year master lease agreement with an initial annual cash yield of 7%, and annual escalators of 2.5%. The care homes, comparable to ALFs in the U.S., are located throughout the East Anglia region (north of London) of the U.K. Healthcare Homes is headquartered in Colchester (Essex County), England. We recorded approximately $193.8 million of assets consisting of land ($20.7 million), building and site improvements ($152.1 million), furniture and fixtures ($5.3 million) and goodwill ($15.7 million). For the year ended December 31, 2015, we recognized approximately $9.5 million of rental revenue and expensed approximately $3.2 million of acquisition related costs associated with the Care Homes Transaction. Aviv Merger On April 1, 2015, Omega completed the Aviv Merger, which was structured as a stock-for-stock merger. Under the terms of the Merger Agreement, each outstanding share of Aviv common stock was converted into 0.90 of a share of Omega Common Stock. In connection with the Aviv Merger, Omega issued approximately 43.7 million shares of Omega Common Stock to former Aviv stockholders. As a result of the Aviv Merger, Omega acquired 342 facilities, two facilities subject to direct financing leases, one medical office building, two mortgages and other investments. Omega also assumed certain outstanding equity awards and other debt and liabilities. Based on the closing price of Omega’s common stock on April 1, 2015, the fair value of the consideration exchanged was approximately $2.3 billion. 49 The following table highlights the final allocation of the assets acquired, liabilities assumed and consideration transferred on April 1, 2015: (in thousands) Fair value of net assets acquired: Land and buildings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 3,107,530 Investment in direct financing leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mortgages notes receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26,823 19,246 23,619 Total investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,177,218 Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630,679 Accounts receivables and other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cash acquired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17,144 84,858 Accrued expenses and other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (223,002) Debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,410,637) Fair value of net assets acquired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 2,276,260 The completion of the final valuation in the first quarter of 2016 did not result in material changes to our Consolidated Statements of Operations or our Consolidated Balance Sheets from our preliminary purchase price allocation reflected in the December 31, 2015 Form 10-K. For the year ended December 31, 2015, we recognized approximately $188.4 million of total revenue and expensed approximately $52.1 million in acquisition and merger related costs in connection with the Aviv Merger. Included within accrued expenses and other liabilities is a $67.3 million contingent liability related to a leasing arrangement with an operator assumed as a result of the Aviv Merger. 2014 Acquisitions and Other Number of Facilities Period SNF ALF State Q1 . . . . . . — Q2/Q3 . . . . Q3 . . . . . . Q4 . . . . . . — 1 3 — 1 — 4 AZ GA, SC TX PA, OR, AR 4 5 Total Investment $ 4.7 34.6 8.2 84.2 $131.7 Land $0.4 0.9 0.4 5.1 $6.8 Building & Site Improvements Furniture & Fixtures Initial Annual Cash Yield (%) (in millions) $ 3.9 32.1 7.4 76.7 $120.1 $0.4 1.6 0.4 2.4 $4.8 9.75 9.50 9.75 6.00 For the year ended December 31, 2014, we recognized rental revenue of approximately $3.2 million and expensed $3.9 million of acquisition costs related to the above transactions. No goodwill was recorded in connection with these acquisitions. Transition of Two West Virginia Facilities to a New Operator On July 1, 2014, we transitioned two West Virginia SNFs that we previously leased to Diversicare Healthcare Services (“Diversicare” and formerly known as Advocat) to a new unrelated third party operator. The two facilities represented 150 operating beds. We amended our Diversicare master lease to reflect the transition of the two facilities to the new operator and for the year ended December 31, 2014 recorded a $0.8 million provision for uncollectible straight-line accounts receivable. Simultaneous with the Diversicare master lease amendment, we entered into a 12-year master lease with a new third party operator. 50 $415 Million of Refinancing/Consolidating Mortgage Loans due 2029 On June 30, 2014, we entered into an agreement to refinance/consolidate $117 million in existing mortgages with maturity dates ranging from 2021 to 2023 on 17 facilities into one mortgage and simultaneously provide mortgage financing for an additional 14 facilities. The original $415 million mortgage matures in 2029 and was secured by 31 facilities. The new loan bore an initial annual cash interest rate of 9.0% that increases by 0.225% per year (e.g., beginning in year 2 the annual cash interest rate will be 9.225%, in year 3 the annual cash interest rate will be 9.45%, etc.). The mortgage is cross-defaulted and cross-collateralized with our existing master lease and other investment notes with the operator. One of the existing mortgages that was refinanced/consolidated into the new $415 million mortgage included annual interest rate escalators and required the mortgagee to pay a prepayment penalty in the event the mortgage was retired early which required us to record an effective yield interest receivable. In connection with the refinancing/consolidating transaction which was entered into at market terms, the old mortgage was considered to be retired early since the modifications made to the terms of the mortgage were more than minor. As of the date of the refinancing/consolidation transaction, the effective yield interest receivable was approximately $2.0 million. We forgave the prepayment penalty associated with the retired mortgage and recorded a $2.0 million provision to write-off the effective yield interest receivable related to the retired mortgage. $112.5 Million of New Mortgage Loan On January 17, 2014, we entered into a $112.5 million first mortgage loan with an existing operator. The loan is secured by 7 SNFs and 2 ALFs located in Pennsylvania (7) and Ohio (2). The mortgage is cross-defaulted and cross-collateralized with our existing master lease with the operator. Mortgage Note due 2028 On April 29, 2016, an existing operator exercised an option to repay certain mortgage notes. We received proceeds of approximately $47.8 million for the mortgage notes due. In connection with the repayment of the mortgage notes we recognized a net gain of approximately $5.4 million which is recorded in mortgage interest income on our Consolidated Statement of Operations. Asset Sales, Impairments and Other In 2016, we sold 38 facilities (21 previously held-for-sale) for approximately $169.6 million in net proceeds recognizing a gain of approximately $50.2 million. We also recorded a total of $58.7 million provision for impairment related to 29 facilities to reduce their net book value to their estimated fair value less costs to sell. To estimate the fair value of these facilities we utilized a market approach and Level 3 inputs (which generally consist of non-binding offers from unrelated third parties). In 2015, we sold seven SNFs (four previously held-for-sale) for total cash proceeds of approximately $41.5 million, generating a gain of approximately $6.4 million. We also recorded a total of $17.7 million provision for impairment related to six SNFs to reduce their net book value to their estimated fair value less costs to sell. To estimate the fair value of these facilities we utilized a market approach and Level 3 inputs. In 2014, we sold four SNFs (three previously held-for-sale) and a parcel of land for total cash proceeds of $4.1 million, resulting in a $2.9 million gain. We also closed two SNFs and recorded a $3.7 million provision for impairment related to these facilities. To estimate the fair value of these facilities we utilized a market approach and Level 3 inputs. The recorded 2016 impairments were primarily the result of a decision to exit certain non-strategic facilities and operators primarily related to facilities acquired in the Aviv Merger. The recorded 2015 and 2014 impairments are primarily the result of closing facilities or updating the estimated proceeds we expected to receive for the sale of closed facilities at that time. See “Note 8 – Assets Held For Sale” for more details. As of December 31, 2016, 2015 and 2014, we do not have any material properties or operators with facilities that are not materially occupied. 51 Results of Operations The following is our discussion of the consolidated results of operations, financial position and liquidity and capital resources, which should be read in conjunction with our audited consolidated financial statements and accompanying notes. Year Ended December 31, 2016 compared to Year Ended December 31, 2015 Operating Revenues Our operating revenues for the year ended December 31, 2016, were $900.8 million, an increase of $157.2 million over the same period in 2015. Following is a description of certain of the changes in operating revenues for the year ended December 31, 2016 compared to 2015: • • Rental income was $743.9 million, an increase of $137.9 million over the same period in 2015. The increase was the result of the Aviv Merger and Care Homes Transaction and other acquisitions and lease amendments made throughout 2015 and 2016. Direct financing lease income was $62.3 million, an increase of $2.4 million over the same period in 2015. The increase was primarily related to the full year impact of two direct financing leases assumed in the Aviv Merger and incremental revenue associated with the New Ark direct financing lease. • Mortgage interest income totaled $69.8 million, an increase of $0.9 million over the same period in 2015. The increase was primarily due to a net gain of approximately $5.4 million resulting from an operator repaying certain mortgage notes and $2.3 million of incremental interest income due to additional funding to existing operators, offset by reduction of approximately $6.9 million of interest income resulting from mortgage loan payoffs. • Other investment income totaled $21.9 million, an increase of $14.3 million over the same period in 2015. The increase was primarily related to the issuance of new notes and additional funding to existing operators. Operating Expenses Operating expenses for the year ended December 31, 2016, were $391.1 million, an increase of approximately $58.7 million over the same period in 2015. Following is a description of certain of the changes in our operating expenses for the year ended December 31, 2016 compared to 2015: • • • • • Our depreciation and amortization expense was $267.1 million for the year ended December 31, 2016, compared to $210.7 million for the same period in 2015. The increase of $56.4 million was primarily due to the acquisitions made throughout 2015 and 2016. Our general and administrative expense was $45.9 million, compared to $38.6 million for the same period in 2015. The increase is primarily related to additional employees resulting from the Aviv Merger and professional service costs. In 2016, acquisition and merger related costs were $9.6 million, compared to $57.5 million for the same period in 2015. The $47.9 million decrease was primarily the result of the Aviv Merger in April 2015 and Care Homes Transaction in May 2015. In 2016, we recorded $58.7 million of provision for impairment, compared to $17.7 million for the same period in 2015. The 2016 impairment related to 29 facilities to reduce their net book value to their estimated fair value less costs to sell. In 2015, we impaired six SNFs and recorded a $17.7 million provision for impairment related to these facilities. Our provision for uncollectible mortgages, notes and accounts receivable was $9.8 million, compared to $7.9 million for the same period in 2015. In 2016, we recorded a $5.6 million provision on three loans reducing their book value to the fair value of the underlying collateral. In addition, we entered into agreements to transition 28 facilities from one of our former operators to a new existing operator. As a result of the transition, we wrote-off approximately $3.4 million 52 of straight line receivable from the former operator. In 2015, we wrote-off $4.7 million of straight line receivable and effective interest balances associated with four leases and three mortgages with an existing operator. We transitioned the facilities to a new operator in January 2016. We also recorded a $3.0 million provision for a note that we impaired in 2015. Other Income (Expense) For the year ended December 31, 2016, total other expenses were $175.6 million, a decrease of approximately $7.5 million over the same period in 2015. The $7.5 million decrease was primarily the result of a $26.7 million decrease in interest refinancing charges related to the prepayment of debt in 2015. The decrease was offset by a $16.7 million increase in interest expense primarily due to an increase in borrowings outstanding to fund new investments and a $2.4 million increase in interest – amortization of deferred financing cost. 2016 Taxes Because we qualify as a REIT, we generally are not subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions. For tax year 2016, we made common dividend payments of $453.2 million to satisfy REIT requirements relating to qualifying income. Subject to the limitation under the REIT asset test rules, we are permitted to own up to 100% of the stock of one or more taxable REIT subsidiaries (“TRSs”). We have elected for two of our subsidiaries to be treated as TRSs. One of our TRSs is subject to federal, state and local income taxes at the applicable corporate rates and the other is subject to foreign income taxes. As of December 31, 2016, one of our TRSs had a net operating loss carry-forward of approximately $0.8 million. The loss carry-forward is fully reserved as of December 31, 2016 with a valuation allowance due to uncertainties regarding realization. During the year ended December 31, 2016, we recorded approximately $3.3 million of federal, state and local income tax provision and approximately $1.9 million of tax benefit for foreign income taxes. Net Income Net income for the year ended December 31, 2016 was $383.4 million compared to $233.3 million for the same period in 2015. National Association of Real Estate Investment Trusts Funds From Operations Our funds from operations (“NAREIT FFO”), for the year ended December 31, 2016, was $660.1 million, compared to $455.3 million for the same period in 2015. We calculate and report NAREIT FFO in accordance with the definition of Funds from Operations and interpretive guidelines issued by the National Association of Real Estate Investment Trusts (“NAREIT”), and, consequently, NAREIT FFO is defined as net income (computed in accordance with GAAP), adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairment on real estate assets, and after adjustments for unconsolidated partnerships and joint ventures. Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect funds from operations on the same basis. We believe that NAREIT FFO is an important supplemental measure of our operating performance. Because the historical cost accounting convention used for real estate assets requires depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time, while real estate values instead have historically risen or fallen with market conditions. NAREIT FFO was designed by the real estate industry to address this issue. NAREIT FFO herein is not necessarily comparable to NAREIT FFO of other REITs that do not use the same definition or implementation guidelines or interpret the standards differently from us. NAREIT FFO is a non-GAAP financial measure. We use NAREIT FFO as one of several criteria to measure the operating performance of our business. We further believe that by excluding the effect of depreciation, amortization, impairment on real estate assets and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, NAREIT FFO can facilitate comparisons of operating performance between periods and 53 between other REITs. We offer this measure to assist the users of our financial statements in evaluating our financial performance under GAAP, and NAREIT FFO should not be considered a measure of liquidity, an alternative to net income or an indicator of any other performance measure determined in accordance with GAAP. Investors and potential investors in our securities should not rely on this measure as a substitute for any GAAP measure, including net income. The following table presents our NAREIT FFO results for the years ended December 31, 2016 and 2015: Year Ended December 31, 2016 2015 (in thousands) Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $383,367 $233,315 Deduct gain from real estate dispositions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (50,208) (6,353) Elimination of non-cash items included in net income: Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267,062 210,703 Depreciation – unconsolidated joint venture . . . . . . . . . . . . . . . . . . . . . . . . . . Add back impairments on real estate properties . . . . . . . . . . . . . . . . . . . . . . . . 1,107 58,726 — 17,681 NAREIT FFO(a) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $660,054 $455,346 333,159 226,962 (a) Includes amounts allocated to Omega stockholders and Omega OP Unit holders. Year Ended December 31, 2015 compared to Year Ended December 31, 2014 Operating Revenues Our operating revenues for the year ended December 31, 2015, were $743.6 million, an increase of $238.8 million over the same period in 2014. Following is a description of certain of the changes in operating revenues for the year ended December 31, 2015 compared to 2014: • • Rental income was $606.0 million, an increase of $217.5 million over the same period in 2014. The increase was the result of the Aviv Merger and Care Homes Transaction and other acquisitions and lease amendments made throughout 2014 and 2015. Direct financing lease income was $59.9 million, an increase of $3.2 million over the same period in 2014. The increase was primarily related to two direct financing leases assumed in the Aviv Merger and incremental revenue associated with the New Ark direct financing lease. • Mortgage interest income totaled $68.9 million, an increase of $15.9 million over the same period in 2014. The increase was primarily due to timing of mortgage investments. During the second quarter of 2014, we entered into a $415 million mortgage with an existing operator. See “Portfolio and Other Developments” above for additional information. • Other investment income totaled $7.5 million, an increase of $1.2 million over the same period in 2014. The increase was primarily related to interest received from loans related to the Aviv Merger in April 2015. Operating Expenses Operating expenses for the year ended December 31, 2015, were $332.3 million, an increase of approximately $172.9 million over the same period in 2014. Following is a description of certain of the changes in our operating expenses for the year ended December 31, 2015 compared to 2014: • Our depreciation and amortization expense was $210.7 million for the year ended December 31, 2015, compared to $123.3 million for the same period in 2014. The increase of $87.4 million was primarily due to the Aviv Merger and Care Homes Transaction. 54 • • • • Our general and administrative expense was $38.6 million, compared to $25.9 million for the same including additional period in 2014. The increase is primarily related to the Aviv Merger, stock-based compensation expense. In 2015, acquisition and merger related costs were $57.5 million, compared to $3.9 million for the same period in 2014. The $53.6 million increase was primarily the result of the Aviv Merger in April 2015 and Care Homes Transaction in May 2015. In 2015, we recorded $17.7 million of provision for impairment, compared to $3.7 million for the same period in 2014. The 2015 impairment related to six SNFs to reduce their net book values to their estimated fair values less costs to sell. In 2014, we closed two SNFs and recorded a $3.7 million provision for impairment related to these facilities. Our provision for uncollectible mortgages, notes and accounts receivable was $7.9 million, compared to $2.7 million for the same period in 2014. In 2015, we wrote-off $4.7 million of straight line receivable and effective interest balances associated with four leases and three mortgages with an existing operator. We transitioned the facilities to a new operator in January 2016. We also recorded a $3.0 million provision for a note that we impaired in 2015. In 2014, we recorded $2.7 million provision for uncollectible receivables related to (i) a write-off of an effective yield interest receivable related to the refinancing (termination) of a mortgage receivable (see $415 Million of Refinancing/Consolidating Mortgage Loan above) and (ii) a straight-line receivable related to the transition of two facilities from an existing operator to a new operator. Other Income (Expense) For the year ended December 31, 2015, total other expenses were $183.1 million, an increase of approximately $56.3 million over the same period in 2014. The $56.3 million increase was primarily the result of: (i) a $28.0 million increase in interest expense due to an increase in borrowings outstanding to fund new investments since January 2014 including the April 1, 2015 Aviv Merger and May 1, 2015 Care Homes Transaction and (ii) a $25.8 million increase in interest refinancing charges. 2015 Taxes Because we qualify as a REIT, we generally are not subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions. For tax year 2015, we made common dividend payments of $358.2 million to satisfy REIT requirements relating to qualifying income. Subject to the limitation under the REIT asset test rules, we are permitted to own up to 100% of the stock of one or more TRSs. We have elected for two of our subsidiaries to be treated as TRSs. One of our TRSs is subject to federal, state and local income taxes at the applicable corporate rates and the other is subject to foreign income taxes. As of December 31, 2015, one of our TRSs had a net operating loss carry-forward of approximately $0.9 million. The loss carry-forward is fully reserved as of December 31, 2015 with a valuation allowance due to uncertainties regarding realization. In connection with the Care Homes Transaction in May 2015, we acquired 10 legal entities consisting of 23 facilities. The tax basis in these legal entities acquired for U.K. taxes was approximately $82 million less than the purchase price. We recorded a preliminary initial deferred tax liability associated with the temporary tax basis difference of approximately $15 million. During the year ended December 31, 2015, we recorded approximately $1.0 million of state and local income tax provision and approximately $0.2 million of provision for foreign income taxes. Net Income Net income for the year ended December 31, 2015 was $233.3 million compared to $221.3 million for the same period in 2014. 55 National Association of Real Estate Investment Trusts Funds From Operations Our NAREIT FFO for the year ended December 31, 2015, was $455.3 million, compared to $345.4 million for the same period in 2014. The following table presents our NAREIT FFO results for the years ended December 31, 2015 and 2014: Year Ended December 31, 2015 2014 (in thousands) Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $233,315 $221,349 Deduct gain from real estate dispositions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (6,353) (2,863) Elimination of non-cash items included in net income: Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210,703 123,257 Add back impairments on real estate properties . . . . . . . . . . . . . . . . . . . . . . . . 17,681 3,660 NAREIT FFO(a) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $455,346 $345,403 226,962 218,486 (a) Includes amounts allocated to Omega stockholders and Omega OP Unit holders. Liquidity and Capital Resources At December 31, 2016, we had total assets of $8.9 billion, total equity of $4.2 billion and debt of $4.4 billion, with such debt representing approximately 50.9% of total capitalization. The following table shows the amounts due in connection with the contractual obligations described below as of December 31, 2016: Payments due by period Total Less than 1 year Years 2 – 3 Years 4 – 5 (in thousands) More than 5 years Debt(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . Interest payments on long-term debt . . . . . . Operating lease and other obligations . . . . . $4,417,954 1,412,368 16,109 $302,788 184,993 2,341 $394,197 346,816 5,070 $372,868 330,596 4,603 $3,348,101 549,963 4,095 Total . . . . . . . . . . . . . . . . . . . . . . . . . . $5,846,431 $490,122 $746,083 $708,067 $3,902,159 (1) The $4.4 billion of debt outstanding includes: (i) $190.0 million in borrowings under the Revolving Credit Facility due in June 2018; (ii) $200 million under the Tranche A-1 Term Loan Facility due on June 2019, (iii) $200 million under the Tranche A-2 Term Loan Facility due June 2017, (iv) $100 million under the Omega OP Term Loan Facility due June 2017, (v) $250 million under the 2015 Term Loan Facility due December 2022, (vi) $350 million under the Tranche A-3 Term Loan Facility due January 2021; (vii) $400 million of 5.875% Senior Notes due March 2024; (viii) $400 million of 4.95% Senior Notes due April 2024; (ix) $250 million of 4.50% Senior Notes due January 2025; (x) $600 million of 5.25% Senior Notes due January 2026; (xi) $700 million of 4.375% Senior Notes due August 2023; (xii) $700 million of 4.5% Senior Notes due April 2027; (xiii) $20 million of 9.0% per annum subordinated debt maturing in December 2021 and (xiv) $55 million of HUD debt at 3.06% per annum maturing in July 2044. Financing Activities and Borrowing Arrangements Mortgage Term Loan As a result of the Aviv Merger in April 2015, we acquired two subsidiaries that were borrowers under a $180.0 million mortgage term loan secured by mortgages on 28 healthcare facilities owned by one of the borrowers. On July 25, 2016, we purchased the $180.0 million mortgage term loan, effectively eliminating the debt on our consolidated financial statements. The term loan was secured by real estate assets having a 56 net carrying value of $290.5 million at June 30, 2016. The interest rate was based on LIBOR, with a floor of 50 basis points, plus a margin of 350 basis points. The interest rate at June 30, 2016 was 4.13% per annum. We paid $180.0 million plus a 1% premium to purchase the debt. $700 Million 4.375% Senior Notes due 2023 On July 12, 2016, we issued $700 million aggregate principal amount of our 4.375% Senior Notes due 2023 (the “2023 Notes”). The 2023 Notes were sold at an issue price of 99.739% of their face value before the underwriters’ discount. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately $692.0 million. The net proceeds from the offering were used to repay outstanding borrowings under our revolving credit facility, to purchase the $180.0 million mortgage term loan and for general corporate purposes. The 2023 Notes mature on August 1, 2023 and pay interest semi-annually. Credit Facilities On January 29, 2016, we entered into the Third Amendment to Credit Agreement (the “Third Amendment to Omega Credit Agreement,” as defined below) which amended and restated the existing Credit Agreement, dated June 27, 2014 (as amended and restated pursuant to the First Amendment to Credit Agreement, dated April 1, 2015, the Second Amendment to Credit Agreement, dated August 7, 2015 and the Third Amendment to Omega Credit Agreement, collectively the “Omega Credit Agreement”). As a result of the amendments, the Omega Credit Facilities (as defined below) now includes a $1.25 billion senior unsecured revolving credit facility (the “Revolving Credit Facility”), a $200 million senior unsecured term loan facility (the “Tranche A-1 Term Loan Facility”), a $200 million senior unsecured incremental term loan facility (the “Tranche A-2 Term Loan Facility”) and a $350 million senior unsecured incremental term loan facility which was borrowed in 2016 (the “Tranche A-3 Term Loan Facility” and, together with the Revolving Credit Facility, the Tranche A-1 Term Loan Facility and the Tranche A-2 Term Loan Facility, collectively, the “Omega Credit Facilities”). The Tranche A-1 Term Loan Facility, the Tranche A-2 Term Loan Facility and the Tranche A-3 Term Loan Facility may be referred to collectively herein as the “Omega Term Loan Facilities”. Borrowings under the Revolving Credit Facility bear interest at LIBOR plus an applicable percentage (beginning at 130 basis points, with a range of 92.5 to 170 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings, plus a facility fee based on the same ratings (initially 25 basis points, with a range of 12.5 to 30 basis points). The Revolving Credit Facility is used for acquisitions and general corporate purposes. The Revolving Credit Facility matures on June 27, 2018, subject to a one-time option by us to extend such maturity date by one year. The Tranche A-1 Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 150 basis points, with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Tranche A-1 Term Loan Facility matures on June 27, 2019. The Tranche A-2 Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 150 basis points, with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Tranche A-2 Term Loan Facility matures on June 27, 2017, subject to Omega’s option to extend the maturity date of the Tranche A-2 Term Loan Facility twice, the first extension until June 27, 2018 and the second extension until June 27, 2019. The Tranche A-3 Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 150 basis points, with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Tranche A-3 Term Loan Facility matures on January 29, 2021. As of December 31, 2016, we have approximately $940 million outstanding on the Omega Credit Facilities. $500 Million Equity Shelf Program On September 3, 2015, we entered into separate Equity Distribution Agreements (collectively, the “Equity Shelf Agreements”) to sell shares of our common stock having an aggregate gross sales price of up to $500 million (the “2015 Equity Shelf Program”) with several financial institutions, each as a sales agent 57 and/or principal (collectively, the “Managers”). Under the terms of the Equity Shelf Agreements, we may sell shares of our common stock, from time to time, through or to the Managers having an aggregate gross sales price of up to $500 million. Sales of the shares, if any, will be made by means of ordinary brokers’ transactions on the New York Stock Exchange at market prices, or as otherwise agreed with the applicable Manager. We will pay each Manager compensation for sales of the shares equal to 2% of the gross sales price per share for shares sold through such Manager under the applicable Equity Shelf Agreement. For the year ended December 31, 2016, we issued approximately 0.7 million shares under the 2015 Equity Shelf Program, at an average price of $29.97 per share, generating gross proceeds of approximately $20.4 million, before $0.7 million of commissions and expenses. For the year ended December 31, 2015, we did not issue any shares under the 2015 Equity Shelf Program. Dividends In order to qualify as a REIT, we are required to distribute dividends (other than capital gain dividends) to our stockholders in an amount at least equal to (A) the sum of (i) 90% of our “REIT taxable income” (computed without regard to the dividends paid deduction and our net capital gain), and (ii) 90% of the net income (after tax), if any, from foreclosure property, minus (B) the sum of certain items of non-cash income. In addition, if we dispose of any built-in gain asset during a recognition period, we will be required to distribute at least 90% of the built-in gain (after tax), if any, recognized on the disposition of such asset. Such distributions must be paid in the taxable year to which they relate, or in the following taxable year if declared before we timely file our tax return for such year and paid on or before the first regular dividend payment after such declaration. In addition, such distributions are required to be made pro rata, with no preference to any share of stock as compared with other shares of the same class, and with no preference to one class of stock as compared with another class except to the extent that such class is entitled to such a preference. To the extent that we do not distribute all of our net capital gain or do distribute at least 90%, but less than 100% of our “REIT taxable income” as adjusted, we will be subject to tax thereon at regular ordinary and capital gain corporate tax rates. In 2016, we paid dividends of $453.2 million to our common stockholders. Common Dividends On January 12, 2017, the Board of Directors declared a common stock dividend of $0.62 per share, increasing the quarterly common dividend by $0.01 per share over the prior quarter. The common dividends were paid February 15, 2017 to common stockholders of record on January 31, 2017. On October 13, 2016, the Board of Directors declared a common stock dividend of $0.61 per share, increasing the quarterly common dividend rate by $0.01 per share over the previous quarter. The common dividends were paid November 15, 2016 to common stockholders of record as of the close of business on October 31, 2016. On July 14, 2016, the Board of Directors declared a common stock dividend of $0.60 per share, increasing the quarterly common dividend rate by $0.02 per share over the prior quarter. The common dividends were paid on August 15, 2016 to common stockholders of record as of the close of business on August 1, 2016. On April 14, 2016, the Board of Directors declared a common stock dividend of $0.58 per share, increasing the quarterly common dividend by $0.01 per share over the prior quarter. The common dividends were paid May 16, 2016 to common stockholders of record on May 2, 2016. On January 14, 2016, the Board of Directors declared a common stock dividend of $0.57 per share, increasing the quarterly common dividend by $0.01 per share over the previous quarter. The common dividends were paid February 16, 2016 to common stockholders of record as of February 2, 2016. Liquidity We believe our liquidity and various sources of available capital, including cash from operations, our existing availability under our Omega Credit Facilities, as amended and expected proceeds from mortgage payoffs are adequate to finance operations, meet recurring debt service requirements and fund future investments through the next twelve months. 58 We regularly review our liquidity needs, the adequacy of cash flow from operations, and other expected liquidity sources to meet these needs. We believe our principal short-term liquidity needs are to fund: • • • • • normal recurring expenses; debt service payments; capital improvement programs; common stock dividends; and growth through acquisitions of additional properties. The primary source of liquidity is our cash flows from operations. Operating cash flows have historically been determined by: (i) the number of facilities we lease or have mortgages on; (ii) rental and mortgage rates; (iii) our debt service obligations; and (iv) general and administrative expenses. The timing, source and amount of cash flows provided by/used in financing activities and used in investing activities are sensitive to the capital markets environment, especially to changes in interest rates. Changes in the capital markets environment may impact the availability of cost-effective capital and affect our plans for acquisition and disposition activity. Cash and cash equivalents totaled $93.7 million as of December 31, 2016, an increase of $88.3 million as compared to the balance at December 31, 2015. The following is a discussion of changes in cash and cash equivalents due to operating, investing and financing activities, which are presented in our Consolidated Statements of Cash Flows. Operating Activities — Operating activities generated $625.8 million of net cash flow for the year ended December 31, 2016, as compared to $463.9 million for the same period in 2015. The increase was primarily related to additional cash flow generated from the approximate $1.3 billion of new investments in 2016 plus the full year impact of the 2015 acquisitions, including the Aviv Merger and Care Homes Transaction. Investing Activities — Net cash flow from investing activities was an outflow of $1.1 billion for the year ended December 31, 2016, as compared to an outflow of $397.4 million for the same period in 2015. The $716.5 million increase in cash outflow from investing activities related primarily to (i) an increase of $665.6 million in acquisitions in 2016 compared to the same period of 2015, (ii) an increase of net cash outflow of $155.2 million from other investments – net in 2016 compared to the same period of 2015, (iii) an increase of $50.0 million in investment in unconsolidated joint venture in 2016 compared to the same period of 2015, (iv) an increase of $34.7 million in mortgage investments in 2016 compared to the same period of 2015 and (v) an increase of $14.1 million in our capital renovation programs in 2016 compared to the same period of 2015. Offsetting these cash outflows was: (i) a $128.1 million increase in proceeds from the sale of real estate investments in 2016 compared to the same period in 2015, (ii) a decrease of $95.2 million in investment in construction in progress in 2016 as compared to the same period of 2015, (iii) a $84.9 million decrease in cash resulting from the Aviv Merger in 2015, (iv) a $58.6 million increase in the collection of mortgage principal primarily related to existing operators repaying certain mortgages. Financing Activities — Net cash flow from financing activities was an inflow of $576.3 million for the year ended December 31, 2016 as compared to an outflow of $65.3 million for the same period in 2015. The $641.6 million increase in cash flow from financing activities was primarily related to (i) inflows of $866.9 million in net long-term borrowings in 2016 as compared to a use of approximately $349.2 million in cash in 2015 and (ii) an increase in net proceeds of $89.2 million from our dividend reinvestment plan in 2016 as compared to the same period in 2015. Offsetting these inflows was (i) a net decrease in cash provided by our credit facility of $185.0 million, in 2015 our credit facility provided $145.0 million in cash as compared to a use of $40.0 million in cash in 2016, (ii) in 2016 dividends paid increased by $94.9 million and (iii) a $419.7 million decrease in cash proceeds from the issuance of common stock in 2016 compared to the same period in 2015. Critical Accounting Policies and Estimates The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States requires management to make estimates and assumptions that affect the 59 reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Our significant accounting policies are described in “Note 2 – Summary of Significant Accounting Policies.” These policies were followed in preparing the consolidated financial statements for all periods presented. Actual results could differ from those estimates. We have identified four significant accounting policies that we believe are critical accounting policies. These critical accounting policies are those that have the most impact on the reporting of our financial condition and those requiring significant assumptions, judgments and estimates. With respect to these critical accounting policies, we believe the application of judgments and assessments is consistently applied and produces financial information that fairly presents the results of operations for all periods presented. The four critical accounting policies are: Lease Accounting At the inception of the lease and during the amendment process, we evaluate each lease to determine if the lease should be considered an operating lease, a sales-type lease or direct financing lease. We have determined that all but seven of our leases should be accounted for as operating leases. The other seven leases are accounted for as direct financing leases. For leases accounted for as operating leases, we retain ownership of the asset and record depreciation expense. We also record lease revenue based on the contractual terms of the operating lease agreement which often includes annual rent escalators, see “Revenue Recognition and Allowance for Doubtful Accounts” below for further discussion regarding the recordation of revenue on our operating leases. For leases accounted for as direct financing leases, we record the present value of the future minimum lease payments (utilizing a constant interest rate over the term of the lease agreement) as a receivable and record interest income based on the contractual terms of the lease agreement. As of December 31, 2016 and 2015, $3.3 million and $3.3 million, respectively, of unamortized direct costs related to originating the direct financing leases have been deferred and recorded in our Consolidated Balance Sheets. Revenue Recognition and Allowance for Doubtful Accounts We have various different investments that generate revenue, including leased and mortgaged properties, as well as, other investments, including working capital loans. We recognized rental income and mortgage interest income and other investment income as earned over the terms of the related leases and notes, respectively. Interest income is recorded on an accrual basis to the extent that such amounts are expected to be collected using the effective interest method. In applying the effective interest method, the effective yield on a loan is determined based on its contractual payment terms, adjusted for prepayment terms. Substantially all of our leases contain provisions for specified annual increases over the rents of the prior year and are generally computed in one of three methods depending on specific provisions of each lease as follows: (i) a specific annual increase over the prior year’s rent, generally between 2.0% and 3.0%; (ii) an increase based on the change in pre-determined formulas from year to year (i.e., such as increases in the Consumer Price Index); or (iii) specific dollar increases over prior years. Revenue under lease the lease on a arrangements with fixed and determinable increases is recognized over the term of straight-line basis. The authoritative guidance does not provide for the recognition of contingent revenue until all possible contingencies have been eliminated. We consider the operating history of the lessee, the payment history, the general condition of the industry and various other factors when evaluating whether all possible contingencies have been eliminated. We do not include contingent rents as income until the contingencies are resolved. In the case of rental revenue recognized on a straight-line basis, we generally record reserves against earned revenues from leases when collection becomes questionable or when negotiations for restructurings of troubled operators result in significant uncertainty regarding ultimate collection. The amount of the reserve is estimated based on what management believes will likely be collected. We continually evaluate the collectability of our straight-line rent assets. If it appears that we will not collect future rent due under our leases, we will record a provision for loss related to the straight-line rent asset. 60 We record direct financing lease income on a constant interest rate basis over the term of the lease. The costs related to originating the direct financing leases have been deferred and are being amortized on a straight-line basis as a reduction to income from direct financing leases over the term of the direct financing leases. Mortgage interest income is recognized as earned over the terms of the related mortgage notes, using the effective yield method. Allowances are provided against earned revenues from mortgage interest when collection of amounts due becomes questionable or when negotiations for restructurings of troubled operators lead to lower expectations regarding ultimate collection. When collection is uncertain, mortgage interest income on impaired mortgage loans is recognized as received after taking into account the application of security deposits. We review our accounts receivable to determine their collectability. The determination of collectability of these assets requires significant judgment and is affected by several factors relating to the credit quality of our operators that we regularly monitor, including (i) payment history, (ii) the age of the contractual receivables, (iii) the current economic conditions and reimbursement environment, (iv) the ability of the tenant to perform under the terms of their lease and/or contractual loan agreements and (v) the value of the underlying collateral of the agreement. If we determine collectability of any of our contractual receivables is at risk, we estimate the potential uncollectible amounts and provide an allowance. In the case of a lease recognized on a straight-line basis, a mortgage recognized on an effective yield basis or the existence of lease inducements, we generally provide an allowance for straight-line, effective interest, and or lease inducement accounts receivable when certain conditions or indicators of adverse collectability are present. If the accounts receivable balance is subsequently deemed uncollectible, the receivable and allowance for doubtful account balance are written off. Gains on sales of real estate assets are recognized in accordance with the authoritative guidance for sales of real estate. The specific timing of the recognition of the sale and the related gain is measured against the various criteria in the guidance related to the terms of the transactions and any continuing involvement associated with the assets sold. To the extent the sales criteria are not met, we defer gain recognition until the sales criteria are met. Depreciation and Asset Impairment Under GAAP, real estate assets are stated at the lower of depreciated cost or fair value, if deemed impaired. Depreciation is computed on a straight-line basis over the estimated useful lives of 20 to 40 years for buildings, eight to 15 years for site improvements and three to ten years for furniture, fixtures and equipment. Management evaluates our real estate investments for impairment indicators, including the evaluation of our assets’ useful lives. The judgment regarding the existence of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance, legal structure as well as our intent with respect to holding or disposing of the asset. If indicators of impairment are present, management evaluates the carrying value of the related real estate investments in relation to the future undiscounted cash flows of the underlying facilities. Provisions for impairment losses related to long-lived assets are recognized when expected future undiscounted cash flows are determined to be less than the carrying values of the assets. An adjustment is made to the net carrying value of the leased properties and other long-lived assets for the excess of historical cost over fair value. The fair value of the real estate investment is determined by market research, which includes valuing the property as a nursing home as well as other alternative uses. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to reflect the new value assigned to the asset. Changes in the facts and circumstances that drive management’s assumptions may result in an impairment of the Company’s assets in a future period that could be material to the Company’s results of operations. If we decide to sell rental properties or land holdings, we evaluate the recoverability of the carrying amounts of the assets. If the evaluation indicates that the carrying value is not recoverable from estimated net sales proceeds, the property is written down to estimated fair value less costs to sell. Our estimates of cash flows and fair values of the properties are based on current market conditions and consider matters such as rental rates and occupancies for comparable properties, recent sales data for comparable properties, and, where applicable, contracts or the results of negotiations with purchasers or prospective purchasers. 61 For the years ended December 31, 2016, 2015, and 2014, we recognized impairment losses of $58.7 million, $17.7 million and $3.7 million, respectively. Loan and Direct Financing Lease Impairment Management evaluates our outstanding mortgage notes, direct financing leases and other notes receivable. When management identifies potential loan or direct financing lease impairment indicators, such as non-payment under the loan documents, impairment of the underlying collateral, financial difficulty of the operator or other circumstances that may impair full execution of the loan documents or direct financing leases, and management believes it is probable that all amounts will not be collected under the contractual terms of the loan or direct financing leases, the loan or direct financing lease is written down to the present value of the expected future cash flows. In cases where expected future cash flows are not readily determinable, the loan or direct financing lease is written down to the fair value of the collateral. The fair value of the loan or direct financing leases is determined by market research, which includes valuing the property as a nursing home as well as other alternative uses. We currently account for impaired loans and direct financing leases using (a) the cost-recovery method, and/or (b) the cash basis method. We generally utilize the cost recovery method for impaired loans or direct financing leases for which impairment reserves were recorded. We utilize the cash basis method for impairment loans or direct financing leases for which no impairment reserves were recorded because the net present value of the discounted cash flows expected under the loan or direct financing lease and or the underlying collateral supporting the loan or direct financing lease were equal to or exceeded the book value of the loans or direct financing leases. Under the cost recovery method, we apply cash received against the outstanding loan balance or direct financing leases prior to recording interest income. Under the cash basis method, we apply cash received to principal or interest income based on the terms of the agreement. As of December 31, 2016 and 2015, we had $8.7 million and $3.0 million, respectively, of reserves on our mortgages and other investments and no reserves on our direct financing leases. Item 7A — Quantitative and Qualitative Disclosures About Market Risk We are exposed to various market risks, including the potential loss arising from adverse changes in interest rates. We do not enter into derivatives or other financial instruments for trading or speculative purposes, but we seek to mitigate the effects of fluctuations in interest rates by matching the term of new investments with new long-term fixed rate borrowing to the extent possible. The following disclosures of estimated fair value of financial instruments are subjective in nature and are dependent on a number of important assumptions, including estimates of future cash flows, risks, discount rates and relevant comparable market information associated with each financial instrument. Readers are cautioned that many of the statements contained in these paragraphs are forward-looking and should be read in conjunction with our disclosures under the heading “Forward-looking Statements, Reimbursement Issues and Other Factors Affecting Future Results” set forth above. The use of different market assumptions and estimation methodologies may have a material effect on the reported estimated fair value amounts. Accordingly, the estimates presented below are not necessarily indicative of the amounts we would realize in a current market exchange. Mortgage notes receivable — The fair value of mortgage notes receivable is estimated by discounting the future cash flows using the current rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities. Direct Financing Leases — The fair value of direct financing receivable is estimated by discounting the future cash flows using the current rates at which similar leases would be made to borrowers with similar credit ratings and for the same remaining maturities. Other investments — The fair value of other investments is estimated by discounting the future cash flows using the current rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities. Borrowings under variable rate agreements — Our variable rate debt as of December 31, 2016 includes our credit facilities and term loans. The fair value of our borrowings under variable rate agreements is estimated using an expected present value technique based on expected cash flows discounted using the current credit-adjusted risk-free rate. 62 Senior unsecured notes — The fair value of the senior unsecured notes is estimated based on open market trading activity provided by third parties. The market value of our long-term fixed rate borrowings and mortgages is subject to interest rate risks. Generally, the market value of fixed rate financial instruments will decrease as interest rates rise and increase as interest rates fall. The estimated fair value of our total long-term borrowings at December 31, 2016 was approximately $4.4 billion. A one percent increase in interest rates would result in a decrease in the fair value of long-term borrowings by approximately $246 million at December 31, 2016. We may enter into certain types of derivative financial instruments to further reduce interest rate risk. We use interest rate swap agreements, for example, to convert some of our variable rate debt to a fixed-rate basis or to hedge anticipated financing transactions. We use derivatives for hedging purposes rather than speculation and do not enter into financial instruments for trading purposes. We entered into interest rate swap agreements that effectively fixes the interest rate on the 2015 Term Loan Facility at 3.8005% per annum beginning December 30, 2016 through its maturity date and extension options, subject to adjustments based on our consolidated leverage ratio. At December 31, 2016 and December 31, 2015, we had $1.5 million and $0.7 million, respectively, of qualifying cash flow hedges recorded at fair value in accrued expenses and other liabilities on our Consolidated Balance Sheets. The forward-starting swap contract was deemed to be a highly effective cash flow hedge and we elected to designate the forward-starting swap contract as an accounting hedge. Item 8 — Financial Statements and Supplementary Data The consolidated financial statements and the report of Ernst & Young LLP, Independent Registered Public Accounting Firm, on such financial statements are filed as part of this report beginning on page F-1. The summary of unaudited quarterly results of operations for the years ended December 31, 2016 and 2015 is included in “Note 20 – Summary of Quarterly Results (Unaudited)” to our audited consolidated financial statements, which is incorporated herein by reference in response to Item 302 of Regulation S-K. Item 9 — Changes in and Disagreements with Accountants on Accounting and Financial Disclosure None. Item 9A — Controls and Procedures Evaluation of Disclosure Controls and Procedures Disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In connection with the preparation of our Form 10-K as of and for the year ended December 31, 2016, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2016. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2016. Management’s Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, a company’s principal executive and principal financial officers, or persons performing similar functions, and effected by 63 a company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that: • • • Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company; Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements. All internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. In connection with the preparation of our Form 10-K, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2016. In making that assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway in Internal Control-Integrated Framework (“2013 framework”). Based on Commission (“COSO”) management’s assessment, management believes that, as of December 31, 2016, our internal control over financial reporting was effective based on those criteria. Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, we have included above a report of management’s assessment of the design and effectiveness of our internal controls as part of this Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Our independent registered public accounting firm also reported on the effectiveness of internal control over financial reporting. The independent registered public accounting firm’s attestation report is included in our 2016 financial statements under the caption entitled “Report of Independent Registered Public Accounting Firm” and is incorporated herein by reference. Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended December 31, 2016 identified in connection with the evaluation of our disclosure controls and procedures described above that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Item 9B — Other Information None. 64 PART III Item 10 — Directors, Executive Officers of the Registrant and Corporate Governance The information required by this item is incorporated herein by reference to our Company’s definitive proxy statement for the 2017 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation 14A. For information regarding executive officers of our Company, see “Item 1 – Business – Executive Officers of Our Company.” Code of Business Conduct and Ethics. We have adopted a written Code of Business Conduct and Ethics (“Code of Ethics”) that applies to all of our directors and employees, including our chief executive officer, chief financial officer, chief accounting officer and controller. A copy of our Code of Ethics is available on our website at www.omegahealthcare.com, and print copies are available upon request without charge. You can request print copies by contacting our Chief Financial Officer in writing at Omega Healthcare Investors, Inc., 200 International Circle, Suite 3500, Hunt Valley, Maryland 21030 or by telephone at 410-427-1700. Any amendment to our Code of Ethics or any waiver of our Code of Ethics will be disclosed on our website at www.omegahealthcare.com promptly following the date of such amendment or waiver. Item 11 — Executive Compensation The information required by this item is incorporated herein by reference to our Company’s definitive proxy statement for the 2017 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation 14A. Item 12 — Security Ownership of Certain Beneficial Owners and Management The information required by this item is incorporated herein by reference to our Company’s definitive proxy statement for the 2017 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation 14A. Item 13 — Certain Relationships and Related Transactions, and Director Independence The information required by this item, if any, is incorporated herein by reference to our Company’s definitive proxy statement for the 2017 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation 14A. Item 14 — Principal Accounting Fees and Services The information required by this item is incorporated herein by reference to our Company’s definitive proxy statement for the 2017 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation 14A. 65 PART IV Item 15 — Exhibits and Financial Statement Schedules (a)(1) Listing of Consolidated Financial Statements Title of Document Reports of Independent Registered Public Accounting Firm . . . . . . . . . . . . . . . . . . Consolidated Balance Sheets as of December 31, 2016 and 2015 . . . . . . . . . . . . . . . Page Number F-1 F-3 Consolidated Statements of Operations for the years ended December 31, 2016, 2015 and 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-4 Consolidated Statements of Comprehensive Income for the years ended December 31, 2016, 2015 and 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-5 Consolidated Statements of Changes in Equity for the years ended December 31, 2016, 2015 and 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-6 Consolidated Statements of Cash Flows for the years ended December 31, 2016, 2015 and 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-7 F-9 (a)(2) Listing of Financial Statement Schedules. The following consolidated financial statement schedules are included herein: Schedule III — Real Estate and Accumulated Depreciation . . . . . . . . . . . . . . . . . . . Schedule IV — Mortgage Loans on Real Estate . . . . . . . . . . . . . . . . . . . . . . . . . . . F-57 F-59 All other schedules for which provision is made in the applicable accounting regulation of the Securities and Exchange Commission are not required under the related instructions or are inapplicable or have been omitted because sufficient information has been included in the notes to the Consolidated Financial Statements. (a)(3) Listing of Exhibits — See “Index to Exhibits” beginning on Page I-1 of this report. (b) Exhibits — See “Index to Exhibits” beginning on Page I-1 of this report. (c) Financial Statement Schedules — The following consolidated financial statement schedules are included herein: Schedule III — Real Estate and Accumulated Depreciation. Schedule IV — Mortgage Loans on Real Estate. Item 16 — Summary Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information. 66 Report of Independent Registered Public Accounting Firm The Board of Directors and Stockholders of Omega Healthcare Investors, Inc. We have audited the accompanying consolidated balance sheets of Omega Healthcare Investors, Inc. as of December 31, 2016 and 2015, and the related consolidated statements of operations, comprehensive income, changes in equity and cash flows for each of the three years in the period ended December 31, 2016. Our audits also included the financial statement schedules listed in the Index at Item 15(a)(2). These financial statements and schedules are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and schedules based on our audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Omega Healthcare Investors, Inc. at December 31, 2016 and 2015, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2016, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedules, when considered in relation to the basic financial statements taken as a whole, present fairly in all material respects the information set forth therein. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Omega Healthcare Investors, Inc.’s internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 24, 2017 expressed an unqualified opinion thereon. /s/ Ernst & Young LLP Baltimore, Maryland February 24, 2017 F-1 Report of Independent Registered Public Accounting Firm The Board of Directors and Stockholders of Omega Healthcare Investors, Inc. We have audited Omega Healthcare Investors, Inc.’s internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). Omega Healthcare Investors, Inc.’s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. In our opinion, Omega Healthcare Investors, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2016, based on the COSO criteria. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Omega Healthcare Investors, Inc. as of December 31, 2016 and 2015, and the related consolidated statements of operations, comprehensive income, changes in equity, and cash flows for each of the three years in the period ended December 31, 2016 and our report dated February 24, 2017 expressed an unqualified opinion thereon. /s/ Ernst & Young LLP Baltimore, Maryland February 24, 2017 F-2 OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except per share amounts) December 31, 2016 2015 Real estate properties ASSETS Real estate investments (see Note 3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 7,566,358 $ 6,743,958 Less accumulated depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,240,336) (1,019,150) Real estate investments – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,326,022 5,724,808 Investments in direct financing leases – net . . . . . . . . . . . . . . . . . . . . . . . . Mortgage notes receivable – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601,938 639,343 587,701 679,795 7,567,303 6,992,304 Other investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256,846 Investment in unconsolidated joint venture . . . . . . . . . . . . . . . . . . . . . . . . . Assets held for sale – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Restricted cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Accounts receivable – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48,776 52,868 7,925,793 93,687 13,589 240,035 643,474 32,682 89,299 — 6,599 7,088,202 5,424 14,607 203,862 645,683 32,158 Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 8,949,260 $ 7,989,936 LIABILITIES AND EQUITY Revolving line of credit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Term loans – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Secured borrowings – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Unsecured borrowings – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Accrued expenses and other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 190,000 1,094,343 54,365 3,028,146 360,514 9,906 $ 230,000 745,693 235,593 2,328,727 333,706 15,352 Total liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,737,274 3,889,071 Equity: Common stock $.10 par value authorized – 350,000 shares, issued and outstanding – 196,142 shares as of December 31, 2016 and 187,399 as of December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Common stock – additional paid-in capital Cumulative net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cumulative dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Accumulated other comprehensive loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19,614 4,861,408 1,738,937 (2,707,387) (53,827) 18,740 4,609,474 1,372,522 (2,254,038) (8,712) Total stockholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,858,745 3,737,986 Noncontrolling interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 353,241 362,879 Total equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,211,986 4,100,865 Total liabilities and equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 8,949,260 $ 7,989,936 See accompanying notes. F-3 OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Year Ended December 31, 2016 2015 2014 Revenue Rental income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 743,885 $ 605,991 $ 388,443 Income from direct financing leases . . . . . . . . . . . . . . . . . . . . . . Mortgage interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other investment income – net . . . . . . . . . . . . . . . . . . . . . . . . . . Miscellaneous income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62,298 69,811 21,852 2,981 59,936 68,910 7,534 1,246 56,719 53,007 6,369 249 Total operating revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 900,827 743,617 504,787 Expenses Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . 267,062 210,703 123,257 General and administrative . . . . . . . . . . . . . . . . . . . . . . . . . . . . Acquisition and merger related costs . . . . . . . . . . . . . . . . . . . . . . Impairment loss on real estate properties . . . . . . . . . . . . . . . . . . . Provisions for uncollectible mortgages, notes and accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Income before other income and expense . . . . . . . . . . . . . . . . . . . . . Other income (expense) Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Interest – amortization of deferred financing costs . . . . . . . . . . . . Interest – refinancing costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . Realized loss on foreign exchange . . . . . . . . . . . . . . . . . . . . . . . . Total other expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Income before gain on assets sold . . . . . . . . . . . . . . . . . . . . . . . . . . Gain on assets sold – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Income from continuing operations . . . . . . . . . . . . . . . . . . . . . . . . . Income tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Income from unconsolidated joint venture . . . . . . . . . . . . . . . . . . 45,867 9,582 58,726 9,845 391,082 509,745 173 (164,103) (9,345) (2,113) (232) (175,620) 334,125 50,208 384,333 (1,405) 439 38,568 57,525 17,681 7,871 332,348 411,269 285 (147,381) (6,990) (28,837) (173) (183,096) 228,173 6,353 234,526 (1,211) — Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 383,367 233,315 Net income attributable to noncontrolling interest . . . . . . . . . . . . . . . (16,952) (8,791) 25,888 3,948 3,660 2,723 159,476 345,311 44 (119,369) (4,459) (3,041) — (126,825) 218,486 2,863 221,349 — — 221,349 — Net income available to common stockholders . . . . . . . . . . . . . . . . . . $ 366,415 $ 224,524 $ 221,349 Income per common share available to common stockholders: Basic: Net income available to common stockholders . . . . . . . . . . . . . . . Diluted: Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ $ 1.91 1.90 $ $ 1.30 1.29 $ $ 1.75 1.74 Weighted-average shares outstanding, basic . . . . . . . . . . . . . . . . . . . 191,781 172,242 126,550 Weighted-average shares outstanding, diluted . . . . . . . . . . . . . . . . . 201,635 180,508 127,294 See accompanying notes. F-4 OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (in thousands) Year Ended December 31, 2016 2015 2014 Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $383,367 $233,315 $221,349 Other comprehensive income (loss) Foreign currency translation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (46,535) (8,413) Cash flow hedges . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (702) (718) Total other comprehensive income (loss) . . . . . . . . . . . . . . . . . . . . . . (47,237) (9,131) — — — Comprehensive income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Comprehensive income attributable to noncontrolling interest(1) 336,130 (14,830) 224,184 (8,373) 221,349 — Comprehensive income attributable to common stockholders(1) . . . . . . . . $321,300 $215,811 $221,349 (1) The 2015 amount has been adjusted to increase the comprehensive income attributable to the noncontrolling interest and decrease the comprehensive income attributable to common stockholders by $8.8 million. See accompanying notes. F-5 OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (in thousands, except per share amounts) Balance at December 31, 2013 (123,530 common shares) . . $12,353 $1,998,169 $ 926,649 $(1,637,068) $ — $1,300,103 $ — $1,300,103 Common Stock Par Value Additional Paid-in Capital Cumulative Net Earnings Cumulative Dividends Paid Accumulated Other Comprehensive Loss Total Stockholders’ Equity Noncontrolling Interest Total Equity Grant of restricted stock to company directors (12 shares at $35.79 per share) . . . . . . . . . . . . . . . Stock-based compensation expense . . . . . . . . . . . . Vesting of restricted stock, net of tax withholdings (126 shares) . . . . . . . . . . . . . . . . . . . . . . . Dividend reinvestment plan (2,084 shares at $34.32 per share) an average of $35.52 per share) . . . . . . . . . . . . . . . . . . . . . . . . Grant of stock as payment of directors fees (6 shares at . . . . . . . . . . . . Equity Shelf Program (1,848 shares at $34.33 per share, net of issuance costs) . . . . . . . . . . . . . . . . . . Common dividends declared ($2.02 per share). . . . . . Net income . . . . . . . . . . . . . . . . . . . . . . . . . Balance at December 31, 2014 (127,606 common shares) . . 1 — 13 (1) 8,382 (3,590) 208 71,279 1 199 — — — — — — — — — — 185 — — 12,761 61,796 — — 2,136,234 — — 221,349 1,147,998 — (258,598) — (1,895,666) — — — — — — — — — — — — — — — — — — — 8,382 (3,577) 71,487 200 61,981 (258,598) 221,349 1,401,327 — 11,133 (26,706) 150,847 109,346 12,644 313 1,444 439,322 — — — — — — 8,382 (3,577) 71,487 200 61,981 — (258,598) — — 221,349 — 1,401,327 — — — — — — — — — — 11,133 (26,706) 150,847 109,346 12,644 313 1,444 439,322 — — — — — — — — — — — — — — — — — — — — — — — — — 224,524 — (358,372) — — — — — — — — — — — (8,027) (685) — 1,780,876 (358,372) — 1,780,876 (358,372) — 373,394 — 373,394 (7,251) (7,251) — (11,636) (11,636) — (8,413) (386) (8,027) (718) (33) (685) 233,315 8,791 224,524 — — — — — — — — — — — — — — — (453,349) — — — — — — — — — — — — — 366,415 — — — — — — — (44,468) (647) — — — — 13,790 (23,426) 240,041 325 (129) 19,651 (453,349) 2,566 (10) — (44,468) (647) 366,415 — — — — — — — — — (3,289) (21,179) (2,067) (55) 16,952 — 13,790 (23,426) 240,041 325 (129) 19,651 (453,349) 2,566 (3,299) (21,179) (46,535) (702) 383,367 18,740 4,609,474 1,372,522 (2,254,038) (8,712) 3,737,986 362,879 4,100,865 Grant of restricted stock to company directors (21 shares at $35.70 per share) . . . . . . . . . . . . . . . Stock-based compensation expense . . . . . . . . . . . . Vesting/exercising of equity compensation, net of tax withholdings (941 shares) . . . . . . . . . . . . . . . Dividend reinvestment plan (4,184 shares at $36.06 per share) . . . . . . . . . . . . . . . . . . . . . . . . Value of assumed options in Aviv Merger . . . . . . . . Value of assumed other equity compensation plan in an average of $35.94 per share) Aviv Merger . . . . . . . . . . . . . . . . . . . . . . . Grant of stock as payment of directors fees (9 shares at . . . . . . . . . . . . Deferred compensation directors . . . . . . . . . . . . . Issuance of common stock (10,925 shares at an average of $40.32 per share) . . . . . . . . . . . . . . . . . . . Issuance of common stock – Aviv Merger – related (43,713 shares) . . . . . . . . . . . . . . . . . . . . . Common dividends declared ($2.18 per share) . . . . . . . . . . . . . . . . . . . . OP units issuance (9,165 units) Conversion of OP units (209 units) . . . . . . . . . . . . OP units distributions . . . . . . . . . . . . . . . . . . . Foreign currency translation . . . . . . . . . . . . . . . . Cash flow hedges . . . . . . . . . . . . . . . . . . . . . . Net income . . . . . . . . . . . . . . . . . . . . . . . . . Balance at December 31, 2015 (187,399 shares & 8,956 OP Units) . . . . . . . . . . . . . . . . . . . . . . . . . . Grant of restricted stock to company directors (18 shares at $33.09 per share) . . . . . . . . . . . . . . . Stock-based compensation expense . . . . . . . . . . . . Vesting/exercising of equity compensation, net of tax withholdings (773 shares) . . . . . . . . . . . . . . . Dividend reinvestment plan (7,215 shares at $33.27 2 — 94 418 — — 1 — (2) 11,133 (26,800) 150,429 109,346 12,644 312 1,444 1,093 438,229 4,371 — — — — — — — 1,776,505 — — — — — — — 2 — 77 (2) 13,790 (23,503) per share) . . . . . . . . . . . . . . . . . . . . . . . . 721 239,320 Grant of stock as payment of directors fees (10 shares at an average of $31.27 per share) . . . . . . . . . . . Deferred compensation directors . . . . . . . . . . . . . Equity Shelf Program (656 shares at $29.97 per share, net of issuance costs) . . . . . . . . . . . . . . . . . . Common dividends declared ($2.36 per share) . . . . . . Conversion of OP units to common stock (72 shares at $35.68 per share) . . . . . . . . . . . . . . . . . . . . Redemption of OP units (94 units) . . . . . . . . . . . . OP units distributions . . . . . . . . . . . . . . . . . . . Foreign currency translation . . . . . . . . . . . . . . . . Cash flow hedges . . . . . . . . . . . . . . . . . . . . . . Net income . . . . . . . . . . . . . . . . . . . . . . . . . Balance at December 31, 2016 (196,142 shares & 8,862 1 — 66 — 7 — — — — — 324 (129) 19,585 — 2,559 (10) — — — — OP Units) . . . . . . . . . . . . . . . . . . . . . . . . . . $19,614 $4,861,408 $1,738,937 $(2,707,387) $(53,827) $3,858,745 $353,241 $4,211,986 See accompanying notes. F-6 OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Year Ended December 31, 2015 2014 2016 Cash flows from operating activities Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Adjustment to reconcile net income to net cash provided by operating activities: Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Impairment loss on real estate properties . . . . . . . . . . . . . . . . . . . . . . . . Provision for uncollectible mortgages, notes and accounts receivable . . . . . . . . . Refinancing costs and amortization of deferred financing costs . . . . . . . . . . . Accretion of direct financing leases . . . . . . . . . . . . . . . . . . . . . . . . . . . Stock-based compensation expense . . . . . . . . . . . . . . . . . . . . . . . . . . . Gain on assets sold – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Amortization of acquired in-place leases – net . . . . . . . . . . . . . . . . . . . . . Change in operating assets and liabilities – net of amounts assumed/acquired: Accounts receivable, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Straight-line rent receivables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Lease inducements Effective yield receivable on mortgage notes . . . . . . . . . . . . . . . . . . . . . . Other operating assets and liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net cash provided by operating activities Cash flows from investing activities Acquisition of real estate – net of liabilities assumed and escrows acquired . . . . . . . . . Cash acquired in merger . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investments in construction in progress Investments in direct financing leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Placement of mortgage loans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investments in unconsolidated joint venture . . . . . . . . . . . . . . . . . . . . . . . . . . Distributions from unconsolidated joint venture . . . . . . . . . . . . . . . . . . . . . . . Proceeds from sale of real estate investments . . . . . . . . . . . . . . . . . . . . . . . . . Capital improvements to real estate investments . . . . . . . . . . . . . . . . . . . . . . . . Proceeds from other investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investments in other investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Collection of mortgage principal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net cash used in investing activities Cash flows from financing activities Proceeds from credit facility borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . Payments on credit facility borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Receipts of other long-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Payments of other long-term borrowings Payments of financing related costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Receipts from dividend reinvestment plan . . . . . . . . . . . . . . . . . . . . . . . . . . . Payments for exercised options and restricted stock . . . . . . . . . . . . . . . . . . . . . Net proceeds from issuance of common stock . . . . . . . . . . . . . . . . . . . . . . . . . Dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Redemption of OP Units . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Distributions to OP Unit Holders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net cash provided by (used in) financing activities . . . . . . . . . . . . . . . . . . . . . . Effect of foreign currency translation on cash and cash equivalents . . . . . . . . . . . . . Increase in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cash and cash equivalents at beginning of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cash and cash equivalents at end of year Interest paid during the year, net of amounts capitalized . . . . . . . . . . . . . . . . . . . Taxes paid during the year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 383,367 $ 233,315 $ 221,349 267,062 58,726 9,845 11,458 (12,157) 13,790 (50,208) (13,991) (4,876) (42,091) 2,589 (721) 2,998 625,791 (959,748) — (68,983) (2,080) (48,722) (50,032) 1,318 169,603 (40,471) 96,789 (271,557) 59,975 (1,113,908) 1,304,000 (1,344,000) 1,048,173 (181,249) (11,830) 240,041 (23,426) 19,651 (453,152) (733) (21,179) 576,296 84 88,263 5,424 93,687 $ 210,703 17,681 7,871 35,827 (11,007) 11,133 (6,353) (13,846) 248 (36,057) 994 (4,065) 17,441 463,885 (294,182) 84,858 (164,226) (6,793) (14,042) — — 41,543 (26,397) 45,871 (65,402) 1,359 (397,411) 123,257 3,660 2,723 7,500 (9,787) 8,592 (2,863) (4,986) (2,264) (20,956) 2,656 (2,878) 11,537 337,540 (131,689) — — — (529,548) — — 4,077 (17,917) 13,589 (9,441) 122,984 (547,945) 1,826,000 (1,681,000) 1,838,124 (2,187,314) (54,721) 150,847 (26,706) 439,322 (358,232) — (11,636) (65,316) (223) 935 4,489 5,424 $ 900,000 (1,141,000) 842,148 (242,544) (17,716) 71,487 (3,577) 61,981 (258,501) — — 212,278 — 1,873 2,616 4,489 $ $ $ 148,326 4,922 $ $ 145,929 1,016 $ $ 110,919 — See accompanying notes. F-7 OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (continued) (in thousands) Year Ended December 31, 2015 2014 2016 Non-cash investing and financing activities: Non-cash investing activities: Non-cash acquisition of businesses (see Note 3 and Note 5 for details) . . . . . . . . . Non-cash surrender of mortgage (see Note 5 for details) . . . . . . . . . . . . . . . . . Non-cash surrender of other investment (see Note 3 for details) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total $(60,079) 25,000 5,500 $(29,579) $(3,602,040) — — $(3,602,040) Non-cash financing activities Assumed Aviv debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Stock exchanged in merger . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . OP Units exchanged in merger Purchase option buyout obligation (see Note 3 for details) . . . . . . . . . . . . . . . . Change in fair value of cash flow hedges . . . . . . . . . . . . . . . . . . . . . . . . . . Other unsecured long term borrowing (see Note 3 and Note 12 for details) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total $ — — — 29,579 764 3,000 $ 33,343 $ 1,410,637 1,902,866 373,394 — 718 — $ 3,687,615 $ — — — $ — $ — — — — — — $ — See accompanying notes. F-8 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 — ORGANIZATION AND BASIS OF PRESENTATION Organization Omega Healthcare Investors, Inc. (“Omega,” “we,” “our” or the “Company”) has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States (“U.S.”) and the United Kingdom (“U.K.”). Our core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (“SNFs”). Our core portfolio consists of long-term leases and mortgage agreements. All of our leases are “triple-net” leases, which require the tenants to pay all property-related expenses. Our mortgage revenue derives from fixed rate mortgage loans, which are secured by first mortgage liens on the underlying real estate and personal property of the mortgagor. Omega was formed as a real estate investment trust (“REIT”) and incorporated in the State of Maryland on March 31, 1992. In April 2015, Aviv REIT, Inc., a Maryland corporation (“Aviv”), merged (the “Aviv Merger”) with and into a wholly-owned subsidiary of Omega, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of October 30, 2014 (the “Merger Agreement”), by and among the Company, Aviv, OHI Healthcare Properties Holdco, Inc., a Delaware corporation and a direct wholly-owned subsidiary of Omega (“Merger Sub”), OHI Healthcare Properties Limited Partnership, a Delaware limited partnership (“Omega OP”), and Aviv Healthcare Properties Limited Partnership, a Delaware limited partnership (the “Aviv OP”). Prior to April 1, 2015 and in accordance with the Merger Agreement, Omega restructured the manner in which it holds its assets by converting to an umbrella partnership real estate investment trust structure (the “UPREIT Conversion”). As a result of the UPREIT Conversion and following the consummation of the Aviv Merger, substantially all of the Company’s assets are held by Omega OP. Omega OP is governed by the Second Amended and Restated Agreement of Limited Partnership of OHI Healthcare Properties Limited Partnership, dated as of April 1, 2015 (the “Partnership Agreement”). Pursuant to the Partnership Agreement, the Company and Merger Sub are the general partners of Omega OP, and have exclusive control over Omega OP’s day-to-day management. As of December 31, 2016, the Company owned approximately 96% of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and other investors owned approximately 4% of the Omega OP Units. Consolidation Our consolidated financial statements include the accounts of (i) Omega, (ii) Omega OP and (iii) all direct and indirect wholly-owned subsidiaries of Omega. All inter-company transactions and balances have been eliminated in consolidation, and our net earnings are reduced by the portion of net earnings attributable to noncontrolling interests. NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. F-9 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued Fair Value Measurement The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy: • • • Level 1 – quoted prices for identical instruments in active markets; Level 2 – quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and Level 3 – fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures fair value using a set of standardized procedures that are outlined herein for all assets and liabilities which are required to be measured at fair value. When available, the Company utilizes quoted market prices from an independent third party source to determine fair value and classifies such items in Level 1. In some instances where a market price is available, but the instrument is in an inactive or over-the-counter market, the Company consistently applies the dealer (market maker) pricing estimate and classifies such items in Level 2. If quoted market prices or inputs are not available, fair value measurements are based upon valuation models that utilize current market or independently sourced market inputs, such as interest rates, option volatilities, credit spreads and/or market capitalization rates. Items valued using such internally-generated valuation techniques are classified according to the lowest level input that is significant to the fair value measurement. As a result, these items could be classified in either Level 2 or Level 3 even though there may be some significant inputs that are readily observable. Internal fair value models and techniques used by the Company include discounted cash flow and Monte Carlo valuation models. Risks and Uncertainties Our Company is subject to certain risks and uncertainties affecting the healthcare industry as a result of healthcare legislation and growing regulation by federal, state and local governments. Additionally, we are subject to risks and uncertainties as a result of changes affecting operators of nursing home facilities due to the actions of governmental agencies and insurers to limit the rising cost of healthcare services (see Note 10 – Concentration of Risk). Business Combinations We record the purchase of properties to net tangible and identified intangible assets acquired and liabilities assumed at fair value. Transaction costs are expensed as incurred as part of a business combination. In making estimates of fair value for purposes of recording the purchase, we utilize a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. We also consider information obtained about each property as a result of our pre-acquisition due diligence, marketing and leasing activities as well as other critical valuation metrics such as current capitalization rates and discount rates used to estimate the fair value of the tangible and intangible assets acquired (Level 3). When liabilities are assumed as part of a transaction, we consider information obtained about the liabilities and use similar valuation metrics (Level 3). In some instances when debt is assumed and an identifiable active market for similar debt is present, we use market interest rates for similar debt to estimate the fair value of the debt assumed (Level 2). The Company determines fair value as follows: • Land is determined based on third party appraisals which typically include market comparables. F-10 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued • • • • • • • Buildings and site improvements acquired are valued using a combination of discounted cash flow projections that assume certain future revenues and costs and consider capitalization and discount rates using current market conditions as well as replacement cost analysis. Furniture and fixtures are determined based on third party appraisals which typically utilize a replacement cost approach. Intangible assets and liabilities acquired are valued using a combination of discounted cash flow projections as well as other valuation techniques based on current market conditions for the intangible asset or liability being acquired. When evaluating below market leases we consider extension options controlled by the lessee in our evaluation. For additional information regarding above and below market leases assumed as part of an acquisition see “In-Place Leases” below. Other assets acquired and liabilities assumed are typically valued at stated amounts, which approximate fair value on the date of the acquisition. Assumed debt balances are valued by discounting the remaining contractual cash flows using a current market rate of interest. Stock based compensation and noncontrolling interests are valued using a stock price on the acquisition date. Goodwill represents the purchase price in excess of the fair value of assets acquired and liabilities assumed and the cost associated with expanding our investment portfolio. Goodwill is not amortized. Asset Acquisitions For acquisitions not accounted for as a business combination, assets and liabilities are recognized based on their cost to the Company which generally includes transaction costs. The costs of the acquisition are allocated to the assets and liabilities acquired on a relative fair value basis. Real Estate Investments and Depreciation The costs of significant improvements, renovations and replacements, including interest are capitalized. In addition, we capitalize leasehold improvements when certain criteria are met, including when we supervise construction and will own the improvement. Expenditures for maintenance and repairs are charged to operations as they are incurred. Depreciation is computed on a straight-line basis over the estimated useful lives ranging from 20 to 40 years for buildings, eight to 15 years for site improvements, and three to ten years for furniture, fixtures and equipment. Leasehold interests are amortized over the shorter of the estimated useful life or term of the lease. As of December 31, 2016 and 2015, we had identified conditional asset retirement obligations primarily related to the future removal and disposal of asbestos that is contained within certain of our real estate investment properties. The asbestos is appropriately contained, and we believe we are compliant with current environmental regulations. If these properties undergo major renovations or are demolished, certain environmental regulations are in place, which specify the manner in which asbestos must be handled and disposed. We are required to record the fair value of these conditional liabilities if they can be reasonably estimated. As of December 31, 2016 and 2015, sufficient information was not available to estimate our liability for conditional asset retirement obligations as the obligations to remove the asbestos from these properties have indeterminable settlement dates. As such, no liability for conditional asset retirement obligations was recorded on our accompanying Consolidated Balance Sheets as of December 31, 2016 and 2015. F-11 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued Lease Accounting At the inception of the lease and during the amendment process, we evaluate each lease to determine if the lease should be considered an operating lease, sales-type lease, or direct financing lease. We have determined that all but seven of our leases should be accounted for as operating leases. The other seven leases are accounted for as direct financing leases. For leases accounted for as operating leases, we retain ownership of the asset and record depreciation expense, see “Business Combinations” and “Real Estate Investments and Depreciation” above for additional information regarding our investment in real estate leased under operating lease agreements. We also record lease revenue based on the contractual terms of the operating lease agreement which often includes annual rent escalators, see “Revenue Recognition” below for further discussion regarding the recordation of revenue on our operating leases. For leases accounted for as direct financing leases, we record the present value of the future minimum lease payments (utilizing a constant interest rate over the term of the lease agreement) as a receivable and record interest income based on the contractual terms of the lease agreement. Certain direct financing leases include annual rent escalators; see “Revenue Recognition” below for further discussion regarding the recording of interest income on our direct financing leases. As of December 31, 2016 and 2015, $3.3 million and $3.3 million, respectively, of unamortized direct costs related to originating the direct financing leases have been deferred and recorded in our Consolidated Balance Sheets. In-Place Leases In-place lease assets and liabilities result when we assume a lease as part of a facility purchase or business combination. The fair value of in-place leases consists of the following components, as applicable (1) the estimated cost to replace the leases, and (2) the above or below market cash flow of the leases, determined by comparing the projected cash flows of the leases in place at the time of acquisition to projected cash flows of comparable market-rate leases (referred to as Lease Intangibles). Lease Intangible assets and liabilities are classified as lease contracts above and below market value, respectively, in other assets and accrued expenses and other liabilities on our Consolidated Balance Sheets, and amortized on a straight-line basis as decreases and increases, respectively, to rental income over the estimated remaining term of the underlying leases. Should a tenant terminate the lease, the unamortized portion of the lease intangible is recognized immediately as income or expense. For additional information, see Note 9 – Intangibles. Asset Impairment Management evaluates our real estate investments for impairment indicators at each reporting period, including the evaluation of our assets’ useful lives. The judgment regarding the existence of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance, legal structure, as well as our intent with respect to holding or disposing of the asset. If indicators of impairment are present, management evaluates the carrying value of the related real estate investments in relation to the future undiscounted cash flows of the underlying facilities. Provisions for impairment losses related to long-lived assets are recognized when expected future undiscounted cash flows based on our intended use of the property are determined to be less than the carrying values of the assets. An adjustment is made to the net carrying value of the real estate investments for the excess of carrying value over fair value. The fair value of the real estate investment is determined by market research, which includes valuing the property as a nursing home as well as other alternative uses. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to reflect the new value assigned to the asset. Management’s impairment evaluation process, and when applicable, impairment calculations involve estimation of the future cash flows from management’s intended use of the property. Changes in the facts and circumstances that drive management’s assumptions may result in an impairment of the Company’s assets in a future period that could be material to the Company’s results of operations. F-12 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued If we decide to sell real estate properties or land holdings, we evaluate the recoverability of the carrying amounts of the assets. If the evaluation indicates that the carrying value is not recoverable from estimated net sales proceeds, the property is written down to estimated fair value less costs to sell. Our estimates of cash flows and fair values of the properties are based on current market conditions and consider matters such as rental rates and occupancies for comparable properties, recent sales data for comparable properties, and, where applicable, contracts or the results of negotiations with purchasers or prospective purchasers. For the years ended December 31, 2016, 2015 and 2014, we recognized impairment losses of $58.7 million, $17.7 million and $3.7 million, respectively. For additional information, see Note 3 – Properties and Note 8 – Assets Held For Sale. Loan and Direct Financing Lease Impairment Management evaluates our outstanding mortgage notes, direct financing leases and other notes receivable for impairment. When management identifies potential loan or direct financing lease impairment indicators, such as non-payment under the loan documents, impairment of the underlying collateral, financial difficulty of the operator or other circumstances that may impair full execution of the loan documents or direct financing leases, and management believes it is probable that all amounts will not be collected under the contractual terms of the loan or direct financing lease, the loan or direct financing lease is written down to the present value of the expected future cash flows. In cases where expected future cash flows are not readily determinable, the loan or direct financing lease is written down to the fair value of the collateral. The fair value of the loan or direct financing lease is determined by market research, which includes valuing the property as a nursing home as well as other alternative uses. We account for impaired loans and direct financing leases using (a) the cost-recovery method, and/or (b) the cash basis method. We generally utilize the cost-recovery method for impaired loans or direct financing leases for which impairment reserves were recorded. We utilize the cash basis method for impaired loans or direct financing leases for which no impairment reserves were recorded because the net present value of the discounted cash flows expected under the loan or direct financing lease and/or the underlying collateral supporting the loan or direct financing lease were equal to or exceeded the book value of the loans or direct financing leases. Under the cost-recovery method, we apply cash received against the outstanding loan balance or direct financing lease prior to recording interest income. Under the cash basis method, we apply cash received to principal or interest income based on the terms of the agreement. As of December 31, 2016 and 2015, we had $8.7 million and $3.0 million, respectively, of reserves on our mortgages and other investments and no reserves on our direct financing leases. For additional information, see Note 4 – Direct Financing Leases, Note 5 – Mortgage Notes Receivable and Note 6 – Other Investments. Investment in Unconsolidated Joint Venture We account for our investment in an unconsolidated joint venture using the equity method of accounting as we exercise significant influence, but do not control the entity. Under the equity method of accounting, the net equity investment of the Company is reflected in the accompanying Consolidated Balance Sheets and the Company’s share of net income and comprehensive income from the joint venture is included in the accompanying Consolidated Statements of Operations and Consolidated Statements of Comprehensive Income, respectively. On a periodic basis, management assesses whether there are any indicators that the value of the Company’s investment in the unconsolidated joint venture may be other-than-temporarily-impaired. An investment is impaired only if management’s estimate of the value of the investment is less than the carrying value of the investment, and such a decline in value is deemed to be other-than-temporary. To the extent impairment has occurred, the loss is measured as the excess of the carrying amount of the investment over the estimated fair value of the investment. The estimated fair value of the investment is determined using a F-13 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued discounted cash flow model which is a Level 3 valuation. We consider a number of assumptions that are subject to economic and market uncertainties including, among others, rental rates, operating costs, capitalization rates, holding periods and discount rates. No impairment loss on our investment in unconsolidated joint venture was recognized during the year ended December 31, 2016. Assets Held for Sale We consider properties to be assets held for sale when (1) management commits to a plan to sell the property; (2) it is unlikely that the disposal plan will be significantly modified or discontinued; (3) the property is available for immediate sale in its present condition; (4) actions required to complete the sale of the property have been initiated; (5) sale of the property is probable and we expect the completed sale will occur within one year; and (6) the property is actively being marketed for sale at a price that is reasonable given our estimate of current market value. Upon designation of a property as an asset held for sale, we record the property’s value at the lower of its carrying value or its estimated fair value, less estimated costs to sell, and we cease depreciation. For additional information, see Note 8 – Assets Held for Sale. Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand and highly liquid investments with a maturity date of three months or less when purchased. These investments are stated at cost, which approximates fair value. The majority of our cash and cash equivalents are held at major commercial banks. Restricted Cash Restricted cash consists primarily of funds escrowed for tenants’ security deposits required by us pursuant to certain contractual terms (see Note 11 – Lease and Mortgage Deposits). Accounts Receivable Accounts receivable includes: contractual receivables, effective yield interest receivables, straight-line rent receivables and lease inducements, net of an estimated provision for losses related to uncollectible and disputed accounts. Contractual receivables relate to the amounts currently owed to us under the terms of our lease and loan agreements. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis over the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line rent receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts currently due to us according to the contractual agreement. Lease inducements result from value provided by us to the lessee, at the inception or renewal of the lease, and are amortized as a reduction of rental revenue over the non-cancellable lease term. On a quarterly basis, we review our accounts receivable to determine their collectability. The determination of collectability of these assets requires significant judgment and is affected by several factors relating to the credit quality of our operators that we regularly monitor, including (i) payment history, (ii) the age of the contractual receivables, (iii) the current economic conditions and reimbursement environment, (iv) the ability of the tenant to perform under the terms of their lease and/or contractual loan agreements and (v) the value of the underlying collateral of the agreement. If we determine collectability of any of our contractual receivables is at risk, we estimate the potential uncollectible amounts and provide an allowance. In the case of a lease recognized on a straight-line basis, a mortgage recognized on an effective yield basis or the existence of lease inducements, we generally provide an allowance for straight-line, effective interest, and or lease inducement accounts receivable when certain conditions or indicators of adverse collectability are present. If the accounts receivable balance is subsequently deemed uncollectible, the receivable and allowance for doubtful account balance are written off. F-14 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued A summary of our net receivables by type is as follows: December 31, 2016 2015 (in thousands) Contractual receivables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 13,376 $ 8,452 Effective yield interest receivables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9,749 9,028 Straight-line rent receivables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208,874 175,709 Lease inducements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8,393 (357) 10,982 (309) Accounts receivable – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $240,035 $203,862 In 2016, we wrote-off approximately $4.3 million of straight-line rent receivable. The write-off primarily related to the transition of facilities from a former operator to a current operator. In 2015, we wrote-off $3.2 million of straight-line rent receivables and $1.5 million of effective yield interest receivables associated with four facilities that were transitioned to a new operator and three mortgages that were repaid prior to their maturity. This transaction closed in 2016. In 2014, we wrote-off $0.8 million of straight-line rent receivables associated with a lease amendment to an existing operator for two facilities that were transitioned to a new operator and $2.0 million of effective yield interest receivables associated with the termination of a mortgage note that was due November 2021. Goodwill Impairment We assess goodwill for potential impairment during the fourth quarter of each fiscal year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the net assets of the reporting unit. In evaluating goodwill for impairment on an interim basis, we assess qualitative factors such as a significant decline in real estate valuations, current macroeconomic conditions, state of the equity and capital markets and our overall financial and operating performance or a significant decline in the value of our market capitalization, to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of the reporting unit is less than its carrying amount. On an annual basis during the fourth quarter of each fiscal year, or on an interim basis if we conclude it is more likely than not that the fair value of the reporting unit is less than its carrying value, we perform a two-step goodwill impairment test to identify potential impairment and measure the amount of impairment we will recognize, if any. The goodwill is not deductible for tax purposes. In the first step of the two-step goodwill impairment test (“Step 1”), we compare the fair value of the reporting unit to its net book value, including goodwill. As the Company has only one reporting unit, the fair value of the reporting unit is determined by reference to the market capitalization of the Company as determined through quoted market prices and adjusted for other relevant factors. A potential impairment exists if the fair value of the reporting unit is lower than its net book value. The second step (“Step 2”) of the process is only performed if a potential impairment exists, and it involves determining the difference between the fair value of the reporting unit’s net assets other than goodwill and the fair value of the reporting unit. If the difference is less than the net book value of goodwill, impairment exists and is recorded. The Company has not been required to perform Step 2 of the process because the fair value of the reporting unit has significantly exceeded its book value at the measurement date. There was no impairment of goodwill during 2016 and 2015. F-15 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued Income Taxes We were organized to qualify for taxation as a REIT under Section 856 through 860 of the Internal Revenue Code (“Code”). As long as we qualify as a REIT; we will not be subject to federal income taxes on the REIT taxable income that we distributed to stockholders, subject to certain exceptions. However, with respect to certain of our subsidiaries that have elected to be treated as taxable REIT subsidiaries (“TRSs”), we record income tax expense or benefit, as those entities are subject to federal income tax similar to regular corporations. We account for deferred income taxes using the asset and liability method and recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in our financial statements or tax returns. Under this method, we determine deferred tax assets and liabilities based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Any increase or decrease in the deferred tax liability that results from a change in circumstances, and that causes us to change our judgment about expected future tax consequences of events, is included in the tax provision when such changes occur. Deferred income taxes also reflect the impact of operating loss and tax credit carryforwards. A valuation allowance is provided if we believe it is more likely than not that all or some portion of the deferred tax asset will not be realized. Any increase or decrease in the valuation allowance that results from a change in circumstances, and that causes us to change our judgment about the realizability of the related deferred tax asset, is included in the tax provision when such changes occur. For additional information on income taxes, see Note 14 – Taxes. Revenue Recognition We have various different investments that generate revenue, including leased and mortgaged properties, as well as other investments, including working capital loans. We recognize rental income and other investment income as earned over the terms of the related leases and notes, respectively. Interest income is recorded on an accrual basis to the extent that such amounts are expected to be collected using the effective interest method. In applying the effective interest method, the effective yield on a loan is determined based on its contractual payment terms, adjusted for prepayment terms. Substantially all of our operating leases contain provisions for specified annual increases over the rents of the prior year and are generally computed in one of three methods depending on specific provisions of each lease as follows: (i) a specific annual increase over the prior year’s rent, generally between 2.0% and 3.0%; (ii) an increase based on the change in pre-determined formulas from year to year (e.g. increases in the Consumer Price Index); or (iii) specific dollar increases over prior years. Revenue under lease arrangements with minimum fixed and determinable increases is recognized over the non-cancellable term of the lease on a straight-line basis. The authoritative guidance does not provide for the recognition of contingent revenue until all possible contingencies have been eliminated. We consider the operating history of the lessee, the payment history, the general condition of the industry and various other factors when evaluating whether all possible contingencies have been eliminated. We do not recognize contingent rents as income until the contingencies have been resolved. In the case of rental revenue recognized on a straight-line basis, we generally record reserves against earned revenues from leases when collection becomes questionable or when negotiations for restructurings of troubled operators result in significant uncertainty regarding ultimate collection. The amount of the reserve is estimated based on what management believes will likely be collected. We continually evaluate the collectability of our straight-line rent assets. If it appears that we will not collect future rent due under our leases, we will record a provision for loss related to the straight-line rent asset. We record direct financing lease income on a constant interest rate basis over the term of the lease. The costs related to originating the direct financing leases have been deferred and are being amortized on a straight-line basis as a reduction to income from direct financing leases over the term of the direct financing leases. F-16 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued Mortgage interest income is recognized as earned over the terms of the related mortgage notes, using the effective yield method. Allowances are provided against earned revenues from mortgage interest when collection of amounts due becomes questionable or when negotiations for restructurings of troubled operators lead to lower expectations regarding ultimate collection. When collection is uncertain, mortgage interest income on impaired mortgage loans is recognized as received after taking into account the application of security deposits. Gains on sales of real estate assets are recognized in accordance with the authoritative guidance for sales of real estate. The specific timing of the recognition of the sale and the related gain is measured against the various criteria in the guidance related to the terms of the transactions and any continuing involvement associated with the assets sold. To the extent the sales criteria are not met, we defer gain recognition until the sales criteria are met. Stock-Based Compensation We recognize stock-based compensation expense adjusted for estimated forfeitures to employees and directors, in general and administrative in our Consolidated Statements of Operations on a straight-line basis over the requisite service period of the awards, see Note 17 – Stock-Based Compensation for additional details. Deferred Financing Costs and Original Issuance Premium and/or Discounts for Debt Issuance In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-03, Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”), which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Also in August 2015, the FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (“ASU 2015-15”), which clarifies the SEC staff’s position not objecting to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing such costs, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. We adopted ASU 2015-03 and ASU 2015-15 as of December 31, 2016 using the full retrospective method and adjusted the balance sheet for each period presented to reflect the new accounting guidance. See “Change in Accounting Principle” below. External costs incurred from the placement of our debt are capitalized and amortized on a straight-line basis over the terms of the related borrowings which approximates the effective interest method. Deferred financing costs related to our revolving line of credit are included in other assets on our Consolidated Balance Sheets and deferred financing costs related to our other borrowings are included as a direct deduction from the carrying amount of the related debt liability on our Consolidated Balance Sheets. Original issuance premium or discounts reflect the difference between the face amount of the debt issued and the cash proceeds received and are amortized on a straight-line basis over the term of the related borrowings. All premiums and discounts are recorded as an addition to or reduction from debt on our Consolidated Balance Sheets. Amortization of deferred financing costs and original issuance premiums or discounts totaled $9.3 million, $7.0 million and $4.5 million in 2016, 2015 and 2014, respectively, and are classified as interest – amortization of deferred financing costs on our Consolidated Statements of Operations. When financings are terminated, unamortized deferred financing costs and unamortized premiums or discounts, as well as charges incurred for the termination, are recognized as expense or income at the time the termination is made. Gains and losses from the extinguishment of debt are presented in interest-refinancing costs on our Consolidated Statements of Operations. Earnings Per Share Basic earnings per common share (“EPS”) is computed by dividing net income available to common stockholders by the weighted-average number of shares of common stock outstanding during the year. Diluted EPS is computed using the treasury stock method, which is net income divided by the total F-17 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued weighted-average number of common outstanding shares plus the effect of dilutive common equivalent shares during the respective period. Dilutive common shares reflect the assumed issuance of additional common shares pursuant to certain of our share-based compensation plans, including stock options, restricted stock and performance restricted stock units and the assumed issuance of additional shares related to Omega OP Units held by outside investors. All outstanding unvested share-based payment awards that contain rights to non-forfeitable dividends or dividend equivalents that participate in undistributed earnings with common stockholders are considered participating securities that shall be included in the two-class method of computing basic EPS. The impact of the two class method is immaterial. For additional information, see Note 21 – Earnings Per Share. Redeemable Limited Partnership Unitholder Interests and Noncontrolling Interests As of April 1, 2015 and after giving effect to the Aviv Merger, the Company owned approximately 138.8 million Omega OP Units and Aviv OP owned approximately 52.9 million Omega OP Units. Each of the Omega OP Units (other than the Omega OP Units owned by Omega) is redeemable at the election of the Omega OP Unit holder for cash equal to the then-fair market value of one share of Omega common stock, par value $0.10 per share (“Omega Common Stock”), subject to the Company’s election to exchange the Omega OP Units tendered for redemption for unregistered shares of Omega Common Stock on a one-for-one basis, subject to adjustment as set forth in the Partnership Agreement. Effective June 30, 2015, the Company (through Merger Sub, in its capacity as the general partner of Aviv OP) caused Aviv OP to make a distribution of Omega OP Units held by Aviv OP (or equivalent value) to Aviv OP investors (the “Aviv OP Distribution”) in connection with the liquidation of Aviv OP. As a result of the Aviv OP Distribution, Omega directly and indirectly owned approximately 95% of the outstanding Omega OP Units, and the other investors owned approximately 5% of the outstanding Omega OP Units. As a part of the Aviv OP Distribution, Omega settled approximately 0.2 million units via cash settlement. As of December 31, 2016, Omega directly and indirectly owns approximately 96% of the outstanding Omega OP Units, and the other investors own approximately 4% of the outstanding Omega OP Units. Noncontrolling Interests Noncontrolling interests is the portion of equity in the Omega OP not attributable to the Company. We present the portion of any equity that we do not own in consolidated entities as noncontrolling interests and classify those interests as a component of total equity, separate from total stockholders’ equity, on our Consolidated Balance Sheets. We include net income attributable to the noncontrolling interests in net income in our Consolidated Statements of Operations. As our ownership of a controlled subsidiary increases or decreases, any difference between the aggregate consideration paid to acquire the noncontrolling interests and our noncontrolling interest balance is recorded as a component of equity in additional paid-in capital, so long as we maintain a controlling ownership interest. Foreign Operations The U.S. dollar is the functional currency for our consolidated subsidiaries operating in the United States. The functional currency for our consolidated subsidiaries operating in countries other than the United States is the principal currency in which the entity primarily generates and expends cash. For our consolidated subsidiaries whose functional currency is not the U.S. dollar, we translate their financial statements into the U.S. dollar. We translate assets and liabilities at the exchange rate in effect as of the financial statement date. Revenue and expense accounts are translated using an average exchange rate for the period. Gains and losses resulting from this translation are included in accumulated other comprehensive loss (“AOCL”) as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest. We and certain of our consolidated subsidiaries may have intercompany and third-party debt that is not denominated in the entity’s functional currency. When the debt is remeasured against the functional F-18 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued currency of the entity, a gain or loss can result. The resulting adjustment is reflected in results of operations, unless it is intercompany debt that is deemed to be long-term in nature and then the adjustments are included in AOCL. Derivative Instruments During our normal course of business, we may use certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at the inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with the Company’s related assertions. The Company recognizes all derivative instruments, including embedded derivatives required to be bifurcated, as assets or liabilities on the Consolidated Balance Sheets at fair value which is determined using a market approach and Level 2 inputs. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in earnings. For derivatives designated as qualifying cash flow hedging relationships, the change in fair value of the effective portion of the derivatives is recognized in AOCL as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest, whereas the change in fair value of the ineffective portion is recognized in earnings. We formally document all relationships between hedging instruments and hedged items, as well as our risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific forecasted transactions as well as recognized liabilities or assets on the Consolidated Balance Sheets. We also assess and document, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, we discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the current fair value of the derivative. As a matter of policy, we do not use derivatives for trading or speculative purposes. At December 2016 and 2015, we had $1.5 million and $0.7 million, respectively, of qualifying cash flow hedges recorded at fair value in accrued expenses and other liabilities on our Consolidated Balance Sheets. Related Party Transactions The Company has a policy which generally requires related party transactions to be approved or ratified by the Audit Committee. On February 1, 2016, we acquired 10 SNFs from Laurel Healthcare Holdings, Inc. (“Laurel”) for approximately $169.0 million in cash and leased them to an unrelated existing operator. A former member of the Board of Directors of the Company, together with certain members of his immediate family, beneficially owned approximately 34% of the equity of Laurel prior to the transaction. Immediately following our acquisition, the unrelated existing operator acquired all of the outstanding equity interests of Laurel, including the interests previously held by the former director of the Company and his family. Reclassification Certain prior year amounts have been reclassified to conform with the current year presentation. Change in Accounting Principle We have retrospectively adjusted the presentation of deferred financing costs on the Company’s Consolidated Balance Sheets for all prior periods, as required by ASU 2015-03 and ASU 2015-15. The guidance requires debt issuance costs to be presented as a direct deduction from the related debt liability rather than as an asset, except for costs associated with our revolving credit facility. The prior period amounts that have been impacted by the new accounting guidance were retrospectively adjusted to their respective debt liability line items on the Company’s Consolidated Balance Sheets. F-19 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued The following table presents the impact of the change in accounting principle to the Consolidated Balance Sheets of the Company as of December 31, 2016: As of December 31, 2016 Term Loans, net Secured Borrowings, net Unsecured Borrowings, net (in thousands) Prior to change in accounting principle . . . . . . . . . . . . . . . . . $1,100,000 $54,954 $3,055,849 Impact of change in accounting principle . . . . . . . . . . . . . . . . (5,657) (589) (27,703) As reported . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $1,094,343 $54,365 $3,028,146 The following table presents the impact of the change in accounting principle to the Consolidated Balance Sheets of the Company as of December 31, 2015: As of December 31, 2015 Term Loans, net Secured Borrowings, net Unsecured Borrowings, net As previously reported . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Impact of change in accounting principle . . . . . . . . . . . . . . . . $750,000 (4,307) (in thousands) $236,204 (611) $2,352,882 (24,155) As adjusted and currently reported . . . . . . . . . . . . . . . . . . . $745,693 $235,593 $2,328,727 Recently Adopted Accounting Pronouncements In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis (“ASU 2015-02”), which amends certain requirements for determining whether a variable interest entity must be consolidated. The amendments in ASU 2015-02 are effective for annual and interim reporting periods of public entities beginning after December 31, 2015 and were adopted by the Company during the quarter ended March 31, 2016. The effect of this guidance was immaterial to the Company’s consolidated results of operations, financial position and cash flows. In January 2017, the FASB issued ASU 2017-01, Business Combinations – Clarifying the Definition of a Business (“ASU 2017-01”), which provides a screen to determine when an integrated set of assets and activities (collectively referred to as a set) is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. To be considered a business, a set must include, at a minimum an input and a substantive process that together significantly contribute to the ability to create outputs and removes the evaluation of whether a market participant could replace the missing elements. ASU 2017-01 provides a framework to assist entities in evaluating whether both an input and a substantive process are present. The framework includes two sets of criteria to consider that depend on whether a set has outputs. Although outputs are not required for a set to be a business, outputs generally are a key element of a business. Lastly, ASU 2017-01 narrows the definition of the term output so that the term is consistent with how outputs are described in ASU 2014-09. We expect this guidance to result in fewer business combinations for the Company. We adopted ASU 2017-01 during the fourth quarter of 2016 as permitted. The impact of adopting ASU 2017-01 was not material to the Company’s consolidated results of operations, financial position and cash flows as of and for the year ended December 31, 2016. No additional disclosures are required at transition. Recent Accounting Pronouncements – Pending Adoption In 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised F-20 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment. ASU 2014-09 is effective for the Company beginning January 1, 2018. In addition, the FASB has begun to issue targeted updates to clarify specific implementation issues of ASU 2014-09. These updates include ASU 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016-10, Identifying Performance Obligations and Licensing, and ASU 2016-12, Narrow-Scope Improvements and Practical Expedients. The Company is currently evaluating the provisions of ASU 2014-09 and its related updates and will be closely monitoring developments and additional guidance to determine the potential impact of the new standard. The Company intends to adopt ASU 2014-09 and its subsequent updates in accordance with the modified retrospective approach. We do not expect the adoption of ASU 2014-09 and its updates to have a significant impact on our consolidated financial statements, as a substantial portion of our revenue consists of rental income from leasing arrangements and interest income from loan arrangements, both of which are specifically excluded from ASU 2014-09. In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”), which amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective for the Company beginning January 1, 2019. Early adoption of ASU 2016-02 as of its issuance is permitted. The new standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact of adopting ASU 2016-02 on our consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718) (“ASU 2016-09”). ASU 2016-09 amends the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2016, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2016-09 on our consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) (“ASU 2016-13”), which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. ASU 2016-13 is effective for annual and interim periods beginning after December 15, 2019 and early adoption is permitted for annual and interim periods beginning after December 15, 2018. We are currently evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or extinguishment costs, the maturing of a zero coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity interests obtained in a financial asset securitization. ASU 2016-15 method investees and beneficial designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be applied prospectively as of the earliest date practicable. ASU 2016-15 is effective for annual and interim periods beginning after December 15, 2017 and early adoption is permitted. We do not expect the adoption of ASU 2016-15 to have a material impact on our Consolidated Statements of Cash Flows. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) Restricted Cash (“ASU 2016-18”), which requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash. Therefore, amounts generally described as restricted cash will be included with cash and cash equivalents when F-21 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for annual and interim periods beginning after December 15, 2017 and early adoption is permitted using a retrospective transition method to each period presented. We do not expect the adoption of ASU 2016-18 to have a material impact on our Consolidated Statements of Cash Flows. NOTE 3 — PROPERTIES Leased Property Our leased real estate properties, represented by 809 SNFs, 101 assisted living facilities (“ALFs”), 16 specialty facilities and one medical office building at December 31, 2016, are leased under provisions of single leases and master leases with initial terms typically ranging from 5 to 15 years, plus renewal options. Substantially all of the single leases and master leases provide for minimum annual rentals that are typically subject to annual increases. Under the terms of the leases, the lessee is responsible for all maintenance, repairs, taxes and insurance on the leased properties. A summary of our investment in leased real estate properties is as follows: December 31, 2016 2015 (in thousands) Buildings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Land . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Furniture, fixtures and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Site improvements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Construction in progress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 5,954,771 759,295 454,760 206,206 191,326 $ 5,320,482 670,916 426,040 132,182 194,338 Total real estate investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Less accumulated depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,566,358 (1,240,336) 6,743,958 (1,019,150) Real estate investments – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 6,326,022 $ 5,724,808 For the years ended December 31, 2016 and 2015, we capitalized $6.6 million and $3.7 million, respectively of interest to our projects under development. The future minimum estimated contractual rents due for the remainder of the initial terms of the leases are as follows at December 31, 2016: 2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 718,999 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Thereafter 711,714 689,641 701,543 705,418 3,732,920 Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $7,260,235 (in thousands) F-22 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued The following tables summarize the significant transactions that occurred between 2016 and 2014. The 2015 table excludes the acquisition of Care Homes in the U.K. and the Aviv Merger in the second quarter of 2015, which are discussed separately below. 2016 Acquisitions and Other Period Number of Facilities SNF ALF Country/ State Total Investment Land Building & Site Improvements Furniture & Fixtures Initial Annual Cash Yield (%) Q1 . . . . . . . . . — 1 Q1 . . . . . . . . . — 1 UK UK Q1 . . . . . . . . . 10 — OH, VA, MI Q1 . . . . . . . . . — 2 GA MD 3 — UK TX 3 — CO, MO Q1 . . . . . . . . . Q1 . . . . . . . . . 21 — VA, NC Q2 . . . . . . . . . — 10 Q2 . . . . . . . . . — 3 Q2 . . . . . . . . . Q3 . . . . . . . . . — 1 Q3 . . . . . . . . . — 1 Q3 . . . . . . . . . — 1 1 — Q3 . . . . . . . . . Q3 . . . . . . . . . 1 — Q3 . . . . . . . . . 31 — FL, KY, TN FL GA FL SC OH $ 8.3 $ 1.4 $ 6.7 $ 0.2 (in millions) 6.1 169.0(3) 20.2 25.0 212.5 111.9(4) 66.0(5) 31.8 4.3 2.5 16.5 10.1 9.0(6) 329.6(1)(2) 0.6 10.5 0.8 2.5 19.3 24.8 5.8 3.1 2.3 0.2 1.8 2.7 — 24.6 5.3 152.5 18.3 19.9 181.1 83.9 58.6 26.2 1.8 2.1 14.3 6.5 8.6 290.8 0.2 6.0 1.1 2.6 12.1 3.2 1.6 2.5 0.2 0.2 0.4 0.9 0.4 14.2 7.00 7.00 8.50 7.50 8.50 8.50 7.00 6.80 9.00 8.00 8.00 8.00 9.00 9.00 9.00 Total . . . . . . . . 70 20 $1,022.8 $100.4 $876.6 $45.8 (1) (2) The Company estimated the fair value of the assets acquired on the acquisition date based on certain valuation analyses that have yet to be finalized, and accordingly, the assets acquired, as detailed, are subject to adjustment once the analysis is completed. The Company’s investment includes a purchase option buyout obligation with a fair value of approximately $29.6 million. The future buyout obligation is recorded in accrued expenses and other liabilities on our Consolidated Balance Sheet. The Company also acquired a term loan with a fair value of approximately $37.0 million which is recorded in other investments on our Consolidated Balance Sheet. Refer to Note – 6 Other Investments. (3) Acquired from a related party. Refer to Note – 2 Summary of Significant Accounting Policies – Related Party Transactions. (4) Omega also recorded a deferred tax asset of approximately $1.9 million in connection with the acquisition. (5) The Company paid $63.0 million in cash at closing to acquire the facilities. We have agreed to pay an additional $1.5 million in April 2017 and the remaining $1.5 million in April 2018. The additional consideration to be paid is contractually determined and not contingent on other factors. The $3.0 million liability is recorded in unsecured borrowings – net on our Consolidated Balance Sheet. (6) The Company paid approximately $3.5 million in cash to acquire the facility. The remainder of (approximately $5.5 million) was funded with the redemption of an other investment note. the purchase price During 2016, the Company also acquired five parcels of land which are not reflected in the table above for approximately $8.3 million with the intent of building new facilities for existing operators. For the year ended December 31, 2016, we recognized rental revenue of approximately $58.1 million and expensed approximately $9.6 million of acquisition related costs in connection with the aforementioned acquisitions. No goodwill was recorded in connection with these acquisitions. F-23 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued 2015 Acquisitions and Other Number of Facilities Period SNF ALF State Total Investment Land Building & Site Improvements Furniture & Fixtures Initial Annual Cash Yield (%) (in millions) Q1 . . . . . . . . . 1 — TX $ 6.8 $ Q3 . . . . . . . . . 6 — NE Q3 . . . . . . . . . 1 2 WA Q3 . . . . . . . . . — 2 GA Q3 . . . . . . . . . Q3 . . . . . . . . . 1 — VA 2 — FL Q3 . . . . . . . . . — — NY 1 — AZ Q4 . . . . . . . . . 1 — TX Q4 . . . . . . . . . 15.0 18.0 10.8 28.5(1) 32.0 111.7(2)(3) 0.6(3) 5.3 0.1 1.4 2.2 1.2 1.9 1.4 111.7 0.3 1.8 $ 6.1 $0.6 12.1 14.9 9.0 24.2 29.0 — 0.3 3.0 1.5 0.9 0.6 2.4 1.6 — — 0.5 Total . . . . . . . . 13 4 $228.7 $122.0 $98.6 $8.1 9.50 9.00 8.00 7.00 9.25 9.00 — 9.00 9.50 (1) In July 2015, we leased the facility to a new operator with an initial lease term of 10 years. (2) On July 24, 2015, we purchased five buildings located in New York City, New York for approximately $111.7 million. We and our operator plan to construct a 201,000 square-foot assisted living and memory care facility. The properties were added to the operator’s existing master lease. The lease provides for a 5% annual cash yield on the land during the construction phase. Upon issuance of a certification of occupancy, the annual cash yield will increase to 7% in year one and 8% in year two with 2.5% annual escalators thereafter. (3) Accounted for as an asset acquisition. For the year ended December 31, 2015, we recognized rental revenue of approximately $4.9 million and expensed $2.2 million of acquisition related costs related to the aforementioned acquisitions. No goodwill was recorded in connection with these acquisitions. Acquisition of Care Homes in the U.K. On May 1, 2015, we closed on a purchase/leaseback Care Homes Transaction (the “Care Homes Transaction”) for 23 care homes located in the U.K. and operated by Healthcare Homes Holding Limited (“Healthcare Homes”). As part of the transaction, we acquired title to the 23 care homes with 1,018 registered beds and leased them back to Healthcare Homes pursuant to a 12-year master lease agreement with an initial annual cash yield of 7%, and annual escalators of 2.5%. The care homes, comparable to ALFs in the U.S., are located throughout the East Anglia region (north of London) of the U.K. Healthcare Homes is headquartered in Colchester (Essex County), England. We recorded approximately $193.8 million of assets consisting of land ($20.7 million), building and site improvements ($152.1 million), furniture and fixtures ($5.3 million) and goodwill ($15.7 million). For the year ended December 31, 2015, we recognized approximately $9.5 million of rental revenue and expensed approximately $3.2 million of acquisition related costs associated with the Care Homes Transaction. Aviv Merger On April 1, 2015, Omega completed the Aviv Merger, which was structured as a stock-for-stock merger. Under the terms of the Merger Agreement, each outstanding share of Aviv common stock was converted into 0.90 of a share of Omega Common Stock. In connection with the Aviv Merger, Omega issued approximately 43.7 million shares of Omega Common Stock to former Aviv stockholders. As a result of the Aviv Merger, Omega acquired 342 facilities, two facilities subject to direct financing leases, one F-24 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued medical office building, two mortgages and other investments. Omega also assumed certain outstanding equity awards and other debt and liabilities. Based on the closing price of Omega’s common stock on April 1, 2015, the fair value of the consideration exchanged was approximately $2.3 billion. The following table highlights the final allocation of the assets acquired and liabilities assumed and consideration transferred on April 1, 2015: Fair value of net assets acquired: Land and buildings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investment in direct financing leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mortgages notes receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Goodwill Accounts receivables and other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cash acquired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Accrued expenses and other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Debt Fair value of net assets acquired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (in thousands) $ 3,107,530 26,823 19,246 23,619 3,177,218 630,679 17,144 84,858 (223,002) (1,410,637) $ 2,276,260 The completion of the final valuation in the first quarter of 2016 did not result in material changes to our Consolidated Statements of Operations or our Consolidated Balance Sheets from our preliminary purchase price allocation reflected in the December 31, 2015 Form 10-K. For the year ended December 31, 2015, we recognized approximately $188.4 million of total revenue and expensed approximately $52.1 million in acquisition and merger related costs in connection with the Aviv Merger. Included within accrued expenses and other liabilities is a $67.3 million contingent liability related to a leasing arrangement with an operator assumed as a result of the Aviv Merger. 2014 Acquisitions and Other Number of Facilities Period SNF ALF State AZ Q1 . . . . . . . . . — 1 Q2/Q3 . . . . . . . Q3 . . . . . . . . . Q4 . . . . . . . . . — 4 PA, OR, AR 3 — GA, SC 1 — TX 4 5 Total Investment $ 4.7 34.6 8.2 84.2 $131.7 Land $0.4 0.9 0.4 5.1 $6.8 Building & Site Improvements Furniture & Fixtures Initial Annual Cash Yield (%) (in millions) $ 3.9 32.1 7.4 76.7 $120.1 $0.4 1.6 0.4 2.4 $4.8 9.75 9.50 9.75 6.00 For the year ended December 31, 2014, we recognized rental revenue of approximately $3.2 million and expensed $3.9 million of acquisition costs related to the above transactions. No goodwill was recorded in connection with these acquisitions. Transition of Two West Virginia Facilities to a New Operator On July 1, 2014, we transitioned two West Virginia SNFs that we previously leased to Diversicare Healthcare Services (“Diversicare” and formerly known as Advocat) to a new unrelated third party operator. The two facilities represented 150 operating beds. We amended our Diversicare master lease to reflect the F-25 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued transition of the two facilities to the new operator and for the year ended December 31, 2014 recorded a $0.8 million provision for uncollectible straight-line accounts receivable. Simultaneous with the Diversicare master lease amendment, we entered into a 12-year master lease with a new third party operator. Pro Forma Acquisition Results The businesses acquired in 2015 and 2014 are included in our results of operations from the dates of acquisition. The following unaudited pro forma results reflect the impact of the acquisitions as if they occurred on January 1, 2014. In the opinion of management, all significant necessary adjustments to reflect the effect of the acquisitions have been made. The following pro forma information is not indicative of future operations. Pro forma revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pro forma net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Earnings per share – diluted: Pro Forma Year Ended December 31, 2015 2014 (in thousands, except per share amounts, unaudited) $817,642 $258,927 $789,270 $318,271 Net income – as reported . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net income – pro forma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ $ 1.29 1.33 $ $ 1.74 1.74 Asset Sales, Impairments and Other In 2016, we sold 38 facilities (21 previously held-for-sale) for approximately $169.6 million in net proceeds recognizing a gain of approximately $50.2 million. We also recorded a total of $58.7 million provision for impairment related to 29 facilities to reduce their net book value to their estimated fair value less costs to sell. To estimate the fair value of these facilities we utilized a market approach and Level 3 inputs (which generally consist of non-binding offers from unrelated third parties). In 2015, we sold seven SNFs (four previously held-for-sale) for total cash proceeds of approximately $41.5 million, generating a gain of approximately $6.4 million. We also recorded a total of $17.7 million provision for impairment related to six SNFs to reduce their net book value to their estimated fair value less costs to sell. To estimate the fair value of these facilities we utilized a market approach and Level 3 inputs. In 2014, we sold four SNFs (three previously held-for-sale) and a parcel of land for total cash proceeds of $4.1 million, resulting in a $2.9 million gain. We also closed two SNFs and recorded a $3.7 million provision for impairment related to these facilities. To estimate the fair value of these facilities we utilized a market approach and Level 3 inputs. The recorded 2016 impairments were primarily the result of a decision to exit certain non-strategic facilities and operators primarily related to facilities acquired in the Aviv Merger. The recorded 2015 and 2014 impairments are primarily the result of closing facilities or updating the estimated proceeds we expected to receive for the sale of closed facilities at that time. See Note 8 – Assets Held For Sale for more details. NOTE 4 — DIRECT FINANCING LEASES The components of investments in direct financing leases consist of the following: Minimum lease payments receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Less unearned income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investment in direct financing leases – net . . . . . . . . . . . . . . . . . . . . . . . . . . $ 4,287,069 (3,685,131) 601,938 $ $ 4,320,876 (3,733,175) 587,701 $ Properties subject to direct financing leases . . . . . . . . . . . . . . . . . . . . . . . . . 58 59 December 31, 2016 2015 (in thousands) F-26 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued As of December 31, 2016 and 2015 we had seven direct financing leases with four different operators. The following table summarizes our investments in the direct financing leases by operator: December 31, 2016 2015 (in thousands) New Ark . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Reliance Health Care Management, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sun Mar Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Markleysburg Healthcare Investors, LP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investment in direct financing leases – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $574,581 15,498 11,443 416 $601,938 $560,308 15,509 11,381 503 $587,701 New Ark Investment Inc. On November 27, 2013, we closed an aggregate $529 million purchase/leaseback transaction in connection with the acquisition of Ark Holding Company, Inc. (“Ark Holding”) by 4 West Holdings Inc. At closing, we acquired 55 SNFs and 1 ALF operated by Ark Holding and leased the facilities back to Ark Holding, now known as New Ark Investment Inc. (“New Ark”), pursuant to four 50-year master leases with rental payments yielding 10.6% per annum over the term of the leases. The purchase/leaseback transaction is being accounted for as a direct financing lease. The lease agreements allow the tenant the right to purchase the facilities for a bargain purchase price plus closing costs at the end of the lease term. In addition, commencing in the 41st year of each lease, the tenant will have the right to prepay the remainder of its obligations thereunder for an amount equal to the sum of the unamortized portion of the original aggregate $529 million investment plus the net present value of the remaining payments under the lease and closing costs. In the event the tenant exercises either of these options, we have the right to purchase the properties for fair value at the time. The 56 facilities represent 5,623 licensed beds located in 12 states, predominantly in the southeastern United States. The 56 facilities are separated by region and divided amongst four cross-defaulted master leases. The four regions include the Southeast (39 facilities), the Northwest (7 facilities), Texas (9 facilities) and Indiana (1 facility). Additionally, we own four facilities and lease them to New Ark under a master lease which expires in 2026. The four facility lease is being accounted for as an operating lease. Aviv Merger On April 1, 2015, we acquired two additional direct financing leases as a result of the Aviv Merger. As of December 31, 2016, the following minimum rents are due under our direct financing leases for the next five years (in thousands): 2017 $50,772 2018 $52,098 2019 $53,377 2020 $54,677 2021 $55,919 NOTE 5 — MORTGAGE NOTES RECEIVABLE As of December 31, 2016, mortgage notes receivable relate to 25 fixed rate mortgages on 47 long-term care facilities. The mortgage notes are secured by first mortgage liens on the borrowers’ underlying real estate and personal property. The mortgage notes receivable relate to facilities located in ten states, operated by seven independent healthcare operating companies. We monitor compliance with mortgages and when necessary have initiated collection, foreclosure and other proceedings with respect to certain outstanding loans. F-27 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued The outstanding principal amounts of mortgage notes receivable, net of allowances, were as follows: Mortgage note due 2024; interest at 9.79% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mortgage note due 2028; interest at 11.00% . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mortgage note due 2029; interest at 9.45% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other mortgage notes outstanding(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mortgage notes receivable, gross . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Allowance for loss on mortgage notes receivable . . . . . . . . . . . . . . . . . . . . . . . . . Total mortgages – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . December 31, 2016 2015 (in thousands) $112,500 35,964 412,140 82,673 643,277 (3,934) $639,343 $112,500 69,928 413,399 83,968 679,795 — $679,795 (1) Other mortgage notes outstanding have stated interest rates ranging from 8.35% to 12.0% per annum and maturity dates through 2029. $112.5 Million of Mortgage Note due 2024 On January 17, 2014, we entered into a $112.5 million first mortgage loan with an existing operator. The loan is secured by 7 SNFs and 2 ALFs located in Pennsylvania (7) and Ohio (2). The mortgage is cross-defaulted and cross-collateralized with our existing master lease with the operator. Mortgage Note due 2028 On April 29, 2016, an existing operator exercised an option to repay certain mortgage notes. We received proceeds of approximately $47.8 million for the mortgage notes due. In connection with the repayment of the mortgage notes we recognized a net gain of approximately $5.4 million which is recorded in mortgage interest income on our Consolidated Statement of Operations. The remaining $36.0 million interest only mortgage is secured by three facilities located in Maryland. The interest rate will accrue at a fixed rate of 11% per annum through April 2018. After April 2018, the interest rate will increase to 13.75% per annum. The initial maturity date was extended to December 2028. The mortgage is cross-defaulted and cross-collateralized with our existing master lease and other investment notes with the operator. $415 Million of Refinancing/Consolidating Mortgage Loans due 2029 On June 30, 2014, we entered into an agreement to refinance/consolidate $117 million in existing mortgages with maturity dates ranging from 2021 to 2023 on 17 facilities into one mortgage and simultaneously provide mortgage financing for an additional 14 facilities. The original $415 million mortgage matures in 2029 and was secured by 31 facilities. The new loan bore an initial annual cash interest rate of 9.0% that increases by 0.225% per year (e.g., beginning in year 2 the annual cash interest rate will be 9.225%, in year 3 the annual cash interest rate will be 9.45%, etc.). The mortgage is cross-defaulted and cross-collateralized with our existing master lease and other investment notes with the operator. One of the existing mortgages that was refinanced/consolidated into the new $415 million mortgage included annual interest rate escalators and required the mortgagee to pay a prepayment penalty in the event the mortgage was retired early which resulted in us recording an effective yield interest receivable. In connection with the refinancing/consolidating transaction which was entered into at market terms, the old mortgage was considered to be retired early since the modifications made to the terms of the mortgage were more than minor. As of the date of the refinancing/consolidation transaction, the effective yield interest receivable was approximately $2.0 million. We forgave the prepayment penalty associated with the retired mortgage and recorded a $2.0 million provision to write-off the effective yield interest receivable related to the retired mortgage. F-28 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued Conversion of Mortgage Notes due 2046 to Leased Properties In January 2016, we acquired three facilities via a deed-in-lieu of foreclosure from a mortgagor. The fair value of the facilities approximated the $25 million carrying value of the mortgages. These facilities are located in Maryland. Simultaneously, we leased these facilities to an existing operator. NOTE 6 — OTHER INVESTMENTS A summary of our other investments is as follows: Other investment note due 2019; interest at 10.50% . . . . . . . . . . . . . . . . . . . . . . Other investment note due 2020; interest at 10.00% . . . . . . . . . . . . . . . . . . . . . . Other investment note due 2020; interest at 14.00% . . . . . . . . . . . . . . . . . . . . . . Other investment note due 2022, interest at 9.00% . . . . . . . . . . . . . . . . . . . . . . . Other investment note due 2030; interest at 6.66% . . . . . . . . . . . . . . . . . . . . . . . Other investment notes outstanding(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other investments, gross . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Allowance for loss on other investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total other investments December 31, 2016 2015 (in thousands) $ 49,458 23,000 47,913 31,987 44,595 64,691 261,644 (4,798) $256,846 $ — 23,000 — — 26,966 42,293 92,259 (2,960) $89,299 (1) Other investment notes have maturity dates through 2028 and interest rates ranging from 6.50% to 13.0% per annum. The following is an overview of certain notes entered into or repaid in 2016 and 2015. Other Investment note due 2019 On February 26, 2016, we acquired and funded a $50.0 million mezzanine note at a discount of approximately $0.75 million to a new operator. The mezzanine note bears interest at 10.50% per annum and matures in February 2019. Other Investment notes due 2020 In December 2015, we amended our five year $28.0 million loan agreement with an existing operator. The amendment permits the operator to re-borrow $6.0 million under the original loan agreement. We funded $6.0 million to the operator in December 2015. The loan bears interest at 10% per annum and the maturity date was extended from 2017 to 2020. As of December 31, 2016, approximately $23.0 million remains outstanding. On July 29, 2016, we provided an existing operator $48.0 million of term loan funding. The term loan bears interest at 14% per annum (LIBOR with a floor of 1% plus 13%) and matures on July 29, 2020. The term loan requires monthly principal payments of $0.25 million through July 2019, and $0.5 million from August 2019 through maturity. In addition, a portion of the monthly interest may be accrued to the outstanding principal balance of the loan. Other Investment notes due 2022 On September 30, 2016, we acquired and amended a term loan with a fair value of approximately $37.0 million with an existing operator. A $5.0 million tranche of the term loan bears interest at 13% and matures on September 30, 2019 and a $32.0 million tranche of the term loan bears interest at 9% per annum and matures on March 31, 2022. F-29 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued Other Investment note due 2030 On June 30, 2015, we entered into a $50.0 million revolving credit facility with an operator. The note bears interest at approximately 6.66% per annum and matures in 2030. As of December 31, 2016, approximately $44.6 million has been drawn and remains outstanding. Other Investment notes paid off On April 29, 2016, an existing operator exercised its option to pay off a working capital note due in 2022 and ten working capital notes due in 2023, for approximately $7.6 million. On March 1, 2016, we provided an operator a $15.0 million secured working capital note. The working capital note bore interest at 8.5% per annum and initially matured in March 2017. The loan was paid off in December 2016. On March 1, 2016, we provided an operator a $20.0 million acquisition note. The acquisition note bore interest at 8.5% per annum (increasing annually by 2.5% per annum) and initially matured in March 2028. The loan was paid off in October 2016. NOTE 7 — INVESTMENT IN UNCONSOLIDATED JOINT VENTURE On November 1, 2016, we invested approximately $50.0 million for an approximate 15% ownership interest in a joint venture operating as Second Spring Healthcare Investments. The other approximate 85% interest is owned by affiliates of Lindsey Goldberg LLC. We account for the joint venture using the equity method. On November 1, 2016, the joint venture acquired 64 SNFs from Welltower Inc. for approximately $1.1 billion. We receive asset management fees from the joint venture for services provided. For the year ended December 31, 2016, we recognized $0.3 million of asset management fees. These fees are included in miscellaneous income in the accompanying Consolidated Statement of Operations. The accounting policies for the unconsolidated joint venture are the same as those of the Company. NOTE 8 — ASSETS HELD FOR SALE The following is a summary of our assets held for sale: December 31, 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Properties sold/other(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Properties added(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Properties sold/other(3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Properties added(4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . December 31, 2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Properties Held-For-Sale Number of Properties 4 (5) 4 3 (24) 41 20 Net Book Value (in thousands) $ 12,792 (16,877) 10,684 6,599 (75,948) 122,217 $ 52,868 $ (1) (2) (3) (4) In 2015, a parcel of land was reclassified to closed facilities. In addition, we sold four facilities for approximately $25.5 million in net proceeds recognizing gains on sales of approximately $8.8 million. In 2015, we recorded a $3.0 million impairment charge on a SNF in New Mexico to reduce its net book value to its estimated fair value less costs to sell. In 2016, we sold 21 SNFs for approximately $86.7 million in net proceeds recognizing gains on sales of approximately $16.5 million. We also recorded approximately $4.9 million of impairments on 16 facilities to reduce their net book values to their estimated fair value less costs to sell. Two SNFs and one ALF classified as assets held for sale in the second quarter were no longer considered held for sale and were reclassified in the third quarter back to leased properties at their fair values (approximately $7.0 million). In 2016, we reclassified ten ALFs and 31 SNFs to assets held for sale (including the two SNFs and one ALF mentioned above that were reclassified back to leased properties in the third quarter). We recorded approximately $49.4 million of impairment charges on 20 of these facilities to reduce their net book values to their estimated fair value less costs to sell. F-30 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued NOTE 9 — INTANGIBLES The following is a summary of our intangibles as of December 31, 2016 and 2015: December 31, 2016 2015 (in thousands) Assets: Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $643,474 $645,683 Above market leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . In-place leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Accumulated amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 22,476 167 (15,864) 6,779 $ $ 21,901 386 (14,162) $ 8,125 Liabilities: Below market leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Accumulated amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net intangible liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $165,028 (70,738) $ 94,290 $165,331 (55,131) $110,200 Goodwill was recorded in connection with the Aviv Merger and Care Homes Transaction and is shown as a separate line on our Consolidated Balance Sheets. Above market leases and in-place leases, net of accumulated amortization, are included in other assets on our Consolidated Balance Sheets. Below market leases, net of accumulated amortization, are included in accrued expenses and other liabilities on our Consolidated Balance Sheets. The net amortization related to the above and below market leases is included in our Consolidated Statements of Operations as an adjustment to rental income. For the years ended December 31, 2016, 2015 and 2014, our net amortization related to intangibles was $13.9 million, $13.9 million and $5.0 million, respectively. The estimated net amortization related to these intangibles for the subsequent five years is as follows: 2017 – $12.0 million; 2018 – $10.6 million; 2019 – $9.5 million; 2020 – $9.3 million; 2021 – $8.7 million and $37.3 million thereafter. As of December 31, 2016 the weighted average remaining amortization period of above market lease assets and below market lease liabilities is 8.1 years and 9.5 years, respectively. The following is a summary of our goodwill as of December 31 2016: Balance as of December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Add: additional valuation adjustments related to preliminary valuations . . . . . . . . . . . . . . Less: foreign currency translation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Balance as of December 31, 2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (in thousands) $645,683 275 (2,484) $643,474 NOTE 10 — CONCENTRATION OF RISK As of December 31, 2016, our portfolio of real estate investments consisted of 996 healthcare facilities, located in 42 states and the U.K. and operated by 79 third party operators. Our investments in these facilities, net of impairments and reserve for uncollectible loans, totaled approximately $8.9 billion at December 31, 2016, with approximately 99% of our real estate investments related to long-term care facilities. Our portfolio is made up of 809 SNFs, 101 ALFs, 16 specialty facilities, one medical office building, fixed rate mortgages on 44 SNFs and two ALFs, and 23 facilities that are closed/held-for-sale. At December 31, 2016, we also held other investments of approximately $256.8 million, consisting primarily of secured loans to third-party operators of our facilities. At December 31, 2016, the three states in which we had our highest concentration of investments were Ohio (10%), Florida (9%) and Texas (9%). No single operator or manager generated more than 10% of our total revenues for the year ended December 31, 2016. F-31 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued NOTE 11 — LEASE AND MORTGAGE DEPOSITS We obtain liquidity deposits, security deposits and letters of credit from most operators pursuant to our lease and mortgage agreements with the operators. These generally represent the rental and mortgage interest for periods ranging from three to six months with respect to certain of our investments. At December 31, 2016, we held $5.7 million in liquidity deposits, $49.8 million in security deposits and $66.8 million in letters of credit. The liquidity deposits, security deposits and the letters of credit may be used in the event of lease and or loan defaults, subject to applicable limitations under bankruptcy law with respect to operators filing under Chapter 11 of the United States Bankruptcy Code. Liquidity deposits are recorded as restricted cash on our Consolidated Balance Sheets with the offset recorded as a liability in accrued expenses and other liabilities on our Consolidated Balance Sheets. Security deposits related to cash received from the operator are recorded in accrued expenses and other liabilities on our Consolidated Balance Sheets. Additional security for rental and mortgage interest revenue from operators is provided by covenants regarding minimum working capital and net worth, liens on accounts receivable and other operating assets of the operators, provisions for cross default, provisions for cross-collateralization and by corporate or personal guarantees. NOTE 12 — BORROWING ARRANGEMENTS The following is a summary of our long-term borrowings: Secured borrowings: Mortgage term loan . . . . . . . . . . . . . . . . . . . . HUD mortgages assumed December 2011(1) . . . . . Deferred financing costs – net . . . . . . . . . . . . . . . . . . . . . . . . . . . Total secured borrowings – net Unsecured borrowings: Revolving line of credit . . . . . . . . . . . . . . . . . . Tranche A-1 term loan . . . . . . . . . . . . . . . . . . Tranche A-2 term loan . . . . . . . . . . . . . . . . . . Tranche A-3 term loan . . . . . . . . . . . . . . . . . . Omega OP term loan . . . . . . . . . . . . . . . . . . . 2015 term loan . . . . . . . . . . . . . . . . . . . . . . . Deferred financing costs – net . . . . . . . . . . . . . . Total term loans – net . . . . . . . . . . . . . . . . . . . 2023 notes . . . . . . . . . . . . . . . . . . . . . . . . . . 2024 notes . . . . . . . . . . . . . . . . . . . . . . . . . . 2024 notes . . . . . . . . . . . . . . . . . . . . . . . . . . 2025 notes . . . . . . . . . . . . . . . . . . . . . . . . . . 2026 notes . . . . . . . . . . . . . . . . . . . . . . . . . . 2027 notes . . . . . . . . . . . . . . . . . . . . . . . . . . Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Subordinated debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Discount – net Deferred financing costs – net . . . . . . . . . . . . . . Total unsecured borrowings – net . . . . . . . . . . . . Interest Rate as of December 31, 2016 Maturity 2044 3.06% 2018 2019 2017 2021 2017 2022 2023 2024 2024 2025 2026 2027 2018 2021 2.06% 2.27% 2.19% 2.27% 2.19% 3.80% 4.375% 5.875% 4.95% 4.50% 5.25% 4.50% — 9.00% December 31, 2016 2015 (in thousands) $ — $ 180,000 56,204 (611) 235,593 54,954 (589) 54,365 190,000 230,000 200,000 200,000 350,000 100,000 250,000 (5,657) 1,094,343 700,000 400,000 400,000 250,000 600,000 700,000 3,000 20,000 (17,151) (27,703) 3,028,146 200,000 200,000 — 100,000 250,000 (4,307) 745,693 — 400,000 400,000 250,000 600,000 700,000 — 20,000 (17,118) (24,155) 2,328,727 Total secured and unsecured borrowings – net . . . . $4,366,854 $3,540,013 (1) Reflects the weighted average annual contractual interest rate on the mortgages at December 31, 2016 excluding a third-party administration fee of approximately 0.5%. Secured by real estate assets with a net carrying value of $65.7 million as of December 31, 2016. F-32 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued Secured Borrowings Mortgage Term Loan As a result of the Aviv Merger in April 2015, we acquired two subsidiaries that were borrowers under a $180.0 million mortgage term loan secured by mortgages on 28 healthcare facilities owned by one of the borrowers. On July 25, 2016, we purchased the $180.0 million mortgage term loan, effectively eliminating the debt on our consolidated financial statements. The term loan was secured by real estate assets having a net carrying value of $290.5 million at June 30, 2016. The interest rate was based on LIBOR, with a floor of 50 basis points, plus a margin of 350 basis points. The interest rate at June 30, 2016 was 4.13% per annum. We paid $180.0 million plus a 1% premium to purchase the debt. HUD Mortgages Loans Payoff On December 31, 2015, we paid approximately $25.1 million to retire two mortgage loans guaranteed by the U.S. Department of Housing and Urban Development (“HUD”). The loans were assumed as part of an acquisition in a prior year, and had a blended interest rate of 5.5% per annum with maturities on March 1 and April 1, 2036. The payoff resulted in a $0.9 million gain on the extinguishment of the debt due to the write-off of the $2.1 million unamortized fair value adjustment recorded at the time of acquisition offset by a prepayment fee of approximately $1.2 million. On April 30, 2015, we paid approximately $9.1 million to retire one mortgage loan guaranteed by HUD. The loan was assumed as part of an acquisition in a prior year, and had an interest rate of 4.35% per annum with maturity on March 1, 2041. The payoff resulted in a $1.0 million gain on the extinguishment of the debt due to the write-off of the $1.5 million unamortized fair value adjustment recorded at the time of acquisition offset by a prepayment fee of approximately $0.5 million. On March 31, 2015, we paid approximately $154.3 million to retire 21 mortgage loans guaranteed by HUD, totaling approximately $146.9 million. 18 loans had an all-in blended interest rate of 5.35% per annum with maturities between January 2040 and January 2045 and three loans had an all-in blended interest rate of 5.23% per annum with maturities between February 2040 and February 2045. The payoff resulted in a $2.3 million gain on the extinguishment of the debt due to the write-off of the $9.7 million unamortized debt premium recorded at the time of acquisition offset by a prepayment fee of approximately $7.4 million. Unsecured Borrowings Unsecured Credit Facility On January 29, 2016, we entered into the Third Amendment to Credit Agreement (the “Third Amendment to Omega Credit Agreement,” as defined below) which amended and restated the existing Credit Agreement, dated June 27, 2014 (as amended and restated pursuant to the First Amendment to Credit Agreement, dated April 1, 2015, the Second Amendment to Credit Agreement, dated August 7, 2015 and the Third Amendment to Omega Credit Agreement, collectively the “Omega Credit Agreement”). As a result of the amendments, the Omega Credit Facilities (as defined below) now includes a $1.25 billion senior unsecured revolving credit facility (the “Revolving Credit Facility”), a $200 million senior unsecured term loan facility (the “Tranche A-1 Term Loan Facility”), a $200 million senior unsecured incremental term loan facility (the “Tranche A-2 Term Loan Facility”) and a $350 million senior unsecured incremental term loan facility which was borrowed in 2016 (the “Tranche A-3 Term Loan Facility” and, together with the Revolving Credit Facility, the Tranche A-1 Term Loan Facility and the Tranche A-2 Term Loan Facility, collectively, the “Omega Credit Facilities”). The Tranche A-1 Term Loan Facility, the Tranche A-2 Term Loan Facility and the Tranche A-3 Term Loan Facility may be referred to collectively herein as the “Omega Term Loan Facilities”. Borrowings under the Revolving Credit Facility bear interest at LIBOR plus an applicable percentage (beginning at 130 basis points, with a range of 92.5 to 170 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings, plus a facility fee based on the same ratings (initially 25 F-33 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued basis points, with a range of 12.5 to 30 basis points). The Revolving Credit Facility is used for acquisitions and general corporate purposes. The Revolving Credit Facility matures on June 27, 2018, subject to a one-time option by us to extend such maturity date by one year. The Tranche A-1 Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 150 basis points, with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Tranche A-1 Term Loan Facility matures on June 27, 2019. The Tranche A-2 Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 150 basis points, with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Tranche A-2 Term Loan Facility matures on June 27, 2017, subject to Omega’s option to extend the maturity date of the Tranche A-2 Term Loan Facility twice, the first extension until June 27, 2018 and the second extension until June 27, 2019. The Tranche A-3 Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 150 basis points, with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Tranche A-3 Term Loan Facility matures on January 29, 2021. Omega OP Term Loan Facility On April 1, 2015, Omega OP entered into a credit agreement (the “Omega OP Credit Agreement”) providing it with a $100 million senior unsecured term loan facility (the “Omega OP Term Loan Facility”). The Omega OP Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 150 basis points, with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Omega OP Term Loan Facility matures on June 27, 2017, subject to Omega OP’s option to extend such maturity date twice, the first extension until June 27, 2018 and the second extension until June 27, 2019. $250 Million Term Loan Facility On December 16, 2015, we entered into a $250 million senior unsecured term loan facility (the “2015 Term Loan Facility”). The 2015 Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 180 basis points, with a range of 140 to 235 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The 2015 Term Loan Facility may be increased to an aggregate amount of $400 million. We used the proceeds from this loan to repay existing indebtedness and for general corporate purposes. The 2015 Term Loan Facility matures on December 16, 2022. As a result of exposure to interest rate movements associated with the 2015 Term Loan Facility, on December 16, 2015, we entered into various forward-starting interest rate swap arrangements, which effectively converted $250 million of our variable-rate debt based on one-month LIBOR to an aggregate fixed rate of approximately 3.8005% effective December 30, 2016. The effective fixed rate achieved by the combination of the 2015 Term Loan Facility and the interest rate swaps could fluctuate up by 55 basis points or down by 40 basis points based on future changes to our credit ratings. Each of these swaps began on December 30, 2016 and mature on December 15, 2022. On the date of inception, we designated the interest rate swaps as cash flow hedges in accordance with accounting guidance for derivatives and hedges and linked the interest rate swaps to the 2015 Term Loan Facility. Because the critical terms of the interest rate swaps and 2015 Term Loan Facility coincided, the hedges are expected to exactly offset changes in expected cash flows as a result of fluctuations in 1-month LIBOR over the term of the hedges. The purpose of entering into the swaps was to reduce our exposure to future changes in variable interest rates. The interest rate swaps settle on a monthly basis when interest payments are made. These settlements will occur through the maturity date of the 2015 Term Loan Facility. The interest rate for the 2015 Term Loan Facility was not hedged for the portion of the term prior to December 30, 2016. $700 Million 4.375% Senior Notes due 2023 On July 12, 2016, we issued $700 million aggregate principal amount of our 4.375% Senior Notes due 2023 (the “2023 Notes”). The 2023 Notes were sold at an issue price of 99.739% of their face value before F-34 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued the underwriters’ discount. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately $692.0 million. The net proceeds from the offering were used to repay outstanding borrowings under our revolving credit facility, to purchase the $180.0 million mortgage term loan and for general corporate purposes. The 2023 Notes mature on August 1, 2023 and pay interest semi-annually. $400 Million 5.875% Senior Notes due 2024 On March 19, 2012, we issued $400 million aggregate principal amount of our 5.875% Senior Notes due 2024. These notes mature on March 15, 2024 and pay interest semi-annually. $400 Million 4.95% Senior Notes due 2024 On March 11, 2014, we sold $400 million aggregate principal amount of our 4.95% Senior Notes due 2024 (the “2024 Notes”). These notes were sold at an issue price of 98.58% of the principal amount of the notes, before the initial purchasers’ discount resulting in gross proceeds of approximately $394.3 million. The 2024 Notes mature on April 1, 2024 and pay interest semi-annually. $250 Million 4.5% Senior Notes due 2025 On September 11, 2014, we sold $250 million aggregate principal amount of our 4.5% Senior Notes due 2025 (the “2025 Notes”). The 2025 Notes were sold at an issue price of 99.131% of their face value before the initial purchasers’ discount resulting in gross proceeds of approximately $247.8 million. The 2025 Notes mature on January 15, 2025 and pay interest semi-annually. $600 Million 5.25% Senior Notes due 2026 On September 23, 2015, we sold $600 million aggregate principal amount of our 5.250% Senior Notes due 2026 (the “2026 Notes”). The 2026 Notes were sold at an issue price of 99.717% of their face value before the initial purchasers’ discount. Our total net proceeds from the offering, after deducting initial purchasers’ discounts and other offering expenses, were approximately $594.4 million. The net proceeds of the offering were used to repay our outstanding $575 million aggregate principal amount 6.75% Senior Notes due 2022 and for general corporate purposes. The 2026 Notes mature on January 15, 2026 and pay interest semi-annually. $700 Million 4.5% Senior Notes due 2027 On March 18, 2015, we sold $700 million aggregate principal amount of our 4.5% Senior Notes due 2027 (the “2027 Notes”). The 2027 Notes were sold at an issue price of 98.546% of their face value before the initial purchasers’ discount. Our total net proceeds from the offering, after deducting initial purchasers’ discounts and other offering expenses, were approximately $683 million. The net proceeds of the offering were used for general corporate purposes, including the repayment of Aviv indebtedness on April 1, 2015 in connection with the Aviv Merger, and repayment of future maturities on our outstanding debt. The 2027 Notes mature on April 1, 2027 and pay interest semi-annually. $575 Million 6.75% Senior Notes due 2022 Redemption On October 26, 2015, we redeemed all of our outstanding 6.75% Senior Notes due 2022 (the “2022 Notes”). As a result of the redemption, during the fourth quarter of 2015, we recorded approximately $21.3 million in redemption related costs and write-offs, including $19.4 million for the early redemption or call premiums and $1.9 million in net write-offs associated with unamortized deferred financing costs and original issuance premiums/discounts. $200 Million 7.5% Senior Notes due 2020 Redemption On March 13, 2015, Omega redeemed all of its outstanding $200 million 7.5% Senior Notes due 2020 (the “2020 Notes”) at a redemption price of approximately $208.7 million, consisting of 103.750% of the principal amount, plus accrued and unpaid interest on such notes to, but not including, the date of redemption. F-35 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued In connection with the redemption, we recorded approximately $11.7 million redemption related costs and write-offs, including $7.5 million in prepayment fees for early redemption and $4.2 million of write-offs associated with unamortized deferred financing costs and discount. The consideration for the redemption of the 2020 Notes was funded from the net proceeds of the 10.925 million share common stock offering. See Note 16 – Stockholders’ Equity for additional details. Other Debt Repayments In connection with the Aviv Merger on April 1, 2015, we assumed notes payable with a face amount of $650 million and a revolving credit facility with an outstanding balance of $525 million. In connection with the Aviv Merger, we repaid this debt assumed from Aviv on April 1, 2015. Due to the contractual requirements for early repayments; we paid approximately $705.6 million to retire the $650 million notes assumed. The amount repaid in connection with the revolving credit facility was $525 million. General Certain of our other secured and unsecured borrowings are subject to customary affirmative and negative covenants, including financial covenants. As of December 31, 2016 and 2015, we were in compliance with all affirmative and negative covenants, including financial covenants, for our secured and unsecured borrowings. The required principal payments, excluding the premium or discount and deferred financing costs on our secured and unsecured borrowings, for each of the five years following December 31, 2016 and the aggregate due thereafter are set forth below: 2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Thereafter Totals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (in thousands) $ 302,788 192,828 201,369 1,412 371,456 3,348,101 $4,417,954 The following summarizes the refinancing related costs: 2016 Year Ended December 31, 2015 (in thousands) 2014 Write-off of deferred financing cost and unamortized premiums due to Prepayment and other costs associated with refinancing(4) refinancing(1)(2)(3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total debt extinguishment costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 301 1,812 $2,113 $ (7,134) $1,180 1,861 $3,041 35,971 $28,837 (1) (2) (3) In 2016, we recorded $0.3 million of write-offs of unamortized deferred financing costs associated with three facilities that were acquired via a deed-in-lieu foreclosure. In 2015, we recorded: (a) $4.2 million of write-offs of unamortized deferred financing costs and discount associated with the early redemption of our 2020 Notes, (b) $1.9 million in net write-offs associated with unamortized deferred financing costs and original issuance premiums/discounts associated with the early redemption of our 2022 Notes, offset by (c) $13.2 million gain related to the early extinguishment of debt from the write-off of unamortized premium on the HUD debt paid off in March, April and December 2015. In 2014, we recorded: (a) $2.6 million write-off of deferred financing costs associated with the termination of the $700 million 2012 credit facilities, (b) $2.0 million write-off of deferred financing costs associated with the termination of our $200 million 2013 term loan facility offset by (c) $3.5 million gain related to the early extinguishment of debt from the write-off of unamortized premium on the HUD debt paid off in September and December 2014. F-36 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued (4) In 2016, we purchased a $180 million mortgage term loan and paid a 1% premium of approximately $1.8 million to purchase the debt. In 2015, we made: (a) $7.5 million of prepayment penalties associated with the early redemption of our 2020 Notes, (b) $19.4 million of prepayment penalties associated with the early redemption of our 2022 Notes and (c) $9.1 million of prepayment penalties associated with 24 HUD mortgage loans that we paid off in March, April and December 2015. In 2014, we made prepayment penalties of $1.9 million associated with five HUD mortgage loans that we paid off in September and October 2014. NOTE 13 — FINANCIAL INSTRUMENTS At December 31, 2016 and 2015, the carrying amounts and fair values of our financial instruments were as follows: Assets: 2016 2015 Carrying Amount Fair Value Carrying Amount Fair Value (in thousands) Cash and cash equivalents . . . . . . . . . . . . . . . . . Restricted cash . . . . . . . . . . . . . . . . . . . . . . . . . Investments in direct financing leases – net . . . . . . Mortgage notes receivable – net . . . . . . . . . . . . . Other investments – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total $ 93,687 13,589 601,938 639,343 256,846 $1,605,403 $ 93,687 13,589 598,665 644,961 253,385 $1,604,287 $ 5,424 14,607 587,701 679,795 89,299 $1,376,826 $ 5,424 14,607 584,358 687,130 90,745 $1,382,264 Liabilities: Revolving line of credit . . . . . . . . . . . . . . . . . . . Tranche A-1 term loan . . . . . . . . . . . . . . . . . . . . Tranche A-2 term loan . . . . . . . . . . . . . . . . . . . . Tranche A-3 term loan . . . . . . . . . . . . . . . . . . . . Omega OP term loan . . . . . . . . . . . . . . . . . . . . . 2015 term loan . . . . . . . . . . . . . . . . . . . . . . . . . 4.375% notes due 2023 – net . . . . . . . . . . . . . . . . 5.875% notes due 2024 – net . . . . . . . . . . . . . . . . 4.95% notes due 2024 – net . . . . . . . . . . . . . . . . . 4.50% notes due 2025 – net . . . . . . . . . . . . . . . . . 5.25% notes due 2026 – net . . . . . . . . . . . . . . . . . 4.50% notes due 2027 – net . . . . . . . . . . . . . . . . . Mortgage term loan due 2019 . . . . . . . . . . . . . . . HUD debt – net . . . . . . . . . . . . . . . . . . . . . . . . Subordinated debt – net . . . . . . . . . . . . . . . . . . . Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total $ 190,000 198,830 200,000 347,449 100,000 248,064 692,305 395,065 392,669 245,949 593,616 685,052 — 54,365 20,490 3,000 $4,366,854 $ 190,000 200,000 200,000 350,000 100,000 250,000 693,505 432,938 406,361 249,075 611,461 681,978 — 52,510 23,944 3,000 $4,444,772 $ 230,000 197,699 200,000 — 100,000 247,994 — 394,382 391,658 245,446 593,032 683,596 180,000 55,593 20,613 — $3,540,013 $ 230,000 200,000 200,000 — 100,000 250,000 — 429,956 403,064 242,532 612,760 667,651 180,000 52,678 24,366 — $3,593,007 Fair value estimates are subjective in nature and are dependent on a number of important assumptions, including estimates of future cash flows, risks, discount rates and relevant comparable market information associated with each financial instrument (see Note 2 – Summary of Significant Accounting Policies). The use of different market assumptions and estimation methodologies may have a material effect on the reported estimated fair value amounts. The following methods and assumptions were used in estimating fair value disclosures for financial instruments. • Cash and cash equivalents and restricted cash: The carrying amount of cash and cash equivalents and restricted cash reported in the Consolidated Balance Sheets approximates fair value because of the short maturity of these instruments (i.e., less than 90 days) (Level 1). F-37 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued • Direct financing leases: The fair value of the investments in direct financing leases are estimated using a discounted cash flow analysis, using interest rates being offered for similar leases to borrowers with similar credit ratings (Level 3). • Mortgage notes receivable: The fair value of the mortgage notes receivables are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3). • • • • Other investments: Other investments are primarily comprised of notes receivable. The fair values of notes receivable are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3). Revolving line of credit and term loans: The fair value of our borrowings under variable rate agreements are estimated using a present value technique based on expected cash flows discounted using the current market rates (Level 3). Senior notes and subordinated debt: The fair value of our borrowings under fixed rate agreements are estimated using a present value technique based on inputs from trading activity provided by a third party (Level 2). HUD debt: The fair value of our borrowings under HUD debt agreements are estimated using an expected present value technique based on quotes obtained by HUD debt brokers (Level 2). NOTE 14 — TAXES We were organized, have operated, and intend to continue to operate in a manner that enables us to qualify for taxation as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (the “Code”). On a quarterly and annual basis we perform several analyses to test our compliance within the REIT taxation rules. In order to qualify as a REIT, in addition to other requirements, we must: (i) distribute dividends (other than capital gain dividends) to our stockholders in an amount at least equal to (A) the sum of (a) 90% of our “REIT taxable income” (computed without regard to the dividends paid deduction and our net capital gain), and (b) 90% of the net income (after tax), if any, from foreclosure property, minus (B) the sum of certain items of non-cash income on an annual basis, (ii) ensure that at least 75% and 95%, respectively of our gross income is generated from qualifying sources that are described in the REIT tax law, (iii) ensure that at least 75% of our assets consist of qualifying assets, such as real property, mortgages, and other qualifying assets described in the REIT tax law, (iv) ensure that we do not own greater than 10% in voting power or value of securities of any one issuer, (v) ensure that we do not own either debt or equity securities of another company that are in excess of 5% of our total assets and (vi) ensure that no more than 25% of our assets are invested in one or more taxable REIT subsidiaries (and with respect to taxable years beginning after December 31, 2017, no more than 20%). In addition to the above requirements, the REIT rules require that no less than 100 stockholders own shares or an interest in the REIT and that five or fewer individuals do not own (directly or indirectly) more than 50% of the shares or proportionate interest in the REIT during the last half of any taxable year. If we fail to meet the above or any other requirements for qualification as a REIT in any tax year, we will be subject to federal income tax on our taxable income at regular corporate rates and may not be able to qualify as a REIT for the four subsequent years, unless we qualify for certain relief provisions that are available in the event we fail to satisfy any of these requirements. We are also subject to federal taxation of 100% of the net income derived from the sale or other disposition of property, other than foreclosure property, that we held primarily for sale to customers in the ordinary course of a trade or business. We believe that we do not hold assets for sale to customers in the ordinary course of business and that none of the assets currently held for sale or that have been sold would be considered a prohibited transaction within the REIT taxation rules. So long as we qualify as a REIT under the Code, we generally will not be subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions. In 2016 and 2015, we distributed dividends in excess of our taxable income. F-38 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued Since the year 2000, the definition of foreclosure property has included any “qualified health care property,” as defined in Code Section 856(e)(6) acquired by us as the result of the termination or expiration of a lease of such property. We have from time to time operated qualified healthcare facilities acquired in this manner for up to two years (or longer if an extension was granted). Properties that we had taken back in a foreclosure or bankruptcy and operated for our own account were treated as foreclosure properties for income tax purposes, pursuant to Code Section 856(e). Gross income from foreclosure properties was classified as “good income” for purposes of the annual REIT income tests upon making the election on the tax return. Once made, the income was classified as “good” for a period of three years, or until the properties were no longer operated for our own account. In all cases of foreclosure property, we utilized an independent contractor to conduct day-to-day operations to maintain REIT status. In certain cases, we operated these facilities through a taxable REIT subsidiary. For those properties operated through the taxable REIT subsidiary, we formed a new entity (TC Healthcare) to act as the eligible independent contractor on our behalf and conduct the day-to-day operations with respect to the health care facilities we held as foreclosure property in order for us to maintain REIT status. We have not held foreclosure property since 2011. As a result of the foregoing, we do not believe that our past participation in the operation of nursing homes increased the risk that we would fail to qualify as a REIT. Through our 2016 taxable year, we had not paid any tax on our foreclosure property because those properties had been producing losses. As a result of our UPREIT Conversion, our Company and its subsidiaries may be subject to income or franchise taxes in certain states and municipalities. In connection with our UPREIT Conversion in 2015, we created five subsidiary REITs that are subject to all of the REIT qualification rules set forth in the Code, which were then consolidated through intercompany transfers of ownership that occurred at the end of 2015, which created a single REIT subsidiary with four wholly-owned qualified REIT subsidiaries. In 2016, we elected REIT status for another of our subsidiaries and in December of 2016, we transferred the ownership of that entity to our REIT subsidiary so that we now have a single REIT subsidiary that holds all the ownership interests in several qualified REIT subsidiaries. Our REIT subsidiary remains subject to all of the REIT qualification rules set forth in the Code as outlined above. Subject to the limitation under the REIT asset test rules, we are permitted to own up to 100% of the stock of one or more taxable REIT subsidiaries (“TRSs”). We have elected for two of our active subsidiaries to be treated as TRSs. One of our active TRSs is subject to federal, state and local income taxes at the applicable corporate rates and the other is subject to foreign income taxes. As of December 31, 2016, our TRS that is subject to federal, state and local income taxes at the applicable corporate rates had a net operating loss carry-forward of approximately $0.8 million. The loss carry-forward is fully reserved as of December 31, 2016 with a valuation allowance due to uncertainties regarding realization. In connection with our acquisition of Care Homes in May 2015, we acquired 10 legal entities consisting of 23 facilities. The tax basis in these legal entities acquired for U.K. taxes was approximately $82 million less than the purchase price. We recorded an initial deferred tax liability associated with the temporary tax basis difference of approximately $15 million. During the year ended December 31, 2016, we recorded approximately $3.3 million of federal, state and local income tax provision and approximately $1.9 million of tax benefit for foreign income taxes. NOTE 15 — RETIREMENT ARRANGEMENTS Our Company has a 401(k) Profit Sharing Plan covering all eligible employees. Under this plan, employees are eligible to make contributions, and we, at our discretion, may match contributions and make a profit sharing contribution. Amounts charged to operations with respect to these retirement arrangements totaled approximately $0.5 million, $0.4 million, $0.3 million in 2016, 2015 and 2014, respectively. In addition, we have a deferred stock compensation plan that allows employees and directors the ability to defer the receipt of stock awards. The deferred stock awards (units) participate in future dividends as well as the change in the value of the Company’s common stock. As of December 31, 2016 and 2015, the Company had 384,107 and 400,814 deferred stock units outstanding. F-39 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued NOTE 16 — STOCKHOLDERS’ EQUITY $500 Million Equity Shelf Program On September 3, 2015, we entered into separate Equity Distribution Agreements (collectively, the “Equity Shelf Agreements”) to sell shares of our common stock having an aggregate gross sales price of up to $500 million (the “2015 Equity Shelf Program”) with several financial institutions, each as a sales agent and or principal (collectively, the “Managers”). Under the terms of the Equity Shelf Agreements, we may sell shares of our common stock, from time to time, through or to the Managers having an aggregate gross sales price of up to $500 million. Sales of the shares, if any, will be made by means of ordinary brokers’ transactions on the New York Stock Exchange at market prices, or as otherwise agreed with the applicable Manager. We will pay each Manager compensation for sales of the shares equal to 2% of the gross sales price per share for shares sold through such Manager under the applicable Equity Shelf Agreements. For the year ended December 31, 2015, we did not issue any shares under the 2015 Equity Shelf Program. For the year ended December 31, 2016, we issued approximately 0.7 million shares under the 2015 Equity Shelf Program, at an average price of $29.97 per share, generating gross proceeds of approximately $20.4 million, before $0.7 million of commissions and expenses. $250 Million Equity Shelf Program Termination Also on September 3, 2015, we terminated our $250 million Equity Shelf Program (the “2013 Equity Shelf Program”) that we entered into with several financial institutions on March 18, 2013. In 2015, we did not issue any shares under the 2013 Equity Shelf Program. For the year ended December 31, 2014, we issued approximately 1.8 million shares under the 2013 Equity Shelf Program, at an average price of $34.33 per share, generating gross proceeds of approximately $63.5 million, before $1.5 million of commissions and expenses. Since inception of the 2013 Equity Shelf Program, we sold a total of 7.4 million shares of common stock generating total gross proceeds of $233.8 million under the program, before $4.7 million of commissions. As a result of the termination of the 2013 Equity Shelf Program, no additional shares may be issued under the 2013 Equity Shelf Program. Increase of Authorized Omega Common Stock On March 27, 2015, we amended our charter to increase the number of authorized shares of our capital stock from 220 million to 370 million and the number of authorized shares of our common stock from 200 million to 350 million. 10.925 Million Common Stock Offering On February 9, 2015, we completed an underwritten public offering of 10.925 million shares of our common stock at $42.00 per share before underwriting and other offering expenses. The Company’s total net proceeds from the offering were approximately $440 million, after deducting underwriting discounts and commissions and other estimated offering expenses. Dividend Reinvestment and Common Stock Purchase Plan We have a Dividend Reinvestment and Common Stock Purchase Plan (the “DRSPP”) that allows for the reinvestment of dividends and the optional purchase of our common stock. For the year ended December 31, 2016, we issued 7.2 million shares of common stock for gross proceeds of approximately $240.0 million. For the year ended December 31, 2015, we issued 4.2 million shares of common stock for gross proceeds of approximately $150.8 million. For the year ended December 31, 2014, we issued 2.1 million shares of common stock for gross proceeds of approximately $71.5 million. F-40 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued Accumulated Other Comprehensive Loss The following is a summary of our accumulated other comprehensive loss, net of tax where applicable: Foreign currency translation adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cash flow hedge adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total accumulated other comprehensive loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . December 31, 2016 2015 (in thousands) $(52,495) $(8,027) (685) $(53,827) $(8,712) (1,332) NOTE 17 — STOCK-BASED COMPENSATION Restricted Stock and Restricted Stock Units Restricted stock and restricted stock units (“RSUs”) are subject to forfeiture if the holder’s service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of employment or a change in control of the Company. Prior to vesting, ownership of the shares/units cannot be transferred. The restricted stock has the same dividend and voting rights as our common stock. RSUs accrue dividend equivalents but have no voting rights. Restricted stock and RSUs are valued at the price of our common stock on the date of grant. We expense the cost of these awards ratably over their vesting period. The RSUs assumed from Aviv as part of the Aviv Merger were valued at the closing price of our stock on the date of the transaction. The portion of the vesting accruing prior to the acquisition was recorded as part of the purchase price consideration. The expense associated with the vesting that will occur after the date of the transaction will be recorded as stock compensation expense ratably over the remaining life of the RSUs. The following table summarizes the activity in restricted stock and RSUs for the years ended December 31, 2014, 2015 and 2016: Non-vested at December 31, 2013 . . . . . . . . . . . . . . . . . . . . . Granted during 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . Vested during 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Non-vested at December 31, 2014 . . . . . . . . . . . . . . . . . . . . . Granted during 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . Assumed in Aviv Merger(2) . . . . . . . . . . . . . . . . . . . . . . . . Cancelled during 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . Vested during 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Non-vested at December 31, 2015 . . . . . . . . . . . . . . . . . . . . . Granted during 2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cancelled during 2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . Vested during 2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Non-vested at December 31, 2016 . . . . . . . . . . . . . . . . . . . . . Number of Shares/Units 257,198 143,637 (90,901) 309,934 233,483 38,268 (61,911) (106,146) 413,628 158,506 (905) (235,176) 336,053 Weighted-Average Grant-Date Fair Value per Share $29.32 30.70 28.87 $30.08 39.25 23.50 33.77 28.72 $34.45 34.49 24.92 30.41 $37.32 Compensation Cost(1) (in millions) $4.4 $9.2 $0.9 $5.5 (1) Total compensation cost to be recognized on the awards based on grant date fair value, which is based on the market price of the Company’s common stock on the date of grant. (2) Omega stock price on April 1, 2015 was $40.74. The weighted average stock price indicated in the table above represents the expense per unit that we will record related to the assumed Aviv RSUs. Performance Based Incentive Stock Units Performance restricted stock units (“PRSUs”) and long term incentive plan units (“LTIP Units”) are subject to forfeiture if the performance requirements are not achieved or if the holder’s service to us F-41 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of employment or a change in control of the Company. The PRSUs awarded in January 2011, January 2013, December 2013, January 2014, March 2015, April 2015 July 2015, and March 2016 and the LTIP Units awarded in March 2015, April 2015, July 2015 and March 2016 have varying degrees of performance requirements to achieve vesting, and each PRSU and LTIP Units award represents the right to a variable number of shares of common stock or partnership units (each LTIP Unit once earned is convertible into one Omega OP Unit in Omega OP, subject to certain conditions). The vesting requirements are based on either the (i) total shareholders return (“TSR”) of Omega or (ii) Omega’s TSR relative to other real estate investment trusts in the MSCI U.S. REIT Index for awards before 2016 and in the FTSE NAREIT Equity Health Care Index for awards in 2016 (“Relative TSR”). We expense the cost of these awards ratably over their service period. Prior to vesting and the distribution of shares, ownership of the PRSUs cannot be transferred. Dividends on the PRSUs are accrued and only paid to the extent the applicable performance requirements are met. While each LTIP Unit is unearned, the employee receives a partnership distribution equal to 10% of the quarterly approved regular periodic distributions per Omega OP Unit. The remaining partnership distributions (which in the case of normal periodic distributions is equal to the total approved quarterly dividend on Omega’s common stock) on the LTIP Units accumulate, and if the LTIP Units are earned, the accumulated distributions are paid. We used a Monte Carlo model to estimate the fair value for the PRSUs and LTIP Units granted to the employees. The following are the significant assumptions used in estimating the value of the awards for grants made on the following dates: Closing price on date of grant Dividend yield Risk free interest rate at time of grant Expected volatility December 31, 2013 and January 1, 2014 $29.80 6.44% 0.04% to 0.86% 24.16% to 25.86% January 1, 2013 $23.85 4.24% 0.05% to 0.43% 15.56% to 23.83% March 31, 2015 $40.57 5.23% 0.10% to 0.94% 20.06% to 21.09% April 1, 2015 $40.74 5.20% 0.09% to 0.91% 20.06% to 21.08% July 31, 2015 $36.26 6.07% 0.13% to 1.08% 20.06% to 20.21% March 17, 2016 $34.78 6.56% 0.05% to 1.14% 23.92% to 24.88% The following table summarizes the activity in PRSUs and LTIP Units for the years ended December 31, 2014, 2015 and 2016: Non-vested at December 31, 2013 . . . . . . . . . . . . . . . . . . . . . Granted during 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . Vested during 2014(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . Non-vested at December 31, 2014 . . . . . . . . . . . . . . . . . . . . . Granted during 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cancelled during 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . Forfeited during 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . Vested during 2015(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . Non-vested at December 31, 2015 . . . . . . . . . . . . . . . . . . . . . Granted during 2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . Forfeited during 2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . Vested during 2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Non-vested at December 31, 2016 . . . . . . . . . . . . . . . . . . . . . F-42 Weighted-Average Grant-Date Fair Value per Share $10.72 11.46 10.75 $10.97 18.51 14.11 12.04 10.10 $14.87 14.67 12.10 — $16.08 Number of Shares 1,038,024 309,168 (496,979) 850,213 537,923 (165,570) (128,073) (181,406) 913,087 679,549 (518,638) — 1,073,998 Compensation Cost(1) (in millions) $ 3.5 $10.0 $10.0 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued (1) (2) Total compensation cost to be recognized on the awards was based on the grant date fair value or the modification date fair value. PRSUs are shown as vesting in the year that the Compensation Committee determines the level of achievement of the applicable performance measures. The following table summarizes our total unrecognized compensation cost as of December 31, 2016 associated with restricted stock, restricted stock units, PRSU awards, and LTIP Unit awards to employees: Grant Date Average Fair Value Per Unit/ Share Total Compensation Cost (in millions)(1) Weighted Average Period of Expense Recognition (in months) Unrecognized Compensation Cost (in millions) Grant Year Shares/ Units RSUs 3/31/15 RSU . . . . . . . . . . . . . . 2015 4/1/15 RSU . . . . . . . . . . . . . . 2015 Assumed Aviv RSU . . . . . . . . . . 2015 3/17/16 RSU . . . . . . . . . . . . . . 2016 Restricted Stock Units Total . . . . 109,985 40,464 7,799 131,006 289,254 40.57 40.74 35.08 34.78 $37.82 TSR PRSUs and LTIP Units 2016 TSR . . . . . . . . . . . . . . . 2014 135,634 8.67 3/31/15 2017 LTIP Units . . . . . . . 2015 137,249 14.66 4/1/2015 2017 LTIP Units . . . . . . 2015 54,151 14.80 3/17/2016 2018 LTIP Units . . . . . . 2016 372,069 13.21 4.5 1.6 0.3 4.6 $11.0 1.2 2.0 0.8 4.9 TSR PRSUs & LTIP Total . . . . 699,103 $12.74 $ 8.9 Relative TSR PRSUs 2016 Relative TSR . . . . . . . . . . 2014 135,634 14.24 3/31/15 2017 Relative TSR . . . . . . 2015 137,249 22.50 4/1/2015 2017 Relative TSR . . . . . 2015 54,151 22.91 3/17/2016 2018 Relative TSR . . . . . 2016 307,480 16.45 1.9 3.1 1.2 5.1 Relative TSR PRSUs Total . . . . Grand Total . . . . . . . . . . . 634,514 1,622,871 $17.84 $19.20 $11.3 $31.2 (1) Total compensation costs are net of shares cancelled. Stock Options and Tax Withholding 33 33 33 33 48 45 45 45 48 45 45 45 1.6 0.6 0.1 3.3 $ 5.6 0.3 1.1 0.4 3.9 $ 5.7 0.5 1.6 0.7 4.0 $ 6.8 $18.1 Performance Period Vesting Dates N/A N/A N/A N/A 12/31/2017 12/31/2017 11/1/2017 12/31/2018 1/1/2014 – 12/31/2016 1/1/2015 – 12/31/2017 1/1/2015 – 12/31/2017 1/1/2016 – 12/31/2018 Quarterly in 2017 Quarterly in 2018 Quarterly in 2018 Quarterly in 2019 1/1/2014 – 12/31/2016 1/1/2015 – 12/31/2017 1/1/2015 – 12/31/2017 1/1/2016 – 12/31/2018 Quarterly in 2017 Quarterly in 2018 Quarterly in 2018 Quarterly in 2019 As part of the Aviv Merger, we assumed approximately 5.7 million Aviv employee stock options that were fully vested prior to the merger. On April 1, 2015, the Aviv stock options were converted into Omega stock options at an exchange ratio of 0.9 resulting in issuance of approximately 5.1 million Omega stock options. The intrinsic value of the stock option assumed on April 1, 2015 was approximately $99.2 million the consideration provided in the merger. During 2016 and 2015, and was recorded as part of approximately 2.5 million and 2.6 million options, respectively, were exercised at a weighted average price of $19.38 per share and $19.38 per share, respectively. At December 31, 2016, approximately 26 thousand options remain outstanding and exercisable. Options outstanding have a weighted average exercise price of $18.97. The aggregate intrinsic value of these options is $0.3 million and represents the total pre-tax intrinsic value (based upon the difference between the Company’s closing stock price on the last trading day of 2016 of $31.26 and the exercise price) for all in-the-money options as of December 31, 2016. Options outstanding have no contractual term limitations. F-43 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued Stock withheld to pay minimum statutory tax withholdings for equity instruments granted under stock-based payment arrangements for the years ended December 31, 2016, 2015 and 2014, was $23.4 million, $26.7 million and $3.6 million, respectively. Shares Available for Issuance for Compensation Purposes On June 6, 2013, at our Company’s Annual Meeting, our stockholders approved the 2013 Stock Incentive Plan (the “2013 Plan”), which amended and restated the Company’s 2004 Stock Incentive Plan. The 2013 Plan is a comprehensive incentive compensation plan that allows for various types of equity-based compensation, including restricted stock units (including performance-based restricted stock units and LTIP units), stock awards, deferred restricted stock units, incentive stock options, non-qualified stock options, stock appreciation rights, dividend equivalent rights and certain cash-based awards (including performance-based cash awards). The 2013 Plan increased the number of shares reserved for issuance for compensation purposes by 3,000,000. As of December 31, 2016, approximately 2.0 million shares of common stock were reserved for issuance to our employees, directors and consultants under our stock incentive plans. Awards under our stock incentive plans may be in the form of stock, stock options, restricted stock and performance restricted stock units. Director Restricted Stock Grants In 2014, 2015 and 2016, we issued 21,500, 30,500 and 27,500 shares of restricted stock to members of our Board of Directors. The fair value of these awards was approximately $0.8 million, $1.1 million and $0.9 million, respectively, for 2014, 2015 and 2016. As of December 31, 2016, we had 51,999 shares of restricted stock outstanding to directors. The directors’ restricted shares are scheduled to vest over the next three years. As of December 31, 2016, the unrecognized compensation cost associated with outstanding director restricted stock grants is approximately $1.4 million. NOTE 18 — DIVIDENDS Common Dividends On January 12, 2017, the Board of Directors declared a common stock dividend of $0.62 per share, increasing the quarterly common dividend by $0.01 per share over the prior quarter. The common dividends were paid February 15, 2017 to common stockholders of record as of the close of business on January 31, 2017. On October 13, 2016, the Board of Directors declared a common stock dividend of $0.61 per share, increasing the quarterly common dividend rate by $0.01 per share over the previous quarter. The common dividends were paid November 15, 2016 to common stockholders of record as of the close of business on October 31, 2016. On July 14, 2016, the Board of Directors declared a common stock dividend of $0.60 per share, increasing the quarterly common dividend rate by $0.02 per share over the prior quarter. The common dividends were paid on August 15, 2016 to common stockholders of record as of the close of business on August 1, 2016. On April 14, 2016, the Board of Directors declared a common stock dividend of $0.58 per share, increasing the quarterly common dividend by $0.01 per share over the prior quarter. The common dividends were paid May 16, 2016 to common stockholders of record on May 2, 2016. On January 14, 2016, the Board of Directors declared a common stock dividend of $0.57 per share, increasing the quarterly common dividend by $0.01 per share over the previous quarter. The common dividends were paid February 16, 2016 to common stockholders of record as of February 2, 2016. F-44 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued Per Share Distributions Per share distributions by our Company were characterized in the following manner for income tax purposes (unaudited): Year Ended December 31, 2015 2014 2016 Common Ordinary income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Return of capital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Capital gains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $1.968 0.322 0.070 $2.360 $1.133 1.047 — $2.180 $1.834 0.186 — $2.020 For additional information regarding dividends, see Note 14 – Taxes. NOTE 19 — LITIGATION We are subject to various legal proceedings, claims and other actions arising out of the normal course of business. While any legal proceeding or claim has an element of uncertainty, management believes that the outcome of each lawsuit, claim or legal proceeding that is pending or threatened, or all of them combined, will not have a material adverse effect on our consolidated financial position or results of operations. NOTE 20 — SUMMARY OF QUARTERLY RESULTS (UNAUDITED) The following summarizes quarterly results of operations for the years ended December 31, 2016 and 2015: 2016 Revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net income available to common stockholders . . . . . . . . Net income available to common per share: Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net income per share: Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cash dividends paid on common stock . . . . . . . . . . . . . 2015 Revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net income available to common stockholders . . . . . . . . Net income available to common per share: Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net income per share: Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cash dividends paid on common stock . . . . . . . . . . . . . March 31 June 30 September 30 December 31 (in thousands, except per share amounts) $212,879 58,196 55,555 $228,824 113,154 108,052 $224,638 82,134 78,549 $234,486 129,883 124,259 $ $ $ 0.30 0.29 0.57 $ $ $ 0.57 0.57 0.58 $ $ $ 0.40 0.40 0.60 $ $ $ 0.63 0.63 0.61 $133,420 43,052 43,052 $197,711 43,466 41,428 $201,974 83,254 79,402 $210,512 63,543 60,642 $ $ $ 0.32 0.32 0.53 $ $ $ 0.23 0.22 0.54 $ $ $ 0.43 0.43 0.55 $ $ $ 0.32 0.32 0.56 F-45 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued NOTE 21 — EARNINGS PER SHARE The following tables set forth the computation of basic and diluted earnings per share: Year Ended December 31, 2015 (in thousands, except per share amounts) 2014 2016 Numerator: Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Less: Net income attributable to noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . Net income available to common stockholders $383,367 (16,952) $366,415 $233,315 (8,791) $224,524 $221,349 — $221,349 Denominator: Denominator for basic earnings per share . . . . . . . . . . . . . . . . . . . . Effect of dilutive securities: 191,781 172,242 126,550 Common stock equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . Noncontrolling interest – OP units . . . . . . . . . . . . . . . . . . . . . . . Denominator for diluted earnings per share . . . . . . . . . . . . . . . . . . 956 8,898 201,635 1,539 6,727 180,508 744 — 127,294 Earnings per share – basic: Net income available to common stockholders . . . . . . . . . . . . . . . . Earnings per share – diluted: Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ $ 1.91 1.90 $ $ 1.30 1.29 $ $ 1.75 1.74 NOTE 22 — CONSOLIDATING FINANCIAL STATEMENTS As of December 31, 2016, we had outstanding: (i) $700 million 4.375% Senior Notes due 2023, (ii) $400 million 5.875% Senior Notes due 2024, (iii) $400 million 4.95% Senior Notes due 2024, (iv) $250 million 4.50% Senior Notes due 2025, (v) $600 million 5.25% Senior Notes due 2026 and (vi) $700 million 4.5% Senior Notes due 2027 (collectively, the “Senior Notes”). The Senior Notes are fully and unconditionally guaranteed, jointly and severally, by each of our subsidiaries that guarantee other indebtedness of Omega or any of the subsidiary guarantors. All of our subsidiaries that guarantee the Senior Notes also guarantee amounts outstanding under the Omega Credit Facilities and 2015 Term Loan Facility listed in Note 12 – Borrowing Arrangements. In addition, all such subsidiary guarantors that are subsidiaries of Omega OP also guarantee amounts outstanding under the Omega OP Term Loan listed in Note 12 – Borrowing Arrangements. The following summarized condensed consolidating financial information segregates the financial information of the non-guarantor subsidiaries from the financial information of Omega Healthcare Investors, Inc. and the subsidiary guarantors under the Senior Notes. Our non-guarantor subsidiaries include, among others, all subsidiaries securing secured debt that is currently outstanding and our U.K. subsidiaries. The results and financial position of acquired entities are included from the dates of their respective acquisitions. The 2014 and 2015 financial statements presented below have been adjusted to reflect our current guarantor and non-guarantor relationships as of December 31, 2016. F-46 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATING BALANCE SHEET (in thousands) December 31, 2016 Issuer & Subsidiary Guarantors Non-Guarantor Subsidiaries Elimination Consolidated Real estate properties ASSETS Real estate investments . . . . . . . . . . . . . . . . . Less accumulated depreciation . . . . . . . . . . . . Real estate investments – net . . . . . . . . . . . . Investment in direct financing leases – net . . . . Mortgage notes receivable – net . . . . . . . . . . . Other investments . . . . . . . . . . . . . . . . . . . . . . Investment in unconsolidated joint venture . . . . . Assets held for sale – net . . . . . . . . . . . . . . . . . . Total investments . . . . . . . . . . . . . . . . . . . . . Cash and cash equivalents . . . . . . . . . . . . . . . . . Restricted cash . . . . . . . . . . . . . . . . . . . . . . . . Accounts receivable – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Goodwill Investments in and advances to affiliates . . . . . . . Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . Total assets . . . . . . . . . . . . . . . . . . . . . . . . . LIABILITIES AND EQUITY Revolving line of credit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Term loans – net . . . . . . . . . . . . . . . . . Secured borrowings – net Unsecured borrowings – net . . . . . . . . . . . . . . . Accrued expenses and other liabilities . . . . . . . . . Deferred income taxes . . . . . . . . . . . . . . . . . . . Intercompany payable . . . . . . . . . . . . . . . . . . . Total liabilities . . . . . . . . . . . . . . . . . . . . . . . Equity: Common stock . . . . . . . . . . . . . . . . . . . . . . . . Equity investment from affiliates . . . . . . . . . . . . Common stock – additional paid-in capital . . . . . Cumulative net earnings . . . . . . . . . . . . . . . . . . Cumulative dividends paid . . . . . . . . . . . . . . . . Accumulated other comprehensive (loss) income . Total stockholders’ equity . . . . . . . . . . . . . . . Noncontrolling interest . . . . . . . . . . . . . . . . . . . Total equity . . . . . . . . . . . . . . . . . . . . . . . . . Total liabilities and equity . . . . . . . . . . . . . . . $ 6,923,469 (1,191,117) 5,732,352 601,938 639,343 6,973,633 256,846 48,776 52,868 7,332,123 87,098 6,915 230,097 630,679 569,194 21,293 $ 8,877,399 $ 190,000 1,094,343 — 3,028,146 352,924 — — 4,665,413 19,614 — 4,861,408 1,738,937 (2,707,387) (53,827) 3,858,745 353,241 4,211,986 $ 8,877,399 F-47 $ 642,889 (49,219) 593,670 — — 593,670 — — — 593,670 6,589 6,674 9,938 12,795 — 11,389 $ 641,055 $ — $ 7,566,358 — (1,240,336) 6,326,022 — 601,938 — — 639,343 7,567,303 — 256,846 — 48,776 — — 52,868 7,925,793 — — — — — (569,194) — 93,687 13,589 240,035 643,474 — 32,682 $ (569,194) $ 8,949,260 $ — $ — 429,214 — 7,590 9,906 7,890 454,600 — $ — (374,849) — — — (7,890) (382,739) 190,000 1,094,343 54,365 3,028,146 360,514 9,906 — 4,737,274 — 156,446 — 29,479 — 530 186,455 — 186,455 $ 641,055 — (156,446) — (29,479) 19,614 — 4,861,408 1,738,937 — (2,707,387) (53,827) 3,858,745 353,241 4,211,986 $ (569,194) $ 8,949,260 (530) (186,455) — (186,455) OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATING BALANCE SHEET (in thousands) December 31, 2015 Issuer & Subsidiary Guarantors Non-Guarantor Subsidiaries Elimination Consolidated Real estate properties ASSETS Real estate investments . . . . . . . . . . . . . . . . . Less accumulated depreciation . . . . . . . . . . . . Real estate investments – net . . . . . . . . . . . . Investment in direct financing leases – net . . . . Mortgage notes receivable – net . . . . . . . . . . . Other investments . . . . . . . . . . . . . . . . . . . . . . Assets held for sale – net . . . . . . . . . . . . . . . . . . Total investments . . . . . . . . . . . . . . . . . . . . . Cash and cash equivalents . . . . . . . . . . . . . . . . . Restricted cash . . . . . . . . . . . . . . . . . . . . . . . . Accounts receivable – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Goodwill Investments in and advances to affiliates . . . . . . . Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . Total assets . . . . . . . . . . . . . . . . . . . . . . . . . LIABILITIES AND EQUITY Revolving line of credit . . . . . . . . . . . . . . . . . . . Term loans – net . . . . . . . . . . . . . . . . . . . . . . . Secured borrowings - net . . . . . . . . . . . . . . . . . . Unsecured borrowings – net . . . . . . . . . . . . . . . Accrued expenses and other liabilities . . . . . . . . . Deferred income taxes . . . . . . . . . . . . . . . . . . . Intercompany payable . . . . . . . . . . . . . . . . . . . Total liabilities . . . . . . . . . . . . . . . . . . . . . . . Equity: Common stock . . . . . . . . . . . . . . . . . . . . . . . . Equity investment from affiliates . . . . . . . . . . . . Common stock – additional paid-in capital . . . . . Cumulative net earnings . . . . . . . . . . . . . . . . . . Cumulative dividends paid . . . . . . . . . . . . . . . . Accumulated other comprehensive (loss) income . Total stockholders’ equity . . . . . . . . . . . . . . . Noncontrolling interest . . . . . . . . . . . . . . . . . . . Total equity . . . . . . . . . . . . . . . . . . . . . . . . . Total liabilities and equity . . . . . . . . . . . . . . . $ 6,184,507 (991,314) 5,193,193 587,701 679,795 6,460,689 89,299 6,599 6,556,587 1,592 8,058 196,107 630,404 300,409 25,270 $ 7,718,427 $ 230,000 745,693 — 2,328,727 326,815 — (13,673) 3,617,562 18,740 — 4,609,474 1,372,522 (2,254,038) (8,712) 3,737,986 362,879 4,100,865 $ 7,718,427 F-48 $ 559,451 (27,836) 531,615 — — 531,615 — — 531,615 3,832 6,549 7,755 15,279 — 6,888 $ 571,918 $ — $ 6,743,958 — (1,019,150) 5,724,808 — 587,701 — — 679,795 6,992,304 — 89,299 — — 6,599 7,088,202 — — — — — (300,409) — 5,424 14,607 203,862 645,683 — 32,158 $ (300,409) $ 7,989,936 $ — $ — 360,849 — 6,891 15,352 13,673 396,765 — $ — (125,256) — — — — (125,256) 230,000 745,693 235,593 2,328,727 333,706 15,352 — 3,889,071 — 156,830 — 18,246 — 77 175,153 — 175,153 $ 571,918 — (156,830) — (18,246) 18,740 — 4,609,474 1,372,522 — (2,254,038) (8,712) (77) 3,737,986 (175,153) 362,879 — 4,100,865 (175,153) $ (300,409) $ 7,989,936 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATING STATEMENT OF OPERATIONS (in thousands) Year Ended December 31, 2016 Issuer & Subsidiary Guarantors Non-Guarantor Subsidiaries Elimination Consolidated Revenue Rental income . . . . . . . . . . . . . . . . . . . . . . . . . . $ 684,771 $ 59,114 $ — $ 743,885 Income from direct financing leases . . . . . . . . . . . Mortgage interest income . . . . . . . . . . . . . . . . . . Other investment income – net . . . . . . . . . . . . . . . Miscellaneous income . . . . . . . . . . . . . . . . . . . . . 62,298 69,811 25,056 2,981 — — 56 — — — (3,260) — 62,298 69,811 21,852 2,981 Total operating revenues . . . . . . . . . . . . . . . . . . . . . 844,917 59,170 (3,260) 900,827 Expenses Depreciation and amortization . . . . . . . . . . . . . . . General and administrative . . . . . . . . . . . . . . . . . Acquisition and merger related costs . . . . . . . . . . . Impairment loss on real estate properties . . . . . . . . Provisions for uncollectible mortgages, notes and 244,290 45,413 5,777 58,508 accounts receivable . . . . . . . . . . . . . . . . . . . . . 6,583 Total operating expenses . . . . . . . . . . . . . . . . . . . . . 360,571 22,772 454 3,805 218 3,262 30,511 — — — — — — 267,062 45,867 9,582 58,726 9,845 391,082 Income before other income and expense . . . . . . . . . . Other income (expense): 484,346 28,659 (3,260) 509,745 Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . Interest – amortization of deferred financing costs . Interest – refinancing costs . . . . . . . . . . . . . . . . . Realized loss on foreign exchange . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Equity in earnings 161 (148,092) (9,302) (2,113) (232) 11,233 Total other expense . . . . . . . . . . . . . . . . . . . . . . . . (148,345) Income before gain on assets sold . . . . . . . . . . . . . . . 336,001 Gain on assets sold – net . . . . . . . . . . . . . . . . . . . 50,208 Income from continuing operations . . . . . . . . . . . . . . 386,209 Income tax expense . . . . . . . . . . . . . . . . . . . . . . . . Income from unconsolidated joint venture . . . . . . . . (3,281) 439 12 (19,271) (43) — — — (19,302) 9,357 — 9,357 1,876 — — 3,260 — — — (11,233) 173 (164,103) (9,345) (2,113) (232) — (7,973) (175,620) (11,233) 334,125 — 50,208 (11,233) 384,333 — — (1,405) 439 Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 383,367 11,233 (11,233) 383,367 Net income attributable to noncontrolling interest . . . . (16,952) — — (16,952) Net income available to common stockholders . . . . . . . $ 366,415 $ 11,233 $ (11,233) $ 366,415 F-49 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (in thousands) Year Ended December 31, 2016 Issuer & Subsidiary Guarantors Non-Guarantor Subsidiaries Elimination Consolidated Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $383,367 $11,233 $(11,233) $383,367 Other comprehensive income (loss) Foreign currency translation . . . . . . . . . . . . . . . . . (46,535) Cash flow hedges . . . . . . . . . . . . . . . . . . . . . . . . . (702) Total other comprehensive income (loss) . . . . . . . . . . . (47,237) — — — — — — (46,535) (702) (47,237) Comprehensive income . . . . . . . . . . . . . . . . . . . . . . . . 336,130 11,233 (11,233) 336,130 Comprehensive income attributable to noncontrolling interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (14,830) — — (14,830) Comprehensive income attributable to common stockholders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $321,300 $11,233 $(11,233) $321,300 F-50 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATING STATEMENT OF OPERATIONS (in thousands) Year Ended December 31, 2015 Issuer & Subsidiary Guarantors Non-Guarantor Subsidiaries Elimination Consolidated Revenue Rental income . . . . . . . . . . . . . . . . . . . . . . . . . . $ 564,112 $ 41,879 $ — $ 605,991 Income from direct financing leases . . . . . . . . . . . Mortgage interest income . . . . . . . . . . . . . . . . . . Other investment income – net . . . . . . . . . . . . . . . Miscellaneous income – net . . . . . . . . . . . . . . . . . 59,936 68,910 7,534 1,246 — — — — Total operating revenues . . . . . . . . . . . . . . . . . . . . . 701,738 41,879 Expenses Depreciation and amortization . . . . . . . . . . . . . . . General and administrative . . . . . . . . . . . . . . . . . Acquisition and merger related costs . . . . . . . . . . . Impairment loss on real estate properties . . . . . . . . Provisions for uncollectible mortgages, notes and 194,328 38,140 55,012 17,681 16,375 428 2,513 — accounts receivable . . . . . . . . . . . . . . . . . . . . . 7,871 — Total operating expenses . . . . . . . . . . . . . . . . . . . . . 313,032 19,316 Income before other income and expense . . . . . . . . . . Other income (expense): 388,706 22,563 Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . Interest – amortization of deferred financing costs . Interest – refinancing costs . . . . . . . . . . . . . . . . . Realized loss on foreign exchange . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Equity in earnings 272 (135,631) (6,969) (28,837) (173) 10,610 Total other expense . . . . . . . . . . . . . . . . . . . . . . . . (160,728) 13 (11,750) (21) — — — (11,758) — — — — — — — — — — — — 59,936 68,910 7,534 1,246 743,617 210,703 38,568 57,525 17,681 7,871 332,348 411,269 — 285 — (147,381) (6,990) — (28,837) — (173) — — (10,610) (10,610) (183,096) Income before gain on assets sold . . . . . . . . . . . . . . . 227,978 10,805 (10,610) 228,173 Gain on assets sold – net . . . . . . . . . . . . . . . . . . . 6,353 — — 6,353 Income from continuing operations . . . . . . . . . . . . . . 234,331 10,805 (10,610) 234,526 Income tax expense . . . . . . . . . . . . . . . . . . . . . . . . (1,016) (195) — (1,211) Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233,315 10,610 (10,610) 233,315 Net income attributable to noncontrolling interest . . . . (8,791) — — (8,791) Net income available to common stockholders . . . . . . . $ 224,524 $ 10,610 $ (10,610) $ 224,524 F-51 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (in thousands) Year Ended December 31, 2015 Issuer & Subsidiary Guarantors Non–Guarantor Subsidiaries Elimination Consolidated Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $233,315 $10,610 $(10,610) $233,315 Other comprehensive income (loss) Foreign currency translation . . . . . . . . . . . . . . . . . Cash flow hedges . . . . . . . . . . . . . . . . . . . . . . . . . Total other comprehensive income (loss) . . . . . . . . . . (8,413) (718) (9,131) — — — — — — (8,413) (718) (9,131) Comprehensive income . . . . . . . . . . . . . . . . . . . . . . . 224,184 10,610 (10,610) 224,184 Comprehensive income attributable to noncontrolling interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (8,373) — — (8,373) Comprehensive income attributable to common stockholders . . . . . . . . . . . . . . . . . . . . . . . . . . . . $215,811 $10,610 $(10,610) $215,811 F-52 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATING STATEMENT OF OPERATIONS (in thousands) Year Ended December 31, 2014 Issuer & Subsidiary Guarantors Non-Guarantor Subsidiaries Elimination Consolidated Revenue Rental income . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 379,180 $ 9,263 $ — $ 388,443 Income from direct financing leases . . . . . . . . . . . . Mortgage interest income . . . . . . . . . . . . . . . . . . . Other investment income – net . . . . . . . . . . . . . . . Miscellaneous income – net . . . . . . . . . . . . . . . . . 56,719 53,007 6,369 249 — — — — Total operating revenues . . . . . . . . . . . . . . . . . . . . . 495,524 9,263 Expenses Depreciation and amortization . . . . . . . . . . . . . . . General and administrative . . . . . . . . . . . . . . . . . . Acquisition costs . . . . . . . . . . . . . . . . . . . . . . . . . Impairment loss on real estate properties . . . . . . . . Provisions for uncollectible mortgages, notes and 119,367 25,778 3,948 3,660 accounts receivable . . . . . . . . . . . . . . . . . . . . . . 2,723 Total operating expenses . . . . . . . . . . . . . . . . . . . . . 155,476 Income before other income and expense . . . . . . . . . . . Other income (expense): Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . Interest – amortization of deferred financing costs . Interest – refinancing costs . . . . . . . . . . . . . . . . . . Equity in earnings . . . . . . . . . . . . . . . . . . . . . . . . 340,048 32 (117,258) (4,438) (3,041) 3,143 Total other expense . . . . . . . . . . . . . . . . . . . . . . . . . (121,562) Income before gain on assets sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gain on assets sold – net 218,486 2,863 3,890 110 — — — 4,000 5,263 12 (2,111) (21) — — (2,120) 3,143 — — — — — — — — — — — — — 56,719 53,007 6,369 249 504,787 123,257 25,888 3,948 3,660 2,723 159,476 345,311 — 44 — (119,369) (4,459) — (3,041) — — (3,143) (3,143) (126,825) (3,143) — 218,486 2,863 Net income available to common stockholders . . . . . . . $ 221,349 $ 3,143 $ (3,143) $ 221,349 F-53 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATING STATEMENT OF CASH FLOWS (in thousands) Year Ended December 31, 2016 Issuer & Subsidiary Guarantors Non-Guarantor Subsidiaries Elimination Consolidated 383,367 $ 11,233 $ (11,233) $ 383,367 Cash flows from operating activities Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ Adjustment to reconcile net income to net cash provided by operating activities: Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Impairment loss on real estate properties . . . . . . . . . . . . . . . . . . . . . . . . . Provision for uncollectible mortgages, notes and accounts receivable . . . . . . . . Refinancing costs and amortization of deferred financing costs . . . . . . . . . . . Accretion of direct financing leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . Stock-based compensation expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gain on assets sold – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Amortization of acquired in-place leases – net . . . . . . . . . . . . . . . . . . . . . . Equity in earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Change in operating assets and liabilities – net of amounts assumed/acquired: Accounts receivable, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Straight-line rent receivables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Lease inducements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Effective yield receivable on mortgage notes . . . . . . . . . . . . . . . . . . . . . . . Other operating assets and liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net cash provided by operating activities 244,290 58,508 6,583 11,415 (12,157) 13,790 (50,208) (13,991) (11,233) (4,876) (36,263) 2,589 (721) 18,661 609,754 Cash flows from investing activities Acquisition of real estate – net of liabilities assumed and escrows acquired . . . . . . . Investments in construction in progress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investment in U.K. subsidiary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investments in direct financing leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Placement of mortgage loans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investments in unconsolidated joint venture . . . . . . . . . . . . . . . . . . . . . . . . . . Distributions from unconsolidated joint venture . . . . . . . . . . . . . . . . . . . . . . . . Proceeds from sale of real estate investments . . . . . . . . . . . . . . . . . . . . . . . . . . Capital improvements to real estate investments . . . . . . . . . . . . . . . . . . . . . . . . Proceeds from other investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investments in other investments Collection of mortgage principal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net cash used in investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (833,390) (68,983) (116,099) (2,080) (48,722) (50,032) 1,318 169,603 (38,824) 94,840 (269,423) 59,975 (1,101,817) Cash flows from financing activities Proceeds from credit facility borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Payments on credit facility borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Receipts of other long-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Payments of other long-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . Payments of financing related costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Receipts from dividend reinvestment plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . Payments for exercised options and restricted stock . . . . . . . . . . . . . . . . . . . . . . Net proceeds from issuance of common stock . . . . . . . . . . . . . . . . . . . . . . . . . Dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Contributions from affiliates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Redemption of OP Units . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Distributions to OP Unit holders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net cash provided by financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . Effect of foreign currency translation on cash and cash equivalents . . . . . . . . . . . . Increase in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cash and cash equivalents at beginning of period . . . . . . . . . . . . . . . . . . . . . . . Cash and cash equivalents at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 1,304,000 (1,344,000) 1,048,173 (180,000) (11,806) 240,041 (23,426) 19,651 (453,152) — (733) (21,179) 577,569 — 85,506 1,592 87,098 F-54 22,772 218 3,262 43 — — — — — — (5,828) — — (15,663) 16,037 (126,358) — — — — — — — (1,647) 1,949 (2,134) — (128,190) — — — (1,249) (24) — — — — 116,099 — — 114,826 84 2,757 3,832 6,589 $ — — — — — — — — 11,233 — — — — — — — — 116,099 — — — — — — — — — 116,099 267,062 58,726 9,845 11,458 (12,157) 13,790 (50,208) (13,991) — (4,876) (42,091) 2,589 (721) 2,998 625,791 (959,748) (68,983) — (2,080) (48,722) (50,032) 1,318 169,603 (40,471) 96,789 (271,557) 59,975 (1,113,908) — 1,304,000 — (1,344,000) — 1,048,173 (181,249) — (11,830) — 240,041 — (23,426) — — 19,651 (453,152) — — (116,099) (733) — (21,179) — 576,296 (116,099) 84 — 88,263 — 5,424 — 93,687 — $ $ OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATING STATEMENT OF CASH FLOWS (in thousands) Year Ended December 31, 2015 Issuer & Subsidiary Guarantors Non-Guarantor Subsidiaries Elimination Consolidated Cash flows from operating activities Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 233,315 $ 10,610 $ (10,610) $ 233,315 Adjustment to reconcile net income to net cash provided by operating activities: Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Impairment loss on real estate properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Provision for uncollectible mortgages, notes and accounts receivable Refinancing costs and amortization of deferred financing costs . . . . . . . . . . . . Accretion of direct financing leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Stock-based compensation expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gain on assets sold – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Amortization of acquired in-place leases – net Change in operating assets and liabilities – net of amounts assumed/acquired: Accounts receivable, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Straight-line rent receivables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Lease inducements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Effective yield receivable on mortgage notes . . . . . . . . . . . . . . . . . . . . . . . . Other operating assets and liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net cash provided by operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cash flows from investing activities Acquisition of real estate – net of liabilities assumed and escrows acquired . . . . . . . . Cash acquired in merger . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investments in construction in progress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investment in U.K. subsidiary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investments in direct financing leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Placement of mortgage loans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Proceeds from sale of real estate investments . . . . . . . . . . . . . . . . . . . . . . . . . . . Capital improvements to real estate investments . . . . . . . . . . . . . . . . . . . . . . . . . Proceeds from other investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Investments in other investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Collection of mortgage principal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net cash used in investing activities 194,328 17,681 7,871 35,806 (11,007) 11,133 (6,353) (13,846) 248 (31,237) 994 (4,065) 10,550 445,418 (116,698) 84,858 (164,226) (166,082) (6,793) (14,042) 41,543 (24,599) 45,871 (65,402) 1,359 (384,211) Cash flows from financing activities Proceeds from credit facility borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Payments on credit facility borrowings Receipts of other long-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Payments of other long-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Payments of financing related costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Receipts from dividend reinvestment plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Payments for exercised options and restricted stock . . . . . . . . . . . . . . . . . . . . . . Net proceeds from issuance of common stock . . . . . . . . . . . . . . . . . . . . . . . . . . Dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Distributions to OP Unit holders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net cash used in financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Effect of foreign currency translation on cash and cash equivalents . . . . . . . . . . . . . (Decrease) increase in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . Cash and cash equivalents at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . Cash and cash equivalents at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 1,826,000 (1,681,000) 1,838,124 (2,186,102) (54,721) 150,847 (26,706) 439,322 (358,232) (11,636) (64,104) — (2,897) 4,489 1,592 16,375 — — 21 — — — — — (4,820) — — (3,719) 18,467 (177,484) — — 166,082 — — — (1,798) — — — (13,200) — — — (1,212) — — — — — — (1,212) (223) 3,832 — 3,832 $ — — — — — — — — — — — — 10,610 — — — — — — — — — — — — — 210,703 17,681 7,871 35,827 (11,007) 11,133 (6,353) (13,846) 248 (36,057) 994 (4,065) 17,441 463,885 (294,182) 84,858 (164,226) — (6,793) (14,042) 41,543 (26,397) 45,871 (65,402) 1,359 (397,411) — 1,826,000 — (1,681,000) — 1,838,124 — (2,187,314) (54,721) — 150,847 — (26,706) — 439,322 — (358,232) — (11,636) — (65,316) — (223) — 935 — 4,489 — 5,424 — $ $ F-55 OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — Continued OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATING STATEMENT OF CASH FLOWS (in thousands) Year Ended December 31, 2014 Issuer & Subsidiary Guarantors Non-Guarantor Subsidiaries Elimination Consolidated 221,349 $ 3,143 $ (3,143) $ 221,349 119,367 3,660 3,890 — Cash flows from operating activities Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ Adjustment to reconcile net income to net cash provided by operating activities: Depreciation and amortization . . . . . . . . . . . . . . . . . Impairment loss on real estate properties . . . . . . . . . . . Provision for uncollectible mortgages, notes and accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Refinancing costs and amortization of deferred financing costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Accretion of direct financing leases . . . . . . . . . . . . . . Stock-based compensation expense . . . . . . . . . . . . . . Gain on assets sold – net . . . . . . . . . . . . . . . . . . . . . . . . . . . . Amortization of acquired in-place leases – net Change in operating assets and liabilities – net of amounts assumed/acquired: Accounts receivable, net . . . . . . . . . . . . . . . . . . . . . Straight-line rent receivables . . . . . . . . . . . . . . . . . . . Lease inducements . . . . . . . . . . . . . . . . . . . . . . . . . Effective yield receivable on mortgage notes . . . . . . . . . Other operating assets and liabilities . . . . . . . . . . . . . . Net cash provided by operating activities . . . . . . . . . . . . . . Cash flows from investing activities Acquisition of real estate – net of liabilities assumed and escrows acquired . . . . . . . . . . . . . . . . . . . . . . . . . . . . Placement of mortgage loans . . . . . . . . . . . . . . . . . . . . . Proceeds from sale of real estate investments . . . . . . . . . . . . Capital improvements to real estate investments . . . . . . . . . . Proceeds from other investments . . . . . . . . . . . . . . . . . . . Investments in other investments . . . . . . . . . . . . . . . . . . . Collection of mortgage principal . . . . . . . . . . . . . . . . . . . Net cash used in investing activities . . . . . . . . . . . . . . . . . . 2,723 7,479 (9,787) 8,592 (2,863) (4,986) (2,264) (20,164) 2,656 (2,878) 11,089 333,973 (131,689) (529,548) 4,077 (15,525) 13,589 (9,441) 122,984 (545,553) Cash flows from financing activities Proceeds from credit facility borrowings . . . . . . . . . . . . . . . Payments on credit facility borrowings . . . . . . . . . . . . . . . . Receipts of other long-term borrowings . . . . . . . . . . . . . . . Payments of other long-term borrowings . . . . . . . . . . . . . . Payments of financing related costs . . . . . . . . . . . . . . . . . . Receipts from dividend reinvestment plan . . . . . . . . . . . . . . Payments for exercised options and restricted stock . . . . . . . . Net proceeds from issuance of common stock . . . . . . . . . . . Dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Net cash provided by (used in) financing activities . . . . . . . . Increase in cash and cash equivalents . . . . . . . . . . . . . . . . . Cash and cash equivalents at beginning of period . . . . . . . . . Cash and cash equivalents at end of period . . . . . . . . . . . . . $ 900,000 (1,141,000) 842,148 (241,369) (17,716) 71,487 (3,577) 61,981 (258,501) 213,453 1,873 2,616 4,489 F-56 — — — — — — — — — — — — 3,143 — — — — — — — — — 123,257 3,660 2,723 7,500 (9,787) 8,592 (2,863) (4,986) (2,264) (20,956) 2,656 (2,878) 11,537 337,540 (131,689) (529,548) 4,077 (17,917) 13,589 (9,441) 122,984 (547,945) — 900,000 — (1,141,000) 842,148 — (242,544) — (17,716) — 71,487 — (3,577) — 61,981 — (258,501) — 212,278 — 1,873 — 2,616 — 4,489 — $ $ — 21 — — — — — (792) — — (2,695) 3,567 — — — (2,392) — — — (2,392) — — — (1,175) — — — — — (1,175) — — $ — SCHEDULE III REAL ESTATE AND ACCUMULATED DEPRECIATION OMEGA HEALTHCARE INVESTORS, INC. December 31, 2016 Initial Cost to Company Encumbrances Land Buildings and Improvements Cost Capitalized Subsequent to Acquisition Carrying Cost Improvements Other(6) Land Gross Amount at Which Carried at Close of Period(3) Buildings and Improvements Total Accumulated Depreciation(4) Date of Construction Date Acquired Life on Which Depreciation in Latest Income Statements is Computed 14,926,960 3,832,748 13,335,341 1,480,000 10,813,664 44,388,713 184,977,257 10,846,566 87,790,543 19,662,571 187,388,817 490,665,754 10,162,810 3,950,028 4,174,496 1,183,051 3,440,595 22,910,980 20,238 — — — — 20,238 — 14,926,960 — 3,832,748 — 13,335,341 — 1,480,000 — 10,813,664 — 44,388,713 195,160,305 14,796,594 91,965,039 20,845,622 190,829,412 513,596,972 210,087,265 18,629,342 105,300,380 22,325,622 201,643,076 557,985,685 47,922,023 1940–1997 1996–2016 8,654,672 1964–1970 19,646,496 1964–1980 1999–2016 20 years to 33 years 6,981,961 1959–1977 29 years to 30 years 2010 2,696,466 1966–2016 2014–2016 25 years to 30 years 85,901,618 3 years to 39 years 20 years 2007 19,531,583 19,041,468 216,537,730 69,409,856 2,241,593 39,267,802 — 342,695 — 19,531,583 (680,345) 19,041,468 218,779,323 108,340,008 238,310,906 127,381,476 12,740,033 1968–2015 5,826,713 1988–2016 118,604,252 3,683,238 160,860,541 8,180,400 294,127,986 — 6,655,755 7,092,469 19,496,317 — 67,661,467 7,435,164 — 118,604,252 — 3,683,238 (680,345) 160,860,541 13,748,224 27,676,717 368,544,272 132,352,476 31,359,955 529,404,813 — — 1,096,131 1999–2016 19,662,877 2015 2015 2015 2015 33 years 30 years to 33 years — 30 years to 33 years 422,935 10,780,000 5,269,177 7,134,354 8,500,000 32,106,466 4,422,325 106,694,700 109,002,482 124,475,985 85,982,265 430,577,757 — 2,312,955 2,438,309 1,825,909 — 6,577,173 321,066 4,086,842 4,330,580 7,703,262 115,546,920 65,027,000 10,342,621 6,300,000 25,381,109 159,846,959 87,771,876 435,896,017 — — — — — — 1,817,320 10,995,190 33,356,170 86,868,402 12,915,787 — 9,057,536 78,596,505 11,279,262 878,937 61,806,778 3,730,000 6,705,560 5,809,737 28,245,140 2,923,947 4,799,714 6,279,163 2,177,542 7,190,000 5,898,952 829,621 10,571,691 2,910,000 7,333,114 1,319,454 1,599,631 5,501,308 1,782,067 9,002,270 3,069,856 35,367,198 4,650,087 3,640,572 11,733,450 161,016,248 423,131,800 88,830,136 4,445,263 481,225,245 47,387,507 62,572,804 111,441,468 366,055,214 68,736,698 47,680,306 123,327,734 52,869,373 74,028,613 41,120,152 30,921,159 52,399,655 49,506,905 121,480,904 11,698,411 23,142,177 50,472,213 19,837,436 68,658,130 52,675,612 439,998,943 36,246,616 45,217,827 206,264,434 13,045,870 2,823,085 7,790,478 980,393 36,333,087 — 1,321,587 510,576 2,332,364 2,084,807 9,250,851 8,677,102 1,749,991 2,518,228 2,160,034 — 653,399 826,654 692,135 — — 8,350,000 1,462,797 130,323 3,550,986 30,731,141 — 2,610,185 11,281,116 — 47,891 — 422,935 — 10,780,000 5,269,177 — 7,134,354 — 8,500,000 (268,000) 32,106,466 — (268,000) — — 47,891 4,422,325 109,055,546 111,172,791 126,301,894 85,982,265 436,934,821 4,845,260 119,835,546 116,441,968 133,436,248 94,482,265 469,041,287 2009 337,550 33 years 2015 4,660,696 1965–2013 20 years to 30 years 2016 6,862,544 1968–2000 2015–2016 30 years to 33 years 2015 8,140,340 1873–2002 3,320,131 1964–2013 2016 23,321,261 33 years 30 years — — — — — — — — — 321,066 — 4,086,842 — 4,330,580 7,703,262 115,546,920 65,027,000 8,024,328 119,633,762 69,357,580 574,610 1973 7,812,153 1964–1997 4,446,154 1927–1997 2015 2015 2015 33 years 33 years 33 years — 10,342,621 — 6,300,000 — 25,381,109 159,846,959 87,771,876 435,896,017 170,189,580 94,071,876 461,277,126 10,349,693 1960–2007 2010–2016 20 years to 33 years 3,220,463 1979–2007 26,403,073 30 years 2016 — 1,817,320 — 10,995,190 46,271,957 86,868,402 48,089,277 97,863,592 30,926,414 1960–1982 1992–1997 31.5 years to 33 years 10,017,581 1949–1999 2012–2015 33 years to 40 years (36,350) — 63,156 — — (5,425,656) 9,057,536 — 78,596,505 — 11,279,262 878,937 948,913 (9,736,615) 61,806,778 — 3,730,000 — — 6,705,560 — — — 5,809,737 — (1,828,124) 28,237,640 — — — — — — — — — 2,923,947 — 4,799,714 — 6,279,163 — 2,177,542 — 7,190,000 — 5,898,952 829,621 — — 10,571,691 — — (152,575) — — — — — 2,910,000 7,333,114 — 1,319,454 — 1,599,631 — 5,501,308 — 1,782,067 — 9,002,270 — — — 3,069,856 — (1,166,009) 35,367,198 — 4,650,087 — — 3,640,572 — — 11,733,450 — 174,025,768 426,018,041 96,620,614 — 508,770,630 47,387,507 63,894,391 111,952,044 366,566,954 70,821,505 56,931,157 132,004,836 54,619,364 76,546,841 43,280,186 30,921,159 53,053,054 50,333,559 122,020,464 11,698,411 23,142,177 58,822,213 21,300,233 68,788,453 56,226,598 469,564,075 36,246,616 47,828,012 217,545,550 183,083,304 504,614,546 107,899,876 878,937 570,577,408 51,117,507 70,599,951 117,761,781 394,804,594 73,745,452 61,730,871 138,283,999 56,796,906 83,736,841 49,179,138 31,750,780 63,624,745 53,243,559 129,353,578 13,017,865 24,741,808 64,323,521 23,082,300 77,790,723 59,296,454 504,931,273 40,896,703 51,468,584 229,279,000 55,208,651 1960–2009 1992–2015 20 years to 38 years 5 years to 35 years 55,083,670 1927–2013 1997–2015 29,232,095 1925–1975 1998–2016 20 years to 39 years — 1999 N/A 150,266,763 1933–2007 1992–2016 N/A 2 years to 40 years 5,230,371 1967–1998 1998–2016 30 years to 40 years 12,106,038 1911–2008 1997–2015 25 years to 39 years 15,117,035 1926–1990 1996–2015 30 years to 33 years 77,812,713 1923–2008 1992–2015 20 years to 40 years 13,120,583 1961–1998 1997–2015 23 years to 33 years 6,164,491 1957–1985 2010–2015 20 years to 33 years 20,157,352 1917–2002 1994–2015 17,883,426 1957–1983 1997–2006 33 years to 39 years 14,350,237 1921–1985 2010–2011 25 years to 30 years 20,605,218 1964–1993 1997–2010 20 years to 39 years 4,655,127 1964–1975 2011–2015 25 years to 33 years 2015 3,949,866 1958–1983 33 years 33 years 14,274,382 1962–1988 2009–2010 20 years to 40 years 14,794,489 1955–1994 1999–2016 30 years to 33 years 33 years 811,679 1963–1971 2,256,512 1963–1969 20 years to 33 years 10,013,989 1972–2004 2009-2015 26 years to 33 years 8,439,787 1963–1999 1998–2006 33 years to 39 years 2015 2015 7,348,628 1960–1989 2008–2015 20 years to 33 years 26,436,775 1964–1987 1994–2010 25 years to 36 years 133,969,181 1920–2008 1994–2015 20 years to 39 years 7,883,686 1965–2013 2010–2015 20 years to 33 years 3,179,897 1959–2004 2014–2015 25 years to 33 years 66,127,725 1942–2012 1998–2015 16 years to 39 years 3,658,261 7,800,000 5,932,773 67,370,202 47,432,242 633,938 317,500 2,566,363 11,719,119 1,972,682 7,377,429 35,082,551 59,782,493 99,743,478 667,695,852 256,409,736 2,986,062 6,005,388 30,009,385 138,054,574 66,945,947 53,224,076 4,792,882 — 4,897,458 24,223,887 1,646,761 — 602,296 — 2,626,926 7,000,345 5,252,877 203,265 — — — (527,491) — 3,658,261 — 7,800,000 5,827,316 (1,000) 67,370,202 — (52,350,758) 39,822,262 633,938 — — — — 317,500 — — 2,566,363 (1,500) 11,717,619 — — 1,972,682 — 7,377,429 — 39,875,433 59,782,493 104,218,902 692,122,004 213,315,719 2,986,062 6,607,684 30,009,385 140,681,500 73,946,292 58,475,453 43,533,694 67,582,493 110,046,218 759,492,206 253,137,981 3,620,000 6,925,184 32,575,748 152,399,119 75,918,974 65,852,882 39 years 16,190,347 1965–1981 2006 5,718,501 1959–2007 2014–2016 20 years to 30 years 46,714,574 1958–1985 1992–2015 20 years to 31 years 2 years to 40 years 97,331,606 1952–2015 1997–2016 30 years 10,141,108 1750–2011 2015–2016 24 years 1977 247,001 39 years 1971 2,416,363 1,582,827 1989–1995 33 years to 40 years 22,271,862 1930–2004 1995–2015 20 years to 33 years 32,588,074 1961–1996 1994–2011 25 years to 39 years 12,420,492 1930–1994 2009–2015 20 years to 33 years 2015 2004 2015 (1,500) 504,282,111 4,898,553,097 215,826,408 1,215,334 (71,227,578) 496,557,674 5,052,091,698 5,548,649,372 1,085,047,116 767,018,940 6,549,820,611 312,976,028 8,718,627 (72,175,923) 759,294,503 6,807,063,780 7,566,358,283 1,240,335,945 . . . . . . . . . . . . . Description(1) Signature Holdings II: . Florida (SNF) Georgia (SNF) . Kentucky (SNF) Maryland (SNF) Tennessee (AL, SNF) Total Signature Maplewood Real Estate . . . . Holdings: Connecticut (AL) . Massachusetts (AL, . . . . New York (AL) . . Ohio (AL) . . . . Total Maplewood . SNF) . . . . . . . . . Saber Health Group: Florida (SNF) . North Carolina (SNF) . . Ohio (SNF, AL) . . . Pennsylvania (SNF) . . Virginia (SNF) . . . Total Saber Health . Group . . . . . . Ciena Healthcare: . Indiana (SNF) . Michigan (SNF, AL) . . North Carolina (ILF, . . . . . Ohio (SNF, AL) . Virginia (SNF) . Total Ciena SNF) . . . . . . . HealthCare . Other: . . . . AL) Alabama (SNF) . . Arizona (TBI, SNF, . . . Arkansas (SNF, AL) . California (SNF, TBI) Colorado (SNF, ILF) Connecticut (land only) Florida (SNF, AL) Georgia (SNF, AL) . Idaho (SNF, AL) Illinois (SNF) . . . Indiana (SNF, ILF, AL, . . . . . . . . . . . . . . . . AL) ILF) . . . MOB, SH) . Iowa (SNF, AL) . Kansas (SNF) . . Kentucky (SNF, AL) . . Louisiana (SNF) Maryland (SNF) . Massachusetts (SNF) . Michigan (SNF) . Minnesota (SNF, AL, . . . . . . . . Mississippi (SNF) . . . Missouri (SNF) . . . Montana (SNF) . Nebraska (SNF) . . Nevada (SNF, SH, TBI) New Hampshire (SNF, . . . . New Mexico (SNF) . . North Carolina (SNF) . . Ohio (SNF, SH, AL) . . Oklahoma (SNF, AL) Oregon (AL, SNF) . . Pennsylvania (SNF, AL, . . . . Rhode Island (SNF) . . South Carolina (SNF) . . Tennessee (SNF) Texas (AL, SNF) . . United Kingdom (AL) . . . Utah (SNF) . Vermont (SNF) . Virginia (SNF) . . Washington (SNF, AL) . . West Virginia (SNF) . . Wisconsin (SNF, AL) . Total Other . . . . ILF) . . . . . . . . . . . . . . . . . . . . . . Total (1) (2) . . . . . . . . . . . . . . . . . . The real estate included in this schedule is being used in either the operation of skilled nursing facilities (SNF), assisted living facilities (AL), independent living facilities (ILF), tramatic brain injury (TBI), medical office building (MOB) or specialty hospitals (SH) located in the states indicated. (2) Certain of the real estate indicated are security for the HUD loan borrowings totaling $54,954,695 at December 31, 2016. F-57 SCHEDULE III REAL ESTATE AND ACCUMULATED DEPRECIATION (continued) OMEGA HEALTHCARE INVESTORS, INC. December 31, 2016 Year Ended December 31, 2014 2015 2016 Balance at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $3,099,547,182 $3,223,785,295 $6,743,957,698 Acquisitions through foreclosure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — 25,000,000 Acquisitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131,689,483 3,371,233,860 1,017,760,963 Impairment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (3,660,381) (12,916,233) (53,716,724) Improvements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17,916,855 220,272,401 95,806,618 Disposals/other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (21,707,844) (58,417,625) (262,450,272) Balance at close of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $3,223,785,295 $6,743,957,698 $7,566,358,283 (3) (4) Balance at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $707,409,888 $ 821,711,991 $1,019,149,678 Provisions for depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123,141,880 210,554,569 266,904,418 Dispositions/other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (8,839,777) (13,116,882) (45,718,151) Balance at close of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $821,711,991 $1,019,149,678 $1,240,335,945 (5) The reported amount of our real estate at December 31, 2016 is greater than the tax basis of the real estate by approximately $1.1 billion. (6) Reflects bed sales, impairments, land easements and impacts from foreign currency exchange rates. Year Ended December 31, 2014 2015 2016 F-58 SCHEDULE IV MORTGAGE LOANS ON REAL ESTATE OMEGA HEALTHCARE INVESTORS, INC. December 31, 2016 Grouping Description(1) Interest Rate Final Maturity Date Periodic Payment Terms Prior Liens Face Amount of Mortgages Principal Amount of Loans Subject to Delinquent Principal or Interest Carrying Amount of Mortgages(2)(3) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Louisiana (1 AL facility) . . . . 8.75% Maryland (3 SNF facilities) . . . 11.00% Michigan (31 SNF facilities) . . 9.45% Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Michigan (1 SNF facility) . . . . Missouri (1 SNF facility) and Tennessee ( 1 SNF facility) . . . 10.77% 10.51% 10.25% 10.25% 10.25% 10.25% 10.25% 10.25% 10.25% 10.25% 9.50% 9.50% 9.50% 9.50% 9.50% 8.50% 8.35% New Jersey (1 AL facility) . . . . 10.00% Ohio (2 SNF facilities) and Pennsylvania (5 SNF and 2 AL facilities) . . . . . . . . . . . . . 9.79% Ohio (1 SNF facility) . . . . . . 11.67% South Carolina (1 AL facility). . Virginia (1 AL facility) . . . . . 8.75% 8.75% 2018 2028 2029 2021 2021 2029 2029 2029 2029 2029 2029 2029 2029 2029 2029 2029 2029 2029 2029 2015 2017 2024 2018 2018 2018 Interest accrues monthly Interest payable monthly Interest plus $105,000 of principal payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest plus $0 of principal payable monthly Interest payable monthly Interest payable monthly Interest payable monthly Interest accrues monthly Interest accrues monthly None None None None None None None None None None None None None None None None None None None None None None None None None 9,870,626 9,870,626 74,927,751 35,963,840 415,000,000 412,140,060 3,917,030 4,111,387 2,214,376 560,601 267,170 100,000 252,241 269,740 4,036,982 4,089,039 597,022 125,930 3,917,030 4,111,387 2,214,376 560,601 267,170 100,000 252,241 269,740 4,036,982 4,089,039 597,022 125,930 1,803,905 1,803,905 432,754 190,842 432,754 190,842 14,044,762 14,044,762 6,997,610 2,500,000 3,195,000 3,195,000 112,500,000 112,500,000 11,874,013 12,254,985 8,762,943 5,142,008 8,762,943 5,142,008 $685,283,732 $639,343,243 — — — — — — — — — — — — — — — — — — — — — — — — — (1) Mortgage loans included in this schedule represent first mortgages on facilities used in the delivery of long-term healthcare of which such facilities are located in the states indicated. The aggregate cost for federal income tax purposes is equal to the carrying amount. (2) (3) Year Ended December 31, 2014 2015 2016 Balance at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 241,514,812 $648,078,550 $679,795,236 Additions during period – Placements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 529,547,836 33,288,320 48,721,953 Deductions during period – collection of principal/other . . . . . . . . . . . . . . . . . . . . (122,984,098) (1,571,634) (89,173,946) Balance at close of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 648,078,550 $679,795,236 $639,343,243 F-59 EXHIBIT NUMBER 2.1 3.1 3.2 4.0 4.1 4.1A 4.1B 4.1C 4.1D INDEX TO EXHIBITS TO 2016 FORM 10-K DESCRIPTION Agreement and Plan of Merger, dated as of October 30, 2014, by and among Omega Healthcare Investors, Inc., OHI Healthcare Properties Holdco, Inc., OHI Healthcare Properties Limited Partnership, L.P., Aviv REIT, Inc., and Aviv Healthcare Properties Limited Partnership (Incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed on November 5, 2014). Amended and Restated Bylaws. (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on April 20, 2011). Articles of Amendment and Restatement of Omega Healthcare Investors, Inc., as amended. (Incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3ASR filed on September 3, 2015). See Exhibits 3.1 to 3.2. Indenture, dated as of March 19, 2012, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, relating to the 5.875% Senior Notes due 2024. (Incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K, filed on March 19, 2012). Form of 5.875% Senior Notes due 2024. (Incorporated by reference to Exhibit A of Exhibit 4.2 to the Company’s Current Report on Form 8-K, filed on March 19, 2012). Form of Subsidiary Guarantee relating to the 5.875% Senior Notes due 2024. (Incorporated by reference to Exhibit E of Exhibit 4.2 to the Company’s Current Report on Form 8-K, filed on March 19, 2012). First Supplemental Indenture, dated as of July 2, 2012, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto , that certain Second Supplemental Indenture, dated as of August 9, 2012, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto, that certain Third Supplemental Indenture, dated as of September 24, 2012, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto, and that certain Fourth Supplemental Indenture, effective as of December 31, 2012, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1C to the Company’s Annual Report on Form 10-K, filed on February 28, 2013). Fifth Supplemental Indenture, dated as of August 1, 2013, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.3 to the Company’s Quarterly Report on Form 10-Q, filed on November 7, 2013) and that certain Sixth Supplemental Indenture, dated as of October 23, 2013 among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1D to the Company’s Annual Report on Form 10-K, filed on February 11, 2014). I-1 4.1E 4.1F 4.1G 4.1H 4.1I 4.1J 4.1K Seventh Supplemental Indenture, dated as of February 14, 2014, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.3A to the Company’s Quarterly Report on Form 10-Q, filed on August 6, 2014) and that certain Eighth Supplemental Indenture, dated as of June 27, 2014, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.3B to the Company’s Quarterly Report on Form 10-Q, filed on August 6, 2014). Ninth Supplemental Indenture, dated as of November 25, 2014, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto and that certain Tenth Supplemental Indenture, dated as of January 23, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1F to the Company’s Annual Report on Form 10-K, filed on February 27, 2015). Eleventh Supplemental Indenture, dated effective as of March 2, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.2B to the Company’s Quarterly Report on Form 10-Q, filed on May 8, 2015). Twelfth Supplemental Indenture, dated as of April 1, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.2C to the Company’s Quarterly Report on Form 10-Q, filed on May 8, 2015). Thirteenth Supplemental Indenture, dated as of August 4, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.2 to the Company’s Quarterly Report on Form 10-Q, filed on November 6, 2015). Fourteenth Supplemental Indenture, dated as of November 9, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1J to the Company’s Annual Report on Form 10-K, filed on February 26, 2016). Fifteenth Supplemental Indenture, dated as of March 29, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed on May 6, 2016). I-2 4.1L 4.1M 4.1N 4.2 4.2A 4.2B 4.2C 4.2D 4.2E Sixteenth Supplemental Indenture, dated as of May 13, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed on August 5, 2016). Seventeenth Supplemental Indenture, dated as of August 9, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed on November 8, 2016). Eighteenth Supplemental Indenture, dated as of November 10, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto.* Indenture, dated as of March 11, 2014, by and among Omega, the guarantors named therein, and U.S. Bank National Association, as trustee related to the 4.950% Senior Notes due 2024, including the Form of 4.95% Senior Notes and Form of Subsidiary Guarantee related thereto. (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed on March 11, 2014). First Supplemental Indenture, dated as of June 27, 2014, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.4 to the Company’s Quarterly Report on Form 10-Q, filed on August 6, 2014). Second Supplemental Indenture, dated as of November 25, 2014, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto and that certain Third Supplemental Indenture, dated as of January 23, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.4B to the Company’s Annual Report on Form 10-K, filed on February 27, 2015). Fourth Supplemental Indenture, dated effective as of March 2, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.3B to the Company’s Quarterly Report on Form 10-Q, filed on May 8, 2015). Fifth Supplemental Indenture, dated as of April 1, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.3C to the Company’s Quarterly Report on Form 10-Q, filed on May 8, 2015). Sixth Supplemental Indenture, dated as of August 4, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.3 to the Company’s Quarterly Report on Form 10-Q, filed on November 6, 2015). I-3 4.2F 4.2G 4.2H 4.2I 4.2J 4.3 4.3A 4.3B Seventh Supplemental Indenture, dated as of November 9, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.2F to the Company’s Annual Report on Form 10-K, filed on February 26, 2016). Eighth Supplemental Indenture, dated as of March 29, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.2 to the Company’s Quarterly Report on Form 10-Q, filed on May 6, 2016). Ninth Supplemental Indenture, dated as of May 13, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed on August 5, 2016). Tenth Supplemental Indenture, dated as of August 9, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed on November 8, 2016). Eleventh Supplemental Indenture, dated as of November 10, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto.* Indenture, dated as of September 11, 2014, by and among Omega, the subsidiary guarantors named therein, and U.S. Bank National Association, as trustee related to the 4.50% Senior including the Form of 4.50% Senior Notes and Form of Subsidiary Notes due 2025, Guarantee related thereto. (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed on September 11, 2014). First Supplemental Indenture, dated as of November 25, 2014, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2024, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto and that certain Second Supplemental Indenture, dated as of January 23, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2024, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.5A to the Company’s Annual Report on Form 10-K, filed on February 27, 2015). Third Supplemental Indenture, dated effective as of March 2, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.2B to the Company’s Registration Statement on Form S-4, filed on April 16, 2015). I-4 4.3C 4.3D 4.3E 4.3F 4.3G 4.3H 4.3I 4.4 4.4A Fourth Supplemental Indenture, dated as of April 1, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.2B to the Company’s Registration Statement on Form S-4, filed on April 16, 2015). Fifth Supplemental Indenture, dated as of August 4, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.4 to the Company’s Quarterly Report on Form 10-Q, filed on November 6, 2015). Sixth Supplemental Indenture, dated as of November 9, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.3E to the Company’s Annual Report on Form 10-K, filed on February 26, 2016). Seventh Supplemental Indenture, dated as of March 29, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.3 to the Company’s Quarterly Report on Form 10-Q, filed on May 6, 2016). Eighth Supplemental Indenture, dated as of May 13, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed on August 5, 2016). Ninth Supplemental Indenture, dated as of August 9, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed on November 8, 2016). Tenth Supplemental Indenture, dated as of November 10, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto.* Indenture, dated as of March 18, 2015, by and among Omega Healthcare Investors, Inc., the subsidiary guarantors named therein and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed on March 24, 2015). First Supplemental Indenture, dated as of April 1, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.5A to the Company’s Quarterly Report on Form 10-Q, filed on May 8, 2015). I-5 4.4B 4.4C 4.4D 4.4E 4.4F 4.4G 4.5 4.5A 4.5B Second Supplemental Indenture, dated as of August 4, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto (incorporated by reference to Exhibit 4.2A to Omega’s Registration Statement on Form S-4 filed on October 6, 2015). Third Supplemental Indenture, dated as of November 9, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto. (incorporated by reference to Exhibit 4.2B to the Amendment to Omega’s Registration Statement on Form S-4 filed on November 10, 2015). Fourth Supplemental Indenture, dated as of March 29, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.4 to the Company’s Quarterly Report on Form 10-Q, filed on May 6, 2016). Fifth Supplemental Indenture, dated as of May 13, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed on August 5, 2016). Sixth Supplemental Indenture, dated as of August 9, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed on November 8, 2016). Seventh Supplemental Indenture, dated as of November 10, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto.* Indenture, dated as of September 23, 2015 by and among Omega, the subsidiary guarantors named therein, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 to Omega’s Current Report on Form 8-K, filed with SEC on September 29, 2015). First Supplemental Indenture, dated as of November 9, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.250% Senior Notes due 2026, including the Form of 5.250% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1A to the Company’s Registration Statement on Form S-4, filed on November 12, 2015). Second Supplemental Indenture, dated as of March 29, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.250% Senior Notes due 2026, including the Form of 5.250% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.5 to the Company’s Quarterly Report on Form 10-Q, filed on May 6, 2016). I-6 4.5C 4.5D 4.5E 4.6 4.6A 4.6B 10.1 10.2 10.3 10.4 10.4A 10.4B Third Supplemental Indenture, dated as of May 13, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.250% Senior Notes due 2026, including the Form of 5.250% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed on August 5, 2016). Fourth Supplemental Indenture, dated as of August 9, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.250% Senior Notes due 2026, including the Form of 5.250% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed on November 8, 2016). Fifth Supplemental Indenture, dated as of November 10, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.250% Senior Notes due 2026, including the Form of 5.250% Senior Notes and Form of Subsidiary Guarantee related thereto.* Indenture, dated as of July 12, 2016, by and among Omega, the subsidiary guarantors named therein, and U.S. Bank National Association, as trustee (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on July 12, 2016). First Supplemental Indenture, dated as of August 9, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.375% Senior Notes due 2023, including the Form of 4.375% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed on November 8, 2016). Second Supplemental Indenture, dated as of November 10, 2016, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.375% Senior Notes due 2023, including the Form of 4.375% Senior Notes and Form of Subsidiary Guarantee related thereto.* Form of Directors and Officers Indemnification Agreement. (Incorporated by reference to Exhibit 10.11 to the Company’s Quarterly Report on Form 10-Q, filed on August 14, 2000). Form of Officers’ Multi-Year Performance Restricted Stock Unit Award for 2011 to 2014 (Incorporated by reference to Exhibit 10.12 of the Company’s Annual Report on Form 10-K, filed on February 27, 2012).+ Amended and Restated Deferred Stock Plan, dated October 16, 2012, and forms of related agreements (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, filed November 7, 2012). Credit Agreement, dated as of June 27, 2014, among Omega Healthcare Investors, Inc., certain subsidiaries of Omega Healthcare Investors, Inc. identified therein as guarantors, the lenders named therein and Bank of America, N.A., as administrative agent for such lenders. (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed July 2, 2014). First Amendment dated April 1, 2015 to the Credit Agreement dated June 27, 2014 by and between Omega Healthcare Investors Inc., the subsidiary guarantors listed therein, a syndicate of financial institutions, as Lenders, and Bank of America, N.A., as Administrative Agent (Incorporated by reference to Exhibit 10.12 to the Company’s Current Report on Form 8-K, filed on April 3, 2015). Second Amendment to Credit Agreement, dated as of August 7, 2015, among Omega Healthcare Investors, Inc., certain subsidiaries of Omega Healthcare Investors, Inc. identified therein as guarantors, the lenders named therein and Bank of America, N.A., as administrative agent for such lenders (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed December 22, 2015). I-7 10.4C 10.4D 10.4E 10.5 10.5A 10.6 10.7 10.7A 10.8 10.9 10.10 10.11 Third Amendment to Credit Agreement, dated as of January 29, 2016, among Omega Healthcare Investors, Inc., certain subsidiaries of Omega Healthcare Investors, Inc. identified therein as guarantors, the lenders named therein and Bank of America, N.A., as administrative agent for such lenders (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed February 3, 2016). Credit Agreement, dated as of December 16, 2015, among Omega Healthcare Investors, Inc., certain subsidiaries of Omega Healthcare Investors, Inc. identified therein as guarantors, the lenders named therein and The Bank of Tokyo-Mitsubishi UFJ, Ltd., as administrative agent for such lenders (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed December 22, 2015). Second Amended and Restated Agreement of Limited Partnership by and among Omega Healthcare Investors, Inc., OHI Healthcare Properties Holdco, Inc., and Aviv Healthcare Properties Limited Partnership (Incorporated by reference to Exhibit 10.11 to the Company’s Current Report on Form 8-K, filed on April 3, 2015). Credit Agreement dated as of April 1, 2015, by and between OHI Healthcare Properties Limited Partnership, each of the subsidiary guarantors listed therein, a syndicate of financial institutions as listed therein as Lenders, and Bank of America, N.A., as Administrative Agent (Incorporated by reference to Exhibit 10.13 to the Company’s Current Report on Form 8-K, filed on April 3, 2015). First Amendment to Credit Agreement, dated as of August 7, 2015, among Omega Healthcare Properties Limited Partnership, certain subsidiaries of Omega Healthcare Properties Limited Partnership identified therein as guarantors, the lenders named therein and Bank of America, N.A., as administrative agent for such lenders (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed January 7, 2016). Form of Equity Distribution Agreement dated September 3, 2015, entered into by and between Omega Healthcare Investors, Inc. and each of BB&T Capital Markets, a division of BB&T Securities, LLC, Capital One Securities, Inc., Credit Agricole Securities (USA) Inc., J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Mitsubishi UFJ Securities (USA), Inc., Morgan Stanley & Co. LLC, RBC Capital Markets, LLC, Stifel, Nicolaus & Company, Incorporated, SunTrust Robinson Humphrey, Inc. and Wells Fargo Securities, LLC (incorporated by reference to Exhibit 1.1 to Omega’s Current Report on Form 8-K filed with the SEC on September 4, 2015). Omega Healthcare Investors, Inc. 2013 Stock Incentive Plan (Incorporated by reference to Annex A to the Registrant’s Proxy Statement on Schedule 14A filed on April 22, 2013). + Amendment to 2013 Stock Incentive Plan (Incorporated by reference to Exhibit 10.10 to the Company’s Current Report on Form 8-K, filed on April 3, 2015). + Form of Officer Deferred Performance Restricted Stock Unit Agreement (Incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q, filed on August 5, 2013). + Employment Agreement, dated November 15, 2013, between Omega Healthcare Investors, Inc. and C. Taylor Pickett (Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed on November 19, 2013). + Employment Agreement, dated November 15, 2013, between Omega Healthcare Investors, Inc. and Daniel Booth (Incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed on November 19, 2013). + Employment Agreement, dated April 1, 2015, between Omega Healthcare Investors, Inc. and Steven J. Insoft (incorporated by reference to Exhibit 10.3 to Company’s Current Report on Form 8-K filed with the SEC on April 3, 2015). I-8 10.12 10.13 10.14 10.15 10.16 10.17 10.18 10.19 10.20 10.22 10.23 10.24 10.25 10.26 10.27 10.27A Employment Agreement, dated November 15, 2013, between Omega Healthcare Investors, Inc. and Robert O. Stephenson (Incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K, filed on November 19, 2013). + Employment Agreement, dated November 15, 2013, between Omega Healthcare Investors, Inc. and Michael Ritz (Incorporated by reference to Exhibit 10.5 of the Company’s Current Report on Form 8-K, filed on November 19, 2013). + Form of 2016 Employment Agreement Amendments (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on March 23, 2016) for the Company’s executive officers.+ Form of 2017 Employment Agreement Amendments (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 13, 2017 ) for the Company’s executive officers.+ for Transition Grants (2013) Form of Time-Based Restricted Stock Unit Agreement (Incorporated by reference to Exhibit 10.6 of the Company’s Current Report on Form 8-K, filed on November 19, 2013). + Form of Time-Based Restricted Stock Unit Agreement for 2015 Grants (Incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K, filed on April 3, 2015). + Form of Time-Based Restricted Stock Unit Agreement for 2016 Grants (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on March 23, 2016).+ Form of Performance-Based Restricted Stock Unit Agreement for Transition Grants (2013) (Incorporated by reference to Exhibit 10.7 of the Company’s Current Report on Form 8-K, filed on November 19, 2013). + Form of Performance-Based Restricted Stock Unit Agreement for 2015 Grants (Incorporated by reference to Exhibit 10.8 to the Company’s Current Report on Form 8-K, filed on April 3, 2015). + Form of Performance-Based Restricted Stock Unit Agreement for 2016 Grants (Incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed with the SEC on March 23, 2016).+ Form of Time-Based Restricted Stock Unit Agreement for Annual Grants (commencing 2014) (Incorporated by reference to Exhibit 10.8 of the Company’s Current Report on Form 8-K, filed on November 19, 2013). + Form of Performance-Based Restricted Stock Unit Agreement for Annual Grants (commencing 2014) (Incorporated by reference to Exhibit 10.9 of the Company’s Current Report on Form 8-K, filed on November 19, 2013). + Form of Performance-Based LTIP Unit Agreement for 2015 Grants (Incorporated by reference to Exhibit 10.9 to the Company’s Current Report on Form 8-K, filed on April 3, 2015). + Form of Performance-Based LTIP Unit Agreement for 2016 Grants (Incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K, filed with the SEC on March 23, 2016).+ Aviv REIT, Inc. 2010 Management Incentive Plan (Incorporated by reference to Exhibit 10.3 to the Aviv REIT, Inc.’s Registration Statement on Form S-4, filed on May 2, 2011). + First Amendment to the Aviv REIT, Inc. 2010 Management Incentive Plan (Incorporated by reference to Exhibit 4.5 to Aviv REIT, Inc.’s Registration Statement on Form S-8, filed on March 25, 2013). + I-9 10.27B 10.27C 10.27D 10.28 10.28A 10.28B 10.29 12.1 21 23 31.1 31.2 32.1 32.2 Second Amendment to the Aviv REIT, Inc. 2010 Management Incentive Plan (Incorporated by reference to Exhibit 4.3 to the Company’s Registration Statement on Form S-8, filed on April 2, 2015). + Form of Time-Based Nonqualified Stock Option Award Agreement under the Aviv REIT, Inc. 2010 Management Incentive Plan (Incorporated by reference to Exhibit 10.4 to Aviv REIT, Inc.’s Registration Statement on Form S-4, filed on May 2, 2011). + Form of Nonlimited Performance-Based Nonqualified Stock Option Award Agreement under the Aviv REIT, Inc. 2010 Management Incentive Plan (Incorporated by reference to Exhibit 10.5 to Aviv REIT, Inc.’s Registration Statement on Form S-4 filed on May 2, 2011). + Aviv REIT, Inc. 2013 Long-Term Incentive Plan (Incorporated by reference to Exhibit 4.3 to Aviv REIT, Inc.’s Registration Statement on Form S-8 filed on March 25, 2013). + Amendment to the Aviv REIT, Inc. 2013 Long-Term Incentive Plan (Incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-8, filed on April 2, 2015). + Form of Restricted Stock Unit Award Agreement for time-based restricted stock units under the Aviv REIT, Inc. 2013 Long-Term Incentive Plan, (Incorporated by reference to Exhibit 10.2 to Aviv REIT, Inc.’s Current Report on Form 8-K, filed on July 15, 2013). + Amended and Restated Phantom Partnership Unit Award Agreement, dated as of September 17, 2010, among Aviv Asset Management, L.L.C., Steven J. Insoft and Aviv Healthcare Properties Limited Partnership, (Incorporated by reference to Exhibit 10.8 to Aviv REIT, Inc.’s Registration Statement on Form S-4, filed on May 2, 2011). + Ratio of Earnings to Fixed Charges.* Subsidiaries of the Registrant.* Consent of Independent Registered Public Accounting Firm. Certification of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.* Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.* Certification of the Chief Executive Officer under Section 906 of the Sarbanes- Oxley Act of 2002.* Certification of the Chief Financial Officer under Section 906 of the Sarbanes- Oxley Act of 2002.* 101.INS XBRL Instance Document. 101.SCH XBRL Taxonomy Extension Schema Document. 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB XBRL Taxonomy Extension Label Linkbase Document. 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document. Exhibits that are filed herewith. * + Management contract or compensatory plan, contract or arrangement. I-10 Pursuant to the requirements of Sections 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SIGNATURES OMEGA HEALTHCARE INVESTORS, INC. By: /s/ C. Taylor Pickett C. Taylor Pickett Chief Executive Officer Date: February 24, 2017 Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities on the date indicated. Signatures Title Date PRINCIPAL EXECUTIVE OFFICER /s/ C. Taylor Pickett C. Taylor Pickett PRINCIPAL FINANCIAL OFFICER /s/ Robert O. Stephenson Robert O. Stephenson /s/ Michael D. Ritz Michael D. Ritz DIRECTORS /s/ Bernard J. Korman Bernard J. Korman /s/ Craig M. Bernfield Craig M. Bernfield /s/ Norman Bobins Norman Bobins /s/ Craig R. Callen Craig R. Callen /s/ Barbara B. Hill Barbara B. Hill /s/ Harold J. Kloosterman Harold J. Kloosterman /s/ Edward Lowenthal Edward Lowenthal /s/ C. Taylor Pickett C. Taylor Pickett /s/ Ben W. Perks Ben W. Perks /s/ Stephen D. Plavin Stephen D. Plavin Chief Executive Officer February 24, 2017 Chief Financial Officer February 24, 2017 Chief Accounting Officer February 24, 2017 Chairman of the Board February 24, 2017 February 24, 2017 February 24, 2017 February 24, 2017 February 24, 2017 February 24, 2017 February 24, 2017 February 24, 2017 February 24, 2017 February 24, 2017 Director Director Director Director Director Director Director Director Director I-11 Exhibit 12.1 RATIO OF EARNINGS TO FIXED CHARGES The following table sets forth our ratio of earnings to fixed charges on a reported basis for the periods indicated. Earnings consist of income from continuing operations plus fixed charges. Fixed charges consist of interest expense, amortization of deferred financing costs and costs related to retiring certain debt early. We have calculated the ratio of earnings to fixed charges by adding net income from continuing operations to fixed charges and dividing that sum by such fixed charges. Year Ended December 31, 2012 2013 2014 2015 2016 (in thousands) Net income . . . . . . . . . . . . . . . . . . . . . . . . . . Interest expense(1) . . . . . . . . . . . . . . . . . . . . . . Income before fixed charges . . . . . . . . . . . . . . . $120,698 106,096 $172,521 92,048 $221,349 126,869 $234,526 183,208 $383,367 175,561 $226,794 $264,569 $348,218 $417,734 $558,928 Capitalized interest . . . . . . . . . . . . . . . . . . . . . Interest expense(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Total fixed charges $ 240 106,096 $ 190 92,048 $ — $ 126,869 3,701 183,208 $ 6,594 175,561 $106,336 $ 92,238 $126,869 $186,909 $182,155 Earnings / fixed charge coverage ratio . . . . . . . . 2.1x 2.9x 2.7x 2.2x 3.1x (1) Includes interest refinancing costs, gains and losses on refinancing and amortization of deferred financing costs. I-12 Exhibit 23 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form S-8 Nos. 333-189144 and 333-117656) related to the 2013 Stock Incentive Plan (formerly known as the 2004 Stock Incentive Plan) of Omega Healthcare Investors, Inc.; (2) Registration Statement (Form S-3 No. 333-206751), an unallocated universal registration statement expiring September 3, 2018; (3) Registration Statement (Form S-3 No. 333-208710), pertaining to the Debt Securities and Guarantees of Debt Securities of Omega Healthcare Investors, Inc. and its subsidiary guarantors; (4) Registration Statement (Form S-8 No. 333-203189) related to assumed awards under certain equity compensation plans of Aviv REIT, Inc.; (5) Registration Statement (Form S-3 No. 333-208061) related to the resale of shares issuable from time to time upon redemption of units of OHI Healthcare Properties Limited Partnership; and (6) Registration Statement (Form S-3 No. 333-215424) related to the Dividend Reinvestment and Common Stock Purchase Plan of Omega Healthcare Investors, Inc. of our reports dated February 24, 2017, with respect to the consolidated financial statements and schedules of Omega Healthcare Investors, Inc. and the effectiveness of internal control over financial reporting of Omega Healthcare Investors, Inc., included in this Annual Report (Form 10-K) of Omega Healthcare Investors, Inc. for the year ended December 31, 2016. /s/ Ernst & Young LLP Baltimore, Maryland February 24, 2017 I-13 Exhibit 31.1 RULE 13a-14(a)/15d-14(a) CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, C. Taylor Pickett, certify that: 1. I have reviewed this Annual Report on Form 10-K of Omega Healthcare Investors, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: February 24, 2017 /S/ C. TAYLOR PICKETT C. Taylor Pickett Chief Executive Officer I-14 Exhibit 31.2 RULE 13a-14(a)/15d-14(a) CERTIFICATION OF CHIEF FINANCIAL OFFICER I, Robert O. Stephenson, certify that: 1. I have reviewed this Annual Report on Form 10-K of Omega Healthcare Investors, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: February 24, 2017 /S/ ROBERT O. STEPHENSON Robert O. Stephenson Chief Financial Officer I-15 Exhibit 32.1 SECTION 1350 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER I, C. Taylor Pickett, hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge: (1) the Annual Report on Form 10-K of Omega Healthcare Investors, Inc. (the “Company”), for the year ended December 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: February 24, 2017 /S/ C. TAYLOR PICKETT C. Taylor Pickett Chief Executive Officer I-16 Exhibit 32.2 SECTION 1350 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER I, Robert O. Stephenson, hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge: (1) the Annual Report on Form 10-K of Omega Healthcare Investors, Inc. (the “Company”), for the year ended December 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: February 24, 2017 /S/ ROBERT O. STEPHENSON Robert O. Stephenson Chief Financial Officer I-17 COMPARISON OF CUMULATIVE TOTAL RETURN Omega Healthcare Investors, Inc. Graph showing cumulative returns December 31, 2016 Comparison of Cumulative Total Return* 300 250 200 150 100 50 - 12/31/2011 12/31/2012 12/30/2013 12/31/2014 12/31/2015 12/31/2016 OHI NAREIT COMPOSITE ALL REITS S&P 500 Russell 2000 * $100 invested on December 31, 2011 in stock or index, including reinvestment of dividends. I-18 STOCKHOLDER INFORMATION Executive Officers and Directors as of April 17, 2017 C. Taylor Pickett (1) Chief Executive Officer Director Daniel J. Booth Chief Operating Officer Steven J. Insoft Chief Corporate Development Officer Robert O. Stephenson Chief Financial Officer Michael D. Ritz Chief Accounting Officer Bernard J. Korman(1), (2), (4) Chairman of the Board Craig M. Bernfield(1) (4) Director Norman R. Bobins(1) Director Craig R. Callen(1) Director Barbara B. Hill(2) Director Harold J. Kloosterman(1), (2), (3), (4) Director Edward Lowenthal(2), (3), (4) Director Ben W. Perks(3) Director Stephen D. Plavin(2), (3), (4) Director (1) Member of Investment Committee (2) Member of Compensation Committee (3) Member of Audit Committee (4) Member of Nominating and Corporate Governance Committee Please call 800-368-5948 for information the Plan, and to request a prospectus Plan enrollment at about and materials www.computershare.com/investor. forms. Alternatively, downloaded directly can be Auditors Ernst & Young LLP Baltimore, Maryland Transfer Agent and Registrar Computershare 525 Washington Blvd. 3rd Floor, Suite 4694 Jersey City, NJ 07310 (800) 368-5948 www.computershare.com/investor Exchange Listing New York Stock Exchange (Symbol: OHI) Corporate Office 303 International Circle Suite 200 Hunt Valley, MD 21030 (410) 427-1700 Phone (410) 427-8800 Fax Annual Meeting The Annual Meeting of the Stockholders will be held at 10:00 A.M. EDT June 8, 2017 at the Company’s principal executive offices at 303 International Circle, Suite 200, Hunt Valley, Maryland. All stockholders are invited to attend. Publications Available To view a copy of press releases or the most recent financial results, please visit the Company’s web site at www.omegahealthcare.com. Upon request, the Company will provide, without charge, its Annual Report, Form 10-K, Form 10-Q and any amendments to same. Dividend Reinvestment and Stock Purchase Plan Member The Dividend Reinvestment and Stock Purchase Plan provides investors and shareholders with a convenient method for reinvesting dividends and purchasing shares of Common Stock directly from the Company without paying any service charges or brokerage commissions. Please see www.omegahealthcare.com and click on “Stock Purchase Program” for plan features. National Association of Real Estate Investment Trusts, Inc. NYSE Certification The Chief Executive Officer’s annual certification pursuant to §303.12(a) of the New York Stock Exchange Listed Company Manual was submitted to the New York Stock Exchange on June 27, 2016. There are no qualifications to that certification. 303 International Circle, Suite 200 Hunt Valley, MD 21030 Phone (410) 427-1700 Fax (410) 427-8800